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Abstract
Drug transporters are increasingly recognised as important drivers in the pharmaco- and 
toxico- kinetic characteristics o f  therapeutic agents. Preclinical assays are used to 
determine the effects o f  transport on the pharmacokinetics and toxicology o f  a new 
compound during drug development. However in vitro cell systems and in vivo animal 
models often give erroneous results due to the differential expression o f  important 
proteins within them. In silico  models have been employed to help bridge the gap and 
make more accurate predictions for drug disposition and metabolism; however such 
models have not incorporated transport kinetics or induction by nuclear receptors. Many 
current models also use a reductionist approach, whereby a multiple component pathway 
is described by a single mathematical term, reducing the ability o f  the simulation to 
determine the effects o f  single parameters.
The first aim o f  this research was therefore to assess the differences in drug transporter 
expression in a variety o f  human and rat hepatocellular systems compared to liver. RT- 
PCR and protein analysis o f  drug transporter levels in vitro and in vivo showed huge 
differences, with influx transporters generally being under-expressed and efflux 
transporters over-expressed in vitro compared to in vivo. These differences were more 
pronounced at the RNA level than protein level. Transporter expression was also shown 
to be dynamic, changing over time in culture and in response to nuclear receptor 
activation. The second aim was to generate an in silico model o f  cellular response to 
stimuli, using a whole-cell approach to investigate system dynamics. Kinetics for the 
lifecycle rhodamine-123 were determined in vitro and incorporated into an in silico 
model o f  human hepatocyte disposition that could accurately simulate outcomes in a 
variety o f cell types and make useful predictions o f  drug disposition from in vitro results.
In conclusion, the in silico model revealed that drug transporter expression and activity 
may affect drug disposition, with uptake processes presenting as the fragile node in the 
network. Such a model would be useful in the early stages o f  drag development to 
improve extrapolation between biological systems and to identify the likely consequences 
o f  different expression levels and species inhibition and induction.
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1 Introduction
Transport across Membranes
The plasm a membrane, which encloses the cell and maintains the bander between the 
cytosol and extracellular environment acts as a semi-permeable barrier to the entry and 
exit o f  both endogenous substrates and xenobiotics. All biological membranes have a 
common general structure: A very thin film o f  lipid and protein molecules, held together 
mainly by non-covalent interactions. The shape and amphipathic nature o f  the lipid 
molecules causes them  to spontaneously form bilayers approximately 5 nm wide when in 
aqueous solution, which serves as a relatively impermeable barrier to most water-soluble 
molecules (Alberts et al., 2008). Inserted into this bilayer are protein molecules that act to 
regulate the movement o f  small polar or larger molecules that are unable to cross the 
membrane unaided by providing channels or specifically acting as carriers (Timbrell,
2000).
Passive and facilitated diffusion o f  molecules across the membrane are both driven by 
concentration gradients; in the former, molecules pass directly through the bilayer, 
whereas in the latter, a protein channel or carrier provides a selective pathway through 
the hydrophobic environment (Figure 1-1). Conversely, active transport moves molecules 
against a concentration gradient. This is achieved by the supply o f  an electromotive 
energy, either by the hydrolysis o f  ATP (primary active transport, figure 1-1), or by the 
co-transport o f  ions such as Na+ or K+ down their concentration gradients either in the 
same (symport) or opposite direction (antiport) as the species to be actively transported 
(secondary active transport) (Lodish et al., 2008). Thus, passive and active transport are 
governed by physico-chemical properties o f  a compound, which determine whether it can 
directly cross the hydrophobic membrane or bind to the active site o f  a transport protein.
As mentioned above, the physico-chemical properties o f  a compound determine the route 
i f  any that it takes across a membrane. For example, drugs with high dipole moment,
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even though un-ionized, have low lipid solubility and penetrate membranes poorly 
(Agatonovic-Kustrin et al., 2001). However, lipid solubility in covalent molecules can be 
facilitated by the presence o f  weak dipoles induced by electronegative groups, promoting 
dipole-dipole attractions with cell membrane structures such as phosphatidyl esters 
(Smith and Williams, 1988). Compound ionization not only reduces lipid solubility but 
also slows movement through charged membranes. In such cases, membrane transport 
proteins that neutralize the charge or shield the molecule are required for absorption 
(Agatonovic-Kustrin et al., 2001).
Diffusion
Facilitated diffusion
> Passive transport
Active transport
Figure 1-1 M echanisms o f Passive and Active Transport across Biological M embranes
Substances can cross the lipid bilayer passively by simple diffusion or facilitated transport, both 
of which move the solute down its concentration gradient. Alternatively, solutes can be actively 
pumped across a bilayer against its concentration gradient by transport proteins utilising ATP 
(Campbell, 1996).
A final way in which molecules may enter cells is by the process o f endocytosis, which 
involves the uptake o f  material into a cell by an invagination o f  the plasma membrane 
and its internalization in a membrane-bounded vesicle. Endocytosis can be divided into
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three main types determined by the size o f  the vesicle formed and the machinery 
involved. The first type is a fluid-phase endocytosis termed pinocytosis, in which small 
vesicles bud o ff  internally from  the plasm a membrane, carrying extracellular fluid and 
dissolved material into the cell. The second type, phagocytosis involves the ingestion o f  
large particles, such as microorganisms or dead cells via large vesicles called 
phagosomes. Lastly, receptor-mediated endocytosis provides a selective concentrating 
mechanism that increases the efficiency o f  internalisation o f  particular ligands more than 
a hundredfold, so that even m inor components o f the extracellular fluid can be 
specifically taken up in large amounts without talcing in a correspondingly large volume 
o f extracellular fluid (Alberts et al., 2008).
1.1.1 Polarised Membranes
The plasm a membranes o f  epithelial and endothelial cells as well as other polarised cells 
such as hepatocytes are divided into two domains; an apical domain, facing the lumen, 
and the basolateral domain forming the basal (base) and lateral surfaces o f  the cell that 
face the extracellular fluid, such as the blood supply. These plasma membrane domains 
have different lipid and protein compositions, which allows them to undertake distinct 
functions within an organ (Simons and Vanmeer, 1987). Such cell polarity is retained by 
tight junctions, located at the boundary between the apical and basolateral membrane 
domains, which act as selective permeable barriers to the paracellular space and as intra- 
membranous obstacles to prevent free mixing o f  membrane domain-specific proteins and 
lipids (Nelson, 2003b). In the case o f  the hepatocyte, the apical membrane is called the 
canalicular membrane, as it faces the bile canalicular lumen and the basolateral 
membrane can be called the sinusoidal membrane as it faces the sinusoidal blood supply.
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1.2 Drug Transporters
Carrier-mediated processes for endogenous substrates are increasingly recognised to play an 
important role in determining drug disposition and are commonly referred to as drag 
transporters in this context. Two major classes of drag transporters are largely involved in the 
uptake and efflux o f drags, drag conjugates and endogenous substrates; designated the solute 
carrier (SLC) superfamily and the ATP binding cassette (ABC) superfamily 
(Venkataramanan et al., 2006). In higher species, ABC transporters are only involved in 
efflux, while SLC transporters are predominantly involved in uptake. Both superfamilies are 
made up o f  families (designated by a letter in the case o f  ABC members or a number in 
the case o f  the SLCs) and sub-families (SLCs only, designated by a letter) while each 
family or sub-family is made up o f  many members (designated by numbers), as specified 
by the Human Genome Organisation (HUGO) Gene Nomenclature Committee 
(http://www.gene.ucl.ac.uk/nomenclature/). The names used in this introduction are those 
most recently attributed as the correct gene and/or protein names, although each 
transporter is known by many aliases, a list o f  which can be found in the appendix 
(Tables 9-1 and 9-2) For the rest o f  this research, both gene and protein are identified by 
the protein name only in order to increase ease o f  reading and avoid unnecessary 
confusion. A brief overview o f  the transporter superfamilies follows with further 
discussion on the specific transporters studied in this work. These were chosen based on 
the expression or functional role o f  the transporters in the liver with regards to selected 
probe substrate transport.
1.2.1 The ABC Superfamily
Proteins are classified as ABC transporters based on the sequence and organization o f 
their ATP-binding domain(s), also known as nucleotide-binding folds or nucleotide- 
binding domains (NBFs/NBDs) (Eclcer and Chiba, 2009). The NBDs contain 
characteristic motifs (W alker A and B) separated by approximately 90-120 amino acids, 
which are essential for the binding and hydrolysis o f  ATP (Walker et al., 1982). ABC
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genes also contain an additional element, the signature (C) motif, located just upstream o f  
the Walker B site (Hyde et al., 1990), which may be involved in ATP hydrolysis or 
substrate translocation (Hewitt and Lehner, 2003). In eukaryotes, the functional protein 
typically contains two NBDs and two transmembrane domains (TMDs) containing 4 -12  
membrane-spanning a-helices that provide the specificity for the substrate (Figure 1-2), 
although half transporters do exist that contain one ATP and one transmembrane domain 
(Ecker and Chiba, 2009; Gillet et al., 2007). The latter must form homodimers or hetero 
dimers in order to form a functional transporter.
TMD1 TMD24------------- » 4------------- »
Figure 1-2 Schematic Representation o f the Structure o f a Full ABC Transporter with Two 
Transm em brane and Two Nucleotide-Binding Domains
Depicted is a full transporter such as ABCB1, ABC 11 or ABCC4 with two transmembrane 
domains (TMD1 and TMD2) consisting of six membrane-spanning a-helices each and two 
ATP-binding sites (NBD/Nucleotide binding domain). The NBDs are located in the cytoplasm 
and transfer the energy to transport the substrate across the membrane. Figure taken from 
(Gillet et al., 2007).
The ABC genes represent a large superfamily o f  transmembrane proteins, consisting to 
date o f  forty eight genes divided into seven families, designated ABCA to ABCG (Dean 
et al., 2001). However, since the ABCE and ABCF subfamilies contain genes that have 
two ATP-binding domains but no TM domains, these proteins cannot be considered as
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transporters even though the NBDs clearly cluster with those o f  other ABC genes 
phylogenetically (Dean and Annilo, 2005). Transporter proteins belonging to the 
remaining families, bind and hydrolyse ATP using the energy to drive the transport o f 
various molecules such as sugars, amino acids, m etal ions, peptides, and proteins, and a 
large number o f  hydrophobic compounds including drugs and metabolites from the inner 
to outer leaflet o f membranes (Dean et al., 2001). M ost ABC transporters, also loiown as 
ABC efflux pumps are found in the membranes o f  distinct cellular compartments, such as 
the plasma membrane, peroxisomes, the inner mitochondrial membrane and the 
endoplasmic reticulum (ER), though none appear to be located in the nuclear envelope 
(Ecker and Chiba, 2009). The ABCB and ABCC subfamilies are discussed in more detail 
below, as these include some o f  the most studied transporter genes due to their 
association with the multidrug resistance phenotype (Gillet et al., 2007).
1.2.1.1 The ABCB family
The ABCB subfamily is unique in mammals in that it contains both full transporters and 
half transporters. So far, four full transporters and seven half transporters have been 
identified and assigned to this family in humans (Dean et al., 2001). ABCB2, ABCB3 
and ABCB9, are half transporters, closely related with regard to their structural and 
functional properties. Although they are targeted to different cellular compartments such 
as the endoplasmic reticulum (ER) and lysosomes, they are all involved in intracellular 
peptide trafficking across membranes (Herget and Tampe, 2007). For example, ABCB2, 
ABCB3 and ABCB9 to a lesser extent transport peptide fragments into the ER for 
loading into major histo-compatibility complex (MHC) molecules to be presented as 
antigens (Herget and Tampe, 2007). The remaining half transporters in this family, 
ABCB6, ABCB7, ABCB8 and ABCB 10 are all localised to the mitochondria, where they 
function in iron metabolism and transport (Dean et al., 2001). The full transporters 
ABCB1, ABCB4, ABCB5 and A B CB 11 are expressed in the apical membranes o f  tissues 
w ith barrier functions (e.g. liver and blood brain barrier) and have all been associated 
with drug resistance (Gillet et al., 2007). ABCB1, ABCB4 and ABCB 11 are all
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predominantly expressed in the liver where they excrete endogenous bile acids, in 
addition to their role in excreting xenobiotics in the bile canaliculus. ABCB5 is only 
expressed in the testes, breast and melanoma, where it has no major endogenous 
substrates that have been identified (Gillet et al., 2007).
The complement o f  ABCB genes is identical in all mammals characterized to date, except 
that the A bcbl gene is duplicated in the rodent genomes, suggesting that the function has 
been well conserved across species (Dean and Annilo, 2005). O f the two rodent isoforms, 
A bcb la  is the predominant isoform expressed in the BBB (Regina et a l ,  1998) and is 
highly expressed in the small intestine (Brady et al., 2002), whereas the A bcblb  isoform 
is more widely expressed (Brady et al., 2002) and is inducible in the liver (Brown et al., 
1993). Since ABCB1 was the first transporter to be cloned (Juliano and Ling, 1976) and 
has been the most extensively studied due to its ability to confer multidrag resistance to 
cancer cells, it has been given further consideration below.
1.2.1.1.1 ABCB1
ABCB1 (p-glycoprotein, MDR1) is expressed in several tissues including the liver, 
kidneys, intestine and blood brain blood brain barrier (BBB) (Ambudkar et al., 1999). In 
the liver, ABCB1 is localized to the canalicular domain o f  the hepatocyte, where it 
facilitates excretion o f  exogenous organic cations and toxicants into bile. In the kidney, 
ABCB1 is located on the luminal membrane o f  the proximal tubule and excretes 
substrates into the urine (Ayrton and Morgan, 2001; Thiebaut et al., 1987). ABCB1 in the 
intestinal epithelium, effluxes drugs that have entered enterocytes back into the lumen 
(von Richter et a l ,  2001), in a similar way to how ABCB1 eliminates substances from the 
endothelial cells o f  the BBB (Schinlcel, 1999). ABCB1 has been demonstrated to be a 
promiscuous transporter, involved in the efflux o f  structurally diverse compounds (Raub,
2006), and as such has been recognised to affect the bioavailability and systemic 
clearance o f  drugs that are substrates, by limiting absorption and enhancing elimination.
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ABCB1 is sometimes also expressed at high level in tumours o f epithelial origin such as 
colon, kidney (Ambudkar et a l ,  2003; Fletcher et a l ,  2010) and breast (Zhang et al.,
2009) where it confers drug resistance during cancer chemotherapy (Gillet et al., 2007). It 
is important to note however that not all tumours over-express ABCB1. ABCB1 is also 
thought to contribute to drug resistance during the treatment o f neurological conditions 
such as epilepsy (van Vliet et al., 2007), Parkinson’s (Uhr et al., 2005), and depression 
(Uhr et al., 2008), due to its capacity to limit drug disposition into the CNS. The efficacy 
o f  some antiretroviral drugs used in the treatment o f  the Human Immunodeficiency Virus 
(HIV) is also reduced as ABCB1 effluxes the drug from CD4 cells (Janneh et al., 2007) 
and limits absorption across the placenta during treatment o f  an infected mother (Gulati 
and Gerlc, 2009).
1.2.1.2 The ABCC family
The ABCC subfamily contains 12 full transporters with a diverse functional spectrum 
that includes ions transport, cell surface receptor, and toxin secretion activities (Dean et 
al., 2001). The core structure o f this family o f  transporters is the same as that shown in 
figure 1-2, comprising two TMDs and two NBDs. However, ABCC1, ABCC2, ABCC3, 
ABCC6 and ABCC7 have an extra N-terminal domain (TMD0), consisting o f  five 
membrane-spanning a-helices (Figure 1-3) (Borst et al., 2000; Gillet et a l ,  2007). The 
TMD0 region o f ABCC2 is essential for targeting o f  the protein to the apical membrane 
o f polarised cells (Fernandez et al., 2002), but its role in the other ABCC transporters is 
less clear, given their basolateral localisation. It has been shown that removal o f  the 
TMD0 region from ABCC1 has no effect on localisation or activity, yet truncation o f  the 
cytoplasmic linker region between TM D0 and TMD1 results in retention o f  the protein in 
the ER and loss o f  activity (W estlake et al., 2005). This suggests that the TMD0 region 
contains redundant signalling motifs that allow basolateral membrane trafficking despite 
its removal (Westlake et al., 2005).
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N- terminal
Figure 1-3 Schematic Representation o f Structure o f a Full ABC Transporter with an 
Additional five Transm em brane Segments at the N-Term inus
Depicted is a full transporter such as ABCC1, ABCC2, ABCC3, ABCC6 or ABCC7 with two 
transmembrane domains (TMD1 and TMD2) consisting of six membrane-spanning a-helices 
each and two ATP-binding sites (NBD/Nucleotide binding domain). An additional 
Transmembrane domain (TMDO) is also present at the N-terminus that is composed of five 
membrane-spanning a-helices. Figure taken from (Gillet et al., 2007).
The majority o f  transporters in the ABCC family are ATP-dependent transporters, 
involved in the transport o f  endogenous metabolites and xenobiotics. However, the 
family also includes three transporters which act as ATP-gated channels and regulators 
with important biological functions: ABCC7 (CFTR) is an ATP-gated channel, mutations 
in which are responsible for causing cystic fibrosis (Aleksandrov et al., 2007); ABCC8 
and ABCC9 function as ATP-dependent potassium channel regulators necessary for 
insulin secretion (Bryan et al., 2007).
Whereas conjugated anions are not substrates for ABCB1, members o f  the ABCC 
subfamily, especially ABCC 1-4, accept glutathione, sulphate or glucuronide conjugates 
o f  compounds (Gotoh et al., 2000; Hirohashi et al., 1999; Jedlitschky et al., 1994; Zelcer 
et al., 2003). Much attention has been paid to the ABCC family due to its involvement in
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m ultidrag resistance through the efflux o f  drugs and their conjugates. For example, 
ABCC1 transports a broad spectrum o f  anticancer drags such as methotrexate, 
doxorubicin and vincristine (Cole et al., 1992). ABCC2 can also transport many ABCC1 
substrates as well as cisplatin, which is not transported by ABCC1 (Guminslci et al., 
2006; Huisman et al., 2005), whereas ABCC3 has narrower substrate specificity (Zelcer 
et al., 2001). ABCC4 and ABCC5 confer resistance to 6-mercaptopurine and 6- 
thioguanine purine analogues (Chen et al., 2001; W ielinga et al., 2003), whereas ABCC6 
has similar functions to ABCC1, ABCC2 and ABCC3 (Belinsky et al., 2002). ABCC10, 
ABCC11 and ABCC12, are o f  m inor importance with respect to drag disposition, with 
the first two potentially involved in the transport o f  several anti-cancer drugs, and the 
latter member remaining to be characterised (Krah et al., 2007). Further consideration o f 
ABCC2 is given below as ABCC2 is the only transporter located to the apical membrane, 
allowing for the study o f  vectorial transport.
1.2.1.2.1 ABCC2
ABCC2 (MRP2, cMOAT) is expressed in the apical membrane o f  hepatocytes (Buchler 
et al., 1996; M ayer et al., 1995) intestinal epithelia (Yu et al., 2007b) and kidney epithelia 
(Schaub et al., 1999) as well as placenta (St-Pierre et al., 2000) and lung (Ushijima et al.,
2007). As mentioned above, ABCC2 substrates include anticancer drugs such as 
doxorubicin, methotrexate, vincristine and cisplatin (Guminslci et al., 2006; Huisman et 
al., 2005), and is thus involved in drug resistance in tum our cells. Also transported are a 
number o f  gluthathione and glucuronide conjugates (Gotoh et a l, 2000; ICeppler et al.,
2002), making ABCC2 a major player in the excretion o f drag metabolites. The 
endogenous substrates o f  ABCC2 include a multitude o f  organic anions such as bile acids 
and glucuronidated bilirubin. Some rare mutations in human ABCC2 are associated with 
reduced expression o f  the protein in the canalicular membrane o f  hepatocytes (Paulusma 
et a l ,  1996); this results in Dubin-Johnson syndrome (DJS), an autosomal recessive 
disorder characterised by hyperbilirubinaemia (Dubin and Johnson, 1954). The same 
mutation in the Abcc2 gene o f  rats causes similar jaundice as a result o f defective organic
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ion transport and has led to the use o f  Abcc2 deficient rats as a model for human DJS (Ito 
et al., 1997).
1.2.2 The SLC Superfamily
The solute-carrier gene (SLC) superfamily is the largest group o f  membrane-bound 
transporters, encompassing 55 gene families encoding at least 362 putatively functional 
protein-coding genes (He et a l ,  2009). The gene products include passive transporters, 
symporters and antiporters, located in all cellular and organelle membranes, except, 
perhaps, the nuclear membrane. Endogenous transport substrates include amino acids and 
oligopeptides, glucose and other sugars, inorganic cations and anions, bile salts, 
carboxylate and other organic anions, acetyl coenzyme A, essential metals, biogenic 
amines, neurotransmitters, vitamins, fatty acids and lipids, nucleosides, ammonium, 
choline, thyroid hormone and urea (He et a l ,  2009). Whereas most transporters in the 
SLC superfamily are highly specific for their substrate, SLC 10, SLCO (SLC21) and 
SLC22 families have a broader substrate specificity and are involved in the uptake o f 
drugs into cells, most usually o f  tissues involved in the elimination o f  compounds via 
hepatocytes and kidney epithelia (Ozawa et al., 2004; Petzinger and Geyer, 2006).
1.2.2.1 The SLC10 Family
The solute earner family 10 (SLC 10) comprises seven members (He et al., 2009) o f 
which the two sodium-dependent bile acid transporters, the Na+/ taurocholate co­
transporting polypeptide (NTCP; SLC10A1) and the apical sodium-dependent bile acid 
transporter (ASBT; SLC10A2) are the most characterised (Geyer et al., 2006; Hagenbuch 
and Dawson, 2004). These transporters are essentially involved in the maintenance o f  the 
enterohepatic circulation o f bile acids mediating the first step o f  active bile acid transport 
through the membrane barriers in the liver (SLC10A1) and intestine (SLC10A2). 
SLC10A1 has also been shown to transport the HM G-CoA reductase inhibitor 
rosuvastatin into human hepatocytes (Ho et al., 2006) and the mushroom toxin alpha-
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amanitin into human cells expressing rat Slcl0a2 (Gundala et al., 2004), suggesting a role 
for this transporter in human liability to toxins. Experimental data supporting the 
sodium-dependent transport o f  bile acids by SLC10A3, 10A4, 10A5 and 10A7 is 
currently not available. However, they should not be assumed to be bile acid transporters, 
since SLC10A6, which shares 70% amino acid similarity to SLC10A2 has been proven to 
transport steroid sulphates in a sodium-dependent manner (Geyer et ah, 2006).
1.2.2.2 The SLCO/OATP Family
The family originally named the ‘SLC21 (organic-anion transporting) family’ has now 
been changed to six highly divergent SLCO families (SLCO l-6), comprising 11 
transmembrane-glycoproteins expressed in various epithelial cells (He et ah, 2009; 
Hediger et ah, 2004). Out o f  the 55 SLC families and barring SLC35, the SLC O l, 2 and 
4 families are the only ones to contain two or more subfamilies (He et al., 2009). The new 
naming system for this group o f  transporters requires that families are determined by a 
number, families are split into sub-families by a letter and individual members are 
designated a number e.g. SLCO IB 1 (Hagenbuch and Meier, 2003). Protein names are 
OATP (for organic anion transporting polypeptide) followed by the unique identifier e.g. 
OATP1B1. This system provides an increased capacity for naming o f  individual proteins, 
as many o f  the human SLCO’s have no orthologue in rodent (Hagenbuch and Meier,
2003), therefore each protein, irrespective o f  species, requires a different name. Figure 1- 
4 below, illustrates the separation o f  OATPs into different families based on amino acid 
identity.
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Figure 1-4 Phylogenetic Tree of the OATP Superfamily
OATPs/Oatps with more than 40% amino acid sequence identity are classified in the same family 
(OATP1, OATP2, OATP3, OATP4, OATP5 and OATP6). Members with more than 60% identity 
are classified in the same sub-family (e.g. OATP 1 A, OATP IB and OATP 1C). Human OATPs are 
represented with capital letters, all other species are indicated with a small letter preceding the 
protein symbol Oatp; b, bovine, c, chicken; m, mouse; r, rat, s, skate. Figure taken from 
(Hagenbuch and Gui, 2008).
All OATPs are predicted to have 12 transmembrane domains (Kullak-Ubliclc et al., 
1995), referred to herein as H I-H I 2. The OATP superfamily signature is a stretch o f 13 
amino acids, located at the extracellular border o f  H6, which are well conserved between 
human, rat and mouse OATPs/Oatps (M eier-Abt et al., 2005) and has been used to search 
protein databases for OATP/Oatp-related proteins (Hagenbuch and Meier, 2003). 
Another region o f  functionally important residues located extracellularly between regions
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H9 and H10 contains 11 conserved disulphide-bonded cysteine residues (Hanggi et al., 
2006). M utation o f  just one o f  these cysteine residues destroys transport function (Hanggi 
et al., 2006), indicating its central role in transporting amphipathic substances across the 
membrane. SLCOs do not utilise the sodium concentration gradient as do some members 
o f  the SLC10 family (Kullak-Ublick et al., 1995), but are possibly involved in anion 
exchange mechanisms (Satlin et al., 1997).
Based on crystal structure analysis o f  several OATPs, Meire-Abt et al., (2006) proposed 
that OATPs/Oatps function in a rocker-switch type o f mechanism, translocating the 
substrate through a central, positively charged pore (Meier-Abt et al., 2005). A 
comparison has been made to the glycerol-3-phosphate (G3P) transporter that transports 
G3P into the cell via an antiport mechanism that is energized by an inorganic phosphate 
(P i) gradient (Elvin et al., 1985; M eier-Abt et al., 2005). Briefly, binding o f  a substrate to 
the pore causes the protein to undergo gross conformational changes in which the N - and 
C-terminal domains participate in a rocker-switch type o f  movement that functions to 
translocate the bound substrate across the membrane (Law et al., 2007). The release o f  
the substrate to the cytoplasmic side o f  the membrane, thereby allows access o f  the 
binding site to the counter substrate, which is then translocated from the cytoplasm to the 
periplasm down a concentration gradient (Law et al., 2007). Glutathione has been 
suggested as the exchange partner for rat O a tp la l (Li et al., 1998), but it has been shown 
that human OATPs are unable to transport this conjugate (Mahagita et al., 2007), and 
thus the search for an exchange partner continues.
The substrates o f  SLCOs are fairly diverse and include organic anions and drags, 
prostaglandins, lipids and thyroid hormone (Hagenbuch and Meier, 2003), yet each 
family and member displays its own substrate specificity. Five o f  the six families are 
involved in the transport o f  organic anions: SLC O l, with four members is involved in 
anionic and cationic drag transport; SLC 03, with a single member transports as yet 
unidentified organic anions, and SLC05 and 6, both families having a single member are 
believed to be important in drag transport (He et al., 2009). SLC 02 contains two 
members; SLC02A 1, which is a known prostaglandin transporter, and SLC 02B1, which
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transports steroid sulphates a limited number o f  organic anions such as fexofenidine 
(Hagenbuch and Gui, 2008; Qiang et al., 2009). The two members o f  the SLC 04 family 
function to transport thyroid hormone (Hagenbuch and Gui, 2008; Hagenbuch and Meier, 
2004; He et al., 2009).
For the puipose o f  discussing drug uptake, five o f  the six families have been implicated, 
and o f  these, the SLCOl family has been best characterised. Despite their associations 
with drug transport, members o f  the SL C 03, SLC 05 and SLC 06 families are either 
expressed at low levels or in tissues other than the liver. For example, SLC03A1 
(SLC21A11), the only member o f  the SLC 03 family is ubiquitously expressed at low 
levels, and SLC05A1 (SLC21A15) and SLC06A1 (SLC21A19), the sole members o f  
SLC 05 and SL C 06 families are only expressed in the kidney and testes respectively 
(Hagenbuch and Meier, 2004). O f the SL C 02 family, SLC02B1 is the only member 
associated with drag absorption and is expressed in many tissues including the liver 
(Hagenbuch and Gui, 2008). For these reasons, the following section focuses on the 
SLC O l/O A TPl family o f drug transporters and the SLC02B1 family member.
1.2.2.2.1 The Human OATP1 and OATP2 Families
The OATP1 family is the largest family subdivided into the OATP1A, O ATP IB and 
OATP1C subfamilies (Figure 1-4) (Hagenbuch and Gui, 2008; He et al., 2009). 
OATP1C1 is mainly expressed in the testes and brain, where it functions to transport 
endogenous substrates (Hagenbuch and Gui, 2008). No exogenous substrates have been 
identified for this transporter, and so it is not given further consideration. OATP1A2 is a 
multispecific transporter expressed in several tissues including liver, kidney, brain and 
small intestine (Glaeser et al., 2007; Kullak-Ublick et al., 1995; Lee et al., 2005b). It has 
been demonstrated that OATP1A2 transports a wide range o f endogenous and exogenous 
amphipathic organic compounds including bile salts, hormones and their conjugates, 
cyclic and linear peptides, toxins, organic cations and numerous drags (Hagenbuch and 
Gui, 2008). Xenobiotics transported by OATP1A2 include fexofenadine (Cvetkovic et
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al., 1999), methotrexate (Badagnani et al., 2006), N-methylquinidine (Van M ontfoort et 
a l ,  1999), pitavastatin (Fujino et a l ,  2005) and rosuvastatin (Ho et al., 2006).
OATP1B1 and OATP1B3 are considered ‘liver specific’ transporters because in healthy 
humans they have only ever been detected at the sinusoidal membrane o f  hepatocytes 
(Abe et al., 1999; Konig et al., 2000). OATP1B1 has a broad substrate specificity and 
shares the endogenous substrates o f  OATP1A2 (Hagenbuch and Gui, 2008). Its wide 
range o f  xenobiotic substrates include antibiotics (Tamai et al., 2000), statins (Kopplow 
et al., 2005; Lau et al., 2007; Shitara et al., 2003a), ACE inhibitors (Liu et al., 2006; 
Nakagomi-ITagihara et al., 2006) and anticancer drags (Abe et a l ,  1999). Whereas 
OATP1B1 is expressed on sinusoidal membranes throughout the liver, OATP1B3 is 
highly expressed in the sinusoidal membranes surrounding the central vein (Konig et al.,
2000), but the physiological relevance o f this localisation is unknown. OATP1B3 is 
capable o f transporting all the substrates that OATP1B1 can, but also exhibits unique 
transport properties, such as the ability to transport digoxin (Hagenbuch and Meier,
2004). Due to the broad substrate specificities o f  both OATP1B1 and OATP1B3 and the 
fact that OATP1B3 has been found in various human cancer tissues such as pancreas, 
gallbladder, colon, lung and brain (Abe et a l ,  2001), much attention has been paid to 
these transporters for the study o f  potential drag-drag interactions and cancer treatment.
The OATP2B1 sub-family member is expressed in the sinusoidal membrane o f  
hepatocytes (Kullak-Ublick et al., 2001), as well as in the endothelial cells o f  capillaries, 
small arteries and veins o f  the heart (Grabe et al., 2006), at the luminal membrane o f  
brain endothelial cells (Bronger et a l ,  2005) and at the brash border membrane o f  the 
small intestine (Kobayashi et al., 2003). At pH 7.4, OATP2B1 has narrow substrate 
specificity, transporting mainly hormone sulphates (Hagenbuch and Gui, 2008) however, 
at acidic pH the substrate specificity is extended to include drags such as statins (Hirano 
et al., 2006; Ho et a l ,  2006; Kopplow et ah, 2005), fexofenidine (Nozawa et al., 2004) 
and glibenclamide (Satoh et al., 2005). Given its ubiquitous expression profile and ability 
to transport drugs in a pH-dependent manner, OATP2B1 could be involved in the 
absorption o f numerous orally administered xenobiotics.
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1.2.2.2.2 The Rat Oatpl and Oatp2 Families
Similar to the human proteins, the rat Oatps are expressed on the basolateral membrane 
o f  polarised cells and transport a distinct but overlapping group o f  substrates. Rodent 
Oatps are organised into the same six families as human OATPs (Figure 1-4) but the 
number and specificities o f  the transporters vary between species. For example, O atpl a 
sub-family is contains an additional four transport proteins (Figure 1-4) that have most 
likely arisen due to gene duplication events (Hagenbuch and Gui, 2008; Hagenbuch and 
Meier, 2004). W ithin this family, O atpl a l is similar to human OATP1A2 in that it is 
expressed in the liver and kidney o f  rats where it transports bile acids such as cholate and 
taurocholate (Jacquemin et al., 1994) and a range o f  dugs including enalapril (Liu et al., 
2006), fexofenidine (Dresser et al., 2002) and pravastatin (Hsiang et a l ,  1999). O atpla4 
is also expressed in the liver as well as the BBB (Noe et al., 1997) where it transports a 
similar range o f  substrates as O atpl a l including bile acids and fexofenadine (Dresser et 
al., 2002) but not pravastatin (Hsiang et al., 1999). Similarly, O atpla5 is expressed in the 
rat small intestine where it is involved with the uptake o f  fexofenadine (Kilcuchi et al.,
2006) and is also expressed brain and lung (Walters et al., 2000).
Rats only have one member o f  their OATP IB subfamily, O atplb2, which suggests that 
the human OATP1B genes were duplicated after divergence o f  the rodents from man 
(Hagenbuch and Gui, 2008). O atplb2 is expressed mainly in the liver where it transports 
bile acids (Donner et al., 2007), but is also found in ciliary body epithelium (Gao et al.,
2005) and at low levels in the placenta (St-Pierre et a l ,  2004). W hereas in humans 
OATP1B3 transports digoxin, in rats, digoxin is not a substrate o f  O atplb2 but is a 
substrate o f  O atpla4, which transports the cardiac glycoside into the rat brain (Noe et al., 
1997). Rats also possess one O atp lc  sub-family member called O a tp lc l (Hagenbuch and 
Gui, 2008) but no reports on its function have been made. Oatp2bl in rats appears to be 
the direct orthologue o f  human OATP2B1, since it is the only transporter within the 
Oatp2b subfamily (Hagenbuch and Gui, 2008), however, as with many Oatps, 
information is limited and no reports on pH  dependent transport are available.
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1.2.2.3 The SLC22/OCT Family
The SLC22 family have similar membrane topology to the SLCO and the ABC families, 
in that they have twelve putative transmembrane spanning a  helices, but their linker 
regions are specific to the family. For example, like in the SLCO family, there is an 
intracellular loop between transmembrane domains six and seven, but in the SLC22 
family, this region contains many phosphorylation sites, possibly involved in regulation 
(Ciarimboli, 2008). Another important area is the extracellular loop between the first and 
second transmembrane domains that contains many glycosylation sites that are well 
conserved in most mammalian orthologues and are involved in membrane localisation 
(Pelis et al., 2006a). A hypothetical tertiary structure proposed for one member (rabbit 
SLC22A1), is analogous to the structure o f  the G3P transporter in E.coli, which was the 
suggested model for the SLCO family (Zhang et a l ,  2005). This structure was further 
confirmed by Pelis et al., 2006 when hom ology modelling was carried out using human 
SLC22A2 (Pelis et al., 2006b). Thus, the SLC22 and SLCO family m ay share many 
similarities, their biggest differences being their substrate specificities and tissue 
locations.
M ost o f  the SLC22 family are polyspecific, meaning that they can transport a broad 
spectrum o f  molecular structures and dimensions (Ciarimboli, 2008). Family members 
are divided into groups based on the various substrates and transport mechanisms, with 
the gene name beginning with ‘SLC22’ and the proteins given alternative names, shown 
in brackets. The first group is composed o f  three organic cation transporters SLC22A1- 
SLC22A3 (OCT 1-3), which as their name suggests, transport organic cations and weak 
bases along electrochemical gradients, in either direction (ICoepsell and Endou, 2004). A 
second subgroup comprises o f  three transporters o f  carnitine and/or cations SLC22A4, 
SLC22A5 and SLC22A16 (OCTN1, OCTN2 and CT2), which act via uniport, anitport or 
co-transport mechanisms (ICoepsell and Endou, 2004). A third group is composed o f  four 
organic anion transporters SLC22A6 -  SLC22A8 and SLC22A11 (OAT1 - OAT4) and 
one urate transporter SLC22A12 (URAT1). Some members o f  this group, for example 
OAT1, can utilise a dicarboxylate gradient for an antiport exchange mechanism (Sekine 
et al., 1997). Within this family, there are also a number o f  structurally related proteins
18
whose transport substrates are unknown SLC22A9-10, SLC22A13-15 and SLC22A17- 
20) (Koepsell and Endou, 2004).
M any o f  the members mentioned above are predominantly involved in the uptake o f 
essential endogenous substrates, such as carnitine (OCTNs), urate (URAT1), choline, 
acetylcholine and monoamine neurotransmitters (OCT1, 2 & 3) (Busch et al., 1996; 
Koepsell, 2004). However some members are also capable o f  drug uptake, for example, 
the proteins OCT2 and 3, OAT1, 2 and 3 are expressed in the basolateral membrane o f  
kidney epithelia where they are involved in renal elimination o f  drugs into the urine 
(Koepsell and Endou, 2004). In the liver, OCT1 (SLC22A1), OCT3 and OAT2 are 
expressed in the basolateral membrane o f  hepatocytes and transport drags into cells for 
metabolism and/or biliary excretion (Koepsell and Endou, 2004). Some family members 
are expressed predominantly in these excretory organs, while others are expressed much 
more widely. OCT1 is predominantly found in liver o f  humans (Gorboulev et al., 1997; 
Zhang et al., 1997), but the small intestine, colon, liver and the kidney in rats 
(Grundemann et al., 1994); OCT2 is most strongly expressed in both hum an and rodent 
kidney (Motohashi et al., 2002; Sweet et al., 2006), whereas OCT3 is primarily expressed 
in placenta o f  rats (ICekuda et al., 1998), has also been more widely detected in various 
tissues, including brain and lung and liver o f  rats and humans (Grundemann et al., 1998; 
ICekuda et al., 1998). Members o f  the OAT sub-family are mainly expressed in the 
kidney, and at low levels in the liver in comparison to the OCT group (Hilgendorf et al.,
2007). For the purposes o f this work, only the hum an liver specific OCT1 family member 
and its rat orthologue have been discussed in further detail below.
1.2.2.3.1 OCT1/Oct1
OCT1 transports a number o f small, hydrophilic compounds across the plasma membrane 
along their concentration gradients, including a number o f  structurally diverse 
xenobiotics. For example, one substrate for human OCT1 is imatinib, a tyrosine kinase 
inhibitor used in the treatment o f  chronic m yeloid leukaemia (Wang et al., 2008). Levels 
o f  OCT1 prior to treatment have proven an important predictor o f  intracellular drag
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levels and hence clinical response to imatinib (W ang et al., 2008). The type II diabetes 
drug metformin is also transported into hepatocytes by OCT1 and efficacy o f  the 
treatment has been shown to vary based on polymorphic OCT1 expression (Becker et a l ,
2010). OCT1 is also involved in the absorption and elimination o f  the histamine H 2- 
receptor agonists rantitidne and famotidine and is likely to be a major determinant o f 
hepatic disposition (Bourdet et al., 2005). The rat and human orthologues share many o f 
the same substrates, for example the endogenous substrate tetraethylammonium (TEA) 
(Dresser et al., 2000; Uralcami et al., 1998) and the xenobiotic metformin (Wang et a l ,
2002). However, the human transporter has been shown to interact with 11- 
tetraalkylammonium (11TAA) compounds with a lower affinity than the rat ortholgue and 
is able to translocate larger nTAAs at comparatively greater rates (Dresser et al., 2000). It 
is thus reasonable to expect that kinetic and selectivity differences exist among the OCT1 
species homo logues in their interactions with drags and toxins.
1.2.3 Genetic Variation in Drug Transporters
The wide variability in the response o f  individuals to standard doses o f  drag therapy is an 
important problem in clinical practice, where it can lead to therapeutic failures or adverse 
drag reactions. Mutations in genes coding for metabolising enzymes and drag 
transporters can affect drag efficacy and toxicity, which is w hy the field o f  
pharmacogenetics aims to identify individuals predisposed to a high risk o f  toxicity and 
low response from standard doses o f  drags. The main transport proteins that have been 
studied with regards to polymorphisms are ABCB1, ABCC2 and OATP1B1, and these 
are considered in more detail below.
Over 100 mutations in the ABCB 1/Abcb 1 gene have been reported, including the most 
prevalent ‘silent’ C3435T mutation that reduces protein expression and results in 
increased plasma digoxin levels after oral administration (Cascorbi et al., 2001; Johne et 
al., 2002; M aeda and Sugiyama, 2008). A potential mechanism whereby this silent 
mutation could result in altered protein function, despite no change in amino acid 
sequence, was proposed by Kim chi-Sarfaty et al., (2007): In this report, it was
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demonstrated that C3435T alters ABCB1 function by usage o f  a rare codon that causes 
translation to pause, allowing the protein to fold into a slightly different conformation, 
thus reducing its substrate affinity (Kimchi-Sarfaty et al., 2007). Regardless o f this 
finding, much conflicting data exists suggesting that the C3435T mutation does not alter 
drag pharmacokinetics (Drescher et al., 2002; Tada et al., 2005). One likely explanation 
for this inconsistency is that the previously overlooked non-synonymous G2677T 
mutation, which is in strong linkage disequilibrium with the C3435T mutation and causes 
a change in transporter activity, is responsible for the positive results o f other studies (Yi 
et al., 2004).
In addition to mutations that lead to decreased protein function, there are mutations such 
as G1199T polymorphism that causes translated ABCB1 to increase drag efflux and 
cause sub-therapeutic concentrations in the target tissue (Green et al., 2008; W oodahl et 
al., 2009). However, despite the prevalence o f A B C B l/A bcbl polymorphisms that have 
the potential to alter drag bioavailability, their influence is minimal in comparison to the 
inter-individual variability o f  expression in the GI tract (Gillet et al., 2007) suggesting 
that other mechanisms such as chemically-activated transcription, are at least as 
important in determining final ABCB1 expression levels. Genes that inherently 
demonstrate such large non-genomic based inter-individual variability in expression are 
therefore inappropriate candidates for individualised drag therapy based on genotype, as 
has been suggested for A B CB1 and some drag metabolising enzymes (DMEs) (Gillet et 
al., 2007; Kirchheiner et al., 2005).
In ABCC2, the most common polymorphism is G1249A (Val471Ile), which occurs in 24, 
14 and 13% o f  the Caucasian, African American and Asian populations respectively 
(Kerb, 2006). This polymorphism however is not associated with any change in the 
pharmacokinetics o f  various drags tested in vitro (Hirouchi et al., 2004), suggesting that 
it has minimal functional importance. M ost o f  the other common polymorphisms detected 
in Japanese populations result in synonymous changes that also have no effect on protein 
activity (Hirouchi et al., 2004). In contrast to the lack o f common nonsynonymous 
polymorphisms, there is an abundance o f  rare amino acid-changing mutations within the 
ABCC2 gene (Suzuki and Sugiyama, 2002); some o f  which have been demonstrated to
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affect the transport function in vitro (Keitel et al., 2003). A multitude o f  point mutations 
in the ABCC2 gene are also the cause o f  Dubin-Johnson syndrome in vivo (Corpechot et 
al., 2006; Dubin and Johnson, 1954). However, as the frequency o f  these mutations is 
generally less than 1 %, then the need to consider them  when predicting response to drag 
therapy is probably limited (Kerb, 2006).
Currently, over 40 variants o f  OATP1B1 have been detected, with A388G (A snl30A sp; 
O A T P lB l* lb ) and T521C (Vall74Ala) occurring most frequently in several populations 
(Maeda and Sugiyama, 2008). The allele frequency o f  A388G is 64, 74 and 40% in 
Asians, African Americans and Caucasians, respectively, while that o f  T521C is 16, 1 
and 14% (Konig et al., 2006). Tight linkage between A388G and T521C in the Japanese 
population has been shown to result in the 0A TP1B1*15 haplotype, associated with 
lower pravastatin uptake compared to the already reduced uptake rates seen exhibited by 
O A T P lB l* lb  alone (Nishizato et al., 2003). Recently, the clearance o f  torasemide, 
which is metabolized extensively by CYP2C9, was reported to be affected by genetic 
polymorphisms o f  both CYP2C9 and OATP1B1 (Vormfelde et al., 2008). The 
CYP2C9*3 allele, whose metabolic clearance is known to be greatly reduced, caused a 
decrease in the hepatic elimination o f  torasemide, whereas T521C mutation in OATP1B1 
decreased and O A T P lB l* lb  allele increased its hepatic clearance (Vormfelde et al.,
2008). Further investigation is required to determine how the O A T P lB l* lb  allele is 
responsible for increased hepatic uptake o f  torasemide and reduced uptake o f  pravastatin 
compared to the wild-type allele. Taken together, such data is suggestive that genetic 
variability in OATP1B1 may have the potential to impact on drag disposition.
In summary, it can be seen that for a number o f important drag transporters there exist a 
number o f  genetic variants that can alter drug pharmacokinetics. However, the current 
opinion is that the impact o f  genetic variability in transporter function on clinical 
outcome in terms o f  drag efficacy is negligible compared to the large inter-individual 
variability in expression that arises from other sources such as chemically-mediated 
transcriptional events (Kerb, 2006). However, genetic variance in transporter genes may 
have the most impact in determining individual susceptibility to toxic injury under
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circumstances where either the drug has a low therapeutic index, such as digoxin, or 
where the dose is close to its maximum tolerated limit, as in chemotherapy. Under these 
circumstances, even a moderate reduction in clearance capacity due to the expression o f  a 
polymorphic gene could result in toxicity.
1.2.4 Summary
In summary, the ABC and SLC transporter superfamilies are made up o f  proteins with 
specialised functions to transport polar substrates across lipid membranes in a vectorial 
manner. W ithin these superfamiles, a number o f  proteins may be designated as ‘drug’ 
transporters due to their ability to transport a diverse range o f  substrates, which are often 
structurally similar to endogenous molecules. Drug transporters are generally expressed 
at high levels in absorptive, excretory and barrier tissues such as intestine, liver, kidney, 
and the BBB and are therefore recognised as important determinants o f  drug disposition. 
Efflux transporters in particular m ay limit drug bioavailability, but also protect against 
the action toxic metabolites and prevent CNS side effects by limiting access to the brain. 
Uptake transporters may limit access o f  those compounds which are not substrates, but 
their specificities can be utilised to reduce ‘off-target’ effects and to increase drag 
concentrations in target tissues expressing the specific uptake transporter to which a drug 
is tailored. Altered levels o f  drag transporters in diseased or cancerous tissues may lead 
to altered drug pharmacokinetics and pharmacodynamics and can manifest in a drug- 
resistant phenotype, whilst genetic variability is likely to have a lesser impact on drug 
pharmacokinetics. Due to the importance o f  drug transporters in setting compound 
disposition, and hence potential response to therapeutic intervention, it is thus important 
to develop appropriate test systems for assessment o f  chemical liability to transporter 
function. Such systems must also be sufficiently robust to allow accurate extrapolation to 
the in vivo situation, aiding in the prediction o f  drug response in vivo.
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1.3 The Role of Transporters in Absorption, Distribution, 
Metabolism and Excretion (ADME)
Oral dosing is the preferred route o f  drug administration if  systemic distribution is 
required, since it is both convenient and cost-effective. For a drug to reach systemic 
circulation and distribute to its site o f  action, it must first be absorbed from the gut lumen 
by traversing the apical membranes o f  the epithelial cells lining the small and large 
intestines (Figure 1-5). It must also survive first-pass metabolic effects in the enterocytes 
and liver. Once within the systemic circulation, in order to achieve further distribution 
into tissues around the body, a compound also needs to cross the membranes o f  many 
different cell types, by passive diffusion or active uptake. Working against the absorption 
and distribution o f  a drug, are the processes o f  metabolism and excretion, which aim to 
remove such xenobiotics from the body (Gibson and Slcett, 2001). System ADME 
characteristics are determined early on in the drag development process to help determine 
likely efficacy and toxicity o f  a compound (Eddershaw et al., 2000). Each o f these 
processes are described below, with a particular focus on the role o f  membrane 
transporters, since the disposition and ultimately the efficacy o f a compound is highly 
dependent on its ability to cross biological membranes (Ayrton and Morgan, 2001; Plant,
2003).
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Figure 1-5 The Selective Barrier of the Intestinal Epithelium
The intestinal epithelium forms a selective barrier against the entry of orally administered 
compounds into blood. (A) Absorption of compounds via the paracellular route is restricted by 
intercellular tight junctions. (B) Carrier-mediated mechanisms at the apical and/or basolateral 
membranes facilitate the transcellular absorption of certain compounds. (C) Efflux transporters at 
the apical membrane may actively drive compounds back into the intestinal lumen thus restricting 
their absorption into blood. (D) Apical efflux transporters may also facilitate the intestinal 
clearance of compounds that are already present in blood. (E) Intracellular metabolising enzymes 
may modify compounds before they enter the blood. (F) Apical efflux transporters and 
intracellular metabolising enzymes may co-ordinately metabolise and excrete compounds, 
forming an effective barrier against intestinal absoiption. Figure taken from (Chan et al., 2004b).
1.3.1 Absorption
For the process o f  absorption to take place, a compound must cross at least one cell 
membrane, and the ease with which is does so will reflect the concentration o f  drug 
achieved in the cells, tissues or body fluids. Some drugs are absorbed from the gut lumen 
by moving between epithelial cells, a process known as paracellular transport (Rang et 
al., 1999), but this form o f  transport is minimal, and limited, due to the presence o f  tight 
junctions between cells (Figure 1-2). Drug permeation mainly occurs by transcellular 
absorption, whereby a drug crosses the apical membrane from the intestinal lumen and is 
transported across the cytosol to exit the cell across the basolateral membrane into the
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bloodstream. Historically, the route o f  drug uptake has been considered to occur by 
passive diffusion through the lipid bilayer, and drugs have been designed and selected on 
the basis o f  such desirable physicochemical properties.
For an estimation o f  passive diffusion across membranes, a log P-value can be derived 
from the distribution o f  drugs between the lipophilic solvent n-octanol and the 
hydrophilic solvent water (Tetko and Braneau 2004). Log-P only describes partitioning 
o f  the neutral form o f  the drag, but if  the molecule contains basic or acidic groups it can 
be ionised meaning that its distribution in rc-octano 1/water becomes pH dependent (Tetko 
and Braneau 2004). The pH dependent distribution coefficient, known as log-D, is an 
important parameter when predicting absorption and distribution. Lipinski’s ‘rule o f  5 ’ 
encompasses four parameters globally associated with solubility and permeability; 
namely molecular weight, log-P, number o f  H-bond acceptors and number o f  H-bond 
donors, and is commonly used to predict lead candidate drug suitability (Lipinski et a l,
2001).
However, there is now increasing evidence that drag uptake is significantly mediated by 
transport proteins embedded in the plasm a membrane (Ayrton and Morgan, 2008; 
Dobson and Kell, 2008; Dobson et al., 2009). It has been suggested that the types o f  
biophysical forces involved in the interaction o f  drags with lipid membranes as defined 
by Lipinslci, in particular the capacity to make or break hydrogen bonds, are no different 
from those involved in their interaction with the active sites o f  proteins, which are 
themselves hydrophobic environments (Dobson and Kell, 2008). Thus, arguments based 
on lipophilicity could also be applied to drag uptake by membrane transporters or 
carriers, which rebuts the assertion o f  Lipinslci et al., that “the ‘rale o f  5 ’ is inadequate to 
predict absorption and permeation o f  compounds that are substrates for biological 
transporters” (Lipinslci et al., 2001). Therefore, contrary to excluding active transport it is 
likely that Lipinski’s rales encompass passive diffusion and transporter mediated 
processes. Given the number o f  compounds that are substrates for transport proteins, and 
that concentrations o f  these compounds within cells often exceed the stoichiometry o f  
internal binding sites, it has been suggested that active uptake by transport proteins are 
the rale rather than the exception (Dobson and Kell, 2008).
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Targeting drugs to specific membrane carriers can impact both the pharmacokinetic and 
pharmacodynamic properties o f  the compound and could be a disadvantage particularly 
where concentrations reach levels where transport process become saturated (Riviere, 
1999). However, it has been proven that targeting drags and pro-drags to absorptive 
membrane carriers tends to positively influence bioavailability and distribution o f  these 
substrates, which can be therapeutically advantageous (Bretschneider et al., 1999). The 
tissue specific expression o f  uptake transporters has also been utilised to increase the 
efficacy o f  drags and to reduce off-target effects, as has been shown in the example 
pravastatin, in the treatment o f  hypercholesterolaemia; pravastatin is taken up by 
OATP IB 1, an uptake carrier specific to the liver, which is the major site o f  cholesterol 
synthesis (Nakai et al., 2001). This recent recognition and acknowledgment o f  the 
magnitude o f  transporter involvement in drug absorption must therefore be taken into 
account for any estimations o f drag disposition.
1.3.2 Distribution
Following access to systemic circulation, compounds are distributed around the body by 
the blood to reach their sites o f  therapeutic action. Tissue distribution however, is not 
equal for several reasons. First, drags are distributed preferentially to some tissues such 
as the brain, liver and kidney is because they have a high perfusion rate whereas tissues 
such as skin and fat have low perfusion rates and therefore receive a lower proportion o f 
the dose (Troy, 2005). Second, distribution also depends on the physicochemical 
properties o f  the compound; water soluble drags such as the antihypertensive atenolol 
may stay in the blood or interstitial fluid for longer than lipid soluble drugs like the 
anaesthetic halo thane, that concentrate in fatty tissues (Gengo et a l, 1989; Holaday, 
1977). Third, some drugs leave the bloodstream  very slowly, because they bind tightly to 
proteins such as albumin circulating in the blood. The protein-bound part is generally 
inactive as it cannot cross membranes, however, as unbound drug is distributed to tissues 
and its level in the bloodstream decreases, blood proteins gradually release the drag
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bound to them  (Troy, 2005). Thus, the bound drug in the bloodstream may act as a 
reservoir for the drug.
Once within the tissue vasculature, distribution into the cells o f  a tissue depends upon the 
mechanisms by which the compound crosses the selectively permeable membrane. As 
discussed above, some compounds can passively diffuse into cells but for many, specific 
carriers play a role. Tissue specific expression and relative abundance o f  such 
transporters can thus determine the extent o f  uptake into tissues. The extent to which a 
drug accumulates within a tissue is frequently limited not so much by its ability to enter 
cells but by its tendency to leave. For example, ABCB1 is expressed highly in the liver, 
kidney intestine and brain plays an important role in the extrusion o f  drags from these 
organs, therefore limiting drag access into these areas (Chan et al., 2004b; Schinkel, 
1999; Suzuki and Sugiyama, 2000). The blood brain barrier (BBB) presents a particular 
problem for the distribution o f  drugs since endothelial cells joined by tight junctions, 
limiting the capacity for entry by paracellular diffusion. Although the cells o f  the BBB 
express an array o f  uptake transporters, efflux transporters such as ABCB1 are highly 
expressed and limit drug accumulation (Urquhart and Kim, 2009). Thus, tissue 
distribution is dependent not only on blood flow rates and protein binding, but the rates o f 
active uptake and extrusion from the cells.
1.3.3 Metabolism
Drug metabolism is the process that converts drags that have been designed to be non­
polar into more polar molecules that can be excreted in the in the urine via the kidneys, or 
the faeces via the liver. M etabolism can be split into two components consisting o f phase 
I and phase II reactions. Phase I reactions involve the oxidation, reduction or hydrolysis 
o f  the drag to unmask or introduce a more reactive functional group such as a hydroxyl 
group (Gibson and Skett, 2001). The products o f  phase I reactions often become 
substrates for phase II enzymes, which conjugate the functional group to a larger, more 
polar molecule to increase water solubility and allow excretion to occur (Gibson and
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Skett, 2001). Alternatively, phase II metabolism can proceed directly if  the parent 
compound is already in possession o f  a suitable functional group.
Cytochrome P450 (CYP) enzymes are the major phase I metabolising enzymes 
converting parent drugs into oxidised metabolites. CY P’s are found in high 
concentrations in the endoplasmic reticulum o f  hepatocytes as well as gut and kidney 
epithelial cells (Nelson et al., 1996). The CYP3A subfamily is considered the major 
phase I group o f  DM Es in humans (Watkins, 1994), comprising 30% o f  total human 
hepatic CYP content (Shimada et al., 1994) and approximately 70% o f  the CYP content 
in human enterocytes (Kolars et al., 1992). CYP3A4 is the major member o f  the CYP3A 
family and metabolises approximately 50 % o f  drugs (Cholerton et al., 1992). The 
CYP2C subfamily also contributes considerably to human metabolism with CYP2C9, 
2C8 and 2C19 making up 20% o f the total CYP content (Shimada et al., 1994), and 
CYP2B6 and 2D6 metabolising up to 25% and 30% o f  all drugs respectively (Shimada et 
al., 1994; Wang et al., 2003; Zuber et al., 2002).
The major phase II reactions involve conjugations to glucuronide, sulphate or glutathione 
moieties and are carried out by UDP-glucuronosyltransferases (UGTs), 
sulphotransferases (SULTs) and glutathione S-transferases (GSTs), respectively (Plant,
2003). Glucuronidation and sulphation reactions are referred to as type I or ‘high energy’ 
reactions as the conjugated molecule contains the reactive energy and will react with 
relatively unreactive groups. Glutathione, itself being un-reactive tends to be conjugated 
to molecules w ith high chemical reactivity; this conjugation is therefore known as a type 
II or ‘low energy’ phase II reaction and usually detoxifies highly reactive chemical 
species that could, for example, easily damage cells by reacting with DNA (Gibson and 
Skett, 2001).
Some orally administered drugs undergo phase I and II metabolism in intestinal 
enterocytes (Figure 1-2), which can limit the bio availability o f these drugs (W acher et al., 
2001). Other drugs escape the gut in their original form and circulate to the liver via the 
hepatic portal vein where they are metabolised. Since the liver and GI tract are the major
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sites o f  drag metabolism, the concentration o f  drag can be considerably reduced before it 
even reaches the systemic circulation, in the process termed ‘first pass metabolism’ 
(Gibson and Skett, 2001). Although metabolism has long been recognised as a major 
determinant o f  drug bioavailability, the involvement o f  transporters, particularly ABCB1 
is now being acknowledged. While transporters themselves are not directly involved in 
xenobiotic metabolism, transport activity is inextricably linked to expression levels o f  
DMEs. For example, CYP3A4 and ABCB1 are induced by many o f  the same compounds 
and have a broad substrate overlap in substrate and inhibitor specificities (W acher et al.,
2001). Thus, together DM Es and carrier proteins act as a concerted barrier to drag 
absorption.
1.3.4 Excretion
The compounds produced by phase I and II metabolic processes are expelled from the 
body via two main routes; biliary and urinary excretion. Active transport is essential for 
both processes as metabolites are hydrophilic in nature, reducing their tendency for 
passive diffusion across the canalicular membranes o f  the hepatocytes and the renal 
tubular membranes o f the kidney. Small, water soluble drags tend to be excreted via the 
kidney, whereas larger, more polar molecules are predominantly excreted by the liver 
(Rang et al., 1999). Generally, the contribution o f  saliva, sweat, breast milk and lungs to 
excretion is small and so the focus remains on biliary and urinary excretion with regard to 
the transport proteins involved in these processes.
1.3.4.1 Biliary Excretion
Clearance and excretion o f  many drags occurs in the liver as a three step process: Firstly 
drugs must enter the hepatocyte across the sinusoidal membrane by passive diffusion or 
active uptake. Secondly, drags undergo varying degrees o f  biotransformation depending 
on then  physicochemical properties and chemical structure. Third, excretion o f  wholly 
unchanged drugs and/or a variety o f  drag metabolites into the bile at the canalicular
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membrane occurs. Active transport is the most efficient means o f  excretion from the 
canalicular membrane since it has a smaller surface area than the sinusoidal membrane 
and compounds must traverse a steep concentration gradient o f 100-1000-fold (Ayrton 
and M organ 2001).
Bile acids, which are produced in the liver by the catabolism o f  cholesterol, drain into 
bile ducts along with effluxed compounds, where they either enter the duodenum directly 
or are stored temporarily in the gall bladder prior to release (Rang et al., 1999). Once in 
the intestine, compounds may be excreted into faeces or may be metabolised back to 
lipophilic molecules by gut micro flora resulting in their reabsorption into the systemic 
circulation. This process o f  solute reabsorption, termed enterohepatic recirculation is 
essential for the reabsorption o f dietary cholesterol and vitamins can significantly prolong 
drug action (Redinger, 2003; Roberts et al., 2002).
1.3.4.1 Urinary Excretion
In the kidney, drug clearance is determined by glomerular filtration, tubular secretion and 
reabsorption (Dresser et al., 2001). Transporters do not have a role in the passive ultra 
filtration process occurring with the glomerulus, which allows the passage o f  molecules 
up to 20 kDa in mass, but are involved in both secretory and reabsorptive processes that 
occur within the tubule o f the nephron (Koepsell and Endou, 2004; Shitara et al., 2006). 
Since the glomerulus limits the size o f  the molecules to be cleared, large drugs o f  those 
bound by plasma proteins cannot be excreted in this way and are either excreted by the 
liver or excreted by the kidneys once un-bound. The majority o f drugs however, do not 
enter the kidney via the glomerulus but do so by active tubular secretion, which involves 
carrier proteins for both basic and acidic drugs and endogenous compounds (Dantzler and 
W right, 1997). Transport proteins are also involved in reabsorption although many drugs 
are reabsorbed by passive diffusion dependent on a high concentration gradient across the 
blood and nephron caused by the reabsorption o f  water (Shitara et al., 2006). The renal 
clearance rate o f  a drug can therefore depend heavily on the balance between active 
secretion and reabsorption rates.
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1.4 Expression and Regulation of ADME Genes and Proteins
As the ‘gatekeepers’ for all cells, membrane transporter expression needs to be tightly 
regulated to control the flux o f  crucial endogenous substrates such as sugars, amino acids 
and inorganic ions into and out o f  the cells. Since many o f  these transporters also 
transport drugs, expression levels o f  these proteins critically influence the absorption, 
distribution, metabolism and elimination o f  drugs in the body. Key players involved in 
the regulation o f  transporters include hormones, protein kinases, nuclear receptors, 
scaffold proteins, and disease conditions (You, 2008). Regulation may be via endogenous 
or exogenous factors and act to alter transport expression at various levels such as 
transcription, mRNA stability, translation and posttranslational m odification (Figure 1-6). 
Transcriptional control, regulating w hen and how often a gene encoding a given 
transporter is transcribed is mediated by transcription factors binding to TATA box, or in 
the case o f  many drug-related transporters including ABCB1, to an initiator element (Inr) 
in the prom oter region (Scotto, 2003).
mRNA stability is dictated by interactions between structural components within an 
mRNA molecule and specific trans-acting factors. These components include the 5 ’-cap 
structure, 5 ’-untranslated region (UTR), the protein coding region, 3 ’-UTR and the 3 ’- 
polyadenylate [poly (A)] tail (Guhaniyogi and Brewer, 2001). For example, the Poly (A) 
tail is often found tightly bound to the poly (A)-binding protein (PABP), an interaction 
which protect the mRNAs from rapid decay in the cytoplasm (Ross, 1995). Premature 
termination codons (PTCs) within the coding region are often targeted by the nonsense- 
mediated decay (NMD) pathway, thus reducing mRNA half-life (Guhaniyogi and 
Brewer, 2001). It has been suggested that for ABCC4, the cellular environment regulates 
alternative splicing pathways that lead to the inclusion o f  PTCs within the transcript, 
providing a post-transcriptional checkpoint for regulating ABCC4 expression (Lamba et 
a l ,  2003). MicroRNAs (miRNAs) represent a large class o f  gene regulatory molecules 
that typically mediate gene regulation by forming imperfect hybrids with the 3 ’UTR 
sequences o f  target mRNAs, inducing translational repression and/or mRNA degradation 
(Doench and Sharp, 2004). It has been demonstrated that an endogenous miRNA (hsa- 
miR-519c) binds to the 3 ’UTR o f  the ABCG2 mRNA thereby reducing m RNA and
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protein levels (To et al., 2008). In cells with a multi-drug resistance phenotype however, 
the 3 ’UTR is truncated and no longer contains the miRNA binding site; thus escape from 
miRNA mediated translational control could lead to ABCG2 over-expression in drug- 
resistant cancer (To et al., 2008).
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Figure 1-6 Factors influencing the expression o f drug transporters.
The activity of drug transporters may be regulated at various levels including transcription, 
mRNA stability, translation, and posttranslational modification. Transcriptional regulation is of 
particular interest, because many extra- and intracellular signals eventually alter the activity of 
transcription factors. In addition to the regulation of various signals, the tissue-specific expression 
of drug transporters is also under transcriptional control. Moreover, posttranslational modification 
may involve glycosylation, phosphorylation, and protein-protein interaction. Figure taken from 
(Terada and Inui, 2007).
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Translational control mechanisms also play an important role in determining final active 
protein levels (Van Der Kelen et al., 2009). A large number o f accessory factors that 
assist the ribosome during initiation, elongation, and termination o f translation are 
required for protein synthesis. 5’-cap-dependent translational control is the main 
regulatory step, occurring mainly during the initiation stage involving eukaryotic 
initiation factors (elFs) and accessory proteins, although cap-independent mechanisms 
also exist (Van Der Kelen et al., 2009). Post-translational modifications such as 
glycosylation, phosphorylation and protein-protein interactions are also important 
determinants o f protein activity and tum-over rates. Fundamental properties o f 
membrane-inserted proteins such as folding, stability, localisation and ligand binding 
have been shown to be affected N-glycosylation (Tanaka et al., 2004), while protein 
phosphorylation status has been associated with stability and activity (Tawfic et a l,
1995). Modification of ABCC2 by attachment o f small ubiquitin-like modifier (SUMO) 
proteins is an example of how protein-protein interactions can increase protein stability 
and regulate expression profiles. SUMOylation o f ABCC2 has been found to be essential 
for protein expression at the canalicular membrane; inhibition o f which results in a 70% 
reduction o f protein expression after 32 hours (Minami et al., 2009). Finally, in the case 
o f transporters, protein at the membrane can also be controlled by the dynamic endocytic 
retrieval and exocytic insertion o f transporters between the canalicular membrane and an 
intracellular pool of storage vesicles (Gerk and Vore, 2002; Kipp et al., 2001).
1.4.1 Nuclear Receptors
The expression o f transporters can also be induced by their own substrates (auto 
induction), including drugs, as they can act as ligands for members o f the nuclear 
receptor (NR) superfamily o f ligand activated transcription factors. These same 
transcription factors are also involved in the regulation of genes involved in drug 
metabolism, allowing a coordinate response to xenobiotics at a transcriptional level, 
ensuring drugs are cleared from cells effectively, which minimises the risk o f toxicity 
(Gibson and Skett, 2001). Induction o f ADME genes, whether it be auto induction or by a
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co-admmistered compound, may result in a drug being cleared too quickly from the body 
causing reduced efficacy; alternatively toxicity o f the compound (or co-administered 
compound) may be increased due to the more rapid production o f toxic metabolites.
Transcriptional regulation occurs via one o f two general pathways, depending on the 
physicochemical properties o f the activator. Hydrophilic ligands tend to bind to receptors 
on the cell surface, triggering an internal signalling cascade o f secondary messengers that 
results in the ultimate activation o f transcription factors (Alberts et al., 2008). 
Hydrophobic ligands or those that are substrates for membrane transporters enter cells 
and bind directly to intracellular NRs, which then act as transcription factors and alter 
gene expression of target genes (Mangelsdorf et a l, 1995). NRs can modulate 
transcription through several distinct mechanisms, which include both activation and 
repression activities. The superfamily o f ligand-activated transcription factors is 
composed o f 48 members in humans, each member having crucial and non-redundant 
roles, notably in the regulation o f many biologically important processes in growth, 
development, and homeostasis (Germain et a l, 2006).
Members o f the nuclear receptor family o f  transcription factors share a common 
structural organisation (Bain et al., 2007) (Figure 1-7). The N-terminal region (A/B 
domain) is highly variable, and contains several transactivation domains; A/B domains 
are variable in amino acid length and their 3-D structure is not yet known. The largest 
domain is the moderately conserved ligand-binding domain (LBD, E domain), whose 
secondary structure o f 12 a-helixes is better conserved than the primary sequence 
(Robinson-Rechavi et al., 2003). Shared amino acid identity between humans and rats for 
example is 75.9% (Jones et al., 2000). The LBD also contains the region that interacts 
with co-activator and co-repressor proteins to initiate transcription (Glass et al., 1997). 
Between the DNA-binding and ligand binding domains is a less conserved region (D 
domain) that behaves as a flexible hinge between the C and E domains, and contains the 
nuclear NLS, which may overlap on the C domain (Robinson-Rechavi et al., 2003). The 
most conserved region is the DNA binding domain (DBD, C domain), with 94% amino 
acid identity between humans and rabbits and 95.5% between humans, rats and mice
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(Jones et al., 2000). The DBD notably contains the P-box, a short motif responsible for 
DNA-binding specificity on sequences typically containing the AGGTCA motif, and is 
involved in dimerisation of nuclear receptors (Nelson et al., 1994; Robinson-Rechavi et 
al., 2003).
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Figure 1-7 Structural Domains of the Nuclear Receptor Super-family
A. Nuclear receptors are made up of five domains consisting of a DNA binding domain (DBD) 
(C) and a ligand-binding domain (LBD) (E), which are separated by a flexible hinge region (D), 
as well as an N- terminal (A/B), and C- terminal (F) domain. B-D, schematic representations of 
the crystal structure of a nuclear receptor showing the coactivator binding site (B) and the 
conformational changes that occur upon ligand binding. In B, alpha helix 12 (highlighted in black 
in C) is bound to the coactivator binding site but is omitted for clarity. C and D show 
conformational changes that occur when binding to different ligands (figure taken from (Koide et 
al., 2002).
Nuclear receptors form homo- or heterodimers in order to bind to DNA and increase 
transcription o f their target genes. The most common binding partner is the retinoid-X 
receptor alpha (RXRa) (Mangelsdorf et al., 1995), which acts as a binding partner to 
nuclear receptors involved in several pathways such as fatty acid metabolism, by binding 
with the peroxisome proliferator-activated receptor (PPAR) (Schoonjans et a l, 1996);
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bile acid homeostasis by dimerising with the farsenoid-X receptor (FXR) (Parks et al.,
1999); and xenobiotic detoxification by forming heterodimers with the PXR (Willson and 
Kliewer, 2002) and the constitutive androstane receptor (CAR) (Honkakoski et a l , 1998). 
The roles o f the PXR, CAR and the glucocorticoid receptor (GR) in relation to ADME 
gene regulation as discussed in more detail below, as these have particular relevance to 
this research.
1.4.2 The Pregnane X Receptor
The pregnane-X receptor (PXR; NR1I2), belonging to the sub-group of orphan nuclear 
receptors is capable o f binding endogenous substances such as pregnanes and 
progesterone but with relatively low (pM) affinities (Kliewer et al., 1998). The search for 
a high affinity endogenous ligand continues, despite the ability o f PXR to bind a number 
of chemically diverse xenobiotics including the antibiotic rifampicin (Bertilsson et al., 
1998), the synthetic steroid dexamethasone (Pascussi et a l, 2001), the active component 
of St John’s Wort, hyperforin (Moore et al., 2000), and the anti-androgen cyproterone 
acetate (CPA) (Lehmann et al., 1998). Due to variability in LBD amino acid identities 
between species, as discussed above, species differences exist in the types o f  ligands that 
activate PXR. For example, rifampicin is a potent inducer o f human PXR but has no 
effect in rodents (Lehmann et al., 1998), whereas pregnenolone-16 a-carbonitrile (PCN) 
and CPA activate rodent PXR but have minimal effects in man (Blumberg et al., 1998; 
Jones et al., 2000).
PXR is a key transcriptional regulator o f many drug DMEs and drug transporters and 
therefore has a central role in regulating genes involved in ADME. Human CYP3A4 and 
rodent Cyp3a are induced by activators of PXR, which are also commonly substrates of 
the enzymes (Blumberg et al., 1998; Lehmann et al., 1998). Upon agonist binding, PXR 
heterodimerises to the RXR (NR2B1) and binds to distinct motifs within the promoter 
area of CYP3A4 (Goodwin et al., 1999), which mediates the transcriptional induction o f 
CYP3 A4 by activators of human PXR. A diverse range o f anticancer agents, including 
paclitaxel, docetaxel, flutamide, ifosfamide, cyclophosphamide, erlotinib and tamoxifen
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have all demonstrated PXR-mediated CYP3A4 induction (Harmsen et al., 2009). This 
finding could help to explain dose non-responsiveness during chemotherapy, since many 
of the agents auto-induce their own clearance. Other phase I enzymes under the control of 
PXR include CYP2C9, which is induced by xenobiotics including rifampicin, 
Phenobarbital and hyperforin (Chen et al., 2004) and CYP2B6, which is induced by 
hyperforin and rifampicin treatment and is mediated by binding o f  PXR to the 
phenobarbital-responsive enhancer module (PBREM) region o f the CYP2B6 gene 
(Goodwin et al., 2001; Mo et al., 2009). Induction o f these enzymes could help to explain 
some clinical drug interactions observed (Mo et al., 2009).
Phase II enzymes such as the UDP-glucuronosyl transferase and sulphotransferase enzymes 
are also included in the list PXR target genes. For example, dexamethasone at 
submicro molar concentrations enhances the PXR activator-mediated expression o f the 
UGT1A1 gene and protein in the human derived HepG2 (Sugatani et a l, 2005), whereas 
methotrexate acts via PXR and CAR to repress and induce SULT1A1 expression 
respectively (Chen et al., 2006). Drug transport processes, sometimes referred to as phase 
III metabolism are also regulated by PXR by the induction o f target genes in response to 
ligand binding.
Dexamethasone, has been shown to induce Abcbl and Abcc2 expression in the liver and 
kidney o f rodents (Demeule et al., 1999a) while rifampicin, the prototypical human PXR 
activator, has been shown to induce ABCB1 and ABCC2 expression in human 
hepatocytes (Nishimura et al., 2006; Synold et al., 2001). Most o f the work earned out on 
elucidating regulation o f rodent Oatps has concentrated on Oatpla4, which is regulated 
by PXR both in rats and mice (Cheng and Klaassen, 2006; Cheng et al., 2005b; Guo et 
al., 2002; Staudinger et al., 2003).
In humans, the relationship between OATPs and PXR has focussed mainly on the role o f 
uptake transporters in modulating the concentration o f PXR ligands, and thus the degree 
o f PXR activation achieved (Tirana et al., 2003). The liver-enriched OATP1B subfamily 
members OATP1B1 and OATP1B3 have been identified as particularly important for
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transporting ligands for both PXR and CAR (Schwabedissen and Kim, 2009). However, 
many PXR ligands are actually competitive substrate inhibitors o f OATP1B1 and 
OATP1B3 transport and in the cases o f stimulation, increased transport function appears 
to be due to increased ligand affinity and not induction by PXR (Gui et al., 2008). 
Although it is lilcely that human OATPs are also targets for PXR-activation, reports are 
sparse; OATP1A2 however, has been suggested as a PXR target gene with a role in 
breast cancer drug therapy (Mild et al., 2006), which agrees with the finding that 
OATP1A2 contains several xenobiotic response elements (XREs) within its promoter 
(ICohle and Bock, 2009).
PXR is highly expressed in the liver and intestine, thereby mirroring the expression o f its 
target genes such as CYP3A4, ABCB1, ABCC2 and phase II conjugating enzymes which 
are also expressed highly in these tissues (Blumberg et al., 1998; Boolcout et al., 2006; 
Maglich et al., 2002). PXR is also expressed in the brain where it acts to prevent 
accumulation o f xenobiotics in the CNS by increasing metabolism and/or efflux o f 
compounds across the BBB (Lamba et al., 2004). In this way patterns o f expression 
indicate PXR’s ability to coordinate the transcriptional programs necessary to affect 
distinct physiologic pathways, such as those needed for a coordinated biotransformation 
system (Kohle and Bock, 2009). The combined effect o f PXR activation on ABCB1 and 
CYP3A4 levels can sometimes lead to drugs being cleared so quickly from the body that 
drug efficacy is compromised, for example in the case o f cyclosporine A, self-medication 
o f St. John’s Wort extracts as an antidepressant has led to serious drag interactions, such 
as heart transplant rejection due to loss o f cyclosporin-mediated immunosuppression 
(Ruschitzka et al., 2000).
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1.4.3 The Constitutive Androstane Receptor
Unlike PXR, which resides predominantly in the nucleus and shuttles between the 
nuclear and cytoplasmic compartments (Saradhi et al., 2005), the constitutive androstane 
receptor (CAR; NR1I3) is normally sequestered in the cytoplasm o f untreated liver cells 
and translocates to the nucleus after exposure to agonist (Yoshinari et al., 2003). The 
cytoplasmic CAR retention protein (CCRP; Dnajc) has been shown to maintain the 
cytoplasmic localisation o f CAR by forming a complex with CAR and hsp90 (Staudinger 
and Lichti, 2008). In response to ligand binding, the complex recruits protein phosphatase 
2A before translocation o f  CAR to the nucleus (Kawamoto et a l, 1999). Unlike most 
other NR’s CAR can translocate into the nucleus without directly binding to ligand (Baes 
et al., 1994; Swales and Negishi, 2004). Taken together, these data suggest that the 
phosphorylation status o f CAR is related to its cytoplasmic retention and nuclear 
translocation.
Since CAR has no identified endogenous ligands and many o f its activators are 
xenobiotics, CAR joined its mammalian relative, PXR as a xenosensor (Swales and 
Negishi, 2004). Like PXR, CAR regulates the expression of target genes by binding to 
xenobiotic response elements as a heterodimer with RXRa). The DBD of CAR has 66 % 
identity with the PXR DBD in humans (Blumberg et al., 1998) allowing it to bind to 
similar response elements as PXR including the DR4 element in CYP2B6 (Chang et al., 
2003; Goodwin et al., 2001; Mo et al., 2009) and the ER6 in CYP3A4 (Xie et al., 2000). 
CAR is also activated by many o f the same ligands as PXR, such as phenobarbitone (PB) 
and bilirubin (Saini et al., 2005) but the diversity o f the ligands is more restricted 
(Maglich et al., 2002). This cross-talk has been suggested to provide a mechanism for' 
amplifying the body’s detoxification response to a broad range o f chemicals (Maglich et 
al., 2002).
In addition to CYP2B6 and CYP3 A4, CAR also regulates the expression o f multiple drag 
and hormone metabolizing enzymes and transporter proteins such as, CYP2C9, GSTs, 
sulphotransferases, and UGTs, OATP1B1, ABCC2 and ABCC3 (Chen and Raymond,
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2006a; Kullak-Ublick and Becker, 2003; Pascussi et al., 2003a; Yanagiba et al., 2009). A 
good example o f how CAR co-ordinately regulates DMEs and transporters is the PB- 
induced lowering o f bilirubin levels. It has long been known that PB treatment reduced 
plasma bilirubin, but only through the study of CAR activation it is now clear that the 
reduction is caused by induction o f genes in the bilirubin pathway, including UGT1A1, 
OATP1B1, ABCC2 and GST(Al) (Huang et al., 2003). A role for CAR in regulating 
ABCB1 expression in the intestine has also been demonstrated; CAR activates ABCB1 
gene via DR4 motif within the response element and causes increases in ABCB1 
expression (Burk et al., 2005).
1.4.4 The Glucocorticoid Receptor
The human glucocorticoid receptor (GR; NR3C1), is ubiquitously expressed and 
mediates the action o f glucocorticoids, influencing a range of physiological functions 
essential for life. Alternative splicing o f the human GR gene in axon 9 generates two 
highly related receptor iso forms, termed a  and (3 (Nicolaides et al., 2010). The G Ra 
resides primarily in the cytoplasm o f cells and represents the classic glucocorticoid 
receptor that functions as a ligand-dependent transcription factor (Nicolaides et al., 2010) 
The GRp, on the other hand, does not bind glucocorticoid agonists, has intrinsic, GRa- 
independent, gene-specific transcriptional activity, and exerts a dominant negative effect 
upon the transcriptional activity o f G Ra (Nicolaides et al., 2010; Zhou and Cidlowski,
2005). Many G Ra isoforms also exist, all o f which have different transcriptional activity 
in response to dexamethasone, are differentially distributed in the cytoplasm and/or the 
nucleus in the absence of ligand and display distinct transactivation or transrepression 
patterns on global gene expression examined by cDNA microarray analyses (Nicolaides 
et al., 2010). Suppression o f transactivation o f  other transcription factors through protein- 
protein interactions is likely to be an important function o f GR; for example, it may be 
particularly important in suppression o f immune function and inflammation by 
glucocorticoids (Reichardt et al., 2001). Because the receptor gene is expressed in several 
forms, and has the ability to regulate gene transcription directly or by interfering with the
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activities o f other transcription factors it has many pleiotropic effects in different parts of 
the body.
The GR is particularly important in ADME, where the interplay between nuclear 
receptors is apparent. In human hepatocyte cultures, nanomolar concentrations of 
glucocorticoids (dexamethasone, hydrocortisone, prednisolone) activate GR, which in 
turn increases the levels o f CAR, PXR and RXRa mRNAs and proteins, leading to the 
potentiation o f  xenobiotic-mediated induction o f CYP2B6, CYP2C8/9 and CYP3A4 
(Pascussi et al., 2003b). However, at high (supramicromolar) concentrations o f 
glucocorticoids, PXR is activated directly, resulting in CYP3A4 induction o f a greater 
magnitude (Pascussi et al., 2003b). This dose-dependent response ensures up-regulation 
o f specific genes required for biotransformation and elimination o f toxic compounds that 
cause cellular release o f the glucocorticoid hydrocortisone in response to severe stress, 
but also allows circadian fluctuations o f hydrocortisone to selectively activate GR 
(Hewitt et al., 2007).
Dexamethasone has been shown to increase mRNA expression of ABCA1 and ABCG1, 
which are involved in the transfer o f cellular cholesterol and phospholipids to 
apolipoprotein-A-I (apoA-I) and mature HDL respectively (Sporstol et al., 2007). Thus, 
via activation of GR, synthetic glucocorticoids increase reverse cholesterol transport and 
eliminate excess cholesterol from the body via the liver. Efflux o f the glucocorticoids, 
dexamethasone, predisolone, cortisol and triamcinolone by ABCB1 and corticosterone 
and deoxycorticosterone by ABCC1 has also been postulated as a possible mechanism for 
glucocorticoid resistance in the treatment o f multiple diseases (Drigo et al., 2010; 
Webster and Carlstedt-Duke, 2002). ABCB1 and ABCG2 at the BBB are also up- 
regulated via the GR in response to dexamethasone treatment, an effect that can be 
partially abrogated by GR antagonists (Narang et al., 2008). Failure to reach therapeutic 
concentrations of dexamethasone can cause a build up o f intracranial pressure that can 
lead to death.
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1.4.5 Drug Transport and Toxicity: Drug-Drug Interactions
As we have seen in previous sections, drug transporters work cooperatively with DMEs 
in several ways; drug uptake transporters deliver the drug to the detoxification systems to 
facilitate metabolism; drug efflux transporters decrease the load on enzymes thereby 
decreasing the risk o f toxicity; chemical modification, which usually increases the 
amphiphilicity o f drugs, provides export drug pumps with better substrates. However, 
modulation o f drug transporter function, by inhibition, induction or as a result o f genetic 
polymorphisms can profoundly affect the clinical efficacy and safety o f  drugs. The 
consequences o f polymorphisms and induction in relation to drug transporter function 
have already been discussed, leaving this section to focus on transporter inhibition as a 
consequence o f drag-drug interactions (DDIs). O f the various drug transporters involved 
in DDIs, ABCB1 is the most studied, and as a result routine screening tools are now 
available to assess whether a new compound is a substrate or non-competitive inhibitor of 
ABCB1. DDIs involving ABCB1 are now considered with the same concern as DMEs by 
regulatory agencies, as evidenced in the US Food and Drug Administration (USFDA) 
concept paper (2006) ‘Drag Interaction Studies -  Study Design, Data Analysis and 
Implications for Dosing and Labelling’ (draft guidance). Other transport proteins that have 
been identified as responsible for clinically relevant DDIs include OATPs, ABCG2, OATs 
and OCTS, but routine screening for these is not recommended as yet, due to a lack of model 
substrates and inhibitors (Zhang et al., 2008). Examples o f DDIs involving some of these 
transporters are given below.
A classic example o f an ABCB1-mediated interaction at the level o f intestinal absorption 
and biliary efflux is that o f quinidine and digoxin (Endres et al., 2006). Quinidine is well 
known to increase the plasma concentration o f digoxin by 2- to 3-fold resulting in 
toxicity, yet digoxin is not extensively metabolised by cytochrome P450 enzymes 
(Fromm et a l, 1999). Both compounds are however substrates for ABCB1. Evidence 
suggests that quinidine increases the bioavailability of digoxin by inhibiting ABCB1 
efflux in the intestine and the liver during the first-pass effect (Endres et al., 2006). Using 
the human colon carcinoma cell line (Caco-2) expressing p-glycoprotein, the cellular
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efflux o f digoxin was shown to be inhibited at low concentrations o f quinidine (Fromm et 
a l, 1999). In the same study, quinidine also elevated brain digoxin levels in wild-type 
Abcbla (+/+) mice without effecting brain digoxin levels in A bcbla (-/-) mice. Since 
digoxin has a very narrow therapeutic window, a small increase its concentration due to a 
drug interaction can lead to cardiac arrhythmia, heart attack and death (Verstuyft et al., 
2003).
An example of drugs competing with endogenous molecules occurs in the case o f bile 
acid transport, as many o f the proteins that can actively transport drags evolved as part of 
the bile acid recirculation process. Intrahepatic cholestasis can be induced by an 
interference with the vectorial transport o f biliary constituents from blood to bile 
resulting in an intracellular accumulation of bile salts. Several cholestatic compounds 
have been found to inhibit the bile salt efflux pump (BSEP; ABCB 11), for example 
cyclosporin A (Alcashi et al., 2006) rifampicin, rifamycin and glibenclamide (Stieger et 
al., 2000), all inhibit ABCB 11 in rat liver and can induce cholestasis. Troglitazone, 
another type II diabetes drag like glibenclamide, was withdrawn from the market after it 
caused fatal cases o f hepatitis. Toxicity has since in part been attributed to the inhibition 
o f bile acid efflux across the canalicular membrane resulting in hepatic failure (Funic et 
al., 2001).
A drug interaction that may be used for therapeutic benefit is the one resulting co- 
administration o f probenecid, used primarily for the treatment o f gout, and penicillin. 
Probenecid inhibits OATs in the kidney, thereby reducing the tubular secretion of 
penicillin and increasing plasma concentrations (Ho and Kim, 2005). In this case, 
prolongation o f half-life is desirable since renal clearance o f penicillin is rapid, 
necessitating frequent dosing if a high penicillin concentration is required (Ho and Kim,
2005). This DDI has been used intentionally to great effect, allowing lower doses of 
penicillin to be administered for longer periods. It can therefore be seen that drug- 
transporter interactions can play an important role in determining both the clinical 
efficacy and safety o f therapeutic agents and their impact on endogenous systems. It is 
thus important to gain a full understanding o f how all the ADME processes co-ordinately
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function in order to better predict the result o f any competition for components o f the 
system.
1.4.6 Summary
At each stage of a compounds passage through the body, whether it is absorption through 
the gut, distribution to their sites o f efficacy or elimination via the kidneys or liver, a 
compound must cross biological membranes, making transport processes vital 
determinants o f drug disposition. Saturation o f drug transporters or lack o f a specific 
transporter may limit compound access to hepatocytes, where most drug metabolism 
occurs. Drag uptake transporters deliver substrates to phase I and II DME’s, which in 
turn increase the hydrophilicity o f compounds ready for excretion by drug efflux 
transporters. Such co-ordination o f drug metabolism and transport is apparent from the 
groups o f genes under the control o f so called xenosensing ligand-activated nuclear 
receptors PXR and CAR, which carefully regulate gene expression to protect against 
cellular toxicity. Induction and inhibition o f transporters and other ADME genes can lead 
to altered drag pharmacokinetics and pharmacodynamics, which can manifest in either 
reduced drug efficacy due to increased clearance or increased risk o f toxicity due to drug 
accumulation.
45
1.5 Assays to Measure Transporter Function in ADME
Toxicity is a leading cause o f attrition at all stages o f the drag development process. The 
majority o f safety-related attrition occurs pre-clinically, suggesting that approaches to 
identify 'predictable' preclinical safety liabilities earlier in the drug development process 
could lead to the design and/or selection o f better drag candidates (Kramer et al., 2007). 
The cost impact of late-stage failures o f drag candidates has motivated the 
pharmaceutical industiy to develop, validate, and implement a more proactive testing 
paradigm, including an emphasis on conducting predictive in vitro and in vivo studies 
earlier (Fieldent and IColaja, 2008). The previous sections have highlighted the role that 
drug transporters have as key determinants o f drug disposition in the body and because of 
this, studies are now included in addition to basic metabolic assays in early stage ADME- 
toxicology investigations, in order to predict drag fate. Whereas, it is now generally 
accepted that a compound will interact with one or more transporters at some point in its 
journey through the body, these interactions become especially important if they are able 
to limit bio availability and reduce drug efficacy. For example, in cancerous tissue, where 
efflux proteins may be over-expressed, treatment with a chemotherapeutic agent that 
happens to be a substrate may lead to non-responsiveness. As mentioned previously, 
transporter interactions can be an advantage if a drug is to be targeted to a tissue where 
only that influx transporter is expressed (e.g. OATP1B1 in the liver). Thus, transporter 
function is an important parameter to measure and a number of methods exist to do so.
Assays range from simple membrane preparations, in vitro cell based assays and animal 
testing, and are employed before a compound is clinically tested in humans for safety and 
efficacy. The more information that can be elucidated on compounds ADME 
characteristics, the greater chance of success in the clinic. Reducing the attrition rate of 
compounds in the clinic by improving pre-clinical tests is a major focus of the 
pharmaceutical industry, in order to reduce both the cost and time of bringing new drags 
to the market. Thus, the importance o f choosing the correct assays in order to generate 
robust data is paramount.
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1.5.1 Membrane Based Assays
Membrane preparations from cells expressing transporters are used to study the function 
of efflux transporters and determine if  compounds are substrates or inhibitors. These 
preparations usually use membranes from baculovirus-infected insect cells or mammalian 
cell membranes containing high levels o f human or rat wild-type transporters, and can be 
used for the high-throughput screening o f a large number o f potential drags for 
interaction with a multitude o f different transporters. Membrane based assays include the 
ATPase assay and the membrane vesicle uptake assay, which are discussed in more detail 
below.
1.5.1.1 The ATPase Assay
The ATPase assay indirectly measures the activity o f transporters that utilise ATP to 
transport substrates against their concentration gradients. For example, transport of 
substrates via ABC efflux pumps such as ABCB1 and ABCG2 depends on the binding 
and hydrolysis o f ATP within the nucleotide-binding domain (NBD) of the drag 
transporter. Substrates directly interact with transporters and stimulate the hydrolysis o f 
ATP, releasing phosphate, which can be measured colourimetrically (Hristos et al., 2007; 
Shirasaka et al., 2006). For an inhibition assay, potential inhibitors are examined for their 
ability to modify the ATPase activity o f a prototypical substrate. However, while the 
ATPase assay is a high throughput assay, it cannot always differentiate between, for 
example, an ABCB1 substrate and an inhibitor, because at high doses, some substrates 
inhibit ATPase activity (Szakacs et al., 2008). Furthermore, the ATPase activity may also 
be affected by the lipid environment and the experimental conditions, making basal levels 
o f activity very high (Szakacs et al., 2008). To distinguish between background ATPase 
activity and that associated with transporter activation, various inhibitors have to be used; 
EGTA, ouabain and azide are used to inhibit Ca-ATPases, Na+/IC-ATPases and 
mitochondrial ATPases respectively (Zhang et al., 2003)
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1.5.1.2 Membrane Vesicle Assays
A more direct measurement of substrate translocation and its modulation can be achieved 
by the quantitation of the intravesicularly trapped substrates in vesicular transport assays. 
In this assay, accumulation o f the test compound into inside-out membrane vesicles 
prepared from cells transfected with a specific transporter, or from a particular tissue such 
as the hepatic canalicular membrane, is measured. Given the orientation o f ABC 
transporters in cells (where the NBDs are in the intracellular compartment), in inside-out 
vesicles, the NBDs face the incubation medium (accessible to ATP and other chemicals), 
and substrates are actively transported into the vesicles. Rapid filtration, using glass fibre 
filters or nitrocellulose membranes, is used to separate the vesicles from the incubation 
solution and the quantity o f substrate within the vesicle is determined via mass 
spectroscopy, fluorescence or scintillation counting, depending on the properties o f the 
substrate (Szalcacs et al., 2008).
Unlike the ATPase assay, inside-out vesicles will distinguish between substrates and 
inhibitors (Tabas and Dantzig, 2002); however if vesicles are prepared from a tissue it 
may be difficult to identify the transporter responsible for uptake. Another drawback o f 
this method is that hydrophobic compounds may non-specifically bind to lipid 
membranes and filters, and also, may rapidly leak out from the vesicles. For example, in 
case o f  ABCB1, which transports mainly lipophilic compounds, no such transport assay 
can be established for its most relevant substrates (Szakacs et al., 2008).
1.5.2 Cell Based Assays
Cells can be extracted from tissue by digestion with collagenase to release them from the 
extracellular matrix and used for transport assays in suspension (Soars et al., 2007) or 
alternatively so called ‘primary’ cells can be grown in single cell layers on collagen 
coated multi-well plates and exposed to drugs in cell culture medium (Nishimura et al.,
2006). In conventional two-dimensional (2D) cell culture techniques, the cellular 
microenvironment is reduced to a flat, rigid surface o f plastic or glass (basal side o f the
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cellular monolayer) and a volume o f liquid culture medium with uniform concentration 
over the apical side o f the monolayer. In living tissues, however, cells are exposed to a 
three-dimensional (3D) environment that consists o f other cells, extracellular matrix, 
heterogenous concentrations o f soluble molecules, and non-chemical stimuli, such as 
shear stress (Perez-Castillejos, 2010). Higher order tissue functions depend on 
hierarchical structures extending from single cells (-1 0 pm) to functional subunits 
(100pm-1mm) (Khetani and Bhatia, 2008). The sandwich culture o f primary cells 
between two layers o f collagen addresses this issue and results in cells with polarised 
membranes and a functioning canalicular network allowing the study o f biliary efflux 
(Liu et al., 1999), but more advanced 3D scaffolds and micro-tissue units are still under 
development and require more characterisation and validation before their use in drag 
testing paradigms (Khetani and Bhatia, 2008; Perez-Castillejos, 2010; Sivaraman et al.,
2005).
In pharmacological studies, preference is given to genetically engineered cells over cell 
lines selected via cytotoxic agents to over-express a particular ABC transporter, as in the 
latter many other un-identified metabolic changes may have occurred (Szakacs et al., 
2008). Transformed cells can be obtained from tumour cells or alternatively, cells from 
normal tissue can be artificially transformed; these cells will continue to grow and divide 
indefinitely. These cells can then be transfected with the DNA o f a transporter or 
transporters o f interest resulting in over expression in the plasma membrane. Cell-based 
techniques are suitable for the assessment o f kinetic parameters o f the transport and can 
be used in high-throughput mode. A limitation o f this setup is that the varying expression 
levels o f the proteins can greatly influence results.
Another potential limitation with cell lines is their limited metabolic capacity. Since 
many hepatotoxins need metabolic activation prior to the appearance o f their toxic effects 
(Park et a l, 2005), metabolically competent cells are highly desirable for the prediction 
o f hepatotoxicity or drug disposition in vivo. Although cell types differ in then metabolic 
capability, hepatocytes and certain cell lines can be used to investigate the interplay 
between metabolism and transport. Cell-based assays are therefore more complex and 
physiologically relevant models compared to membrane extracts, and can be used to look
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for gene and protein expression changes in response to drug treatment. Membrane 
vesicles, lacking other cellular machinery, are only o f use for determining transport 
potential.
1.5.2.1 Primary Hepatocytes
Since the liver receives a large proportion o f the blood supply and is the major site o f 
drug metabolism and biliary excretion, it is an appropriate tissue in which to determine 
ADME parameters. Isolated hepatocytes are now recognized as one o f the most relevant 
and practical models with which the study o f drug metabolism and transporter 
interactions is best performed (Hewitt et a l, 2007). When isolated and handled 
appropriately, they contain a broad complement o f metabolising enzymes and transport 
proteins, organised in a physiologically relevant context and regulated via cellular 
processes that occur within the liver in vivo (e.g. by nuclear receptor activation). 
However, while most of the transcriptome and proteome o f hepatocytes is similar to liver, 
the expression o f some key proteins does change; for example, CYP expression falls over 
time in culture (Binda et al., 2003) whereas ABCB1 levels rise (Fardel et al., 1992). 
Caution must therefore be used when interpreting the results o f primary hepatocyte 
systems.
Freshly isolated and cyropreserved hepatocytes in suspension can be used for influx 
studies (Hirano et al., 2004; Shitara et al., 2003b), as cells maintain functional uptake 
transporters after hepatocyte isolation. However, cells lose their polarity during isolation 
and efflux transporters tend to be internalised (Hoffmaster et al., 2004), therefore drug 
efflux studies cannot be performed in suspensions o f hepatocytes. Culturing hepatocytes 
in a sandwich configuration between two layers o f gelled extracellular matrix proteins, 
with collagen and matrigel being the most commonly used, has dramatically prolonged 
the longevity o f cultures displaying hepatocyte-specific functions (Hewitt et al., 2007). It 
should be noted, however, that the layer o f collagen or matrigel added to cultured 
hepatocytes could interfere with the bioavailability o f some compounds such as 
polypeptide-based drugs (Hewitt et al., 2007). The sandwich culture method is
50
advantageous in that it results in hepatocytes that repolarise, have functional uptake 
processes, tight junctions between cells, express efflux transporters such as ABCB1 and 
ABCC2 on the canalicular membrane and have functional biliary canalicular networks 
(Hoffmaster et al., 2004; Liu et al., 1999). The time it takes for these networks to form is 
species-dependent, for example in rat hepatocytes bile canaliculi are most extensively 
formed with the highest expression o f ABCB1 on day four after plating (Jorgensen et al., 
2007; Tumcliff et al., 2006), whereas in humans, bile canaliculi and ABCB1 expression 
are optimal at days five to six (Bi et al., 2006; Hoffmaster et al., 2004).
Several studies have shown that primary cultures o f hepatocytes can be used to predict in 
vivo drug metabolism (Hewitt et al., 2001; Ponsoda et al., 2001; Salonen et al., 2003). A 
study by Ponsoda et al. compared the metabolites produced by a culture o f primary cells 
dosed with the anti-inflammatory analgesic aceclofenac to the metabolites produced in 
urine after the drug was given to the patient from whom the cells were taken. This study 
offered the unique opportunity to directly compare, from the same donor, the metabolism 
o f a drag in vitro and in vivo and showed a remarkable similarity in the metabolic profile 
(Ponsoda et al., 2001). A retrospective study also showed that the risk o f toxicity 
involving troglitazone and bosentan could have been predicted pre-clinically had 
sandwich cultured hepatocytes been used in the screening procedure (Kemp et al., 2005). 
Once the mechanism o f toxicity was demonstrated to involve inhibition o f a bile acid 
transporter, lower doses were selected that avoided cholestatic toxicity and bosentan 
returned to the market. Results such as this provide evidence that primary cells can be 
used in ADME studies to predict the in vivo characteristics o f drugs.
B-CLEAR® technology is a patented method to predict in vivo hepatic uptake and biliary 
clearance, and assess drag transporter inhibition. The assay relies on the fact that 
canalicular networks are composed o f ‘bile pockets’ that are excluded from the medium 
by tight junctions between cells. The presence o f calcium in the medium is required to 
maintain the tight junctions sealing the bile pockets and when cells are depleted of 
calcium, the tight junctions are opened and the contents are released. In vitro biliary 
clearance is then calculated by comparing the accumulation o f compound in hepatocytes
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treated in this way, with hepatocytes whose biliary network is complete (Liu et al., 1999). 
Substrates specific for one transporter can also be used to determine transporter-specific 
biliary clearance; for example, the fluorescent substrates rhodamine-123 (R-123) and 
carboxydichlorofluroscein (CDF) have been used as specific substrates for ABCB1 
(Shapiro and Ling, 1997) and ABCC2 respectively (Zamek-Gliszczynski et al., 2003). 
Drug-drug interactions can be determined in this way, by challenging the system with a 
second compound and measuring any differences observed in biliary clearance. One such 
study determined that the ABCB1 inhibitors verapamil and progesterone significantly 
decreased clearance o f R-123, whereas the ABCB1 activator quercitin increased 
clearance (Annaert and Brouwer, 2005).
Although hepatocytes are the ‘gold standard’ in vitro test, human hepatocytes remain 
difficult to obtain. Different donor livers are used for each preparation o f cells and due to 
inter-individual variability o f DME expression and the presence o f genetic 
polymorphisms, each preparation may give a variable result. This problem can be 
minimised by pooling the cells o f several donors, but this is only possible if enough 
donors are available. Cryopreserved cells have been used successfully in metabolic 
(Naritomi et al., 2003), transport (Bi et al., 2006) and induction studies (Martin et al., 
2008), and have the added advantage o f being an ‘off the shelf preparation so the same 
donor can be used for a number o f repeat assays. However, some kinetic parameters, 
namely Km  values tend to be lower in cryopreserved cells, which can lead to an over­
estimation o f drug clearance (Brown et al., 2007; Hallifax and Houston, 2006).
An alternative to human hepatocytes are the easily and cheaply obtainable rat 
hepatocytes. However, rat hepatocytes should be used with caution to predict human 
inductive response due to large differences in CYP isoforms and their substrate 
specificities (Hewitt et al., 2007). As discussed in a previous section, members o f the 
SLC family o f uptake transporters are also functionally different, which poses further 
problems when extrapolating between species. Nevertheless, studies have shown that 
cultured rat hepatocytes are a good model for hepatotoxicity compared to the commonly 
used whole animal models (Kiklcawa et al., 2006).
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1.5.2.2 Cell lines
Cell lines that are either artificially transformed or are derived from human carcinomas 
provide a stable, robust assay system against which the effects o f drugs can be compared 
over a long period, in terms o f both extended time studies and for repeated measures. The 
choice o f human cell lines has the advantage o f eliminating species differences when 
considering development of drugs for use in man. However, cell lines often don’t express 
a full range o f proteins, or display basolateral and apical specific expression compared to 
primary cells or in vivo tissue and this can lead to the misinterpretation o f in vitro results. 
For example, the human hepatocarcinoma-derived HepG2 cell line expresses mainly the 
foetal enzyme CYP3A7, rather than CYP3A4 (Schuetz et al., 1993). In addition, despite 
the presence o f endogenous PXR, CYP3A4 expression is not enhanced by rifampicin 
treatment in HepG2 cells (Ogino et al., 2002), whereas in human hepatocytes, rifampicin 
is considered a prototypical CYP3A4 inducer (Lehmann et al., 1998).
The transfection o f deficient proteins, such as uptake and efflux drag transporters into 
cell lines, allows the study o f transport via a specific transporter from which ADME 
properties o f compounds can be deduced, as well as any DDI’s that may occur involving 
drug transport. However, for these transporters to be expressed at their respective 
basolateral and apical membranes, cultured cells need to maintain cell polarity. While the 
intestinal model system o f Caco-2 cells are almost universally accepted as a powerful 
polarised model o f the intestine, no similar system is available for the liver (Fearn and 
Hirst, 2006). It is therefore necessary to select in vitro systems to suit the requirements o f 
the assay you wish to perform, and to validate that system adequately to determine any 
caveats (Plant, 2004). A number o f commonly used cell culture systems, which are 
employed herein, are discussed below:
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1.5.2.2.1 Huh7
The human hepatoma cell line Huh7 expresses very low levels o f drug metabolising 
enzymes and the nuclear receptor PXR (Phillips et al., 2005). Despite this, the Huh7 cell 
line has been used to investigate the transcriptional induction o f  ABCC3 via ligand 
binding to PXR and has demonstrated similar inductions to those seen in vivo (Teng et 
al., 2003). Huh7 cells are also reported to express ABCB1 and ABCC6, which are 
differentially regulated by hepatocyte nuclear factor 1 alpha (H N Fla) in response to 
interleukin-6 (11-6) exposure (Lee and Piquette-Miller, 2001). SLCOIBI genes with 
active promoter regions have also been reported in Huh7 cells but not in non-hepatic 
HeLa cells, demonstrating the hepatocyte specific expression o f OATP1B1 can be 
maintained in vitro (Jung et al., 2001). However, recognition that cell culture grown 
hepatocyte-derived cell lines, such as Huh7 cells are unable mimic the complex polarised 
phenotype o f hepatocytes in vivo has limited their use as a model system for transport 
processes (Sainz et al., 2009). Huh7 cells have also been used in many studies completed 
by this laboratory and others to look at the induction o f CYP3 A4 via PXR by transfecting 
the cells with a reporter gene plasmid containing the XREM promoter region o f CYP3 A4 
and a PXR expression plasmid. In one such study, a range o f compounds were ranked 
according to then ability to induce CYP3A4 via activation o f PXR (El-Sanlcary et al., 
2001).
1.5.2.2.2 HEK293
Human Embryonic Kidney cells, also known as HEK cells, HEIC 293 or just 293 cells are 
an epithelial cell line originally derived, as their name indicates, from embryonic human 
kidney. Like Huh7, cells HEIC293 cells are extremely easy to work with, being 
straightforward to culture and to transfect, and so can be used in experiments in which the 
behaviour o f the cell itself is not o f interest. Background levels o f transporters are 
generally low in HEK293 cells, however there have been reports o f high levels o f 
endogenous ABCC1 expression (van de Wetering et al., 2007). HEK293 cells have been 
used in a variety of ADME studies, where the protein o f interest is transfected into the
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cell line. Many studies have focussed on compound uptake by human OATP and OCT 
family members (Lohmann et a l, 2007). Doubly transfected HEK293 cells expressing 
OATP IB 1 at their basolateral membrane and the breast cancer resistance gene ABCG2 
(BCRP) at their apical membrane have also been produced to study vectorial transport 
(Hassan et al., 2006). Systems such as this have utility for screening compounds for 
ABCG2 activity prior to developing them for use in the clinic. HEK293 cells have also 
been used to elucidate drug-drag interactions due to inhibition o f bile acid uptake via 
OATP IB 1, which in vivo would prevent bile acid uptake into hepatocytes and cause 
cholestasis (Sharma et al., 2010).
1.5.2.2.3 MDCK II
Madin Darby canine kidney (MDCK II) cells are immortalised cells thought to be 
obtained from the distal tubule or collecting duct o f the nephron (ECACC; Porton Down, 
UK). General features defining cell polarity have been described in cultured MDCK cells 
(Giepmans and van Ijzendoom, 2009; Jamison et al., 1987; Jing and Prekeris, 2009), and 
this cell polarity has been utilised in ADME studies for bi-directional drug transport 
(Konig et al., 2000). Single, double and even quadruple transfectants have been 
developed with ABCB1, ABCC1 and ABCC2, ABCG2 and several OATP members 
including 1B1 and 1B3 (Cui et al., 2001; Evers et al., 1998; ICopplow et al., 2005; 
Matsushima et al., 2005), with each protein correctly localising to its respective 
membrane. MDCK II cells transfected with ABCB1 are also used routinely to screen for 
ABCB1 substrates and inhibitors in the early stages o f drag development (Rautio et al.,
2006), and have been recommended as a suitable cell line for such use by the Food and 
Drug Administration (FDA; recommendations to industry, 2006). Although this cell line 
is used to study the transport properties o f the transfect o f interest, endogenous 
transporters may contribute to transport o f the substrate (Bartholome et al., 2007). For 
this reason, it is important to include the wild-type cell line as a negative control in 
transport assays.
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1.5.3 Whole Organ Perfusion
Isolated perfused liver models closely mimic the hepatic physiological condition 
independently o f  potentially confounding influences from other organs such as intestine 
and kidney. They have the advantage over in vitro assays because as discussed 
previously, cellular studies do not necessarily establish transport directionality or 
transporter-enzyme interactions at the organ level. However, one disadvantage o f this 
system is that it is difficult to dissect out the individual input from each component in the 
system. Thus, organ perfusion is best suited to studies looking at the interplay o f drags 
with multiple transporters and metabolic enzymes (Xia et al., 2007). During isolated liver 
perfusion, compound is added to the perfusion fluid and delivered to the organ. 
Following perfusion, the concentration o f drug is measured within the organ, the 
perfusate and the elimination fluids such as bile to determine biliary clearance rates (Xia 
et al., 2007). One such study utilised a liver perfusion method to show that inhibition of 
digoxin uptake decreased its biliary clearance, yet inhibition of ABCB1-mediated digoxin 
efflux actually increased its clearance from the liver as a result o f increased intracellular 
metabolism (Lau et al., 2004). This type o f interplay between transporter and enzyme 
activity may not have been identified in a simpler system.
In situ perfusion is also o f use where no adequate cell culture method exists, for example 
in the study o f compound access to the brain across the BBB (Cisternino et al., 2001). In 
situ brain perfusion has recently been used to validate two commonly used methods to 
assess BBB permeability; the cell-based MDCKII-ABCB 1 assay and the parallel artificial 
membrane permeability assay (PAMPA) (Di et al., 2009). This study identified that the 
MDCKII-ABCB 1 model correlated poorly with BBB permeability, due to differences in 
the properties of MDCKII and BBB endothelial cell membranes, whereas the PAMPA 
model was more predictive o f passive diffusion (Di et al., 2009). Despite the advantages 
o f whole organ perfusion, it is not routinely performed during ADME studies because o f 
its low throughput and expensive nature. Organ integrity and enzyme/transporter activity 
also degrade rapidly and the technique requires specialised surgical skill (Xia et al.,
2007).
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1.5.3.1 Organ Slice Culture
Precision-cut organ slices can be useful in vitro models to investigate the disposition and 
toxicity o f chemicals as they mimic closely the multi-cellular complexity and extra­
cellular interactions o f the intact organ. The architectural composition o f the various cell 
types is retained, as well as the cell-matrix and cell-cell interactions, allowing the cell to 
function almost as it would in vivo. The advantages o f using organ slices as opposed to 
whole organs include the ability to scale-up experiments and to carry them out over a 
slightly extended time period. Slices from different tissues and from a variety o f animal 
species have been used to study the induction o f cytochrome P450 proteins and phase II 
conjugating enzymes (Drahushuk et a l , 1999; Edwards et al., 2003; Pushparajah et al.,
2007), predict in vivo clearance o f xenobiotics (de Graaf et al., 2006; Worboys et al., 
1997), assess tissue and species-specific toxicity (Price et al., 1996; Vickers, 2009) and to 
investigate pathways o f metabolism (Ball et al., 1996; Elferinlc et al., 2008). Only a few 
studies have been published on transport o f drugs in liver slices, including an explorative 
study to investigate the possibilities and limitations o f liver slices in drug transport 
studies (Olinga et al., 2001). This investigation concluded that liver slices are a valuable 
tool to investigate mechanisms o f cellular uptake.
1.5.4 In Vivo Models
Animal models for the study o f transport mechanisms usually utilise genetic knockout 
mice, where a transporter gene has been artificially disrupted and natural mutant animal 
models, where the transporter is missing due to a naturally occurring mutation. Such 
models have been used to investigate the physiological functions o f transporters and as 
models for human disease and for the study o f ADME. For example, Abcbl (-/-) mice 
models have been used to identify the physiological functions o f the efflux transporter. 
While it is known that Abcbl is expressed in liver, kidney, intestine and the BBB where 
it is important for removal o f toxins, Abcbl is also expressed in the adrenal gland, on 
hematopoietic stem cells, natural killer (NIC) cells, antigen-presenting dendritic cells
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(DC), and T and B lymphocytes (Klimecki et al., 1994; Randolph et al., 1998), where its 
function is less well defined. Abcbl knockout mice knockout mice display a seemingly 
complete immune-cell repertoire (Schinltel et al., 1997), however Abcbl has since been 
suggested to act as a key modulator o f adaptive immunity in neuro-inflammation since 
function o f the DC is severely impaired in Abcbl a/lb-/- knockout mice, and T cell 
stimulatory capacity is significantly decreased (Kooij et al., 2009). The knockout mouse 
could therefore act as a model for human multiple sclerosis and be used for the testing o f 
new immunotherapies. Abcbl knockout mice have also been used to explore the 
possibilities o f Abcbl inhibition in cases of multi-drug resistance, without impairing 
normal physiological function (Schinkel, 1998).
Current in vivo models to study ABCC2 are the transporter-deficient and Eisai 
hyperbilirubinaemic rat strains, which are used as models for Dubin-Johnson syndrome 
(Buchler et al., 1996). In Abcc2 knockout rats, induction of Abcc3 in the sinusoidal 
membrane and differences in U G Tla and cytochrome P450 enzymes have been detected 
as possible compensatory mechanisms to the absence o f functional Abcc2 (Chu et al.,
2006). However, in Abcc2 knockout mice, no compensatory induction o f Abcc3 was 
detected, indicating a species-specific response to hyperbilubinaemia (Chu et al., 2006).
During the last decade, various animal models lacking drag transporters have been 
generated in order to investigate the role o f transporters for drug absorption, distribution 
and elimination (Glaeser and Fromm, 2008). For example, Abcbl and Abcg2 and Abcc2 
knockout animals have been used to show that these transporters are involved in the 
elimination o f Abcbl substrates such as paclitaxel (Chen et al., 2003) and ivermectin 
(ICwei et al., 1999), Abcg2 substrates such as sulfasalazine (Zaher et al., 2006) and 
Abcc2 substrates such as food carcinogens and methotrexate (Vlaming et al., 2006). The 
role o f drag transporters in absorption has also been investigated using knockout animals. 
An example is the Oct (-/-) mouse that demonstrates low penetration o f endogenous 
compounds such as TEA and the anticancer drag metaiodobenzylguanidine in the liver 
(Jonker et al., 2001). An Oatplb2 knockout has also been used to assess the hepatic 
uptake o f cerivastatin, lovastatin acid, pravastatin, simvastatin acid, rifampicin, and 
rifamycin; results suggest that Oatplb2 plays a more significant role in the hepatobiliary
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disposition o f rifampicin and lovastatin than the other compounds tested. Studies like this 
can be a useful in vivo tool to understand drug targeting and disposition in the liver (Chen 
et al., 2008).
Despite their usefulness, in vivo models do have limitations: First, altering the expression 
of one transporter has been found to affect levels o f cytochrome P450s (Schuetz et al.,
2000) and other transporters (Kuroda et al., 2004), which may complicate the 
interpretation o f such studies. Second, differences between species can cause problems; 
for example, uptake transporters such OAT3 can have different functions in non-primate 
species compared to humans (Tahara et al., 2005). This problem can be partially avoided 
by the generation of transgenic ‘knock-in’ mice, as has been done to study drug transport 
mediated by human liver-specific OATP IB 1 (van de Steeg et al., 2009). However, even 
utilising this approach, the presence o f endogenous transporters may lead to 
misinterpretation o f  absorption data. The third drawback is that male and female rats 
express different amounts of transporters for example; Rost et al., 2005 found female rats 
had higher levels o f Oatplb2, Abcc2 and Abcc3 protein in liver samples, whereas male 
rats had higher protein levels o f O atpla4 (Rost et al., 2005). Differential expression 
patterns that exist between genders and species make the task o f  extrapolation to man 
much harder.
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1.5.5 Summary
Drug transporter function can be assessed in a number o f ways, ranging from the simplest 
membrane-based assays, to the intermediate cell-based assays, to the more complex 
organ and whole animal models. Each system comes with advantages and disadvantages, 
depending on whether you desire to elucidate mechanisms, or determine overall drug 
response. For example, the physiological relevance o f data increases with the complexity 
o f the model system, however the ability to determine the mechanistic pathway 
decreases. Vice versa, with simple membrane and cell-based systems, mechanism o f 
action is easy to determine, but the relevance to the human situation remains unknown 
until a more complex model is utilised. Thus, it is often the case that interactions are 
firstly identified using simple systems and in vivo experimentation may follow on the 
basis o f the initial findings. Animal models have the advantage that they can predict drug 
clearance from all aspects o f ADME; however results are impeded by species and sex 
differences.
Selection of the correct model system will depend largely on the biological question you 
are asking and the type o f information you require. Providing a thorough understanding 
o f the advantages and disadvantages o f any chosen assay is reached, correct interpretation 
o f the results and extrapolation to man should be possible. Ideally, for extrapolation 
purposes, the assay should resemble the human situation as closely as possible.
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1.6 In Silico Modelling
In silico modelling is a form o f computer-based modelling often applied in the fields o f 
drug discovery (Japertas et al., 2006), whole cell analysis (Mustacchi et a l, 2006), and 
since the sequencing o f the genome, for the analysis and visualisation o f huge 
heterologous genomic, transcriptomic and proteomic datasets (Lee et al., 2005a). 
Computational biology has risen to the challenge to integrate the vast amounts o f data 
generated by the human genome project into a useful form: The generation o f computer 
models allows for the description o f biological process, which opens up the opportunity 
to rapidly predict biological responses to a multitude o f changing variables, much faster 
than can be done traditionally. It should be noted that in silico models by no means 
remove the need for in vitro and in vivo investigations since they have their limitations. 
Instead, simulations allow the rapid examination o f many individual parameters, allowing 
the generation o f hypothesis’ that can then be tested experimentally.
1.6.1 Systems Biology & ADME modelling
Systems biology is a branch o f modelling that attempts to explain a whole system, such 
as a cell or organism. Unlike molecular biology, which focuses on specific molecules as 
isolated components, systems biology concentrates on the dynamics o f a whole system, 
which although made up o f individual components cannot be explained simply by the 
sum o f them (Kitano 2002). Both the structure o f the system and the functionalities o f its 
components must be considered to understand biology at the system level. An underlying 
principle o f systems biology is that all biological systems have inherent robustness to 
maintain stability in the face o f likely perturbations; for example, systems can adapt to 
fluctuations in temperature or food supply that are common to the environment in which 
they have evolved (Kitano et al., 2004). Based within this concept o f robustness, it can be 
seen that more extreme or sudden, perturbations in an evolutionary context that introduce 
fragility into a system and cause malfunctions typically manifested as disease (Kitano et 
al., 2004). A systems biology approach can help to identify such changes in dynamics
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and the molecular underpinnings o f them gaining a more in depth knowledge o f biology 
in the process. When studying areas in which there are still many unanswered questions, 
such as there are regarding transport protein function and regulation, a ‘bottom-up’ 
approach is often adopted. This simply means that the model starts with a well 
characterised but smaller biological system and greater complexity is achieved as the 
model progresses.
A more traditional pharmacokinetic model uses the reductionist (‘top-down’) approach, 
whereby several biological reactions are described by a single term. In fact, organs and 
specific processes such as blood circulation rates are dealt with as compartments, 
characterised by general kinetic descriptors (Tozer and Rowland, 2006). This approach 
has the advantage that models can be constructed from basic data such as the input and 
output levels from each compartment and some simple metabolic information, but such 
models lack the ability to examine the detail o f the reactions that occur in between. In any 
system, some parameters have more control 0 11 the outcome than others, and it is these 
reactions that are the important ones to identify as pharmacological targets, or as the 
causal factors in disease states. The more that is known about each system parameter, the 
easier it is to extrapolate between species, which may express a different version or 
amount o f a particular protein, or between disease states in which components may be 
missing, malfunctioning or over-expressed.
1.6.2 Transporter-Based Modelling
To date, several mathematical and computational models to describe the drug disposition 
during cell permeation experiments have been published (Heikldnen et a l , 2010). These 
models are utilized for obtaining quantitative insight o f the compounds’ ability to be 
transported across the cell monolayer as well as the mechanisms involved. Furthermore, 
these models are also used for extracting suitable parameters from the in vitro data that 
could be used for prediction o f intestinal absorption in vivo. In general, these models are 
based upon single barrier methods, which derive a composite value for passive diffusion 
across all o f the permeation barriers in the cell monolayer. This method relies on Ficlc’s
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law, assuming a linear concentration gradient across the barrier (Heildcinen et al., 2010), 
and has obvious drawbacks for the assessment o f  low permeability compounds. The 
compartmentalised model is more complex, and takes into account the transfer of a 
compound between several kinetic compartments, and may include formation o f 
metabolites and movement though intracellular organelles (Heildcinen et al., 2010). One 
such three compartment model, describing the discrete transmembrane events occurring 
at the basolateral and apical surfaces in addition to overall transport across cell 
monolayers, was used to describe the contribution o f transcellular and paracellular routes 
in the absoiptive transport o f ranitidine across Caco-2 monolayers (Bourdet et al., 2006).
In another study, an attempt was made to model intestinal drug absorption using an in silico 
model referred to as an epithelio-mimetic device (EMD), so called to reflect the fact that its 
referent system is confluent monolayers of Caco-2 cells (Liu and Hunt, 2005). The in silico 
system was designed to simulate passive paracellular diffusion and carrier mediated bi­
directional drug transport from basolateral to apical surfaces and vice versa. By simulating 
the behaviours of two clinically used drags, alfentanil and digoxin, similar results were 
obtained to the in vitro situation. A Monte Carlo simulation was used to randomly generate 
values for uncertain variables repeatedly to simulate a model. Using this method, the model 
did not determine transporter expression or membrane density in the referent cells, with one 
assigned transporter possibly representing several within an area and was not representative 
of transporter binding affinities or specificities: Hence, such a system, again, models a 
generalised model from a top-down perspective.
Another research group sought to estimate inhibitor concentration-dependent ligand uptake 
into a cell system in the presence of two counteracting earner processes; one a carrier 
involved in facilitated diffusion into cells and the other an active efflux pump synonymous 
with ABCB1 (Ofer et al., 2006). By varying expression levels of the efflux pump and adding 
inhibitors with different affinities for both transporters, multiple scenarios were developed in 
which cellular uptake/extrusion could be modulated to match the experimental data. This is 
of particular relevance in scenarios where the influx/efflux balance of therapeutics is altered, 
for example in tumours expressing the multi-drag resistance phenotype. Such models may 
assist with the administration of optimal doses of substrate analogues or chemosensitisers to
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block the action of ABCB1 while acknowledging the involvement of other transporters in 
maximising cellular uptake of the therapeutic agent.
Despite these advances, in vitro information on hepatic uptake and secretory transporters has 
yet to be incorporated into a mechanistic model of drug clearance, partly due to the lack of 
information regarding tissue abundances and their variance within the liver (Rostami- 
Hodjegan and Tucker, 2007). The ultimate goal of such a model is to extrapolate between 
measured in vitro and in vivo data, to humans and accurately predict drag response. The 
easiest way to do this is with the use of modelling software as discussed below.
1.6.3 CellDesigner™
To facilitate the modelling o f biochemical networks, a growing number o f programs 
provide diagrammatic interfaces using the Systems Biology Graphical Notation (SBGN) 
format. Such programs are capable o f translating graphical representations into the 
machine readable systems biology mark-up language (SBML), a universal XML 
language (Hucka et al., 2003). O f these programs, CellDesigner™ 
(http://www.celldesigner.org) is the most popular stand-alone application (Klipp et al.,
2007), as it provides a user-friendly front-end for complex simulations (Figure 1-8). For 
simulation o f biochemical networks, each reaction must be associated with a kinetic law, 
producing a set o f ordinary differential equations (ODEs). Biological ODE models are 
continuous deterministic models in which variables represent concentrations o f species 
(particles). Models are based on average reaction rates, measured from experiments 
which relate to the change o f concentrations over time. With the reaction equation, initial 
amount o f each species and the rate o f every reaction a model can be constructed. For 
example, in Figure 1-8, individual reactions could represent cellular uptake, metabolism 
and efflux, forming a biological network.
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State Transition
CftllDasignar Reaction and Process Modes
Figure 1-8 CellDesigner Graphical Representation of a Simple Network
Species (s i, s2 etc.) are connected by reactions or interactions (arrows) that can be modified at 
process nodes. Each reaction needs to be associated with a kinetic equation for simulation of a 
biochemical network.
1.6.3.1 COPASI
Simulation o f networks can be undertaken in CellDesigner itself; however only simple 
time simulations and parameters scans can be performed. The SBML script can be 
exported into a more powerful software package such as COPASI 
(http://www.copasi.org/tiki-index.php). the Complex Pathway Simulator (Hoops et al.,
2006). Within COPASI, the user can select a variety o f kinetic reactions from a drop 
down list, generated in accordance with the stoichiometry and the number o f modulators. 
Unknown parameters can be estimated using the parameter estimation tool that runs 
multiple scenarios based on defined model limitations to minimise the difference between 
the model and experimental data. COPASI is also one of the few existing software 
packages that incorporates local sensitivity analysis (Zi et al., 2008). This tool 
systematically changes the model parameters, to determine the robust and fragile nodes 
of the network. For example, in an ADME model a fragile node might be a metabolic 
enzyme or drug transporter that exerts significant control on the network output despite 
undergoing small changes in activity itself.
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1.6.4 Summary
In silico modelling is a valuable tool for interpretation o f  in vitro and in vivo data, and 
can aid extrapolation between model systems and species. Attempts have been made to 
estimate drug access across biological membranes, but these efforts have largely ignored 
specific transporter interactions and have not correlated uptake with drug transporter 
expression levels. For incorporation o f transport kinetic data, a ‘bottom-up’ approach is 
recommended, so that the contribution o f each reaction in the network to overall drug 
distribution can be determined. Software packages such as CellDesigner provide a user- 
friendly interface in which networks can be created, and simulations can be carried out in 
a more complex software package such as COPASI. Using these software packages it is 
possible to simulate multiple outcomes based on altered parameters such as those that 
might be seen due to transporter induction, over-expression or inhibition.
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1.7 Hypothesis, Aims and Objectives
Drag transporters alter the pharmacokinetics o f molecules within the body by facilitating 
or preventing cellular access across the basolateral membrane and by actively effluxing 
molecules from the cell across the apical membrane. The hypothesis o f this work is that 
drag transporters are a key determinant o f drag disposition, and that differences in 
expression levels/activity in biological test systems result in misleading estimates of 
human clearance.
Therefore, the aim of this research is to make an in silico model o f drag disposition, 
using the ABCB1 model substrate rhodamine-123 to exemplify the processes o f ADME 
within a hepatocyte and to determine the role o f transporters within the network.
This aim will be achieved by meeting a number o f objectives:
• First, by measuring the expression o f a number o f drug transporters in commonly 
used in vitro cell systems and tissues and assessing whether transporter expression 
level changes with culture duration.
• Second, by measuring physico-chemical and ADME properties o f rhodamine-123 
in suitable cell systems.
• Third, by dosing human and rat primary hepatocytes with PXR ligands to 
determine the effect on drag transporter expression.
• Fourth, by simulating the effects o f ABCB1 expression level on drug disposition 
as determined in section one, and the effect o f ABCB1 induction and chemical 
inhibition using experimentally derived and literature derived values.
• Fifth, by simulating the effects of different ABCC2 expression levels on drag 
disposition, using a previously defined model (by Dr Kat Howe, (University o f 
Surrey, UK)).
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2. Materials and Methods
2.1 Materials
2.1.1 General Materials
Unless specified in Table 2-1, all chemicals and materials were purchased from Sigma- 
Aldrich (Poole, UIC) and were o f molecular biology standard.
Item Supplier
Cell /Tissue Culture
Huh7 & MDCKII cells
Dulbecco’s modified eagles medium, Trypsin-EDTA, 
non-essential amino acids, foetal bovine serum, penicillin 
and streptomycin
Hanks buffered saline solution (HBSS)
Primary human hepatocytes
Complete InvitroGRO CP culture medium 
Torpedo antibiotic mix 
Primary rat hepatocytes 
Reactivation medium, wash medium
Cells: Dr S. Hood, GSK (Ware, UIC)
Invitrogen GIBCO (Paisley, UK)
Celsis In Vitro Technologies 
(Baltimore, USA)
Abcellute (Cardiff, UK)
Rat liver slices
RPMI 1640 buffer
Earls balanced salt solution (EBSS) Invitrogen GIBCO (Paisley, UIC)
HEIC cells
Geneticin
Dulbecco’s phosphate buffered saline 
DMEM HAMS F-12 culture medium + 10% FBS 
BacMam virus
Invitrogen GIBCO (Paisley, UK) 
GSIC (Ware, UK)
Fluorescent Probe Substrates
Rhodamine 110
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Rhodamine 123 
CDFDA
Biotium (California, USA) 
Invitrogen (Paisley, UK)
Quantitative RT-PCR
RNA isolation (RNeasy minikit), RNA later 
RNAlater ICE
Disposable DNase/RNase free tips 
DNasel and buffers
dNTP’s, random hexamers, DTT, RNase OUT, 
Superscript II,
Synthesis buffers, genomic DNA (Rat, human, dog) 
TaqMan Universal PCR Master Mix, 96-well white 
optical plates, optical adhesive covers 
TaqMan probes (FAM-TAMRA) and primers
Qiagen (Crawley, UK)
Ambion (Austin, USA)
Alpha Laboratories (Hampshire, UK) 
Promega (Southampton, UK) 
Invitrogen (Paisley, UK)
Abgene (Epsom, UK)
MWG Biotech (Ebersberg,
Germany)
Protein Analysis
Protease Inhibitor Tablets 
Bis-acrylamide stock solution (2% w/v) 
Acrylamide stock solution (40% w/v) 
Novex Sharp protein standard 
MagikMark Western protein standard 
Chemiluminescent HRP reagent 
PVDF Western Blotting Membranes
Roche (Lewes, UK)
VWR (Lutterworth UK)
Invitrogen (Paisley, UK)
GE Healthcare (Buckinghamshire, 
UK)
Roche (Lewes, UK)
Primary and Secondary antibodies unless otherwise 
stated
C219 ABCB1 antibody 
LDH antibody
Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Covance (New Jersey, USA)
Abeam (Cambridge, UK)
ABCB1 assays
Amprenavir
GF 120918-A inhibitor
Quinidine
GSIC (Ware, UK)
Arcos Organics (Geel, Belgium)
Table 2-1 Suppliers of specialist materials used in this work
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2.1.2 Immortalised Cell Lines
Wild-type Huh7 and MDCKII cells stably transfected with human ABCB1 were a kind 
gift from Dr Steve Hood (GSK, Ware, UK). Samples o f HEIC 293 cells transiently 
transfected with OATP1A2, OATP IB 1, OATP1B3 and OATP2B1 using the BacMam 
system were also supplied by GlaxoSmithKline (Ware, UK). Wild-type MDCKII cells 
(EC ACC 00062107) were purchased from EC ACC (Porton Down, UK).
2.1.3 Primary Hepatocytes
2.1.3.1 Uptake Studies
Human plateable cryopreserved hepatocytes (M00995-P) were obtained from Celsis In 
Vitro Technologies (Baltimore, USA). Donor information is shown in Table 2-2. 
Preserved male Sprague-Dawley rat hepatocyte suspensions (A5147) were obtained from 
Abcellute (Cardiff, UK).
2.1.3.2 induction Studies
Primary rat hepatocytes isolated from Sprague-Dawley rats were purchased from 
Dominion Pharmalcine (Bizkaia, Spain). Primary human hepatocytes overlaid with 
Geltrex™ (HMFY24) were purchased from Invitrogen (Paisley, UIC) and used for 
induction studies and R-123 efflux assays. Donor information is shown in Table 2-2.
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2.1.4 Human Liver Samples
A sample o f human liver (No.3, 13.11.07) was kindly supplied by Professor Costas 
Ioamiides (University o f Surrey, UK) for the preparation of S9 fraction for metabolic 
studies. Donor information is shown in Table 2-2. Samples from five human livers 
extracted from otherwise healthy donors were also donated by Dr. Nick Plant for protein 
extraction (no donor information available). As these samples are from different sources, 
inter-individual variability has to be considered when interpreting results.
Product
I.D.
Lot no. Age Gender Race Cause of 
death
Drug history Medical history
M00995-P
Human
Hepatocytes
SHM 51 Male Caucasian Stroke + Tobacco 
+ Alcohol 
- Substances
Diabetes 
Hypertension 
Depression/ 
Anxiety 
Kidney disease
HMFY24
Human
Hepatocytes
HuEUlO
06
62 Male Caucasian Unknown + Tobacco
- Alcohol
- Substances
Not reported
No. 3
Human
Liver
13.11.07 67 Female Caucasian Hypoxic
brain
injury
Unknown Diabetes 
Hyperlip idaemia
Table 2-2 Donor information for primary human hepatocytes and human liver
2.1.4.1 Human Liver RNA
A commercial preparation o f female normal human liver RNA (lot#0830508) was 
purchased from Stratagene (Amsterdam, Holland).
2.1.5 Rat Liver Samples
Samples o f male Wistar rat liver for precision cut slicing, RNA and protein extraction 
were kindly provided by Professor Costas Ioamiides (University o f Surrey, UK).
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2.2 Methods
2.2.1 Cell culture of immortalised cell lines
2.2.1.1 Storage of Frozen Cell Lines
All cells were stored in freezing medium (90 % FBS and 10 % DMSO) at a concentration 
o f approximately lxlO6 cells/ml before being transferred to an appropriate storage vessel. 
Huh7 cells were immersed in liquid nitrogen, whilst HEK293-MSRII cells were stored in 
vapour phase liquid nitrogen facilities at GlaxoSmithKline (Ware, UK). MDCKII and 
MDCKII ABCB1 cells were stored in a -80 °C freezer.
2.2.1.2 Recovery of Cells from Storage
Cells were recovered by thawing at 37 °C, in a water bath with gentle agitation of the 
vial. 10 ml o f 37 °C medium (50 ml for HEK293-MSRII cells) was added to the cells 
slowly to avoid osmotic shock. HEK293-MSRII and MDCKII-ABCB 1 cells used for 
uptake and Transwell assays respectively were checked for viability by diluting a 200 pi 
cell suspension aliquot 1:1 with Trypan blue and cell counting using a haemocytometer. 
All cell suspensions were centrifuged at 1000 g for 5 minutes and re-suspended in 10 ml 
fresh medium. For HEK293-MSRII cells, after centrifugation cells were suspended in an 
appropriate volume o f medium for transduction and plating (see section 2.2.1.6.1). Huh7 
and MDCKII cell suspensions were transferred to a 25 cm2 vented tissue culture flask or 
cultured in 24-well plate multi-well insert systems with PET membranes for Transwell 
assays (section 2.2.7.2) and incubated at 37 °C with 5 % CO2. The medium was replaced 
after 24 hours to remove any non-adherent cells.
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2.2.1.3 Huh7 and MDCKII Cell Maintenance
Cells were passaged when they reached approximately 80 % confluence. The medium 
was removed and the cells washed with phosphate buffered saline (PBS). The cells were 
incubated at 37 °C with 2 ml 1 x trypsin-EDTA for 5 minutes. Ten millilitres o f medium 
was added to inactivate the Trypsin-EDTA and the cell suspension was split between new 
75 cm2 vented cell culture flasks. The exact ratio o f cell splitting was dependent on both 
the cell type and the experimental requirement, and varied between 1:2 and 1:10. To 
ensure phenotypic consistency throughout experiments, each cell line was only used for a 
fixed number of passages after recovery storage: Huh7 cells were used up to 12 passages 
after receipt and MDCKII ABCBI cells were used up to passage 54 from a new stock.
2.2.1.4 Huh7 Cell Culture
The human hepatocellular carcinoma (Huh7) cell line, used as an in vitro hepatocyte 
model is a differentiated, immortalised cell line derived from hepatoma tissue 
(Nalcabayashi et al., 1982). Cells were cultured in Dulbecco’s modified eagle medium 
(DMEM) with L-glutamine and phenol red, containing 10 % v/v foetal bovine serum 
(FBS), 1 % v/v non-essential amino acids (NEAAs), lOOU/ml penicillin and 100 pg/ml 
streptomycin.
2.2.1.5 MDCKII / MDCKII ABCB1 Cell Culture
Madin-Darby canine kidney cells, strain II (MDCKII) share some characteristics with 
proximal tubule cells (Svennevig et al., 1995). This strain is thought to be derived from 
the distal tubule or collecting duct of the nephron (ECACC, Porton Down, UK). Use o f 
MDCKII cells for vectorial transport studies has materialised due to the ability to 
maintain cell surface polarity in culture, forming an epithelial mono-layer complete with 
tight junctions (ECACC, Porton Down, UK). MDCKII cells expressing the human
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ABCB1 transporter are used here to measure efflux across the canalicular membrane. 
Cells were cultured in Dulbecco’s modified eagle medium (DMEM) with L-glutamine 
and phenol red, containing 10 % v/v foetal bovine serum (FBS), 1 % v/v non-essential 
amino acids (NEAAs), 100 U/ml penicillin and 100 pg/ml streptomycin.
2.2.1.6 HEK293-MSRII Cell Culture
Human Embryonic Kidney (HEK) cells were originally derived from healthy human 
embryonic kidney and experimentally transformed with adenovirus 5 DNA to produce 
the immortalized cell line designated HEK293 (Graham et al., 1977). The HEK293 cell 
line was later modified to express human Class A macrophage scavenger receptor 
(HEK293-MSRII) to improve cell adherence, and is now one the most versatile and 
powerful cell lines for expression o f recombinant proteins (Robbins and Horlick, 1998).
2.2.1.6.1 Preparation of OATP BacMam Transduced HEK293-MSRII Cells
BacMam viruses and frozen cells were combined either by mixing the two reagents 
together in suspension followed by plating out (batch transduction) or by addition of 
BacMam to previously plated cells (in-well transduction). Batch transduction was used 
for all transporters except for OATP1B1. For both methods, HEK293-MSRII cells 
recovered from vapour phase storage as described in section 2.2.1.2 were re-suspended in 
DMEM pre-supplemented with Hams F I2 nutrient mixture by GlaxoSmithKline and 10 
% FBS added just prior to use. Media volume was dependent on the number o f  plates and 
the final seeding density required for each transduction (Table 2-3). Media was 
supplemented with Geneticin to a final concentration o f 0.4 mg/ml to maintain positive 
selection pressure. 2 mM sodium butyrate was added prior to BacMam addition to 
increase transduction efficiency. BacMam reagent was kept protected from light at 4 °C 
prior to addition to the cell suspension or to plated cells. The volume o f BacMam reagent 
added depended on the maximum permitted percentage o f BacMam, the plaque forming
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units (pfu) per millilitre and the multiplicity o f infection (MOI) (Table 2-3). For 
OATP1B1 in well-transduction, cells were plated and allowed to adhere for 4 hours prior 
to removal o f media and addition of BacMam. All transduced cells were placed in a 
humidified incubator at 37 °C with 5 % CO2 for 48 hours prior to further 
experimentation.
Transfect
name
Pfu/ml Final seeding 
density (cell/well)
MOI
required
Maximum permitted % 
BacMam
OATP1B1 1.78E+08 4E+05 180 20
OATP2B1 6.80E+08 5E+05 40 1
OATP1A2 1.07E+08 5E+05 60 14
OATP1B3 1.54E+08 4E+05 155 20
Table 2-3 BacMam transduction requirements
2.2.2. Preparation and Culture of Rat Liver Slices
Transporter expression profiling at RNA (section 2.2.11) and protein (section 2.2.12) 
levels was carried out at selected time points to determine expression stability in culture 
and thus the suitability o f rat liver slices to predict and study clinically relevant effects of 
candidate drag compounds. Male Wistar albino rats (200 ± 50 g) were purchased from 
B&K Universal Ltd (Hull, UK). Animals were killed by cervical dislocation and livers 
were immediately excised and bathed in slicing media (EBSS buffer containing 25 mM 
glucose, oxygenated and chilled to 4 °C). Slices o f 200 ± 30 pm, were prepared using a 
Kramdieck tissue slicer (Alabama Research and Development Corporation, Alabama, 
USA), as previously described (Hashemi et al., 1999a). Briefly, liver slices were washed 
three times with wash buffer (0.1 M Tris-HCl, 0.154 M KC1, pH 7.4), and each slice was 
incubated with 1.5 ml incubation buffer (RPMI-1640 containing 0.5 mM L-methionine, 5 
% (v/v) foetal calf serum, 1 pM insulin and 50 mg/ml gentamicin) per well o f a 12-well 
plate (zero time point). Liver slices were incubated in a humidified incubator for 30 
minutes at 37 °C with 5 % CO2 (0.5 hour time point). Slices were then washed three times
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with wash buffer, transferred to a clean 12-well plate containing fresh incubation buffer 
and incubated in a humidified incubator at 37 °C with 5 % CO2 until the desired time 
point (6, 12, 24, 48, 72 hours) was reached. A sample o f rat liver taken prior to slicing, 
and slices for each time point were washed and snap frozen in liquid nitrogen. Slices and 
control liver were then processed for RNA and protein isolation, as described in sections 
2.2.11 and 2.2.12.
2.2.3 Preparation of Plated Primary Hepatocytes for Transport Assays
2.2.3.1 Rat Hepatocytes
All preparation and use o f primary rat hepatocytes were undertaken within the DMPIC 
facilities o f GlaxoSmitliKline, Ware, UK.
Non-frozen, preserved rat hepatocytes isolated from Sprague-Dawley rats obtained from 
Abcellute (Cardiff, UK) were reactivated by adding 3ml o f room temperature reactivation 
medium (Abcellute, Cardiff, UK) to each dish o f cells. Dishes were placed in a 
humidified incubator at 37 °C for 30 minutes or until cells were free in suspension. Cell 
suspensions were transferred to sterile tubes along with residual cells that were washed 
from the dish using 5 ml wash medium (Abcellute Cardiff, UK). Cell suspensions were 
centrifuged for 4 minutes at 115 x g at room temperature and the supernatant was 
aspirated. Cells were initially re-suspended in 0.4 ml wash medium and then made up to a 
volume o f 4 ml wash medium per 10 million cells ordered. Cells were assessed for 
viability and number by diluting a 200pl o f cell suspension 1:1 with Trypan blue and 
counting viable and dead cells using a haemocytometer. Cells with less than 80 % 
viability were discarded. Cell suspensions were centrifuged as before and the media was 
aspirated. Finally, cells were re-suspended in Williams E medium (Sigma-Aldrich, Poole, 
UK) to a final concentration o f viable 0.8 xlO6 cells/ml. 500pl o f this cell suspension was 
used per well o f a 24-well plate, giving a well concentration o f 0.4 xlO6 cells per well.
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Cells were ready to use after 2 hours o f incubation in a humidified incubator at 37 °C 
with 5 % CO2.
2.2.3.1 Human Hepatocytes for Uptake Assays
All preparation and use of primary human hepatocytes to be used for uptake assays were 
undertaken within the DMPK facilities o f  GlaxoSmithKline, Ware, UK.
Plateable cryopreserved hepatocytes (M00995-P) bought from Celsis In Vitro 
Technologies (Baltimore, USA) are freshly isolated and cryopreserved on the same day. 
On receipt, frozen cells were rapidly thawed in a 37 °C water bath and transferred 
immediately to 5 ml complete InvitroGRO CP medium, previously prepared by adding 1 
ml Torpedo antibiotic mix per 45 ml o f medium at 37 °C. Hepatocytes were re-suspended 
by gentle tube inversion. Cells were assessed for viability and number by diluting a 200 
pi o f cell suspension 1:1 with Trypan blue and counting viable and dead cells using a 
haemocytometer. Cells were diluted with complete InvitroGRO CP medium to a final 
concentration o f 0.8 xlO6 viable cells/ml. 500 pi o f this cell suspension was used per well 
of a 24-well plate, giving a well concentration o f 0.4 xlO6 cells per well. Plates were 
shaken gently, avoiding circular movements to evenly distribute the cells, and incubated 
for 2 hours in a humidified incubator at 37 °C with 5 % CO2 before use.
2.2.3.2 Human Hepatocytes for Efflux Assays
Primary human plated hepatocytes (HMFY24) overlaid with Geltrex™ and maintained 
for four days in culture were purchased from Invitrogen (Paisley, UK). Upon arrival, 
media was replaced with William’s E medium supplemented with 100 U/ml penicillin, 
100 pg/ml streptomycin, 0.17 pM insulin, 0.03 pM dexamethasone, 50 pg/ml 
gentamycin, 2mM L-glutamine and 1 % (v/v) 1 M Hepes). Cells were cultured for a 
further 24 hours to allow optimal bile canaliculi formation (Bi et al., 2006).
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2.2.4 Transport Assays
Uptake and efflux assays were conducted to both assess the usefulness o f an in vitro 
system to study transport, and to determine transport kinetics human transporters. The 
methods utilised to do this are outlined below.
2.2.4.1 OATP Uptake Assays with Transduced HEK293-MSRII Cells
Transduced HEK293-MSRII cells prepared as described in section 2.2.1.6.1 were used 
for the assessment o f R-123 uptake by individual human OATP transporters. Briefly, 
media was removed from the cells, which were then washed with 1000 pl 37 °C DPBS 
buffer (Invitrogen GIBCO, Paisley, UK) per well. Stock solutions o f R-123 ranging in 
concentration from 0-2 pM were prepared in DPBS, with a constant methanol 
concentration of 1 %. A duplicate set o f R-123 solutions were prepared that also 
contained a final concentration o f 10 nM inhibitor (0.1% DMSO) specific to the transfect 
type (Table 2-4). 400 pl o f each solution was added per well o f a 24-well plate, in 
duplicate for each condition. Solutions were incubated with the cells for exactly 120, 300, 
420 and 600 seconds on a 37 °C heated block or in a humidified incubator. At the end o f 
the timed incubation, solutions were removed from the wells, followed by the immediate 
addition o f 800 pl ice-cold DPBS. Cells were washed a further two times with ice-cold 
DPBS to remove any extracellular R-123. 200 pl DPBS buffer was added to each well 
before determination of R-123 intracellular fluorescence on the POLARstar galaxy plate 
reader (BMG Labtechnologies, Germany; Xex = 485 nm; kem = 535 nm; gain 34). 
Intracellular concentration o f R-123 was determined using R-123 standard curves read 
under the same conditions.
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Transfect name Inhibitor
OATP1B1 Rifamcyin
OATP2B1 Montelukast
OATP1A2 ICetoconazole
OATP1B3 Rifamycin
Table 2-4 Inhibitors used in OATP uptake assays
Radiolabelled model substrate assays for each transporter were carried out to confirm 
transport protein activity in the cell lines. Assays were performed in triplicate under both 
inhibited and un-inliibited conditions and intracellular radioactivity was determined using 
the Topcount NXT™ Microplate Scintillation and Luminescence Counter (Hewlett 
Packard, Bristol, UK). Table 2-5 lists the model substrates used for each transporter.
Transfect name Model Substrate
OATP IB 1 [3H] Estradiol 17P-D-glucuronide
OATP2B1 [JH] Estrone Sulfate
OATP1A2 [3H] Estrone Sulfate
OATP1B3 [3H] Estradiol 17P-D-glucuronide
Table 2-5 Model substrates used in OATP uptake assays
2.2.4.1 Uptake Assays with Primary Rat and Human Hepatocytes
Primary rat and human hepatocytes prepared as described in section 2.2.3.1 and 2.2.3.2 
respectively were used to determine R-123 uptake by endogenous transporters. Briefly, 
media was removed from the cells, which were then washed with lm l 37 °C DPBS buffer 
(Invitrogen GIBCO, Paisley, UK) per well. Stock solutions o f R-123 ranging in 
concentration from 0-2 pM were prepared in DPBS, with a constant methanol 
concentration o f 1 %. lpM  R-123 solutions were prepared that also contained a final 
concentration o f 10 nM o f each type o f inhibitor (0.1% DMSO) (Table 2-4). 400 pi o f 
each solution without inhibitor was added per well o f a 24-well plate, in duplicate for 
time point. Solutions were incubated with the cells for exactly 120, 300, 420 and 600
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seconds on a 37 °C heated block or in a humidified incubator. 1 pM solutions with 
inhibitor were incubated in triplicate with cells for 300 seconds only. At the end o f the 
timed incubation, solutions were removed from the wells, followed by the immediate 
addition o f 800 pi ice-cold DPBS. Cells were washed a further two times with ice-cold 
DPBS to remove any extracellular R-123. 200 pi DPBS buffer was added to each well 
before determination o f R-123 intracellular fluorescence on the POLARstar galaxy plate 
reader (Lex = 485 mn; Lem = 535 nm; gain 34). Intracellular concentration o f R-123 was 
determined using R-123 standard curves read under the same conditions.
A functionality assay using the radio labelled OATP1B3 and OATP1B1 model substrate 
Estradiol 17(3-D-glucuronide was also carried out to confirm transporter activity in the 
hepatocytes. Assays were performed in triplicate under both inhibited and un-inhibited 
conditions and intracellular radioactivity was determined using the Topcount NXT™ 
Microplate Scintillation and Luminescence Counter (Hewlett Packard, Bristol, UIC).
2.2.4.S Intracellular Accumulation of R-123 in MDCKII-ABCB1 Cells
R-123 accumulation was determined in MDCKII-ABCB1 cells when exposure to R-123 
was carried out at 4 °C and at 37 °C in the presence or absence o f  the ABCB1 efflux 
inhibitor, quinidine (99+ % purity). Quinidine concentration was 10 x the R-123 
exposure concentration to ensure that the same proportion o f inhibition was retained. 
Under each condition, 80 % confluent adherent cells in 6-well plates were exposed to 3 
ml of 0-10 pM R-123 (1% methanol) for 10 minutes. Cells were then washed three times 
with cold PBS to remove excess R-123 and lysed with 2 % (v/v) triton-X 100 in HBSS 
with 1 x protease inhibitors. The lysate was then diluted 1:2 with HBSS and the 
fluorescence determined using the Varian Cary Eclipse (California, USA) fluorescence 
spectrometer (Lex = 505 nm; Lem = 525 mn). Concentration o f intracellular R-123 was 
determined by comparison to a standard curve prepared by spiking R-123 into cell lysate 
prepared with 2 % (v/v) triton-X 100 in HBSS.
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Following these initial optimization experiments, intracellular concentration was 
determined at 37 °C in the absence o f quinidine, over the concentration range o f 0-20 pM 
R-123. The experimental protocol was carried out as detailed above; with the addition 
that cell lysate was assayed for protein concentration by Lowry method (Section
2.2.12.2). Intracellular concentrations were then normalised to protein concentration per 
well.
2,2.4.4 Efflux Assays with MDCKII I MDCKII-ABCB1 Cells and Primary 
Human Hepatocytes
To determine the kinetic parameters o f ABCB1-mediated efflux o f R -l 23, MDCKII cells 
stably transduced with human ABCB1 were utilised in a plated format. MDCKII-ABCB 1 
cells grown on Transwell inserts were also used to determine the extent o f B (basolateral) 
to A (apical) and A-B transport to calculate an efflux ratio. An R-123 efflux assay was 
also performed using primary human hepatocytes to determine efflux rates in a human 
model system.
2.2.4.4.1 Plated MDCKII-ABCB1 Cell System
Adherent wild-type MDCKII and MDCKII-ABCB 1 cells at 80 % confluence in 6-well 
plates were exposed to 0-20 pM of R-123 in HBSS (1 % methanol) for 10 minutes at 37 
°C. Cells were washed three times with cold PBS to remove excess R-123 and efflux was 
initiated with the addition o f 3 ml HBSS buffer at 37 °C. R-123 accumulation in the 
buffer after 7.5 minutes was then determined using the Variant Cary Eclipse fluorescence 
spectrometer (kex = 505 nm; 7em = 525 11111). Concentration o f R-123 was determined by 
comparison to a standard curve measured under the same conditions. Cells used in the 
assay were lysed with 2 % (v/v) triton-X 100 in HBSS with 1 x protease inhibitors and 
the resulting cell lysate was assayed for protein concentration by Lowry method (Section
2.2.12.2). Concentrations o f  R-123 effluxed into buffer were then normalised to protein 
concentration per well.
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2.2.4.4.2 Inhibition of R-123 Efflux
During inhibition experiments, 10 pM of R-123 was incubated with MDCKII-ABCB1 
cells for 10 minutes at 37 °C along with increasing concentrations o f quinidine (0-160 
pM). Drug solutions were prepared so that methanol concentration could be maintained at 
2 %. After incubation, cells were washed three times with cold PBS and efflux was 
initiated with the addition of 3ml HBSS buffer at 37 °C. R-123 accumulation in the buffer 
after 7.5 minutes was then determined using the Varian Cary Eclipse fluorescence 
spectrometer (?iex = 505 nm; Xem = 525 nm). Concentration ofR-123 was determined by 
comparison to a standard curve measured under the same conditions.
2.2.4.4.3 MDCKII-ABCB1 Transwell Transport Assay
\
Figure 2-1 Schematic Representation of Transwell Transport Assay Systems.
Polyester Transwell-clear inserts feature a transparent PET membrane that is tissue culture treated 
for optimal cell attachment and growth. Polarised MDCKII-ABCB1 cells grown on the 
membrane support in a 24-well plate format allow assessment of substrate transport from A 
(apical) to (basolateral) (B) and B to A compartments (Transwell™).
Sample
Apical
ABCB1
Basolateral
B>A/A>B=Apical Efflux Ratio
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MDCKII-ABCB1 cells grown on Transwell inserts allow the measurement of 
bidirectional transport which is useful to assess ABCB1 substrate affinity, the extent of 
passive diffusion and inhibition o f ABCB 1 transport (Figure 2-1). First, cells resuscitated 
from frozen (section 2.2.1.2) were diluted to a 1 xlO5 cell suspension with DMEM and 
seeded into 24 well multi-well insert plates with polyester (PET) membranes at a density 
o f 5 x 104 cells per well. 35 ml DMEM was then added to the feeder tray and cells were 
incubated in a humidified incubator at 37 °C with 5 % CO2 for three days, with a change 
o f media after 48 hours.
For the Transwell transport assay, stock and working solutions were prepared as shown 
below, such that the final amount o f organic solvent was consistent over the test systems 
(<2 % (v/v)):
Stock solutions:
Test article:
Positive ABCB1 substrate control: 
ABCB1 inhibitor (I):
Paracellular transport marker:
Working solutions:
Pre-incubation solutions
1 mM R-123 in methanol
3 mM 3H-Amprenavir in DMSO
2 mM GF-120918 in DMSO
10 mM Lucifer yellow in purified water
(-1) -  30 ml DMEM + 150 pi DMSO
(+1) -  30 ml DMEM + 120 pi DMSO + 30 pi 2 mM
GF120918
Receiver solutions (-1) -  30 ml DMEM + 150 pi DMSO
(+1) -  30 ml DMEM + 120 pi DMSO + 30 pi 2 mM
GF120918
Donor solutions (-1) -  15 ml DMEM + 60 pi DMSO
(+1) -  15 ml DMEM + 45 pi DMSO + 15 pi 2 mM
GF120918
(-1) -  15 ml DMEM + 60 pi DMSO + 150 pi 10 mM 
Lucifer yellow
(+1) -  15 ml DMEM + 45 pi DMSO + 15 pi 2 mM 
G F120918 + 150 pi 10 mM Lucifer yellow
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Test articles; R-123 and 3H-Amprenavir were added to donor solutions to give a final 
concentration o f 1 pM and 3 pM respectively. 10 pM Lucifer yellow was included in the 
IT-Amprenavir donor solution as a control for monolayer integrity. All solutions were 
warmed to 37 °C before use. Cell inserts were removed from the feeder tray and placed 
into a clean 24-well plate. Pre-incubation medium with and without 2 pM GF120918 was 
added to separate wells, adding 0.5ml to the apical (top) compartment and 1.5 ml to the 
basolateral (bottom) compartment (Figure 2-1).
Cells were incubated at 37 °C with 5 % CO2 for 30 minutes before discarding the pre­
incubation medium. Inserts, in a clean 24-well plate were then loaded on the TECAN 
Genesis 200 work station (Mannedorf, Switzerland) which added receiver transport 
medium (+/- inhibitor) to appropriate triplicate apical (for B-A transport) and basolateral 
(for A-B transport) compartments. The required volumes for HTS-24 Multiwell insert 
systems are 0.45 ml for apical compartments and 1.3 ml for basolateral compartments. 
Donor working solutions (+/- inhibitor) were added to the appropriate apical (for A-B 
transport) and basolateral (for B-A transport) compartments as above. Plates were 
incubated at 37 °C for 90 minutes in a shaking TECAN incubator. 100 pi aliquots were 
then removed from both apical and basolateral compartments and from working solutions 
for mass balance calculations. All aliquots were dispensed into 96-well clear bottomed 
black fluorescence plates. Both Lucifer yellow and R-123 samples were analysed on the 
POLARstar galaxy (lex  = 430 nm; Xem = 538 mn). 100 pi aliquots were also taken from 
apical and basolateral compartments and working solutions containing 3H-Amprenavir 
and dispensed into 96-well scintillation plates (Deepwell Lumaplates™-96). Plates were 
dried overnight and counted on a Topcount NXT™ Microplate Scintillation and 
Luminescence Counter (Hewlett Packard, Bristol, UK).
2.2.4.4.4 Efflux Assay in Primary Human Hepatocytes
Human hepatocytes cultured as described in section 2.2.3.3 were exposed to 0-20 pM of 
R-123 in HBSS (1 % methanol) for 10 minutes at 37 °C. Cells were washed three times
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with cold PBS to remove excess R-123 and efflux was initiated with the addition o f 1 ml 
HBSS buffer at 37 °C. After 7.5 -  30 minutes, R-123 efflux into canalicular spaces was 
imaged using the Axiovert 135TV microscope (Ziess, Hertfordshire, UK); differential 
interference contrast (DIC) position 3-4, filter wheel in position 1 (Zeiss filter set 09; X.ex 
450-490nm. XEm. Colour = green), with a Lambda 10-2 filter wheel changer (Sutter, 
California, USA). Images were captured using the Starlight Xpress CCD camera 
(Starlight Xpress, Berks, UK) with a 0.1 second exposure, and manipulated in Nebulosity 
2 software (Stark Labs, Pordenone, Italy).
2.2.4.S Carboxydichlorofluoroscein Diacetate Assay
The carboxydichlorofluorescein diacetate (CDFDA) assay was carried out in plated Huh7 
cells to assess the transport function o f ABCC2 in a liver cell line that does not form bile 
canaliculi. CDFDA passively diffuses into cells, where it is hydrolysed to 
Carboxydichlorofluroscein (CDF) and is then effluxed via functional ABCC2 (Zamek- 
Gliszczynski et al., 2003). Since CDF is a fluorescent molecule, measurement of efflux 
via a fluorescent endpoint is possible. Medium was aspirated from adherent cells which 
were then washed twice with HBSS. Cells bathed in HBSS were returned to the 37 °C 
incubator for 10 minutes before replacement o f the buffer with HBSS containing 10 pM 
CDFDA (DMSO 0.1 %). Cells were incubated in the presence of 10 pM CDFDA for 30 
minutes at 37 °C. Cells were then washed three times with HBSS and incubated for a 
further 30 minutes at 37 °C in HBSS. An image was taken at 10 x magnification using as 
Axiovert 200 microscope (Zeiss, Hertfordshire, UK). During imaging cells were exposed 
to fluorescence at 480 nm using a fluorescein isothiocyanate (FITC) filter for 2 seconds 
(Howe et al., 2009). Images were taken using an AxioCam MRm Rev digital camera 
(Zeiss, Hertfordshire, UK) connected to the microscope.
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2.2.5 Preparation of Plated Primary Hepatocytes for Induction Assays
2.2.5.1 Primary Rat Hepatocytes
All preparation and dosing o f primary rat hepatocytes was undertaken by Dr. IC Plant at 
the University o f Surrey, UK (Plant et al., 2006).
Primary rat hepatocytes isolated from Sprague-Dawley rats obtained from Dominion
Phannakine (Bizkaia, Spain), were cultured according to the supplier’s instructions.
6 2
Briefly, hepatocytes were seeded on to collagen coated plates at 1.2 x 10 cells/cm in 
RPMI supplemented with 10 % foetal calf serum, 50 U/ml penicillin and 50 pg/ml 
streptomycin. Culturing medium composed o f RPMI supplemented with 2 % serum,
-7
antibiotics as above and 10 M insulin was replaced daily. Cells were dosed daily with 50 
pM dexamethasone, 50 pM cyproterone acetate or 0.1 % DMSO vehicle control.
2.2.5.2 Primary Human Hepatocytes
Primary human plated hepatocytes overlaid with Geltrex™ and maintained for four days 
in culture were purchased from Invitrogen (Paisley, UK). Upon arrival, medium was 
replaced with William’s E medium supplemented with 100 U/ml penicillin, 100 pg/ml 
streptomycin, 0.17 pM insulin, 0.03 pM dexamethasone, 50 pg/ml gentamycin, 2mM L- 
glutamine and 1 % (v/v) 1 M Hepes). After 24 hours, and daily thereafter, cells were 
dosed with 50 pM dexamethasone, 50 pM rifampicin or 0.1 % DMSO vehicle control.
2.2.6 Assessment of Cell Death Using the LDH Assay
When cells are dosed with a potentially toxic chemical, it is necessary to ensure that the 
concentration used does not lead to unacceptably high levels of cell death; this is
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achieved through measuring lactate dehydrogenase (LDH) activity in buffer. LDH is a 
cytosolic enzyme that is released from the cell following cellular membrane damage. The 
LDH level was quantified using the LDH assay kit (Roche Diagnostics Ltd., Lewes, UK); 
briefly, after centrifugation for 1 minute at 1000 rpm, buffer from treated cells was added 
to an equal volume o f the kit reagents (1:45 bottle 1 : bottle 2) in a 96 well ELISA plate 
and left, protected from light, at room temperature for 30 minutes. When rhodamine was 
the test chemical, cells were first washed three times, and an aliquot o f the final wash 
solution was assayed for LDH activity. This extra step was necessary since rhodamine 
absorbs light at the wavelengths required for LDH measurement. The plate was then read 
at 490 mil in an ELISA plate reader (BioTEK ELx800). Results were adjusted for 
background and compared to a positive control o f cells lysed in 2 % triton-X 100 to 
determine the magnitude o f cell death at different doses o f xenobiotic.
2.2.7 Characterisation of R-123 Physicochemical Properties
Since quantification o f R-123 is by means o f spectroscopy, understanding the factors that 
may change the fluorescence intensity independently o f concentration is essential for 
accurate measurement. Thus, factors such as rate o f natural fluorescence decay, critical 
micelle concentration and solvent and detergent effects have been investigated.
2.2.7.1 Wavelength Optimisation
When R-123 is prepared in 100 % methanol, the A,max is reported to be 511 nm with 
molar extinction coefficient (e) o f 85,200 M 'Vm '1 (Du et al., 1998). Exact starting 
concentrations o f stock solutions prepared in methanol were deduced using the equation:
A=eCl
Where s = 85,200 M_1cm '1, C = concentration and 1 = path length o f light through the 
sample (1 cm).
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Stock solutions were diluted to working concentrations in HBSS with a maximum of 1 % 
methanol. Solutions of 1 pM R-123 and 1 pM R-110 were prepared in HBSS. UV-Vis 
absorption spectra were measured using a Perkin Elmer Lambda 25 (Milan, Italy). 
Fluorescence emission spectra (Lex = 505 nm) were obtained using the Varian Cary 
Eclipse fluorescence spectrometer (California, USA) by monitoring emission over a 500- 
600 11111 range.
2.2.7.2 Stability of R-123 Fluorescence in HBSS
The stability ofR-123 fluorescence in buffer was determined to ensure that any changes 
to fluorescence by experimental means were not due to natural decay. The fluorescence 
intensity o f 2 pM solutions ofR-123 over 1 hour was measured in quadruplicate using 
the Varian Cary Eclipse fluorescence spectrometer kinetics function (Lex = 505 nm; A,em 
= 525 nm). Linear regression was performed using GraphPad Prism software (version 5, 
San Diego, USA).
2.2.7.3 Partitioning of R-123 into HBSS and Octan-1-ol
The partition coefficient ofR-123 at physiological pH (logD) was determined to estimate 
whether R-123 could passively diffuse across cell membranes. Briefly, equal volumes o f 
HBSS and octan-l-ol were mixed to pre-saturate them before the addition o f 0-0.5 pM R- 
123 (methanol 0.5%). Solutions spiked with R-123 were vortexed and the phases allowed 
to separate before determining the fluorescence in each phase using the Varian Cary 
Eclipse fluorescence spectrometer (HBSS phase; Lex = 505 mn; Lem = 525nm; Octan-l- 
ol phase; Lex = 505 mn; A,em = 537 nm). Amount (moles) ofR-123 in the HBSS phase 
was calculated by comparison to an R-123 standard curve prepared in water pre-saturated 
with octan-l-ol. Due to non-linearity ofR-123 fluorescence in octan-l-ol, amount o fR - 
123 in the octan-l-ol phase could only be estimated using the following equation:
Amount in octan-l-ol phase (moles) = Total number o f moles -  Amount in water phase (moles)
2.2.7.4 Determination of the Critical Micelle Concentration of R-123
The critical micelle concentration (CMC) is a measure o f  the concentration o f a solution 
component; in this case R-123, which represents a critical value above which increasing 
the concentration o f that component forces formation o f micelles. In the case o f 
fluorophores, micelle formation may alter fluorescence characteristics, leading to a shift 
in Lmax or a change in fluorescence intensity. Micelle formation may also make a 
component less available for metabolism and transport, and thus should be avoided if 
these processes are o f interest. CMC was determined by measuring the fluorescence 
emission (Varian Cary Eclipse; Lex = 505 nm; Lem = 500-600 nm) o f increasing 
concentrations (0-0.5 pM) o f R-123 in HBSS (methanol 1 %) and plotting the Lmax (530 
nm) at each concentration. Linear regressions were performed using GraphPad Prism 
software, version 5, and the CMC calculated using the equation below:
CMC = (C2-C1) / (M l-M2)
Where C = y axis intercept, M = slope, 1/2 = indicates the number o f the linear regression
2.2.7.5 Determination of the Dielectric Constant of R-123 and R-110
The dielectric constant (E) o f a compound is an index o f its polarity, which in turn gives 
an indication o f its solubility in cell membranes. A series o f solvents o f increasing 
polarity will show a similar increase in dielectric constant. Thus, solvents may be 
classified according to their dielectric constants as polar (E > 50), semi-polar (E = 15 - 
50), or non-polar (E = 1 - 15) (Lowiy and Richardson, 1987). The polarity o f a solvent 
will generally influence the fluorescence-emission spectra o f fluorophores (Barghouthi,
1996), and since Tike dissolves like’, the change in emission spectra can be used to 
estimate the polarity or dielectric constant o f the fluorophore. Briefly, ImM solutions o f 
R-123 and R-110 were prepared in methanol and diluted 1:1000 into each analytical 
grade test solvent (Table 2-6).
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Solvent Dielectric Constant (E)
Octan-l-ol 10.30
2-butanol 17.26
Butanol 17.84
2-propanol 20.18
Ethanol 25.30
Methanol 33
Acetonitrile 36.64
HBSS: Methanol 1:5 40.54
HBSS: Methanol 1:2 48.45
HBSS: Methanol 1:1 56.45
HBSS: Methanol 2:1 64.34
HBSS: Methanol 5:1 72.35
HBSS 80.30
Table 2-6 Dielectric Constants for Common Solvents
Values of E, were obtained from the CRC Handbook of Chemistry and Physics (Lide, 2008).
As such, each sample contained 1 % v/v methanol and 99 % test solvent. Solutions were 
prepared in triplicate and measured in triplicate (Lex 505 mn; k m  500-600 nm). Mean 
fluorescence intensities were correlated against emission wavelength. Emission at 520 
nm against solvent dielectric constant was then plotted to obtain an estimated value o f E 
for each fluorophore.
2.2.7.5.1 The Effect of Methanol on the Fluorescence Spectrum of R-123
Stock solutions ofR -123 were made by solubilising powdered compound in methanol 
and diluting to desired working concentrations using an appropriate buffer. Since solvents 
may alter the fluorescence profiles o f fluorophores, the effect o f methanol concentration 
on R-123 fluorescence was determined. lpM  solutions ofR -123 containing 0-100 % 
methanol were prepared using HBSS buffer as the co-solvent. Fluorescence profiles 
determined using the Varian Cary Eclipse fluorescence spectrometer ( X q x  = 495 nm; Xem 
= 500-600 nm) and plotted in GraphPad prism, version 5.
90
2.2.7.5.2 The Effect of Lysis Buffers on the Fluorescence Spectrum of R-123
For R-123 intracellular accumulation (section 2.2.6) and sequestration studies, (section 
2.2.9) cells were lysed to determine the concentration o f R-123. Detergents in the lysis 
buffer may alter the fluorescence characteristics o f R-123 by causing micelle formation. 
Thus, buffers were tested to determine and minimise fluorescence shift during cell lysis. 
1 pM R-123 was spiked into three commonly used lysis buffers; Ripa buffer (50 mM 
TrisHCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 1 % (v/v) Nonidet p40, 0.1 % (v/v) SDS), 
Western blot protein extraction buffer (0.2 % (v/v) SDS, 2 % (v/v) Nonidet p40 and 1 pM 
dithiothrietol (DTT)) and 2 % (v/v) triton-X 100. R-123 fluorescence was then measured 
using the Varian Cary Eclipse fluorescence spectrometer (A,ex = 505 nm; A,em = 500-600 
nm) and profiles were compared to a control (1 pM R-123 in HBSS).
2.2.8 Metabolism of R-123 to R-110
R-123 is metabolised to R-110 by the removal o f a methyl ester group (Sweatman et al., 
1990). R -l 10 is also a fluorophore but emits with a lesser intensity at the same excitation 
wavelength. Thus, the rate o f conversion o f R-123 to R-110 can be determined by 
measuring the initial fluorescence decrease over time. Metabolism was measured in 
cuvettes containing HBSS supplemented with 5 mM MgCb, 5mM glucose-6-phosphate, 
0.5 mM (3-NADP+ and 0-1.4 pM R-123. The reaction was started by addition o f MDCKII 
or human liver derived S9 fraction (sections 2.2.8.1 & 2.2.8.2) at a final concentration o f 
0.1 mg/ml and 1 mg/ml respectively. Fluorescence decrease over 2 minutes was 
measured using the Varian Cary Eclipse fluorescence spectrometer (Xex = 505 nm; A.em = 
530 nm) and the initial velocity plotted against concentration o f R-123. Controls 
containing no S9 fraction, co-factors or R-123 were also performed as three separate 
reactions to determine fluorescence stability and background fluorescence.
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2.2.8.1 Preparation of Human Liver S9 Fraction
Approximately 2 g o f human liver (Table 2-2 for donor details) was defrosted rapidly 
from -80 °C and scissor minced in an appropriate volume o f 1.15 % ice-cold ICC1, to 
make a 25 % (w/v) solution. Liver was homogenized on ice using a Dounce homogeniser 
and the homogenate was centrifuged for 20 minutes at 9950 x g at 4 °C. The supernatant 
(containing microsomes and soluble fraction) was retained and assayed for protein 
concentration using the Lowry method (section 2.2.12.2).
2.2.8.2 Preparation of MDCKII S9 fraction
Two T75 flasks o f adherent MDCKII cells at 80 % confluence were washed three times 
with PBS and detached from the flask by coating in trypsin-EDTA for 5 minutes. 
Complete DMEM media was added to inactivate the trypsin and to suspend cells. Cell 
suspensions were centrifuged for 5 minutes at 3000 rpm. Media was removed and the 
pellet resuspended in cold HBSS. Cells were then homogenised and lysed by passing 
through a 21-gauge needle. The lysate was centrifuged for 20 minutes at 9000 x g at 4 °C 
and the supernatant (containing microsomes and soluble fraction) assayed for protein 
concentration using the Lowry method (section 2.2.12.2).
2.2.8.3 Identification of Fluorescent Metabolites by TLC
Thin layer chromatography (TLC) separation o f R-123 and R-110 was optimised using 
commercial preparations o f the two dyes. The mobile phase consisted o f 100 ml 
chloroform: methanol (50:50), which was allowed to equilibrate for one hour before 
introduction o f the plate. 5 pM solutions o f each dye prepared in methanol were spotted 
onto the origin line individually (4 pi each) or in combination (2 pi each) and allowed to 
dry before introduction to the tank. Plates were developed until the solvent front reached
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2 cm from the top o f the plate. Spots were visualised under UV light using the Gene 
Genious Bio Imaging System (Syngene, Cambridge, UK).
Following R-123 metabolism, TLC was used to separate and visualise the metabolites to 
confirm the presence o f fluorescent R-110. The mobile phase consisted o f 100 ml 
chloroform: methanol (70:30), which was allowed to equilibrate for one hour before /
introduction o f the plate. The alteration of the mobile phase was required for adequate 
separation o f samples containing S9 fraction. Metabolic reactions were carried out in 100 
jul volumes containing 0.1 mg/ml MDCKII S9 fraction or 1 mg/ml human liver S9 
fraction in HBSS with 5 mM MgCl2, 5 mM glucose-6-phosphate, 0.5 mM |3-NADP+ and 
1 pM R-123. These reaction mixtures were diluted 1:1 with methanol before spotting 5 pi 
onto Whatman glass TLC plates coated with a 1000 pm layer o f silica. Commercial 
samples ofR-123 and R-110 diluted to 2 pM with the same volume o f heat deactivated 
S9 fraction used in the metabolic reactions (to allow for matrix dependent migration) and 
further diluted 1:1 with methanol were also loaded as positive controls. Plates were 
developed until the solvent front reached 2 cm from the top of the plate. Spots were 
visualised under UV light using the Gene Genious Bio Imaging System (Syngene,
Cambridge, UK). The retention factor (Rj) was mathematically described using the ratio:
Rf -  alb, where a represents the distance from the origin to the spot centre o f the sample 
and b the distance from the origin to the solvent front.
2.2.9 Sequestration of R-123 into Soluble and Insoluble Cell Fractions
R-123 is reported to accumulate within the matrix o f mitochondria (Huang et al., 2007), 
which decreases the proportion o f the intracellular dose available for efflux. Thus, the 
amount ofR-123 in the soluble (cytosolic) and insoluble (organelle containing) fractions 
was determined. Confluent Huh7 or MDCKII cells grown in T150 cell culture flasks 
were incubated with either 10 pM R-123 (methanol 1%) in HBSS or vehicle control for 
10 minutes at 37 °C. Excess R-123 was removed and the cells were washed three times 
with 10 ml o f cold PBS. Cells were released from the flask by coating with trypsin-
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EDTA for 5 minutes. Trypsin was inactivated by the addition o f 10 ml o f mitochondrial 
isolation buffer (MIB) (200 mM D-mannitol, 70 mM Sucrose, 10 mM HEPES, 1 mM 
EGTA, pH 7.4). The cell suspension was then centrifuged for 5 minutes at 3000 rpm. The 
resulting pellet was resuspended in MIB and sheered with a 21-gauge needle. Lysate was 
then centrifuged at 9000 x g for 10 minutes. The supernatant was retained as the soluble 
fraction and the pellet was resuspended in MIB to give the insoluble fraction. 
Fluorescence o f each fraction for control and treated cells was determined using the 
Varian Cary Eclipse fluorescence spectrometer (Zex = 505 nm; kem = 530 nm). 
Fluorescence was quantified by comparison to a standard curve o f R-123 fluorescence 
prepared by spiking R-123 into the relevant cell fraction obtained from control cell lysis.
2.2.10 Determination of R-123 Binding to Albumin
Plasma protein binding is known to be an important factor in drug disposition, since only 
the unbound drug is partitioned into the body organs and is subjected to liver and kidney 
excretion. The extent o f R-123 binding to albumin, the most abundant earner protein was 
determined by measuring a decrease in R-123 fluorescence intensity upon binding. 
Solutions o f O.lmM R-123 in methanol and 0.1 mM human serum albumin (HSA) (-99%  
fatty acid free) were prepared. The exact concentration o f R-123 was determined by
measuring the absorption at 511 nm using a molar extinction coefficient (e) o f 85.2mM_1
cm’1 (Du et al., 1998) and that o f albumin determined by measuring the absorption at 279
nm using an epercent o f 5.31 (Zsila et al., 2003). The O.lmM R-123 stock was diluted
1:1000 with HBSS, and 3 ml o f this solution was used to fill a cuvette o f 1cm path length. 
To this R-123 solution, 30 pl aliquots o f 0.1 mM HSA were sequentially added and the 
fluorescence o f the solution measured after each addition using the Varian Cary Eclipse 
fluorescence spectrometer (kex = 505 nm; 7em = 525 mn). Additions were continued 
until fluorescence decrease was due to the dilution effect alone. Dilution effect was 
corrected for by increasing the fluorescence value by the same proportion as R-123 
concentration decrease.
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2.2.11 Characterisation of Ceils at the RNA Level
Correlation between mRNA and protein levels has been shown insufficient to predict 
individual protein expression levels from quantitative mRNA data (Gygi et al., 1999). 
However, relationships between mRNA and protein expression may be retained between 
in vitro and in vivo systems and so a comparison may identify conserved patterns o f 
protein expression. In this study RNA levels o f selected drug transporter genes were 
measured by quantitative RT-PCR in human and rat liver, primary hepatocytes and the 
cell lines named in section 2.2.1, in order to compare expression between cells used in in 
vitro ADME screening and liver.
2.2.11.1 Sample Collection
Samples o f freshly isolated rat liver, or rat liver slices were snap frozen in liquid nitrogen 
and submerged in 10 volumes o f RNA later ICE. Samples were stored for one week at -80 
°C and defrosted for 12 hours at -20 °C prior to removal o f RNA later ICE and processing 
with the RNeasy mini-lcit (Section 2.2.11.2).
Medium was aspirated from adherent cells, which were washed with PBS and lysed 
directly on cell culture plates or flasks using lysis buffer from the RNeasy kit.
2.2.11.2 RNA Isolation
RNA was isolated using the RNeasy mini kit procedure; Following collection, cells or 
tissues (maximum cell number 5 x 106, or maximum mass, 30 mg) were homogenised 
before being applied to a silica-gel based membrane, which binds RNA of >200 
nucleotides in the presence o f ethanol. RNA was washed three times to remove 
contaminants before being eluted in 60 pi water. RNA integrity was checked by running 
2 volumes RNA with 1 volume Orange G loading dye (0.25 % Orange G, 50 % glycerol) 
on a 1 % (w/v) agarose gel, in 1 x TAE buffer (0.04 M Tris acetate, 0.01 M EDTA)
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containing ethidium bromide (50 pg/ml). 28s and 18s rRNA bands were visualised using 
the Gene Genious Bio Imaging System (Syngene, Cambridge, UK). Total RNA 
concentration was measured using the NanoDrop spectrophotometer (NanoDrop 
Technologies, Delaware USA) RNA was stored at -80 °C for up to 6 months prior to 
analysis.
2.2.11.3 Removal of Contaminating DNA with DNase I
Up to five micrograms o f  total RNA was added to 10 % (v/v) DNase buffer and 10 units 
o f DNase I. The mixture was incubated at 37 °C for 30 minutes before inhibiting the 
reaction with the addition o f DNase stop solution (2 mM EGTA) and inactivating by 
heating at 65 °C for 10 minutes.
2.2.11.4 Reverse Transcriptase cDNA Synthesis
One microgram o f  the DNased RNA was added to 1.25 mM dNTP’s and 225 ng random 
hexamers. The reaction was heated to 65 °C for 5 minutes and cooled on ice. The reverse 
transcriptase reaction mixture (50 % (v/v) 5x RT buffer, 25 mM DTT, 12.5 % (v/v) 
RNase OUT, 3.125 % (v/v) Superscript II) was added and incubated for the following 
cycle: 10 minutes at 25 °C, 50 minutes at 42 °C, 15 minutes at 70 °C. A  control 
containing no superscript II (RT minus) was included for all reactions, as this allowed for 
the control o f  contaminating genomic DNA in samples: Quantitative analysis o f  RT 
minus samples showed negligible levels o f  genomic DNA contamination. Generated 
cDNA was stored at minus 20 °C for a maximum o f  1 month prior to analysis.
2.2.11.5 Quantitative Reverse Transcriptase Polymerase Chain Reaction
Five microlitres o f  cDNA was added to 20 pi o f  the real time Reverse Transcriptase 
Polymerase Chain Reaction (RT-PCR) reaction mixture (10 pmol forward primer, 10
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pm ol reverse primer, 2.5 pmol probe, 62.5 % (v/v) 2 x TaqM an Universal PCR 
M asterM ix in a white 96 well optical reaction plate sealed with an optical adhesive cover. 
Sequences o f  TaqMan probes and primers designed using the Applied Biosystems Primer 
Express software, version 2.0 are given in Table 2-7, 2-8 and 2-9. The plate was 
centrifuged at 1000 x g for 1 minute to collect the reaction mixture at the bottom o f  the 
wells. The plate was then cycled in an ABI Prism 7000ITT Sequence Detection System 
(Applied Biosystems, Foster City, CA, USA) for the following program: 50 °C for 2 
minutes, 95 °C for 15 minutes and 40 repeats o f  95 °C for 15 seconds and 60 °C for 1 
minute. Results were compared to standards o f  human, rat or dog genomic DNA, as 
appropriate, over five orders o f magnitude. Data was analysed using the ABI Prism 
software to calculate the number o f  copies o f  RNA per well compared to the standard 
curve. Expression levels o f the endogenous control, GAPDH was determined in a 
samples normalise target gene expression data to compensate for differences in cDNA 
loading.
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2.2.12 Characterisation of Ceils at the Protein Level
There is now increasing evidence that mRNA expression patterns are necessary but are by 
themselves insufficient for the quantitative description o f  biological systems. This 
evidence includes discoveries o f  post-transcriptional mechanisms controlling the protein 
translation rate, the half-lives o f  specific proteins or mRNAs, and the intracellular 
location and molecular association o f  the protein products o f expressed genes (Gygi et a l ,  
1999). Therefore protein expression o f  selected transporters was qualitatively determined 
both in vitro and in vivo to ensure that mRNA expression levels were representative o f 
protein expression levels.
2.2.12.1 Protein Extraction
M edium was aspirated from adherent cells, which were washed in PBS and lysed with 
PBS containing 1 x protease inhibitors, 0.2 % (v/v) SDS, 2 % (v/v) Nonidet p40 and 1 
pM  dithiothrietol (DTT). Lysate was homogenised by passing it through a 21 G needle 
before being spun at 1000 x g for 10 minutes to remove debris. To separate a crude 
membrane fraction, the total protein was centrifuged for 30 minutes at 100000 x g. The 
precipitate was re-suspended in 0.1 M  Tris-HCl and centrifuged for a further 30 minutes 
at 100000 x g. The pellet was re-suspended in 0.1 M Tris-HCl containing protease 
inhibitors with 5 strokes o f a mechanical homogeniser (the crude membrane fraction). A 
fraction was also saved from the supernatant (crude cytosolic fraction), and all protein 
samples were stored at minus 80 °C for a maximum o f  6 months prior to analysis.
Primary cells were lysed using 2 % (v/v) triton-X 100 with 1 x protease inhibitors. Total 
cell lysate was homogenised by passing it through a 21 G needle before being spun at 
1000 x g for 10 minutes to remove debris.
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2.2.12.2 Quantification of Protein by the Lowry Method
All protein fractions were assayed for concentration using the Lowry method (Lowry et 
al., 1951) modified to a 96-well plate format. All fractions were first diluted 20, 50, 80 
and 100 fold with 0.5 M  NaOH. 150 pi copper sulphate solution (10 ml 2 % N a2C 0 3, 0.1
ml 1 % Cu SO -5H O, 0.1 ml 2 % KNaC H O -4H O) was added to 30 pi o f  each
2 4 2  4 4 6 2 ^
sample and bovine serum albumin (BSA) standard assayed in triplicate. After 10 minutes 
at room temperature, 15 pi o f  50 % Folin-Ciocalteau reagent (diluted with water) was 
added to the samples and standards and mixed thoroughly. After 30 minutes, absorbance 
was read at 490 mn on the Bio-Tele EL x 800 plate reader. Sample protein concentration 
was determined by comparison to a standard curve generated using BSA standards 
ranging in concentration from 50-250 pg/ml protein.
2.2.12.3 Separation of Proteins by SDS-PAGE
Proteins were separated on the basis o f  m olecular weight by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). Sample loading buffer (60 mM  Tris pH 
6.8, 12 % glycerol, 2 % SDS, 0.003 % pyronin Y, 0.7M p-mercaptoethanol) was 
prepared in bulk and mixed with an equal volume o f  protein. Proteins were heat 
denatured at 60 °C for 10 minutes before placing on ice. For proteins smaller than 170 
kilodaltons (lcDa), a 12.5 % resolving gel (12.5 % acrylamide, 0.3 % bisacrylamide, 0.4 
M Tris-HCl pH 8.8, 0.1 % SDS, 0.16 % ammonium persulphate, 0.16 % TEMED) and a 
6 % stacking gel (6 % acrylamide, 0.16 % bisacrylamide, 0.2 M Tris-HCl pH  6.8, 0.1 % 
SDS, 0.24 % ammonium persulphate, 0.4 % TEM ED) were used to separate proteins at 
0.2 A for approximately 40 minutes or until the coloured dye reached the end o f  the plate. 
For proteins larger than 170 kDa, a 6 % resolving gel (6 % acrylamide, 0.16 % 
bisacrylamide, 0.4 M Tris-HCl pH 8.8, 0.1 % SDS, 0.16 % ammonium persulphate, 0.16 
% TEMED) and a 4 % stacking gel (4 % acrylamide, 0.11 % bisacrylamide, 0.2 M Tris- 
HCl pH 6.8, 0.1 % SDS, 0.24 % ammonium persulphate, 0.4 % TEM ED) were used to 
separate proteins at 0.1 A for approximately 40 minutes. Gels were ran  in 1 x running
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buffer made by diluting 10 x buffer (1 % SDS w/v, 0.25 M  Tris base, 1.92 M  glycine, pH 
8.3) one part in ten with water. MagicMarlc™ XP W estern protein standards, or Novex 
Sharp pre-stained protein standards were used to calculate the mass o f the separated 
proteins.
2.2.12.4 Identification of Proteins by Western Blotting
Proteins separated by SDS-PAGE were transferred onto an activated PVDF membrane at 
0.3 A for 1.5 hours in 1 x transfer buffer made by diluting 10 x buffer (0.16 M  Tris base, 
1.2 M glycine) one part in ten with water. The membrane was blocked using 20 ml 
blocking solution per membrane (1 x Tris buffered saline with Tween-20 (TBST; 20 mM 
Tris, 140 mM NaCl, 0.1 % Tween20) and 10 % Marvel) for a minimum o f  1 hour rotaiy 
mixer. The membrane was washed three times in 10 ml TBST for 10 minutes each before 
incubating with 5 ml o f  prim ary antibody in antibody buffer (5 % marvel in TBST) for a 
minimum o f  1 hour on a rotaiy mixer (see table 2-10 for antibody conditions). Unbound 
prim ary antibody was removed by washing the membrane as previously, followed by 
incubation with secondary antibody in antibody buffer for a minimum o f  2 hours (Table
2-9 for antibody conditions). Primary and secondary antibody dilutions were optimised 
during this procedure to achieve the best western blot conditions. After another washing 
step the membrane was incubated for 5 minutes with ECL-plus chemiluminescent 
reagent, and then developed onto film.
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Protein / Size (kDa) Protein
loading
Antibody I.D Dilution Incubation times
ABCB1 / -180 50 jig 1° C219 (m)
2° a-mouse (Sc-2005)
1° 1 
2° 1
100
5000
1° 3.5 hour 
2° 2 hours
ABCB 1 / - 1 70 50 pg 1° Sc-55510 (m)
2° a-mouse (Sc-2005)
1°1 
2° 1
750
5000
1° 1 hour 
2° 2 hours
A B C C 2/-190-200 50 pg 1° Sc-5770 (p)
2° a-goat (Sc-2020)
1° 1 
2° 1
100
20,000
1° 1 hour 
2° 2 hours
A B C C 2/-190-200 10 pg 1° Sc-20766 (p) 
2°a-rabbit (Sc-2030)
1°: 1 
2° 1
250
10,000
1° 1 hour 
2° 1 hour
Oatpla4 / -90 30 pg 1° Sc-33610 (p)
2° a-rabbit (Sc-2004)
1°1 
2° 1
200
20,000
1° 1 hour 
2° 2 hours
OCT1 / -60 30 pg 1° AV41516 (p)
2° a-rabbit (Sc-2004)
1° 1
2° 1
300
20,000
1° 2 hours 
2° 1 hour
Actin / -40 50 pg 1° Sc-1616 (p)
2° a-goat (Sc-2020)
1°1 
2° 1
250
20,000
1° 1 hour 
2° 2 hours
LDH / -35 50 pg 1° Ab2101 (p)
2° a-goat (Sc-2020)
1°1
2° 1
1000
30,000
1° 1 hour 
2° 2 hours
5’ nucleotidase / -55 50 pg 1° Sc-32299 (m)
2° a-mouse (Sc-2005)
1°1
2° 1
200
20,000
1°1 hour 
2° 2 hours
Table 2-10 Antibody conditions for W estern blotting
Antibodies with I.Ds beginning with ‘Sc’ were purchased from Santa Cruz Biotechnologies 
(Heidelberg, Germany). The ABCB1 C219 antibody was purchased from Abeam (Cambridge, 
UK) and the AV41516 OCT1 antibody was purchased from Sigma-Aldrich (Sigma-Aldrich, 
Poole, UK). Accession numbers followed by (m) designate monoclonal antibodies and those 
followed by a (p) designate polyclonal antibodies.
Where cross-species comparison o f  protein expression was required, W estern blotting 
was performed using an antibody raised against the target protein in one species and used 
to detect a potential ortholgue in the alternate species. Any protein bands detected in an 
alternative species, o f  the correct molecular mass were identified to be the functional 
orthologue based on the specificity o f  the antibody for particular amino acid sequences.
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2.2.12.5 Membrane Stripping and Re-probing
PVDF membranes were stripped o f  prim ary and secondary antibodies before re-probing 
for loading controls using a m ethod described by the Abeam W estern Blotting Beginners 
Guide (Cambridge, UK: www.abcam.com/technical). Membranes were soaked in a mild 
stripping buffer (1.5 % (w/v) glycine, 0.1 % (w/v) SDS, 1 % (v/v) Tween-20, pH 2.2) for 
15 minutes, before being washed twice for 10 minutes each with PBS. Membranes were 
washed twice more with TBST for 5 minutes each and then incubated for 1 hour in 
blocking solution prior to re-probing. M embranes were stripped a maximum o f  three 
times to minimise protein loss.
2.2.12.6 Semi-quantification of Protein Bands by Densitometry
GeneTools software (SynGene, Cambridge, UK) was used to perform quantification o f  
the raw volume o f  the protein band corresponding to the loading control; actin and the 
target protein. For each lane, the value obtained for the target band was divided by the 
value obtained for the actin band, to obtain a ratio o f  target band raw volume: actin raw 
volume. This ratio is referred to as the normalised protein band density.
2.2.13 Program Information for Data Produced and/or Analysed In 
Silico
2.2.13.1 Clustal X 2.0
Naming o f  newly identified genes or proteins, has often been based on the chronology o f 
identification rather than orthology to already named genes and proteins (Hagenbuch and 
Meier, 2003). Thus, in situations where an orthologue o f  either a transporter or a drug 
metabolising enzyme had not clearly been identified, protein alignments were carried out 
to find likely candidates. Clustal X  2.0 is a new graphical interface to the Clustal W text
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based program, which has been written to provide a single environment in which the user 
can perform  multiple alignments, view the results and, if  necessary, refine and improve 
the aligmnent (Larkin et al., 2007; Thompson et al., 1997). Sequences can be aligned 
across their entire length (global aligmnent) or only in certain regions (local aligmnent). 
In this research, global alignments performed, by importing full amino acid sequences 
obtained from NCBI and identified using a RefSeq accession number. Complete multiple 
alignments were carried out, and results were displayed as a percent identity matrix.
2.2.13.2 CellDesigner™ v.4.0
Cell Designer™  (v.4.0; http://celldesigner.org). which utilises the Systems Biology 
Graphical Notation (SBGN) format was used for all graphical pathway modelling. In this 
program, biological networks were visually represented and each reaction was associated 
with a kinetic law, comprised o f ordinary differential equations (ODEs). For simulation 
o f  networks, the Systems Biology M ark-up Language (SBML) script was exported into 
an alternative modelling package (Funahashi et al., 2003).
2.2.13.3 COPASI
SBML scripts generated in CellDesigner, were imported into the Complex Pathway 
Simulator v.4.5.3 (COPASI; http://www.copasi.com). which was used to simulate 
network dynamics based on ODEs for compartments, species and global quantities. 
COPASI has been used in this research to cany  out parameter scans, tim e-scale analysis 
and sensitivity analysis o f  the biological network. Data output can be viewed in the form 
o f  tables, plots and histograms (Hoops et al., 2006). For modelling purposes, 
concentration units were required to be in the pm ol/pi format. Please note that for 
comparison purposes, the pM  units used in previous chapters are equivalent to pmols/ pi.
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2.2.14 Statistical Analysis of Data
Where results are an average o f  several biological repeats, the mean and standard 
deviation (SD) are used to show how much variation there is among individual 
observations, while standard error o f the mean (SEM) is used to show how good the 
estimate o f  the mean is. The number o f  biological repeats and the analysis used is given 
in the figure legends. Results from dosing studies are given as a percent change from 
control values to allow inter-experiment comparison and expression analysis results are 
given as a percentage o f  the liver expression levels. W hen results are expressed as 
percentage o f  control, repeated measures ANOVA with Bonferroni post-hoc test was 
used to show statistical significance, whereas when there was direct comparison against a 
control group, the post-hoc test employed was D unnet’s. Statistical significance o f results 
was calculated using the most appropriate statistical test for each experiment (for details 
see figure legends) using GraphPad Prism  software (version 5; San Diego, USA). 
Correlation analysis was calculated using a Pearson correlation (GraphPad Prism).
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3. Drug Transporter Expression in in vitro Models for the 
Future Prediction of Drug Disposition in Man
3.1 Introduction
To predict disposition o f newly developed drugs in man and especially to determine the 
clinical implications, in vitro systems as close as possible to the in vivo situation are 
needed. Hepatocytes isolated from human liver are a particularly attractive system to 
study absorption, metabolism and hepatobiliary clearance. However, in cultured human 
hepatocytes the metabolic capacity is attenuated (Aninat et al., 2006; Grondin et al., 
2008) and the expression o f  transport proteins is reduced during culturing, possibly due to 
isolation from then  natural environment and lost cell-cell contacts (Gagne et al., 2006; 
Jigorel et al., 2006). Modification o f  isolation and/or culture methodology can produce 
more representative cells, as seen with hepatocyte cultures in single or dual collagen 
matrixes, potentially allowing hepatocyte transport to be examined. Isolated hepatocytes 
are a powerful model, yet limited by availability, costs in preparation due to labour- 
intensive methods, and due to the individuality o f each hepatocyte preparation. Inter­
donor variability also has to be addressed when using isolated hepatocytes.
Cell lines that are either artificially transformed or are derived from human carcinomas 
provide a stable, robust assay system against which the effects o f  drugs can be compared 
over a long period, in terms o f  both extended time studies and robustness for frequently 
used screening tools. The choice o f  human cell lines has the advantage o f  eliminating 
species differences, when considering development o f  drugs for use in man. However, 
cell lines often don’t express a full range o f proteins, or display basolateral and apical 
specific expression compared to primary cells or in vivo tissue and this can lead to the 
misinterpretation o f in vitro results. While the intestinal model system o f Caco-2 cells are 
almost universally accepted as a robust model o f  the intestine, no similar system is 
available for the liver (Fearn and Hirst, 2006).
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In this chapter, the mRNA transcript levels o f  12 human drug transporter genes and their 
equivalents in rodents and canines were measured using quantitative RT-PCR in Huh7 
cells, prim ary rat hepatocytes, W istar albino rat liver and liver slices, prim ary human 
hepatocytes, human liver and M D C K II cells, as a first step in resolving the differences in 
transporter expression between these m odel systems. Selected transporters were also 
semi-quantified in these systems by W estern blotting, to reveal whether differences in 
expression observed at the mRNA level were present at the protein level. Transcript level 
measurements were compared to levels from human liver samples where possible to 
allow potential in v itro - in vivo correlations to be made.
3.2 Reference Gene Expression in Model Cell Systems
Transporter transcript levels were normalised to GAPDH when relative expression levels 
within a system were to be compared. However, due to differences in GAPDH expression 
in different systems (Figure 3-1), when transporter expression levels were to be compared 
between systems with significantly different GAPDH levels, copy numbers per 50 ng 
m RNA were used. The latter conditions were only deemed acceptable w hen GAPDH 
expression levels were consistent between samples in one system, and mRNA loading 
could be assumed to be consistent. Differences between GAPDH transcript levels were 
not significant between whole liver and prim ary hepatocyte systems (p>0.05), however in 
immortalised cell lines such as Huh7 and M DCKII, GAPDH expression is significantly 
up-regulated when compared to liver samples or prim ary cells (p<0.0001) (Figure 3-1). 
Comparison o f  another commonly used reference gene, 18s rRNA also demonstrated a 
significant difference in expression between human liver and Huh7 cells (p<0.0001).
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Figure 3-1: Reference Gene Expression between M odel Cell Systems
GAPDH transcript expression level in each model system was determined by RT-PCR using 50 
ng of input mRNA. Results were analysed for significant differences in expression between 
systems by one way ANOVA with Tukey post-hoc test (*** = p < 0.0001, NS = not significant, n 
= 3-5: error bars = SEM; where no error bars are observed they are contained within the limits of 
the data point). 18s rRNA transcript level in Huh7 and human liver systems was determined by 
RT-PCR using 50 ng input mRNA. Results were analysed for significant differences in 
expression between systems by unpaired t-test (*** = p < 0.0001, n = 4: error bars = SEM; where 
no error bars are observed they are contained within the limits of the data point).
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3.3 Expression of Drug Transporters in Human Derived Cell 
Lines and Tissues
3.3.1 Human Liver
The human liver is the system that we are attempting to ultimately replicate in vitro in 
order to predict and understand the factors determining drug disposition on a cellular 
level. Human livers are often utilised to isolate prim ary hepatocytes which have become 
the “gold standard” for evaluating hepatic metabolism and toxicity o f  drugs and other 
xenobiotics in vitro. Although primary hepatocytes contain a broad complement o f 
metabolising enzymes and transport proteins organized in a physiologically relevant 
context, the isolation procedure can produce unexpected effects. For example, OATP1A2 
mRNA has not been detected in freshly isolated human hepatocytes (Jigorel et al., 2005), 
despite its expression albeit at low levels in the human liver (Tamai et al., 2000). For a 
realistic estimation o f  the transport proteins expressed, mRNA was extracted from 
sections o f  human liver that had been snap frozen and stored at -80 °C immediately after 
excision with no further processing.
Control human livers generally expressed a higher level o f  uptake transporters in relation 
to those involved in efflux (Figure 3-2). O f the uptake transporters, OATP2B1 and OCT1 
were most highly expressed, but also exhibited the most variability amongst individuals. 
Low levels o f  OATP1A2 were detected in all livers suggesting that the samples were 
processed in such a way that enabled retention o f  transporters that are lost during primary 
hepatocyte isolation. O f the efflux transporters, ABCC2 was the most highly expressed in 
human livers, as it was in control rat livers. The sinusoidal efflux transporter, ABCC4 
was identified in the samples but was not quantifiable as levels were below the limit o f  
quantitation, which was set from the limit o f  detection and the background noise level.
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Figure 3-2 Drug Transporter mRNA Expression in Human Livers
The mRNA expression level of each transporter was quantified by RT-PCR in samples of human 
liver. Absolute expression levels were measured by comparing the signal from samples to human 
genomic DNA standards of known concentration. Expression levels are normalised to GAPDH. 
Results are expressed as mean (n = 5) ± SD; L/D = below the limit of detection.
3.3.2 Basal Expression of Drug Transporters in the Huh7 Cell line
Theoretically, immortalised cell lines derived from liver carcinoma such as Huh7 should 
be more similar to human liver than cell-lines or tissues derived from other species or 
tissues and hence represent more realistic models for the in vivo situation. Therefore the 
mRNA level o f  12 uptake and efflux transporters was measured in the Huh7 cell line and 
in other model systems to establish if this was true. Selected proteins were also semi­
quantified by W estern blotting, to assess whether protein expression reflected mRNA 
transcript levels the utility o f  the cell line for uptake and efflux assays.
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3.3.2.1 mRNA Transcript Expression in the Huh7 Cell line
As can be seen from figure 3-3 (A), the basolateral uptake transporters most highly 
expressed were OATP2B1 and the liver specific OATP1B3; however, a second liver 
specific transporter OATP IB 1 was expressed at only 5 % o f  OATP1B3 levels. O f the 
canalicular efflux transporters, ABCC2 and ABCB1 were most highly expressed, 
followed by ABCC4 and ABCC1. On the basis o f  the results in figure 3-3 (A) alone, the 
Huh7 cell line could be proposed as a model system to assess compound access as it 
expresses a range o f  uptake and efflux transporters. However, as net uptake will be a 
composite o f  both absolute and relative expression o f these transporters, it is important to 
compare the values to those seen in vivo. Therefore, in figure 3-3 (B), Huh7 transcript 
levels have been expressed as a percentage o f the human liver levels previously 
determined in figure 3-2. Due to differences in GAPDH expression between the cell line 
and human liver, expression levels were not normalised for this analysis. Results show 
that at the transcript level, the majority o f  efflux transporters are expressed at 
significantly higher levels (p < 0.001) in Huh7 cells than in human liver. The exception to 
this rule was the efflux transporter ABCC3, which is the only efflux transporter o f those 
investigated that is expressed on the basolateral rather than canalicular membrane.
For the uptake transporters, there was a significant reduction in OCT1 expression 
compared to human liver (p < 0.05), whereas both OATP1A2 and OATP2B1 expression 
was significantly higher (p < 0.001 and p < 0.05 respectively). The transporters 
exhibiting the largest increase in expression from the human liver baseline are the efflux 
transporters ABCB1 and ABCC1 (p < 0.001) and the uptake transporter OATP1A2 (p < 
0.001), being 1000, 2000 and 600 % higher than in vivo levels. Notably, it is clear that the 
balance between uptake and efflux was shifted between the two systems, with the 
potential for a significantly greater efflux capacity in Huh7 cells compared to in vivo. It is 
also important to draw attention to the larger standard deviation between human liver 
samples (Figure 3-2) and Huh7 samples (Figure 3-3 A), demonstrating the issue o f  inter­
individual variability when using primary cells.
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3.3.2.2 Protein Expression of Transporters in the Huh7 Cell line
Quantitative RT-PCR o f  transporter m RNA transcript levels in the Huh7 cell line 
(Section 3.3.2.1) revealed that a variety o f  basolateral and canalicular based transporters 
were transcribed, and at levels higher than those found in the human liver (Figure 3-3 B). 
However, a lack o f  cell polarity in this cell line could prevent trafficking o f  translated 
proteins to the membrane. I f  this were the case, proteins may be rapidly degraded 
resulting in a low or absent signal in the membrane fraction upon W estern blotting. To 
test if  this was the case, the liver specific uptake transporter, OATP IB  1 and the 
canalicular based multidrag resistance transporter, ABCB1 were semi-quantified by 
W estern blotting. To identify the sub-cellular locations o f  these proteins, total cellular 
lysate was fractionated and the cytosolic and membrane fractions tested for the presence 
each transporter (Figure 3-4 A). Lactate dehydrogenase (LDH) and 5 ’nucleotidase were 
used as positive controls in each fraction respectively (Figure 3-4 B).
Figure 3-4 A  demonstrates that both OATP IB 1 and ABCB1 proteins can be detected in 
the Huh7 cell line. However, whereas OATP IB 1 protein appears to be correctly 
localised, w ith the signal being predom inantly membrane, ABCB1 protein is 
predom inantly cytosolic, which is suggestive o f  non-functional protein. LDH was 
detected in total protein and cytosolic fractions but was undetectable in the membrane 
fraction, whereas 5 ’nucleotidase was detected in the total protein and cytosolic fractions 
and to a lesser extent in the membrane fraction (Figure 3-4 B). This confirms that 
cytosolic proteins were removed from membrane fraction by centrifugation, but removal 
o f  membrane proteins from the cytosolic fraction was not complete.
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Figure 3-4 (A) OATP1B1 and ABCB1 Expression in Huh7 Cytosol and Cell M embrane and 
(B) Lactate dehydrogenase and 5 ’ nucleotidase as Cellular Fraction M arkers
Total (1), cytosolic (2) and membrane (3) protein fractions were extracted from Huh7 cells by 
ultracentrifugation and quantified by Lowry assay. Twenty and ten micrograms of protein for 
OATP1B1 and ABCB1 detection respectively was separated by SDS-PAGE and transferred to a 
PVDF membrane (n = 4 for each fraction). Immunodetection of OATP1B1 gave a band 
corresponding to OATP1B1 at approximately 90 kDa. Immunodetection of ABCB1 using the SC- 
55510 antibody gave a triplet of bands around 170 kDa possibly all corresponding to ABCB1 
with different glycosylation states. Band sizes were determined against a pre-stained molecular 
weight protein standard. (B) Forty or fifty micrograms of protein for LDH and 5’ nucleotidase 
respectively was separated by SDS-PAGE and transferred to PVDF membrane. Immunodetection 
of LDH and 5’nucleotidase gave bands at ~35 kDa and -70 kDa respectively, determined by use 
of a protein molecular weight standard (M).
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3.3.2.3 Efflux Transporter Activity in the Huh7 Cell Line
As demonstrated above, protein expression o f  ABCB1 in Huh7 cells was mainly 
cytosolic, suggestive o f  non-functional protein. This is most likely a result o f  the non­
polarised nature o f  the cells, and their inability to form canaliculi, which potentially 
impacts on all canalicular-localised proteins. To examine this, we used a fluorescent 
substrate for ABCC2, which is localised to the canalicular membrane o f  rat and human 
hepatocytes (Buchler et al., 1996; Konig et al., 1999; Schaub et al., 1999). Cells were 
incubated with 10 pM  non-fluorescent CDFDA which passively diffuses into cells and is 
hydrolysed to fluorescent CDF. After washing o ff extracellular CDFDA/CDF cells were 
incubated in HBSS for 30 minutes at 37°C to allow ABCC2 mediated CDF efflux. Figure 
3-5 (A) shows that after 30 minutes, intracellular fluorescence is high, indicating that 
efflux ability is low or absent. When cells form bile canaliculi, CDF fluorescence is low 
within cells but is clearly visible within canalicular networks after a 25 minute efflux 
period (Figure 3-5 B).
Figure 3-5: Fluorescent CDF sequestered within Huh7 cells
(A) Huh7 cells and (B) primary rat hepatocytes cultured in sandwich configuration were dosed 
with 10 pM CDFDA (0.1 % DMSO) and incubated at 37 °C for 30 minutes. Fluorescent images 
were taken after a 30 minute (A) and 25 minute (B) efflux period using an Axiovert 100 
microscope with the integral AxioCam MRm Rev digital camera at 10 x magnification through a 
FITC filter (485 nm). Cells were exposed to fluorescence for 2 seconds before the image was 
taken. Image B was supplied courtesy of Dr. Kat Howe (University of Surrey, UK).
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3.4 Expression of Drug Transporters in Rodent Derived Ceil 
Lines and Tissues
3.4.1 Identification of Rodent Orthologues of Human Transporters & 
Enzymes
The rat is an important pre-clinical species used to predict human drug response. 
However, for accurate extrapolation between species it is important to know the relative 
expression level o f  transporters and/or enzymes between the two systems. Such a 
comparison is complicated by inconsistencies in nomenclature, and hence it is important 
to fust confirm the correct orthologues for rats and human transporters/enzymes. Identity 
between DNA sequences can be used to identify orthologues, but protein sequences are 
more useful as these are more directly indicative to functional relatedness. For this 
research, the cytochrome P450 family o f  drag metabolising enzymes and the solute 
carrier and ATP binding cassette families o f  transporters involved in uptake and efflux 
respectively are o f  particular interest. Whereas, for efflux transporters, rodent orthologues 
for human transporters have been identified and appropriately named, for uptake 
transporters and some drug metabolising enzymes, orthologues are less well defined. 
Global multiple sequence alignments were therefore earned out in Clustal X 2.0 to 
identify likely candidates from a selection o f  possible proteins.
3.4.1.1 Solute Carrier Organic Cation Transporting Polypeptides (OCT)
The Clustal X protein alignment shows that the rat O ctl, 2 and 3 most resemble human 
OCT1, 2 and 3 respectively. Human OCT1 shares 78 % with rat O ctl and 67 % identity 
with rat Oct2. Human OCT2 shares 81 % identity with rat Oct2 and 68 % identity with 
rat O ctl. Human OCT3 shares 87 % identity with rat Oct 3 and only 50 % identity with 
rat Oct2. Individual human OCTs are more similar to their rat orthologues than they are
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to each other. Thus, it appears that the names o f the rat transporters appropriately 
correspond to the human versions when comparing amino acid sequences.
hOCT2 
NP 003049.1
rOct2
NP 113772.1
hO CTl 
NP 003048.1
rO ctl
NP 036829.1
hOCT3 
NP 068812.1
rOct3
NP 062103.1
hOCT2 
NP 003049.1
100 70 68 50 49
rOct2
NP 113772.1
100 67 68 49 48
hOCTl 
NP 003048.1
70 67 100 7 8  H r Y V 50 48
rO ctl
NP 036829.1
68 68 100 49 48
hOCT3 
NP 068812.1
50 59 50 49 100
rOct3
NP 062103.1
49 48 48 48 : '8 7 g a g : i / 100
Table 3-1 Human versus Rat OCT/Oct Percent identity matrix generated by Clustal X  2.0
Complete amino acid sequences for rat Oct and human OCT transporter proteins were obtained 
from NCBI and identified with a unique Reference Sequence ID (prefix NP_). A complete 
multiple alignment was performed using Clustal X 2.0, and a percent identify matrix was 
generated. The matrix shows the percent identity between all amino acid sequences; cells 
highlighted in grey identify the matches with the highest identity between species.
119
3.4.1.2 Solute Carrier Organic Anion Transporting Polypeptides (OATP)
The percent identity matrix generated using Clustal X (Table 3-2), demonstrates that rat 
O atplb2 is the likely orthologue o f hum an OATP1B3 (65 % identity) and OATP IB 1 (63 
% identity). Rat Oatp2bl shares 77 % identity with hum an OATP2B1, and less than 40 % 
identity with any other transporter. Human OATP1A2 has two potential rat paralogues 
with 72 % identity; O atpla5 and O atpla4. OATP1A2 also shares 67 % identity with rat 
O a tp la l, and 66 % identity with O atpla3 (Oatp21a4) and O atpla6. Thus, it is possible 
that human OATP1A2 has five functional rat paralogues. O atpla5 and O atpla3 however, 
are mainly expressed in the jejunum  and choroid plexus, and kidney respectively and not 
in the liver and are therefore o f less relevance to this research (Hagenbuch & Meier, 
2004). In the liver, O atp la4  and O a tp la l are both expressed (Cheng et al., 2005a), but 
out o f  the two, O atpla4 is considered to be the functional ortholgue due to its high 
sequence identity (Kusuhara and Sugiyama, 2005).
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3.4.1.2 Cytochrome P450 3A Orthologues
CYP3A4 is the major member o f  the human CYP3A family and is responsible for the 
primary metabolism o f  approximately 50 % o f  clinically utilised drugs and makes up 30 
% o f  the total CYP content in liver (Shimada et al., 1994; Watkins, 1992). In rats, the 
Cyp3a subfamily is reported to consist o f  five related genes, C yp3al, Cyp3a2, Cyp3a9, 
Cyp3al8, and Cyp3a23 (Anakk et al., 2003). It is now generally accepted that Cyp3a23 is 
an allelic variant o f  Cyp3al (Baldwin et al., 2003; Mahnke et al., 1997). O f the four rat 
Cyp3a subfamily members, Cyp3a9 shares the most amino acid identity (77 %) with 
human CYP3A4 (Table 3-3) and has been recognised in the literature as the most likely 
CYP3A4 orthologue (Cao et al., 2006). Cyp3a2 and Cyp3al//23 both share 72 % amino 
acid identity with CYP3A4 and 86 % identity with each other. C yp3al8 is only 68 % 
similar to human CYP3A4, yet shares 71 % identity with Cyp3al/23. It is clear that 
members o f  the Cyp3a subfamily are closely related and may all contribute to the 
oxidation o f drugs that are metabolised by CYP3A4 in humans.
rCyp3a2 
NP 695224
rCyp3al/23 
NP 037237
rCyp3a9 
NP 671739
hCYP3A4 
NP 059488
rC yp3al8 
NP 665725
rCyp3a2 
NP 695224
100 8 6 72 72 67
rCyp3al/23 
NP 037237
8 6 100 73 72 71
rCyp3a9 
NP 671739
72 73 100 77 68
hCYP3A4 
NP 059488
72 72 77 100 6 8
rCyp3al8 
NP 665725
67 71 6 8 68 100
Table 3-3 Human versus Rat CYP/Cyp Percent identity matrix generated by Clustal X 2.0
Complete amino acid sequences for rat Cyp3a and human CYP3A drug metabolising enzymes 
were obtained from NCBI and identified with a unique Reference Sequence ID (prefix NP_). A 
complete multiple alignment was performed using Clustal X 2.0, and a percent identify matrix 
was generated. The matrix shows the percent identity between all amino acid sequences; cells 
highlighted in grey identify the matches with the highest identity between species.
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3.4.2 Basal Expression of Drug Transporters in Rat Liver Sections
Rats are the most widely used pre-clinical species for testing drugs that are destined for 
use in humans. Thus, expression levels o f  selected rodent transport protein orthologues 
were determined to aid extrapolation o f  ADME and toxicological data from pre-clinical 
to clinical species. A number o f studies have measured levels o f  drug transporters in 
control rat species; however this assessment was carried out to set the basal expression 
level in each rat so that changes occurring due to the preparation or culture o f  rat liver 
slices could be determined. Relative expression levels o f  selected drug transporters in 
control W istar albino rat liver sections are shown in Figure 3-6.
Transporter
Figure 3-6 Drug Transporter mRNA Expression in Control Rat Livers
The mRNA expression level of each transporter was quantified by RT-PCR in samples of control 
Wistar albino rat liver. Absolute expression levels were measured by comparing the signal from 
samples to rat genomic DNA standards of known concentration. Expression levels are normalised 
to Gapdh. Results are expressed as mean (n = 3) ± SD.
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As seen in Figure 3-6, control rat livers generally expressed a higher level o f  uptake 
transporters than efflux transporters, which is the same pattern o f  expression as seen in 
hum an livers (Figure 3-2). O f the uptake transporters and efflux transporters, O atplb2 
and Abcc2 were most highly expressed respectively. ABCC2 was also the most highly 
expressed efflux transporter in human liver (Figure 3-2), but the uptake transporters most 
highly expressed are different (OCT1 and OATP2B1), possibly indicating the altered 
functional roles o f  the rat uptake transporter paralogues.
3.4.2.1 Rat Liver Slices
For the precision-cut tissue slice system to prove successful and to complement in vitro 
systems for the assessment o f  transport protein responses to xenobiotics and their role in 
drug disposition, it is essential that transport proteins remain viable in culture for 
sufficiently long periods o f time, to allow drug uptake and efflux to take place. It is 
known that phase I cytochrome P450 activities decline in culture, the most rapid loss 
occurring at about 8-12 hours o f  culture, with no detectable activity being observed in 72 
hour cultured slices (Hashemi et a l ,  2000). Similar decreases in activity over time in 
culture have also been observed for phase II conjugating enzymes, although for some 
enzymes, activity was still apparent at 72 hours in the rat liver (Hashemi et al., 1999b). 
Transport protein expression in human liver slices has been reported to remain constant 
over at least 24 hours in culture (Elferinlc et al., 2004; Jung et al., 2007). However, soft 
tissue such as rodent liver is more difficult to culture than more dense tissue such as liver 
o f  larger animals or humans (Fisher et al., 2001) and may lose architectural stability and 
viability more rapidly. Since the rat is still the principle laboratory animal employed in 
safety evaluation studies, it was deemed pertinent to study the stability o f  drug transporter 
expression in precision-cut liver slices.
Precision-cut rat liver slices were prepared separately from the livers o f three individual 
male W istar albino rats using the Krumdieclc tissue slicer. mRNA and protein was 
extracted from control rat liver, which was snap frozen immediately after excision and 
from rat liver slices from the point o f  slice production to up to 72 hours in culture. Total
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mRNA and protein levels were quantified in each sample to assess overall effects o f  slice 
preparation and culture on expression levels (Figure 3-7).
Figure 3-7 Total mRNA and protein concentration in rat liver slices over time in culture
Total mRNA and protein was extracted from control Wistar albino rat livers and rat liver slices at 
0, 0.5, 6, 12, 24, 48 and 72 hour time points and quantified using the NanoDrop 
spectrophotometer or by Lowry assay respectively. mRNA and protein concentrations (pg/ml) 
were correlated against time point. Results are expressed as mean (n = 3) ± SD; where no error 
bars are observed, they are contained within the data point.
Total mRNA levels in rat liver slices rem ained comparable to levels in control rat liver 
for up to 12 hours in culture. At 24 hours however, total mRNA decreased to below 
control rat liver levels and was too low for cDNA synthesis at 72 hours. Thus, 
quantitative PCR o f  target genes was only carried out using slices cultured up to 48 
hours, and expression levels were normalised using Gapdh expression which remained 
stable over 48 hours. Total protein levels decreased immediately due to processing o f  the 
slices and remained lower up to 72 hours. After the initial decrease however, protein 
levels were more stable than mRNA and were detectable at 72 hours.
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Transporter mRNA expression levels over time in culture were measured and expressed 
as a percent o f  control rat liver expression for comparison (Figures 3-9, 3-10 and 3-11). 
In this case, it was not possible to express results as a percent o f  human liver expression, 
as clear orthologues could not be identified for all o f  the OATP transporters (Table 3-2). 
In Figure 3-8, expression levels o f  all o f  the selected uptake transporters showed a 
general decrease over time in culture, but their expression levels at the start o f  the culture 
period varied in relation to control rat liver levels. Both O atpla4 and O ctl were 
expressed at levels higher than in control rat liver immediately after slicing (p < 0.05), 
whereas O atpl a l and O atplb2 were expressed at similar and lower levels respectively. 
This indicates that for O atpla4 and O ctl, expression first increased and then decreased, 
but for O a tp la l and O atplb2, only a decrease occurred. At 24 hours, O atp la4  expression 
levels resembled control rat liver expression, but all o f  the other uptake transporters were 
significantly lower by this point (p < 0.01). By 48 hours, mRNA levels for all uptake 
transporters were at approximately less than 25 % o f  their levels in control rat liver, 
which corresponds to the general decrease in total mRNA.
126
a
o a 3
M
m
a ©CO
o >■><
T—H
o3 3 h r—<
co
40 tn co ii;
3
O
a>
l .
3
CN ± 2  
3  
O
CN
UOjSS3JdX3 J0Aj| JBJ J.O %
oo
CO
CO
0
b .
^j* 3  
CN ± 2  
3  
O
CM I
UOjSSSjdXa J3Aj| }BJ JO %
o
4=
C
O
o
oO
? i
CN
X 5
T -
B-
o
o
4=
c
o
O
'd- cc \— 
a .  
TO
O
■ -  {
<D
ro
x—ci-
ro
cd
u
MM
o
ba©
cu
Cm
O
CUtncd
ss
<u
E
cuCL
si
tn
cd
cube
3
3
cu
cu
B
*43
s
&60
CUcua
©
a
3be
<UU
&©
b.
0  
a
CO
3
3
is
a
3
a
P
001
CO
0)be
3
.SI0
s
VO
.bi 03• M
.a
Qh
.a
oCL
34->
■3
©
6
Cm
O
c—
c s
In Figure 3-9, Abcg2 expression levels decreased significantly (p < 0.001), to 
approximately 30 % o f  control rat liver expression immediately after slicing and then 
decreased steadily over the culture period to reach approximately 3 % o f control levels at 
48 hours (p < 0.001). Abcbl and Abcb2 expression levels however, were raised to 
approximately 600 % and 300 % o f control rat liver levels following the slicing 
procedure.
Time in culture (hours)
Abcbl Abcb2 Abcg2 Control Liver
Figure 3-9 Abcb and Abcg transporter expression in rat liver slices over time in culture
Rat liver slices were cultured for 0, 0.5, 6, 12, 24 and 48 hours. The mRNA expression level of 
Abcbl, Abcb2 and Abcg2 at each time point was quantified by RT-PCR. Absolute expression 
levels were measured by comparing the signal from samples to rat genomic DNA standards of 
known concentration, normalised using Gapdh and displayed as a percent of control rat liver 
expression. Results were analysed by repeated measures ANOVA with Bonferroni post-hoc test 
to show where expression in rat liver slices was significantly different to rat liver (*p < 0.05; n = 
3; error bars =SEM; where no error bars are observed they are contained within the limits of the 
data point; the y axis is split from 400-500 %).
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Unlike Abcb2, which then decreased throughout the culture period, A bcbl levels 
continued to rise, peaking at -8000  % o f control levels at 24 hours (Figure 3-9; p < 
0.001). O f the these transporters and the uptake transporters examined in Figure 3-8, 
Abcbl is the only transporter to exhibit levels higher than control rat liver after 48 hours 
in culture (p < 0.01).
In Figure 3-10, A bccl expression levels were lower than control rat liver levels up to 6 
hours in culture but then increased at 12 hours and then sharply at 24 hours (p < 0.001). 
A bccl levels continued to increase up to 48 hours, reaching a maximum 4-fold increase 
compared to control. Abcc3 behaved in a similar way to A bccl, except that levels up to 
12 hours were not significantly different to control rat liver levels, and the increase 
observed after 12 hours was o f  bigger magnitude; at 48 hours, Abcc3 expression was ~5- 
fold higher than control rat liver levels (p < 0.001). Abcc2 increased up to 6 hours in 
culture, reaching a peak 3.5-fold increase compared to control levels (p < 0.01). Beyond 
6 hours, Abcc2 levels decreased steadily, to levels lower than those measured in control 
rat liver. Abcc2 expression varied widely between rat liver slices, making it difficult to 
achieve statistical significance. Abcc4 levels were comparable to control rat liver levels at 
0 and 0.5 hours, but then decreased at 6 hours in culture to approximately 35 % o f  control 
liver levels. Beyond 6 hours, Abcc4 levels gradually recovered and reached control levels 
at 48 hours.
In summary, although response to culture period is isoform dependent, some patterns can 
be observed. W hen total mRNA decreases w ith time in culture, expression o f  some drug 
transporters, such as those involved in uptake, decrease in synchrony, while certain target 
genes such as A bcbl, A bccl and Abcc3 are over-expressed in a time specific manner.
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For a selection o f  drug transporters (A bcbl, Abcc2 and O atpla4), Western blotting was 
also performed to assess whether changes in expression at the gene level, were also 
observed at the functional protein level. For each Western blot, densitometry o f  the bands 
was performed to provide a semi-quantitative representation o f  protein expression 
changes over time. Target protein expression was normalised against the protein actin, 
which was constitutively and stably expressed throughout the culture period.
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Figure 3-11 A bcbl Protein Expression in Rat Liver Slices over Time in Culture
(A) Rat liver slices were cultured for 0, 0.5, 6, 12, 24, 48 and 72 hours. Total protein was 
extracted from control rat liver and rat liver slices at each time point and quantified by Lowry 
assay. Fifty micrograms of sample (up to 48 hours for rat 1, and 72 hours for rats 2 and 3) was 
separated by SDS-PAGE and the band corresponding to Abcbl was identified at 170 kDa by 
immunoblotting against a pre-stained protein standard. PVDF membranes were stripped of Abcb 1 
antibody and re-probed for actin to be used as a loading control. Only one representative actin 
immunoblot is shown. (B) Abcbl and actin bands were semi-quantified by densitometry and 
Abcbl was normalised against corresponding actin raw band volumes. Results were analysed by 
repeated measures ANOVA with Dunnett’s post-hoc test to show where expression in rat liver 
slices was significantly different to control rat liver (* = < 0.05, n = 3; error bars =SEM).
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W estern blots o f  Abcbl protein expression in rat liver slices over time in culture, showed 
a similar pattern o f  increase to the mRNA expression pattern (Figure 3-11). However, 
protein expression peaked at 48 hours (p < 0.05) rather than 24 hours, which may indicate 
the delay between transcription and translation. The increase in protein expression was 
also more gradual and less pronounced than the increase observed at the mRNA level. 
With exception o f  the 48-hour time point, protein expression was not statistically 
different to control rat liver levels due to the variability between individual Western blots 
and the basal expression levels in control rats (Figure 3-11 A). Over the culture period, 
actin protein expression remained stable and was a suitable protein for normalisation o f 
protein loading.
Rat 1 Oatpla4 
Rat 2 Oatp 1 a4 
Rat 3 Oatp 1 a4 
Actin
C 0 0.5 6 12 24 48 72
—  «■» —  —
—  —  —  — -----------
O f t  •  • • m •  • •
c
.2 0.8-1 
(A 8 
2
£■0.61 0)
■<frra
O 0.4- O 
CO
■o
1 °-2H 
ra
o O.o-
z  f
B
I
X
I
1
0 10 nr tP
Time in culture (hours)
I
Figure 3-12 O atp la4 Protein Expression in Rat Liver Slices over Time in Culture
(A) Rat liver slices were cultured for 0, 0.5, 6, 12, 24, 48 and 72 hours. Total protein was 
extracted from control rat liver and rat liver slices at each time point and quantified by Lowry 
assay. Thirty micrograms of protein was separated by SDS-PAGE and the band corresponding to 
Oatpla4 was identified at 90 kDa by immunoblotting against a pre-stained protein standard. 
PVDF membranes were stripped of Oatpla4 antibody and re-probed for actin to be used as a 
loading control. Only one representative actin immunoblot is shown. (B) Oatpla4 and actin bands 
were semi-quantified by densitometry and Oatpla4 was normalised against corresponding actin 
raw band volumes. Results were analysed by repeated measures ANOVA with Dunnett’s post- 
hoc test to show where expression in rat liver slices was significantly different to control rat liver; 
no significance was found (n = 3; error bars = SEM).
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The trend o f  Oatpl a4 expression at the protein level (Figure 3-12 A & B), was similar to 
that seen at the RNA level in that there was a slight increase compared to control rat liver 
levels followed by a decrease. However, due to variability between rats, protein 
expression was not found to be statistically different to control rat liver at any time point.
Rat 1 Abcc2 
Rat 2 Abcc2 
Rat 3 Abcc2 
Actin
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Figure 3-13 Abcc2 Protein Expression in Rat Liver Slices over Time in Culture
(A) Rat liver slices were cultured for 0, 0.5, 6, 12, 24, 48 and 72 hours. Total protein was 
extracted from control rat liver and rat liver slices at each time point and quantified by Lowry 
assay. Fifty micrograms of protein was separated by SDS-PAGE and the band corresponding to 
Abcc2 was identified at 190 kDa by immunoblotting against a pre-stained protein standard. 
PVDF membranes were stripped of Abcc2 antibody and re-probed for actin to be used as a 
loading control. Only one representative actin immunoblot is shown. (B) Abcc2 and actin bands 
were semi-quantified by densitometry and Abcc2 was normalised against corresponding actin raw 
band volumes. Results were analysed by repeated measures ANOVA with Dunnett’s post-hoc test 
to show where expression in rat liver slices was significantly different to control rat liver (* = < 
0.05, ** = p < 0.01; n = 3; error bars = SEM).
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In Figure 3-13 (A & B), Abcc2 protein expression decreases over time, becoming 
significantly reduced compared to control rat liver levels at 24 hours (p < 0.05). Levels 
continue to reduce to 48 hours, where the protein is barely visible on the immunoblot (A, 
rats 1 and 2). Whereas in Figure 3-12, Abcc2 transcript levels increased up to 6 hours and 
then decreased, no such pattern was observed at the protein level.
Thus, o f  the three transporters investigated for protein expression in rat liver slices over 
time in culture it is clear that mRNA and protein levels are not always correlated. Other 
than with A bcbl, no increases in protein level were observed with time. The decreased 
protein expression observed for O atp la4  and Abcc2 may be as a result o f  reduced 
transcript, or could simply be explained by a decrease o f  system viability. That Abcbl 
increases expression at both transcript and protein levels regardless o f  overall decreases 
in expression, is an interesting finding.
3.4.2.1 Cytochrome P450 Expression in Rat Liver Slices
It has been demonstrated in precision-cut hum an liver slices that drug metabolising 
enzymes and transport proteins are regulated co-ordinately in response to inducing agents 
(Olinga et al., 2008). For example CYP3A4 and ABCB1 gene expression were 
concomitantly induced by rifampicin via activation o f  the pregnane X  receptor (PXR; 
NR112) (Olinga et al., 2008). Due to the observed increase in Abcbl expression over time 
in culture, it was decided to investigate cytochrome P450 expression over time, to look 
for evidence o f  a relationship between the two genes. The most likely rat orthologue o f 
human CYP3A4 was identified to be Cyp3a9 by multiple sequence alignment using 
ClustalX 2.0 (Table 3-3). Thus, gene expression o f  Cyp3a9 over the culture period was 
determined by quantitative PCR. As shown in Figure 3-16, no significant changes in 
transcript expression were found over the 48 hour culture period, suggesting the Cyp3a9 
was not co-ordinately regulated with A bcbl in this instance.
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Figure 3-15 Cyp3a9 mRNA Expression in Rat Liver Slices over Time in Culture
Rat liver slices were cultured for 0, 0.5, 6, 12, 24 and 48 hours. The Cyp3a9 mRNA expression 
level at each time point and in control rat liver was quantified by RT-PCR. Absolute expression 
levels were measured by comparing the signal from samples to rat genomic DNA standards of 
known concentration and normalised against Gapdh and displayed as a percent of control rat liver 
expression. Results were analysed by repeated measures ANOVA with Bonferroni post-hoc test 
to show where expression in rat liver slices was significantly different to rat liver. No statistical 
significance was found (n = 3; error = SEM).
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3.4.2.1 Primary Rat Hepatocytes
Freshly isolated and cyropreserved hepatocytes in suspension or monolayer culture can 
be used for influx studies (Hirano et al., 2004; Shitara et al., 2003b), as cells maintain 
functional uptake transporters after hepatocyte isolation. However, cells lose their 
polarity during isolation and efflux transporters tend to be internalised (Hoffmaster et al., 
2004), therefore drug efflux studies cannot be performed in suspensions or monolayers o f  
hepatocytes. The effect o f  monolayer culture period on the expression o f  uptake 
transporters implicated in R-123 uptake (O ctl and O atpla4) was determined in primary 
hepatocytes isolated from the Sprague-Dawley rat strain. The expression o f  A bcbl was 
also investigated to see whether time dependent expression changes were uptake or efflux 
specific. Transcript expression levels for each transporter are expressed as a percent o f  rat 
liver levels to allow comparison between the two model systems (Figure 3-16).
The expression o f  O atp la4  in prim ary rat hepatocytes cultured in monolayers is 
significantly lower at 12 hours (p < 0.01) than the expression in control rat liver and 
decreases with time in culture to ~3 % o f  control levels. This pattern is different than in 
rat liver slices, where O atpla4 first increased in culture and then decreased, which may 
indicate a difference in the viability o f  the two systems. O ctl expression in prim ary rat 
hepatocytes also decreases w ith culture period and is significantly lower than the levels 
measured in rat liver at all time points (p < 0.001). O ctl expression however is closer the 
levels o f  O ctl levels in rat liver than was O atp la4  at the first time point and onwards. 
A bcbl was expressed at significantly (p < 0.001) higher levels in prim ary rat hepatocytes 
at all time points compared to A bcbl in rat liver. Rat Abcbl expression increased from 
12 to 72 hours and then decreased slightly at 96 hours. This pattern o f  A bcbl expression 
increase w ith culture period is similar to that seen in rat liver slices over time in culture 
(Figure 3-9).
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3.5 The MDCKII Cell Line as a Model System
Sections 3.2.2 and 3.2.3 indentified the inability o f  transport proteins, particularly those 
involved in efflux to  be expressed in the plasm a m em brane o f  non-polarised cell lines such as 
Huh7. C ell-cell contact is required to provide spatial cues that serve as landm arks to recruit 
scaffolding and signalling m olecules, w hich define and reinforce luminal, basal, and lateral 
surface dom ains by instructing the reorganisation o f  cytoskeletal netw orks and the 
establishm ent o f  polarised protein-targeting m echanism s (Nelson, 2003a). W hereas, Huh7 
cells do not form  polarised domains, M DCK II epithelial monolayers form  ce ll-ce ll adhesion 
junctions, polarised surface domains, occluding junctions, and epithelial specific m icrotubule 
and actin  organization (Cohen et al., 2007). Thus, such epithelial cell lines have obvious 
utility for the study o f  correctly localised transport proteins.
3.5.1 Canine Orthologues of Human Transporters in the MDCKII cell Line
To identify drug transporter orthologues o f  hum an proteins that m ay be responsible for the 
uptake or efflux o f  R-123 in the M DCKII cell line, amino acid identity betw een hum an and 
canine protein  sequences was used to infer functional relatedness. M em bers o f  the OCT and 
OATP fam ilies o f  uptake transporters have been im plicated in R-123 uptake (Annaert and 
Brouwer, 2005; H eem skerk et al., 2008; M asereeuw  et al., 1997), thus the canine orthologues 
o f  these transporters are o f  particular interest for this research. Previous w ork has identified 
the probable canine ABC orthologues, and these designations are used herein. G lobal 
m ultiple sequence alignm ents for OA TPs and OCTs were therefore carried out in C lustal X  
2.0 to identify likely candidates from a selection o f  possible proteins.
A n obstacle in identifying canine orthologues o f  hum an transporters was the lim ited canine 
genetic inform ation at the time o f  analysis. Thus, full amino acid sequences for hum an 
transporters denoted by an NP_num ber, w ere com pared to m odel protein sequences provided 
by  a genom e annotation process and labelled w ith  an X P_ prefix by the NCBI. Percent amino 
acid identity found betw een sequences m ust therefore be considered as predicted rather than 
absolute identity.
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3.5.1.1 Solute Carrier Organic Anion Transporting Polypeptides (OATP)
hOATPlBl 
NP 006437. 
3
hOATPlB3 
NP 062818. 
1
COATP1B3 
XP 866419. 
1
hOATPlA2 
NP 066580. 
1
COATP1A2 
XP 852839. 
1
hOATP2Bl 
NP 009187. 
1
COATP2B1 
XP 542310. 
2
hOATPlBl 
NP 006437. 
3
100 80 41 42 29 30
hOATPlB3 
NP 062818. 
1
80 100 76+ :;3 f fS' 40 43 30 29
COATP1B3 
XP 866419. 
1
7 3 : , */ , 76 100 43 45 33 32
hOATPlA2 
NP 066580. 
1
41 40 43 100 87; 29 30
COATP1A2 
XP 852839. 
1
42 43 45 87 100 30 31
hOATP2B 1 
NP 009187. 
1
29 30 33 29 30 100
COATP2B1 
XP 542310. 
2
30 29 32 30 31 100
Table 3-4 Human versus Canine OATP Percent identity matrix generated by Clustal X 2.0
Complete (prefix NPJ) and model (prefix XP_J amino acid sequences for human (h) and canine (c) 
OATP transporter proteins respectively were obtained from NCBI and identified with a unique 
Reference Sequence number. A complete multiple alignment was performed using Clustal X 2.0, and 
a percent identify matrix was generated. The matrix shows the percent identity between all amino acid 
sequences; cells highlighted in grey identify the matches with the highest identity between species.
The identity m atrix shows that hum an OATP IB  1 is m ost similar to hum an OATP1B3 (80 
%), followed by canine OATP1B3 (73 %), with all other transporters sharing less than 50 % 
identity. Searches w ithin the NCBI database revealed that the canine OATP IB  sub-family 
currently only has one member, which could reflect the paucity o f  correctly annotated 
sequences. Alternatively, OATP IB  1 and 1B3 in hum ans could be paralogues form ed by a 
duplication event after the divergence o f  canine and hum an lineages. Sequence alignment o f  
the rat and hum an Oatp/OATP family m em bers (Table 3-2) also showed that hum an
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0A TP1B 1 and 1B3 were m irrored by only one O a tp lb  fam ily m em ber in the rat, which 
supports this assumption. H um an OATP1B3 w as show n to share 76 % identity w ith canine 
OATP1B3, w ith all other transporters sharing less than 50 % identity. H um an OATP1A2 
shares 87 % identity w ith canine OATP1A2 and hum an OATP2B1, 80 % identity w ith  canine 
OATP2B1. It appears that members o f  the canine OATP fam ily share m ore identity w ith their 
hum an counterparts than they do w ith each other. Thus, it w ould seem  that, w ith the 
exception o f  hum an OATP IB  1, canine transporters in the OATP fam ily correspond directly 
to the hum an versions w hen com paring protein sequences.
3.5.1.2 Solute Carrier Organic Cation Transporting Polypeptides (OCT)
The identity m atrix below (Table 3-5), shows that canine OCT1, 2 and 3, correspond in terms 
o f  percent amino acid identity to hum an OCT1, 2 and 3 respectively. Thus, the naming o f  
these organic cation transporters appears to correspond to their hum an orthologues.
hOCTl 
NP 003057.2
cOCTl 
XP 850971.1
hOCT2 
NP 003058.2
cOCT2 
XP 533466.2
hOCT3 
NP 068812.1
cOCT3 
XP 533467.2
hOCTl 
NP 003057.2
100 80 70 69 49 50
cOCTl 
XP 850971.1
80 100 69 74 49 51
hOCT2 
NP 003058.2
70 69 100 85 / 50 51
cOCT2 
XP 533466.2
69 74 85 • 100 52 52
hOCT3 
NP 068812.1
49 49 50 52 100 9 3  r '
cOCT3 
XP 533467.2
50 51 51 52 93 100
T able 3-5 H um an versus C anine O C T P ercent identity  m atrix generated by C lustal X 2.0
Complete (prefix NP_J and model (prefix X P £  amino acid sequences for human (h) and canine (c) 
OCT transporter proteins respectively were obtained from NCBI and identified with a unique 
Reference Sequence number. A complete multiple alignment was performed using Clustal X 2.0, and 
a percent identify matrix was generated. The matrix shows the percent identity between all amino acid 
sequences; cells highlighted in grey identify the matches with the highest identity between species.
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3.5.2 The Effect of Transfecting ABCB1 into MDCK II Cells
As discussed in the introduction, over-expression o f  individual hum an transporters in cell 
lines such as M DCKII is a com m on m ethod for exam ining the characteristics o f  potential 
substrates towards single drug transporters. However, it has not so far been determined if  
such an over-expression approach alters the expression level o f  other endogenous drug 
transporters in the system. To examine this, the expression levels o f  a selected set o f  
endogenous transporters in the M DCKII cell line were m easured by RT-PC R in wild-type 
cells and those stably transfected w ith hum an ABCB1. The selection o f  transporters 
m easured included members o f  the OCT and OATP subfamilies that have been implicated in 
R-123 uptake (Annaert and Brouwer, 2005; Heemslcerk et al., 2008; M asereeuw et al., 1997) 
and hum an and canine ABCB1 since it is the accepted efflux transporter o f  R-123 (Tang et 
al., 2004). ABCC2 has also been im plicated in the efflux o f  R-123, but only in an over­
expressed state in the absence o f  ABCB1 (Tw entym an et al., 1994). Thus the transcript level 
o f  ABCC2 was determ ined in M DCKII cells to determine whether ABCC2-m ediated efflux 
o f  R-123 was likely. Due to the large substrate overlap between ABCB1 and ABCG2 
(Taipalensuu et al., 2004), the expression o f  latter transport protein was determ ined in the cell 
line to assess w hether ABCG2 needed to be considered as a potential transporter o f  R-123.
Figure 3-18 shows that when hum an ABCB1 is transfected into wild-type M DCKII cells, the 
transcript level is significantly (p <  0.0001) increased com pared to the expression in wild- 
type cells. This com parison was made using TaqM an probes and prim ers designed against the 
hum an ABCB1 sequence. That hum an ABCB1 was detected in w ild-type M DCKII cells 
shows cross reactivity betw een the canine and hum an transcripts. However, the difference in 
expression betw een wild-type and transfected cells is so large, that the cross reactivity is 
insignificant. All other comparisons betw een transporter expression in w ild-type and ABCB1 
transfected cells were m ade using TaqM an prim ers and probes designed against the predicted 
canine sequences.
Transfection w ith hum an ABCB1 resulted in significant (p <  0.0001) decreases in the OCT2 
uptake transporter and the ABCC2 efflux transporter. Expression o f  canine ABCB1 was not 
significantly altered by the introduction o f  hum an ABCB1; this also indicates specificity o f  
the canine ABCB1 prim er and probe set. The uptake transporters, OCT1, OCT3 and 
OATP1A2, and the efflux transporter ABCG2 w ere not detected in either w ild-type or
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transfected M DCKII cells, indicating a relatively ‘clean’ system in which to study human 
ABCB 1-mediated efflux without endogenous interference. OCT2 was expressed and could 
therefore be involved in active uptake o f  R-123 if  it proved a substrate for this transporter. 
Endogenous ABCC2 expression is low in the cell line compared to hum an ABCB1 levels, 
and thus is unlikely to contribute to R-123 efflux. Possible substrate overlap between ABCB1 
and ABCG2 is also o f  no concern in this cell line, since ABCG2 is not expressed.
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Figure 3-18 m RNA Expression o f  D rug T ransporters in W ild-type and ABCB1 Transfected  
M D C K  II cells.
The mRNA expression level of each transporter was quantified by RT-PCR in wild type MDCKII 
cells and those transfected with human ABCBl. Absolute expression levels were measured by 
comparing the signal from samples to canine (c) and human (h) genomic DNA standards of known 
concentration. Expression levels are normalised to GAPDH. Results were analysed by unpaired two- 
tailed t-test to compare +/- conditions and to show where expression in MDCKII cells transfected with 
human ABCB1 was significantly different to wild type cells ( *** = p < 0.001; n = 4; error bars =
SEM; where no error bars are observed they are contained within the limits of the data point, N/D = 
not detected). The y - axis is split from 0.08 to 0.1.
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3.5.2.1 Human ABCB1 Expression in the MDCKII-ABCB1 Cell Line
The successful use o f  stably transfected cell lines for the study o f  drug disposition relies on 
the constant over-expression o f  the target protein(s) o f  interest throughout the experimental 
period and between subsequent measures. The stably transfected M DCKII-ABCB 1 cell line 
was obtained from GlaxoSm ithKline (W are, UK) at passage 35. Cells were grow n in culture 
until passage 48, at which time mRNA and protein was extracted for ABCB1 expression 
analysis.
M DCKII-ABCB 1 MDCKII
170 kDa
Figure 3-19 ABCB1 Expression in T ransfected M DCK I1-ABCB1 and M DCK II cells
Total protein was extracted from MDCKII-ABCB 1 and MDCKII cells and quantified by Lowry 
assay. Fifty micrograms of protein from each cell type was separated by SDS-PAGE and transferred 
to PVDF (n = 4 for each cell type). Immunodetection of ABCB1 using the C219 antibody gave a 
triplet of bands around 170 kDa possibly all corresponding to ABCB1 with different glycosylation 
states. Band sizes were determined against a pre-stained molecular weight protein standard.
Figure 3-19 shows that hum an ABCB1 is strongly detected in the transfected cells, whereas 
only a weak signal at the same m olecular weight is seen in w ild-type M DCKII cells, which 
most likely corresponds to cross-reactivity with canine ABCB1. Thus, the ABCB1 band 
detected is due to the presence o f  m ainly hum an rather than canine ABCB1.
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Figure 3-20 ABCB1 Transcript and Protein E xpression by Band D ensitom etry and W estern  
Blotting in the M D C K II-A BC B1 Cell Line over passages 48-54
The mRNA transcript level of human ABCB1 was quantified by RT-PCR in MDCKII-ABCB1 cells. 
Absolute expression levels were measured by comparing the signal from samples to human genomic 
DNA standards of known concentration. Expression levels are normalised to canine GAPDH, 
determined using a canine genomic DNA standard curve. Total protein was extracted from MDCKII- 
ABCB1 cells and quantified by Lowry assay. Fifty micrograms of each extract was separated by SDS- 
PAGE and transferred to PVDF membrane. Immunodetection of ABCB1 gave a band at 170 kDa, 
determined by use of a pre-stained protein standard. The PVDF membrane was stripped of antibody 
and re-probed for the protein actin, which was used as a loading control. Bands were semi-quantified 
by densitometry and ABCB1 expression was normalised against actin loading.
Figure 3-20 dem onstrates that ABCB1 transcript and protein expression levels are stable over 
passages 48-54, which equates to approxim ately three weeks o f  cell culture. It is possible that 
expression levels rem ain constant beyond this period, but since it has not been determined, all 
experim entation with the M DCKII-ABCB1 cell line was performed within these limits.
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3.5.3 R-123 Efflux from MDCKII-ABCB1 cells
It was previously determined that human ABCB1 was stably over-expressed in the M DCKII 
cell line (Figure 3-20). To assess transporter functionality, a transport assay utilising the 
fluorescent ABCB1 substrate, R-123 was performed. Cells were incubated with 100 pM  ice- 
cold R-123 for 10 minutes to allow passive diffusion/endocytosis into cells whilst inhibiting 
active efflux. After washing o ff  excess extracellular R-123, intracellular fluorescence was 
imaged using an Axiovert 100 m icroscope with the integral AxioCam  M Rm  Rev digital 
camera at 10 x m agnification through a FITC filter (485 nm) (Figure 3-21, (A)). After 5 
m inutes o f  incubation in ice-cold R-123 free HBSS, intracellular fluorescence was imaged 
again (B). Intracellular fluorescence is sim ilar betw een (A) and (B), suggesting that when 
cells are kept on ice, no active efflux occurs and fluorescence is retained within cells. In (C), 
after five m inute incubation in R-123 free HBSS at 37 °C, intracellular fluorescence intensity 
was clearly reduced, indicating active efflux from the cells m ediated by ABCB1.
Figure 3-21 R-123 is Effluxed from  M DCK I1-ABCB1 Cells
MDCKII-ABCB 1 cells were dosed with 100 pM R-123 (1 % Methanol) and incubated at 4 °C for 10 
minutes. Fluorescent images were taken immediately after washing off excess R-123 (A), after a 5 
minute incubation period on ice (B) and after a 5 minute incubation period at 37 °C (C) using an 
Axiovert 100 microscope with the integral AxioCam MRm Rev digital camera at 10 x magnification 
through a FITC filter (485 nm). Cells were exposed to fluorescence for 2 seconds before the image 
was taken.
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3.6 Comparison of Transporter Expression in Model Cell Systems
Expression o f  uptake and efflux transporters either directly or potentially involved in R-123 
cellular access w as determ ined in several com m only used in vitro systems. Levels o f  
OATP1A2, OCT1, ABCB1 and their rat orthologues were m easured to provide more 
inform ation for the R-123 disposition model, and ABCC2 levels were determ ined for the 
CDF disposition model. Only one sample from  each in vitro system  was assessed per 
transporter, m aking this a crude m ethod for com parison at best. Results in this section should 
therefore be interpreted with caution and used for the purpose for which they w ere intended; 
to provide quantitative protein data for the subsequent in silico model.
3.6.1 ABCB1/Abcb1
In figure 3-22 (A), the recom binant M D CK II cell line over-expressing hum an ABCB1 
expresses significantly (p < 0.001) higher levels o f  ABCB1 transcript than does hum an liver. 
In this case, the m RNA transcript data is in agreem ent w ith the protein expression data, as 
shown in (B) and (C). ABCB1 protein is clearly over-expressed com pared to all m odel 
systems, thus m aking it suitable for m easurem ent o f  A B CB1-m ediated efflux. ABCB1 was 
also significantly (p < 0.001) over-expressed at the transcript level in the Huh7 cell line 
com pared to hum an liver. However, protein data suggests that this over-expression is not 
present at the functional level (B) and (C). In figure 3-5, it was dem onstrated that ABCB1 
protein could be detected in the to tal protein cellular fraction but not in the m em brane 
fraction. In the im m unoblot shown below, the total protein fraction was separated by SDS- 
PAGE, thus explaining the presence o f  ABCB1 in the Huh7 cell line despite absence o f  cell 
polarity.
Hum an and rat prim ary hepatocytes significantly (p < 0.001) over-express ABCB1 at the 
transcript level com pared to hum an liver (A), and this relationship also appears to be true at 
the protein level (B & C). N o significant difference was observed betw een A B C B l/A bcb l 
transcript levels in hum an and rat livers (A). A t the protein level, rat liver appears to express 
a slightly higher level o f  A bcbl than hum an liver expresses ABCB1; however w hether this 
difference is significant cannot be tested statistically. After 0.5 hours o f  culture, rat liver
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slices on average express higher levels o f  A bcb l transcript than control rat liver (A); this 
increase how ever is not large enough to give a significant difference to hum an liver 
expression. In contrast, A bcbl protein level at 0.5 hours was lower than the levels detected in 
control rat liver. This is a consequence o f  sam ple selection for im m unoblotting; rat 1 was 
chosen as the representative o f  the m odel system  and in this rat, the protein levels decreased 
slightly at 0.5 hours (Figure 3-12).
Thus, w ith  the exception o f  Huh7 ABCB1 expression, m RNA and protein levels o f  ABCB1 
are reasonably w ell correlated, giving the same relative expression betw een systems. Rat liver 
and rat liver slices at 0.5 hours in culture express sim ilar levels o f  A bcb l to hum an liver, and 
m ay therefore be suitable m odel system s in w hich to assess drug disposition for know n 
A bcbl substrates. Prim ary rat hepatocytes and other over-expressing system s however, m ay 
be m ore suitable for determ ining potential substrate affinity and kinetics for A bcbl as they 
w ould offer higher sensitivity.
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Figure 3-22 A B C B l/A b cb l m RNA and Protein E xpression in M odel Cell System s
RNA: The ABCBl/Abcbl mRNA expression level in each model system was quantified by RT-PCR. 
Absolute expression levels were measured by comparing the signal from samples to human and rat 
genomic DNA standards of known concentrations respectively. Results were analysed by unpaired 
two-tailed t-test to show where expression in model systems is significantly different to human liver 
(*** = p < 0.001; n = 3; error bars = SEM, where no error bars are observed, they are contained 
within the data point). Protein: Total protein was extracted from one representative of all model cell 
systems and quantified by Lowry assay; 1: MDCKII ABCB1: Recombinant MDCKII cells over­
expressing human ABCB1, 2: Huh7, 3: Human liver, 4: Human monolayer primary hepatocytes, 5: 
Rat monolayer primary hepatocytes, 6: Rat liver 1, 7: RLS = rat liver slices cultured for 0.5 hours. 
Thirty micrograms of protein was separated by SDS-PAGE and the band corresponding to 
ABCBl/Abcbl was identified at 170 kDa by immunoblotting against a pre-stained protein standard. 
Densitometry: ABCBl/Abcbl bands were semi-quantified by densitometry. No statistical analysis can 
be performed on protein data as n = 1.
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3.6.2 0ATP1 A2/Oatp1 a4
A lthough OATP1A2 was originally cloned from  a liver cDN A library, it is actually expressed 
at low levels in the liver and higher levels in the brain and kidney (H agenbuch and M eier, 
2004; Lee et al., 2005b). Thus, it is not surprising that the samples o f  hum an liver analysed 
contained low levels o f  OATP1A2 transcript com pared to other m odel systems (Figure 3-23 
(A)). Huh7 cells expressed higher levels o f  O A TP1A 2 transcript (p <  0.001), com pared to 
hum an liver, however, this relative over-expression is not observed at the protein level. The 
OATP1A2 protein is actually expressed at lower levels in Huh7 cells than in hum an liver (B 
& C), as was ABCB1 in figure 3-22. Again, the low protein expression levels in Huh7 cells 
despite over-expression o f  m RNA could be a consequence o f  absent cell polarity. Research 
has suggested that OATP1A2 is not expressed in hum an hepatocytes (Jigorel et al., 2005), 
however it has been detected herein, albeit at lower transcript levels (p < 0.01) in com parison 
to hum an liver. A t the protein level, OA TP1A 2 in prim ary hum an hepatocytes is expressed at 
sim ilar levels to those in the liver.
The rat orthologue o f  OATP1A2, w hich is m ost likely O atp la4  is expressed at higher levels 
in all rat m odel systems com pared to all non-recom binant hum an system s at both the 
transcript (p < 0.001) and protein levels (Figure 3-23 (A, B & C)); w ith rat liver having the 
highest expression. For im m unoblotting, the rat O a tp la4  antibody was used to identify both 
hum an and rat variants on the basis that the protein detected due to sim ilar amino acid 
identity w ould correspond to the functional orthologue. The risk o f  this approach is that 
antibody affinity m ay vary betw een species, thus, incorrectly representing relative expression 
levels. This m ethod is how ever superior to the alternative o f  using two different antibodies, 
w hich w ould m ore likely have different specificities for then  targets and m ay not identify the 
true functional orthologue.
OATP1A2 transcript levels in the recom binant HEIC293 cell line w ere not determined, 
however the im m unoblot and corresponding band densitom etry (B & C) confirms that 
OATP1A2 was indeed over-expressed in this system  com pared to hum an liver and other 
hum an m odel systems. D etection o f  OATP1A2 in the H E K  cell line acts as a positive control, 
confirm ing the ability o f  the rat O atp la4  antibody to detect hum an OATP1A2, and lending 
confidence that the other bands detected are specific to OATP1A2. Unlike in the case o f  
ABCB1, where transcript and protein expression was reasonably w ell correlated, relative 
levels o f  OATP1A2 and O a tp la4  protein could not be predicted from m RN A  data. This could
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emphasise the importance o f  protein quantification for correct extrapolation between model 
in vitro systems, or could be a consequence o f  antibody cross-reactivity with similar OATPs. 
Thus, both RNA and protein data should be interpreted with caution.
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Figure 3-23 O A T P lA 2 /O a tp la 4  m RNA and Protein E xpression in M odel Cell System s
RNA: The OATPlA2/Oatpla4 mRNA expression level in each model system was quantified by RT- 
PCR. Absolute expression levels were measured by comparing the signal from samples to human and 
rat genomic DNA standards of known concentrations respectively. Results were analysed by unpaired 
two-tailed t-test to show where expression in model systems is significantly different to human liver 
(*** = p < 0.001; n = 3; error bars = SEM, where no error bars are observed, they are contained 
within the data point). Protein: Total protein was extracted from one representative of all model cell 
systems and quantified by Lowry assay; 1: HEK 1A2 = Recombinant human embryonic kidney cells 
over-expressing human OATP1A2, 2: Huh7, 3: Human liver, 4: Human monolayer primary 
hepatocytes, 5: Rat monolayer primary hepatocytes, 6: Rat liver 1,7: RLS = rat liver slices cultured 
for 0.5 hours. Thirty micrograms of protein was separated by SDS-PAGE and the band corresponding 
to OATP1 A2/Oatpla4 was identified at 90 kDa by immunoblotting using the rat Oatpla4 Ab to cross 
react against both species. Densitometry: OATPlA2/Oatpla4 bands were semi-quantified by 
densitometry. No statistical analysis can be performed on protein data as n = 1.
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3.6.3 OCT1/Oct1
O C T l/O ct 1 is the organic cation transporter fam ily m em ber predom inantly involved in drag 
uptake in hum an and rat liver, whereas m em bers 2 and 3 are expressed at lower levels in this 
organ (Koepsell, 2004). A t the transcript level, OCT1 was the m ost highly expressed o f  the 
uptake transporters selected for study in the hum an liver (Figure 3-17), but was expressed at 
m uch lower levels relative to other uptake transporters in the rat liver (Figure 3-7). However, 
com parison o f  expression levels o f  OCT1 and O ctl betw een hum an and rat livers showed 
that transcript and protein levels were com parable (Figure 3-24), suggesting that rats are a 
good m odel system  for determ ining O ctl m ediated drag uptake. In both prim ary hum an and 
rat hepatocytes however, OCT1 and O ctl are over-expressed at the protein level (Figure 3- 
24) in relation to their respective liver system s, m aking it necessary to apply a correction 
factor if  predicting drag uptake using these in vitro models. OCT1 at the RN A  level in 
prim ary hum an hepatocytes is however under-expressed in relation to hum an liver (p <  0.05), 
w hich m ay reflect a tim e-dependent decrease that has not yet m anifested at the protein level.
Rat liver slices are not a useful system  in w hich to study disposition o f  O ctl substrates, since 
after 0.5 hours in culture protein levels have reduced to below  the limit o f  detection (Figure
3-24). Huh7 cells express significantly lower (p < 0.01) transcript levels o f  OCT1 com pared 
to hum an liver, and OCT1 was not detected by im m unoblotting, suggesting that OCT1 
function is lost in the Huh7 cell line. Interestingly, OCT1 protein was detected in the 
recom binant H EK  cell line, suggesting that endogenous transporters could contribute to drug 
uptake attributed to the over-expressed recom binant protein.
As w ith OATP1A2 and O atp la4 , it is apparent that m RNA and protein expression levels for 
OCT1 and O ctl are not well correlated. Thus, for extrapolation o f  drug uptake between 
systems, protein expression data is necessary for a m ore accurate representation o f  the 
functional transport protein levels w ithin them. It is im portant to reiterate here that the 
antibody used to detect both hum an and rat OCT1 was o f  hum an origin, therefore results 
m ust be interpreted w ith caution. For example, the antibody m ay have different affinities for 
the proteins in different species and cross-reactivity w ith other OCT iso forms m ay have 
occurred.
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Figure 3-24 O C T l/O c tl m RNA and Protein E xpression in M odel Cell System s
RNA: The OCTl/Octl mRNA expression level in each model system was quantified by RT-PCR. 
Absolute expression levels were measured by comparing the signal from samples to canine, human 
and rat genomic DNA standards of known concentrations respectively. Results were analysed by 
unpaired two-tailed t-test to show where expression in model systems is significantly different to 
human liver (** = p < 0.01; n = 3; error bars = SEM, where no error bars are observed, they are 
contained within the data point; N/M = not measured). Protein: Total protein was extracted from one 
representative of all model cell systems and quantified by Lowry assay; 1: HEK 1A2 = Recombinant 
human embryonic kidney cells over-expressing human OATP1A2, 2: Huh7, 3: Human liver, 4: 
Human monolayer primary hepatocytes, 5: Rat monolayer primary hepatocytes, 6: Rat liver 1,7: RLS 
= rat liver slices cultured for 0.5 hours. Thirty micrograms of protein was separated by SDS-PAGE 
and the band corresponding to OCTl/Octl was identified at 60 kDa using the human OCT1 Ab to 
cross react against both species. Densitometry: OCTl/Octl bands were semi-quantified by 
densitometry. No statistical analysis can be performed on protein data as n = 1.
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3.6.4 ABCC2/Abcc2
ABCC2 is reported to be a low affinity transporter o fR -123  at best (Twentym an et al., 1994), 
but it is the transporter responsible for the high affinity efflux o f  the fluorescent probe, CDF 
(Tian et al., 2004). Thus, to enable extrapolation o f  CDF disposition betw een different m odel 
systems, expression levels were determ ined and com pared to hum an liver. In the Huh7 cell 
line, ABCC2 transcript levels are significantly (p < 0 .0 0 1 ) elevated com pared to hum an liver 
(Figure 3-25 (A), yet protein expression is lower. ABCC2 transcript expression was lower in 
hum an liver than m ost o f  the other m odel system s investigated, however at the protein level, 
ABCC2 expression was relatively sim ilar (Figure 3-25). The cell system  expressing the 
highest amount o f  ABCC2 protein w as the recom binant M DCKII-ABCB1 cell line, despite 
having low transcript levels. This finding could be a consequence o f  cross-reactivity o f  the 
ABCC2 antibody w ith ABCB1 in the cell line. A lthough com parison o f  band densitom etry 
betw een individual im m unoblots is error prone due to experimental variation, the - 2 0 -fold 
difference in band densitom etry betw een ABCB1 expression in Figure 3-22 and ABCC2 
expression in Figure 3-25 is large enough to  conclude w ith confidence that ABCB1 is 
expressed at high enough levels to ensure that any low -affm ity efflux m ediated by ABCC2 is 
negligible.
Prim ary hum an and rat hepatocytes express sim ilar levels o f  ABCC2/Abcc2 transcript and 
protein com pared to hum an liver, m aking them  suitable m odel system s in w hich to study 
ABCC2 transport if  sim ilarity to the hum an situation is desired. Rat liver slices after 0.5 
hours in culture, express sim ilar levels o f  Abcc2 com pared to the levels o f  ABCC2 in prim ary 
hum an hepatocytes. For extrapolation o f  A B CC 2-m ediated drag disposition betw een m odel 
systems, m RN A  data cannot be used as no correlation exists betw een m RN A  and protein 
levels. Rat liver and rat liver slices both  expressed significantly (p < 0.01) higher levels o f  
Abcc2 transcript, yet protein levels were com parable to human liver. The relationship 
betw een ABCC2 m RN A  and protein expression in M DCKII-ABCB1 and Huh7 cells 
discussed above is also evidence that transcript based expression analysis is insufficient for 
predicting drug disposition using transporter levels.
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Figure 3-25 ABCC2/Abcc2 mRNA and Protein Expression in Model Cell Systems
RNA: The ABCC2/Abcc2 mRNA expression level in each model system was quantified by RT-PCR. 
Absolute expression levels were measured by comparing the signal from samples to canine, human 
and rat genomic DNA standards of known concentrations respectively. Results were analysed by 
unpaired two-tailed t-test to show where expression in model systems is significantly different to 
human liver (* = p < 0.05, ** = p < 0.01, *** = p < 0.001; n = 3; error bars = SEM, where no error 
bars are observed, they are contained within the data point). Protein: Total protein was extracted from 
one representative of all model cell systems and quantified by Lowry assay; 1: MDCKII ABCB1 = 
Recombinant MDCKII cells over-expressing human ABCB1, 2: Huh7, 3: Human liver, 4: Human 
monolayer primary hepatocytes, 5: Rat monolayer primary hepatocytes, 6: Rat liver 1, 7: RLS = rat 
liver slices cultured for 0.5 hours. Thirty micrograms of protein was separated by SDS-PAGE and the 
band corresponding to ABCC2/Abcc2 was identified at 190 kDa by immunoblotting using the human 
ABCC2 Ab to cross react against both species. Densitometry: ABCC2/Abcc2 bands were semi­
quantified by densitometry. No statistical analysis can be performed on protein data as n = 1.
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3.6.5 Correlation Analysis of mRNA & Protein Expression in Model 
Systems
In the previous section, it was dem onstrated that it is not always possible to predict relative 
protein expression levels o f  particular transporters based on relative m RN A  levels within an 
in vitro system. It is not just the absolute level o f  m RN A  or protein that is important, but the 
relative levels. Thus, a further statistical analysis was perform ed on the data to produce 
correlations betw een hum an and rat m odel system s (Figures 3-26 - 3-32). The correlation 
analyses were perform ed on the relative transcript and protein expression data. It is 
hypothesised, based on the findings o f  the previous section that protein expression levels 
should be better correlated than m RN A  expression levels.
3.6.5.1 Rat Liver and Rat Liver Slice Comparison
In figure 3-26, m RNA and protein expression levels in control W istar albino rat liver and rat 
liver slices after 0.5 hours in culture w ere correlated. Considering that rat liver slices are 
derived from  the same rat from w hich they are correlated against, strong relationships w ould 
be expected. Indeed, both m RNA (Linear regression r 2 =  0.79, p < 0.001; Pearson rank 
correlation = 0.92) and protein (Linear regression r2 =  0.98, p < 0.01; Pearson rank 
correlation =  0.98, p < 0.05) were w ell correlated, w ith only the protein correlation being 
statistically significant. The 0.5 hour culture period is the standard tim e selected for dosing 
rat liver slices w ith a com pound; it is thus reassuring that based on transporter expression 
levels, at this tim e point, rat liver slices are a viable alternative to in vivo.
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Figure 3-26 C orrelation o f  the R elative E xpression  o f D rug Transporters in W istar R at L iver  
and R at L iver Slices at 0.5 H our
Correlation of the relative expression of drug transporters between Wistar rat liver and rat liver slices 
using mRNA transcript levels obtained by RT-PCR (RNA; Pearson rank correlation = 0.92), and 
protein levels obtained by immunoblotting and band densitometry (Protein; Pearson rank correlation = 
0.98, significant correlation p < 0.05). Results were also analysed by linear regression to give lines of 
best fit (n = 3 for mRNA; r 2 = 0.79, p < 0.001; n = 1 for protein; r 2 = 0.97, p < 0.01; error bars = 
SEM; where no error bars are observed they are contained within the limits o f the data point). The 
dotted line refers to the 95 % confidence limits of the linear regression.
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3.6.5.2 Rat Liver and Primary Rat Hepatocyte Comparison
In figure 3-27, mRNA and protein expression levels in W istar albino rat liver and Sprague- 
Dawley prim ary rat hepatocytes plated in m onolayers were correlated. As prim ary 
hepatocytes are considered the ‘gold standard’ for in vitro investigations, it would be 
reasonable to expect good correlations for m RN A  and protein expression levels between 
prim ary hepatocytes and whole liver. However, there is a negative correlation betw een 
transporter m RNA levels in rat liver and in prim ary hepatocytes (Linear regression r 2 = 0.37, 
p < 0.01; Pearson rank correlation = -0.71). O atp la4  also falls outside o f  the 95 % confidence 
interval o f  the linear regression due to its large variance.
The correlation betw een protein expression in rat liver and prim ary hepatocytes however was 
m uch better (Linear regression r  2 =  0.81; Pearson rank correlation =  0.90). This indicates that 
at the tune o f  protein extraction, transport protein levels were still com parable to those 
observed in vivo. It is reasonable to suggest that changes in m RNA expression were detected 
earlier than changes in protein expression due to the greater stability and slower turnover 
rates o f  protein com pared to mRNA. Thus, as hypothesised, in this case protein is better 
correlated betw een systems than is mRNA.
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Figure 3-27 Correlation of the Relative Expression of Drug Transporters in W istar Rat Liver 
and Prim ary Rat Hepatocytes
Correlation of the relative expression of drug transporters between Wistar rat liver and primary rat 
hepatocytes using mRNA transcript levels obtained by RT-PCR (RNA; Pearson rank correlation = - 
0.71), and protein levels obtained by immunoblotting and band densitometry (Protein; Pearson rank
correlation = 0.90). Results were also analysed by linear regression to give lines of best fit (n=3 for
2 2 mRNA; r  = 0.38, p < 0.01; n = 1 for protein; r  = 0.81; error bars = SEM; where no error bars are
observed they are contained within the limits of the data point). The dotted line refers to the 95 %
confidence limits of the linear regression.
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3.6.S.3 Human Liver and Rat Liver Com parison
Correlating expression levels o f  drug transporters in hum an and rat liver sections directly 
indicates whether the rat is a useful species in w hich to study drug disposition, as changes in 
drug transporter expression that m anifest as a result o f  cell isolation procedures and culture 
conditions are avoided. Figure 3-28 shows that at the mRNA level, there is 110 correlation 
betw een the expression levels o f  the selected transporters in the two species (Linear 
regression r2 =  0.01; Pearson rank correlation = -0.12). At the protein level however, 
expression levels betw een the two systems are w ell correlated (Linear regression r 2 =  0.99, p 
< 0.01; Pearson rank correlation =  0.99, significant correlation p < 0.01). The correlation 
betw een protein levels thus suggests that the ra t liver is a suitable m odel system  in w hich to 
investigate hum an drug disposition.
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Figure 3-28 Correlation of the Relative Expression of Drug Transporters in H um an Liver and 
W istar R at Liver
Correlation of the relative expression of drug transporters between human liver and Wistar rat liver 
using mRNA transcript levels obtained by RT-PCR (RNA; Pearson rank correlation = -0.12), and 
protein levels obtained by immunoblotting and band densitometry (Protein; Pearson rank correlation = 
0.99, significant correlation p < 0.01). Results were also analysed by linear regression to give lines of 
best fit (n = 3 for mRNA; r 2 =  0.01; n = 1 for protein; r2 =  0.99, p < 0.01; error bars = SEM; where 
no error bars are observed they are contained within the limits of the data point). The dotted line refers 
to the 95 % confidence limits of the linear regression.
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3.6.5.4 Rat Liver S lice and Human Liver Com parison
Transporter expression in rat liver slices cultured for 0.5 hours showed a good correlation to 
rat liver at both m RNA and protein levels (Figure 3-26). However, for rat liver slices to be 
used as a m odel system  to investigate hum an drag disposition, a good correlation betw een 
hum an and rat liver slice expression levels w ould be desirable. Since m RN A  did not correlate 
w ell betw een control rat liver and hum an liver (Figure 3-28), the correlation could be 
expected to degenerate further w ith rat liver slices after 0.5 hours o f  culture. This was shown 
to be true; as shown in Figure 3-29 (Linear regression r2 =  0.06; Pearson rank correlation = - 
0.26). As in Figure 3-28, it is again ABCC2 and ABCB1 expression levels fall outside o f  the 
95 % confidence intervals o f  the linear regression; however, O A T P lA 2 /la4  and OCT1 
contribute the m ost to the poor correlation, as these dem onstrate the m ost different expression 
levels betw een systems. W hereas, protein expression levels o f  the selected transporters were 
significantly correlated betw een rat and hum an livers (Figure 3-28; Pearson rank correlation 
=  0.86) the correlation deteriorated when rat liver slices were cultured for 0.5 hours (Figure 
3-29) and was no longer significant.
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Figure 3-29 Correlation of the Relative Expression of Drug Transporters in H um an Liver and 
Rat Liver Slices at 0.5 Hour
Correlation of the relative expression of drug transporters between human liver and rat liver slices at 
0.5 hour in culture using mRNA transcript levels obtained by RT-PCR (RNA; Pearson rank 
correlation = -0.26), and protein levels obtained by immunoblotting and band densitometry (Protein; 
Pearson rank correlation = 0.86). Results were also analysed by linear regression to give lines of best 
fit (n = 3 for mRNA; r = 0.79; n = 1 for protein; r = 0.06; error bars = SEM; where no error bars 
are observed they are contained within the limits of the data point). The dotted line refers to the 95 % 
confidence limits of the linear regression.
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3.6.S.5 Primary Rat H epatocyte and Human Liver Com parison
Rat hepatocytes are a comm on in v itro  system  used to predict drug access in humans. To 
examine if  rat hepatocytes express comparable levels o f  drug uptake and efflux transporters 
to humans correlations at mRNA and protein level were undertaken. As can be seen in Figure 
3-30, there is no significant correlation betw een m RN A  transcript levels betw een hum an liver 
and prim ary rat hepatocytes (Linear regression r2 =  0.005; Pearson rank correlation = -0.08). 
The transporters that contributed the m ost to the poor correlation were ABCB1 and 
O A T P lA 2/la4 . Both o f  these transporters fall outside o f  the 95 % confidence limits o f  the 
linear regression.
Correlation betw een protein levels o f  transporters in hum an liver and prim ary rat hepatocytes 
however was improved (Figure 3-30; Linear regression r2 =  0.79; Pearson rank correlation = 
0.85), suggesting a better correlation exists at the functional rather than m essage level. This is 
consistent with the findings o f  the previous section, which dem onstrated that although m RNA 
transcript levels for a transporter could be significantly different betw een m odel systems, 
protein expression was comparable. Prim ary rat hepatocytes correlated to hum an liver to a 
similar extent as rat liver slices cultured for up to 0.5 hours (Figure 3-29 (B; Pearson rank 
correlation = 0.86). On this basis, the m odel system s m ay be considered equivalent, however 
rat liver slices m ay be superior based on retained liver architecture.
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Figure 3-30 Correlation of the Relative Expression of D rug Transporters in H um an Liver and 
Prim ary Rat Hepatocytes
Correlation of the relative expression of drug transporters between human liver and primary rat 
hepatocytes using mRNA transcript levels obtained by RT-PCR (RNA; Pearson rank correlation = - 
0.08), and protein levels obtained by immunoblotting and band densitometry (Protein; Pearson rank
correlation = 0.85). Results were also analysed by linear regression to give lines of best fit (n = 3 for
2 * 2  mRNA; r = 0.005; n = 1 for protein; r  — 0.79; error bars — SEM; where no error bars are observed
they are contained within the limits of the data point). The dotted line refers to the 95 % confidence 
limits of the linear regression.
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S.6.5.6 Primary Human H epatocyte and Human Liver Com parison
It w ould be reasonable to assume that for the investigation o f  drag disposition in hum an liver, 
prim ary hum an hepatocytes w ould be the best m odel system. The correlation betw een hum an 
hepatocyte and hum an liver transporter transcript expression (Figure 3-31) was however, 
poor (Linear regression r2 = 0.03; Pearson rank correlation = 0.17). ABCB1 expression in 
prim ary hepatocytes was high, w hereas O A TP1A 2 expression was low, each contributing to 
the poor correlation. Despite this, correlation analysis o f  protein expression, revealed a good 
relationship (Linear regression r2 =  0.79; Pearson rank correlation =  0.89) betw een the 
systems, w ith  all transporters falling w ithin the 95 % confidence intervals o f  the linear 
regression. The correlation how ever is not as good as that observed betw een protein 
expression levels in hum an and rat liver (Figure 3-28, B; Pearson rank correlation = 0.99 p < 
0.01). Thus, it would appear that although prim ary hepatocytes have the advantage that they 
are derived from  the same species, the isolation procedures and culture conditions used to 
grow  them  in m onolayers, alter transporter protein expression sufficiently to diminish the 
correlation.
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Figure 3-31 Correlation of the Relative Expression of D rug T ransporters in H um an Liver and 
Prim ary H um an Hepatocytes
Correlation of the relative expression of drug transporters between human liver and primary human 
hepatocytes using mRNA transcript levels obtained by RT-PCR (RNA; Pearson rank correlation = 
0.17), and protein levels obtained by immunoblotting and band densitometry (Protein; Pearson rank 
correlation = 0.89). Results were also analysed by linear regression to give lines of best fit (n = 3 for 
mRNA; r  2 =  0.03; n  =  1 for protein; r  2 =  0.79; error bars = SEM ; w here no error bars are 
observed they are contained w ithin the lim its o f  the data point). The dotted line refers to the 95 
% confidence limits of the linear regression.
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3.7 D iscussion
Assessm ent o f  drug transporter action in preclinical drag  developm ent ranges from  the use o f  
simple m em brane-based assays to cell based assays and animal models. Simple assays have 
the advantage that a detailed m echanism  o f  a com pounds interaction w ith that transporter can 
be elucidated; however, the assay provides no insight into whether that interaction will affect 
a drugs disposition in hum ans. Systems o f  increasing biological com plexity give m ore 
inform ation about such outcom es; however, cell-based in v itro  models and anim al studies 
m ay be confounded by differences in expression o f  essential proteins such as drug 
transporters and drug m etabolising enzymes. It is possible that no single assay w ill provide 
all the inform ation required to predict drag  m etabolism  and disposition in hum ans. However, 
it is evident that a better understanding o f  the expression profiles in each m odel system  w ill 
aid the correct interpretation o f  the data and enable extrapolation betw een them  and betw een 
test species.
3 .7 .1  m R N A , P r o t e i n  a n d  F u n c t i o n
Historically, it has been acceptable to describe the state o f  biological system s by the 
quantitative m easurem ent o f  system  constituents at the transcript level, using R T-PC R  or 
cDNA m icroarrays. However, there is em erging evidence that m RNA expression levels are 
by them selves insufficient for the quantitative description o f  biological system s, as m RNA 
levels are not always equivalent to protein expression levels, let alone functional activity 
levels. A lthough gene expression depends prim arily  on the rate o f  transcription, m RN A  is 
regulated by various post-transcriptional events (D ay and Tuite, 1998; M oore, 2005), w ith the 
regulation o f  m RN A  decay being a m ajor control point in gene expression. The stability o f  a 
particular m RN A  is controlled by specific interactions betw een its structural elem ents and 
m RN A -binding proteins that can be general or m RNA -specific (G uhaniyogi and Brewer, 
2001). Recent analyses how ever indicate that differences in protein concentrations are only 
20-40 %  attributable to variable m R N A  levels (Brockm ann et al., 2007), underlining the 
importance o f  post-translational m odifications to proteins. Post-translational processes that 
influence the actual protein levels observed, include protein m odification or degradation, 
protein transport to or from  the cytoplasm , and the form ation o f  protein-protein complexes 
(Y ou and Yin, 2000). Additionally, the relationship betw een m RNA and protein expression
167
levels m ay be cell-type specific for a particular gene target. For example, it has been 
dem onstrated that ABCB1 protein levels are linearly correlated with m RNA levels in Caco-2 
cells, but not in M DCKII-ABCB 1 cells, where the m RN A  level was m uch higher, but protein 
levels were alm ost the same in both cell lines (Shirasaka et al., 2009).
Finally, whereas quantitative m RN A  and protein  data give some insight into the function o f  
cellular systems, to truly describe system  function, the activity o f  gene products w ithin that 
system  need to be determined. In the case o f  integral m em brane proteins, the cellular 
m achinery for targeting and inserting proteins into the lipid bilayer m ust be functional in 
order to result in active protein. In some cell lines, especially in un-polarised cell culture 
models o f  polarised cell types such as hepatocytes, these m em brane targeting m echanism s 
m ay be absent, resulting in an over-estim ation o f  function based and m RN A  and protein 
expression levels. A ctivity assays are also invaluable w hen the perpetrator o f  a reaction is 
unidentified; activity can be m easured in each system  without knowledge o f  the precise 
protein(s) responsible. Thus, for gene products or processes directly involved in determ ining 
the disposition o f  R-123; nam ely absorption, m etabolism  and efflux, activity assays were 
perform ed as part o f  the m odel param eterisation process (Chapter 5).
3 .7 .2  T h e  H u h 7  C e ll  L in e
In this study, the basal level o f  a num ber o f  influx and efflux transporters were determined at 
the m RNA level, suggesting a capacity to both actively take up and efflux compounds. 
H owever, w hen a com parison is made to hum an liver levels o f  transporters, it becom es clear 
that in the im m ortalised cell line, w ith the exception o f  OATP1A2 and OATP2B1, uptake 
transporters are generally under expressed and efflux transporters, w ith the exception o f  
ABCC3 are over expressed. The reduction o f  influx transporters in this cell line, suggested by 
reduced m RNA levels could be a m ajor lim itation for their use in ADM E studies involving 
hydrophilic drags, w hich rely on influx transporters to get into cells and could result in a 
‘false negative’ result for drag access. O n the flipside, i f  m RNA were representative o f  the 
levels o f  canalicular efflux transporters, the cell line w ould over-estim ate drag clearance rates 
from  the cell and could lead to toxicity.
Investigation o f  the uptake transporter OATP IB  1 and the efflux transporter ABCB1 at the 
protein level revealed that m RNA expression alone is not sufficient to indicate protein
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localisation to the correct membrane. m RN A  levels o f  OATP IB  1 w ere low com pared to 
ABCB1 levels, and im m unoblotting o f  these proteins in the total protein lysate, confirmed 
this relationship. However, despite high levels o f  ABCB1 protein in the cell, it w as detected 
at low levels in the m em brane fraction, suggesting that it was not correctly processed and 
trafficked in the cell line. Conversely, OATP IB  1 w as concentrated in the m em brane fraction, 
suggesting that it m ight be active how ever a functional assay w ould be required to confirm  
this. The differential location o f  the uptake and efflux transporters implies a different 
m echanism  for the localisation o f  basolateral and canalicular located proteins. It has in fact 
been recognised that neither basolateral nor canalicular trafficking follow a default pathway, 
and that specific signals and interactions are required for inclusion into transport vesicles 
w ithin the trans G olgi netw ork (Nies et al., 2002). Basolateral sorting signals are m ost often 
peptidic; consisting o f  tyrosine- or dileucine-m otifs in the cytoplasm ic dom ains o f  proteins 
(Huet et al., 2003). In contrast, apical targeting is proposed to occur via apical cholesterol- 
and sphingo lip id-rich raft carriers (Ikonen and Simons, 1998), interacting w ith  glycan signals 
within the glycoproteins (Huet et al., 2003). It w ould appear that the basolateral targeting 
system  is m ore robust, and can operate in Huh7 cells, whereas canalicular sorting is polarity 
dependent or relies on a m echanism  that is aberrant in the cell line. It is notew orthy that 
ABCC3, the only efflux transporter to be m easured that resides on the basolateral membrane, 
is under-expressed at the m RNA level in the cell line along with the other basolateral uptake 
transporters, w hich is in support o f  such a hypothesis.
That efflux transporters, including the m ulti-drag resistance transporters ABCB1 and ABCC1 
were over-expressed at the m RNA level in this cell line could be a consequence o f  their 
isolation from  tum our tissue, in w hich over-expression o f  these efflux transporters is comm on 
(O 'Connor, 2007). It could also be result o f  a positive feedback loop m echanism  triggered in 
response to the lack o f  functional transporter in the membrane. O ver-expression m ay also be 
an adaptive response to the culture conditions used, as increases in efflux expression is also 
observed in prim ary cell lines and rat liver slices. Increases in canalicular efflux transporter 
m RN A  could thus be a result o f  a canalicular-specific m echanism  that has yet to be 
explained. As dem onstrated with the CDF efflux assay, if  efflux transporters are not located 
to the canalicular m em brane, no efflux occurs. Thus, those substances that can passively 
diffuse into cells, w ould reach a higher intracellular concentration in v itro , than they w ould 
reach in v ivo , giving an erroneous estim ate o f  drag  disposition. The Huh7 cell line is 
therefore an inappropriate m odel system  in w hich to  study uptake or efflux processes and
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care m ust be taken w hen assessing results using hydrophilic drags, as intracellular 
concentrations m ay be significantly different from  the applied dose.
3 .7 .3  T h e  E f f e c t  o f  C u l t u r e  P e r i o d  o n  D r u g  T r a n s p o r t e r  E x p r e s s i o n
H andling processes and subsequent culture conditions used in the m aintenance o f  prim ary 
hepatocytes and rat liver slices result in changes in the transcriptom e and proteom e, as cells 
adapt to their new surroundings. D rug transporter expression levels were show n to change in 
both  absolute and relative term s in response to culture period. Response to culture length was 
isoform  specific but some broad observations can be m ade in relation to other m odel systems. 
In the case o f  uptake transporters, m RN A  expression generally decreases w ith tim e in culture, 
w hich is parallel to the know n decrease in m etabolic enzymes over culture period (Hashem i 
et al., 1999b; H ashem i et al., 2000). In  prim ary rat hepatocytes, uptake transporter expression 
was significantly lower than in the rat liver, and then decreased steadily w ith time. Rat liver 
slice culture period either caused an im m ediate and sustained decrease in uptake transporter 
expression, as in the case o f  O a tp la l  and O atp lb2  or a slight increase followed by a 
decrease, as dem onstrated by O a tp la4  and O c tl. In the latter case, w hen an increase was 
observed, it was early on in the culture duration and w as m irrored at the protein level w hen 
O atp la4  was detected by im m unoblot. The difference in response betw een rat liver slices and 
prim ary rat hepatocytes m ay reflect a difference in cell viability betw een the two systems. It 
is clear that production o f  prim ary rat hepatocytes causes a greater attrition o f  drug 
transporter expression than does production o f  rat liver slices, as the levels o f  uptake 
transporter are m uch lower at the start o f  the culture period. It is possible the decrease in 
uptake transporter expression observed is sim ply as a result o f  reduced cell function as cell 
viability is lost.
In  the case o f  the efflux transporters, expression was more variable; transporter expression 
could decline in culture, rem ain constant or increase w ith culture period. O f particular interest 
is A bcb l, as the expression profile o f  this transporter was similar in both  o f  the m odel 
systems investigated. In prim ary rat hepatocytes, A bcbl expression was significantly higher 
than the levels found in rat and increased w ith  tim e in culture. The same pattern  was seen in 
rat liver slices, w ith the exception that starting levels were more sim ilar to the rat liver from 
w hich they were produced. D etection o f  A bcb l protein in rat liver slices over tim e in culture
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revealed that protein levels increased w ith tim e in culture corresponding to m RNA levels. 
The peak in protein expression w as at 48 rather than 24 hours, which likely indicates the time 
delay betw een transcription and translation processes. As suggested by m RN A  levels, protein 
levels o f  A bcb l in control prim ary rat hepatocytes were also elevated, but only by an 
additional 6 % o f  rat liver levels. This confirm s that although m RNA levels m ay overestim ate 
the levels o f  A bcbl in rat liver slices and prim ary hepatocytes, increases are still observable 
at the protein level and could impact on the results o f  transporter studies involving substrates 
o f  A bcb l. Sim ilar increases o f  A bcbl expression in prim ary rat hepatocytes over time, in the 
absence o f  drag pressure have also been observed by Fardel et al., 1992, and w ere shown to 
decrease the sensitivity to  doxorubicin i f  cells w ere dosed at 48 hours, when A bcbl protein 
was elevated (Fardel et al., 1992).
Part o f  the attraction o f  using rat liver slices to study drug disposition is that ADM E 
processes should be intact and therefore representative o f  in v ivo . RT-PC R m easurem ent o f  
Cyp3a9 expression over tim e in culture revealed that expression levels stable up to 24 hours 
and dropped at 48 hours, suggesting that rat liver slices are suitable for the study o f  m etabolic 
processes. Cyp3a9 did not appear to be co-ordinately regulated w ith A b cb l, since no 
significant increases in expression w ere observed at 24 hours. In the reports o f  A bcbl and 
cytochrom e P450 co-ordinated induction, the m echanism  was via PX R  activation (O linga et 
al., 2008); in this study there is no evidence to suggest that the increase in A bcbl is m ediated 
by PX R  and therefore no reason to assume that Cyp3a9 should be co-ordinately regulated in 
this case.
Thus, for some efflux transporters, expression can increase, despite a general trend o f  
decreasing m R N A  levels w ith tim e in culture. This observation m ight indicate a survival 
response; a proposed m echanism  is that in the early  stages o f  adaptation, uptake transporters 
are up-regulated for the uptake o f  nutrients, w hereas at the later stages, w hen cell death is 
occurring, efflux transporters are up-regulated to counteract the build up o f  toxic m etabolites 
in the cell. It should be noted that this observation does not hold true for all o f  the tested 
systems: In  the Huh7 cell line, ABCC3 was under-expressed, along w ith  m any o f  the uptake 
transporters co-located on the basolateral m em brane, suggesting a canalicular-specific m RNA 
regulation mechanism. By comparison, in rat liver slices, Abcc3 becom es over-expressed at 
48 hours, along w ith som e o f  the efflux transporters based on the canalicular m em brane. The 
disagreem ent betw een the results could be due to the nature o f  the cells; Huh7 cells are not 
polarised, w hich appears to predom inantly affect localisation o f  canalicular transporters, rat
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liver slices in contrast have retained cell polarity, so the increase in Abcc3 observed could be 
due to an increased requirem ent for efflux as cells die.
Interestingly, the pattern o f  relatively low expression o f  influx transporters and high 
expression o f  efflux transporters w hen com pared to liver m RNA levels seen in prim ary rat 
hepatocytes is the same as that observed in the Huh7 cell line. By the same m echanism  that 
was proposed for Huh7 cells, canalicular efflux transporter m RNA m ay be up-regulated as a 
com pensatory response to loss o f  cell polarity  and disrupted canalicular surfaces, caused as a 
result o f  the isolation procedure.
One aim  o f  this study was to ascertain the u tility  o f  m odel systems over the culture period to 
be used for assays involving drag transport, and to identify tim es that m ay be m ore reflective 
o f  the in v ivo  condition. It is evident that assays earned  out in either prim ary rat hepatocytes 
or rat liver slices could potentially underestim ate drag access due to  decreased uptake 
transporter and increased efflux transporter expression. This underestim ation w ould be 
greater in prim ary cells and w ould w orsen w ith  tim e in culture for both  systems. I f  
transporter-m ediated uptake is a significant com ponent, as occurs for hydrophilic drags, rat 
liver slices dosed betw een 0.5 and 6 hours w ould be the best m odel system. Increases in 
A bcbl expression w ith  tim e in culture could be advantageous, if  the aim  o f  the assay was to 
assess w hether drag accum ulation could be com prom ised by A bcbl efflux, or to represent 
individuals w ith a m ulti-drag resistance phenotype. Thus, depending on the puipose o f  the 
experiment, different m odel system s and culture periods could be advantageous. m RNA 
levels in this case are sufficient to give an indication o f  the processes occurring during the 
culture period but for an estim ation o f  functionality, protein  levels need to be determined.
3 .7 .4  E x p r e s s i o n  o f  D r u g  T r a n s p o r t e r s  in  M o d e l  C e ll  S y s t e m s  C o m p a r e d  
t o  L iv e r
In this study, the basal levels o f  several influx and efflux transporters was show n to differ 
greatly betw een, hum an and rat prim ary hepatocytes, liver sections and rat liver slices. As a 
general com m ent, protein levels were m ore sim ilar betw een system s than were m RN A  levels, 
m aking protein quantification a m ore useful param eter for extrapolation o f  drag disposition 
(Figure 3-32). It m ust also be noted that in m any cases, m RN A  levels were not a predictor o f
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protein expression, w hich is now  a generally accepted concept (Gerner et al., 2002; Izzotti et 
al., 2004; Pradet-Balade et al., 2001). G iven that transcriptom es and proteom es reflect the 
outcom es o f  com plex and often opposing processes that bring about biosynthesis and 
destruction, some question w hether a correlation exists at all (Beynon, 2005). Thus for the 
time being, individual relationships betw een m RN A  and protein levels are therefore 
necessary for the accurate description o f  a m odel system.
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Figure 3-32 System Correlations for RNA and Protein
The Pearson correlation coefficients for RNA and protein expression levels are shown for all model 
systems tested. The correlation ranges from 0 to 1, with the sign indicating a positive or negative 
slope. 1 denotes the relationship with the highest correlation (0.99), 2 denotes the relationship with the 
second highest correlation (0.98).
m RNA levels betw een closely related system s such as rat liver and rat liver slices (Figure 3- 
32) were closely correlated, but this correlation w as w eakened w hen the in v itro  system  was 
single-cell based. The correlation betw een rat liver and rat hepatocyte RN A was poor, which 
could be a consequence o f  two factors; the first being that different rat strains were used in
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the com parison and the second being that the m RNA and protein was extracted from  prim ary 
hepatocytes cultured in monolayers. It is know n that expression o f  transport proteins is 
altered in prim ary hepatocytes cultured in m onolayers due to loss o f  the three-dim ensional 
architecture that is present in the liver (H offm aster et a l ,  2004). Thus, m RN A  expression 
levels m ay have been altered in response to  the hepatocyte isolation procedure. Prim ary 
hum an hepatocytes also expressed different levels o f  transport proteins com pared to hum an 
liver. A t the transcript level, ABCB1 and ABCC2 w ere over-expressed and OATP1A2 and 
OCT1 were under-expressed. This is in agreem ent to the pattern o f  expression in rat 
hepatocytes following isolation. A n im portant finding was that hum an hepatocytes expressed 
detectable levels o f  OATP1A2 at transcript and protein levels, which is contrary to previous 
research (Jigorel et al., 2005) and m ay be a result o f  recent im provem ents in hepatocyte 
isolation procedures (Hewitt et al., 2007).
Protein levels w ere m ore robust, w ith all correlations rem aining greater than 70 %, providing 
evidence o f  expression correlation betw een m odel systems w ithin and betw een species 
(Figure 3-32). That m RNA levels can vary  widely, w hilst protein levels rem ain relatively 
stable m ay be a consequence o f  biological necessity. Protein levels could be constrained 
w ithin tighter limits to ensure that essential functions are retained, w hereas m essage level 
could vary  as a first response to environm ental challenge. A lteration in protein expression 
levels could thus occur only if  a challenge is sufficient or applied for long enough to 
necessitate an adaptive response. Though it is energetically unfavourable for a cell to produce 
m RNA that is not translated, the ‘translation on dem and’ concept for som e genes has been 
proven in yeast, where stores o f  un-translated m RN A  are generated in the cell so that the 
stress response is rapid, if  the cells are exposed to detrim ental conditions (Brockm ann et al., 
2007).
Surprisingly, correlation o f  protein  levels betw een hum an and rat liver (r =  0.99) were 
stronger than betw een hum an liver and prim ary hum an hepatocytes (r =  0.79). It must be 
recognised nevertheless, that a strong correlation alone does not m ean that rat liver is a better 
m odel system  in w hich to study drug disposition; substrate specificities and affinities for rat 
orthologues m ay be different and other transport proteins or metabolic enzym es m ay be 
present o r absent, all o f  w hich could alter drag  access. It was shown that rat m odel systems 
on the whole express m ore protein than  hum an m odel systems. Thus, appropriate correction 
factors m ust be applied w hen investigations are carried out in system s expressing different
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levels o f  transport protein, to reflect these differences in both relative and absolute transport 
capacity.
Correlation analysis also confirm ed the previous findings that uptake transporter levels 
decrease and efflux transporters increase over tim e in culture in hum an hepatocytes, rat 
hepatocytes and rat liver slices. However, at 0.5 hours, RLS protein expression levels are 
significantly correlated to liver levels and are a suitable alternative to in v ivo  dosing or whole 
liver perfusion. This analysis also validates the use o f  rat liver slices in preference to prim ary 
rat hepatocytes. The weaker correlation betw een rat liver and rat prim ary hepatocytes is likely 
to be due to the previously identified alteration in uptake and efflux transporter expression as 
a result o f  cell isolation.
3 .7 .4 .1  F u tu re  D ire c t io n s
In contrast to the abundance o f  m RN A  expression data, considerably few er quantitative 
protein expression datasets are available due to the com paratively recent advent o f  m ethods 
for m easuring protein abundance on a large scale (such as the use o f  ICAT, iTRAQ and 
protein A Q U A  w ith m ass spectrometry) and the difficulty o f  these experim ents relative to 
chip-based m RN A  studies (Gerber et al., 2003; Y u et al., 2007a). A  lim itation o f  this study 
was the small sample size for protein analysis, necessitated by the identification m ethod 
employed. Such small sample sizes introduce error into the analysis and make it hard to 
achieve significant correlations. M any o f  the antibodies were polyclonal, m eaning that they 
recognise a num ber o f  different epitopes. This further reduces the specificity o f  W estern 
blotting and increases the risk o f  cross-reactivity w ith other proteins. A  future improvement 
w ould be to m easure protein expression using a m ore sensitive and accurate method 
applicable for high throughput. The protein expression data presented here are therefore only 
representative o f  a sm all data set, and should not be assum ed to represent a larger population.
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3 .7 .5  S u m m ary
In  conclusion, prim ary hepatocytes are a good m odel system  in w hich to study transporter 
m ediated drag access, but rat liver slices are a superior system  based on protein expression 
levels com pared to hum an liver. Such a system  could be used to measure the biliary efflux o f  
compounds and to gain a better understanding o f  how  drags are absorbed and excreted from 
the body. In  cell system s w ith lim ited viability, culture period reduces the sim ilarity to hum an 
liver and could cause m isinterpretation o f  drag accum ulation and efflux concentrations unless 
corrected for. The im m ortalised Huh7 cell line derived from the hum an liver has the 
advantage o f  relative expression stability and cell viability for longer periods, but expression 
levels are not representative o f  those in v ivo . In such cell lines, under-expression o f  uptake 
transporters and loss o f  vectorial transport makes them  unsuitable for transport studies. The 
recom binant M DCKII-ABCB1 cell line has been show n to over-express stable levels o f  
m RN A  and protein and can be used for the study o fR -1 2 3  efflux kinetics. The presence o f  
endogenous transporters the w ild-type and recom binant cells has been characterised and 
deem ed to pose no significant contribution to the R-123 efflux kinetics attributed to A B C B l. 
Thus, M DCKII-ABCB1 cells are useful for the derivation o f  kinetic param eters, but for 
prediction o f  in v ivo  disposition, m ore com plex cell lines expressing all the components 
involved in ADM E processes are required.
Only through com prehensive knowledge o f  drag transporter levels in in v itro  cellular systems 
can we aim  to make robust pharm acokinetic and toxicological predictions for new 
compounds. In a forthcom ing chapter, the relative drug transporter expression levels and 
expression patterns obtained herein w ill be used to m odel the effect and m agnitude o f  drag 
transporter expression variance on R-123 disposition.
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4 .  O p t i m i s a t i o n  o f  R h o d a m i n e - 1 2 3  D e t e c t i o n  a n d  
Q u a n t i t a t i o n  i n  v i t r o
4 .1  I n t r o d u c t i o n
Rhodam ine-123 (R-123) is a fluorescent m onovalent cation, w hich is reported to cross 
m em branes easily due to its lipophilic nature and then to accum ulate in areas w ith negative 
m em brane potentials such as w ithin the m atrix o f  m itochondria (Huang et al., 2007; Jancis et 
al., 1993). The advantages o f  using R-123 as an indicator o f  intracellular accum ulation and 
ABCB 1-m ediated efflux include its com m ercial availability, high sensitivity (high quantum  
yield), specificity (against other environm ental changes) non-invasive detection and low 
interference w ith underlying m etabolic processes (Em aus et al., 1986). However, the intensity 
o f  R-123 fluorescence (AEx = 503 nm, X E m  =  527 mn) has been show n to  deviate from  
linearity beyond concentrations o f  5 pM  in aqueous solution w ith intensity dim inishing 
tow ard zero at higher concentrations o f  R-123 (Huang et al., 2007). In addition, R - l23- 
m em brane binding m ay further reduce the upper lim it o f  linearity to 1 pM  total R-123 
(Huang et al., 2007) by causing a 12-nm red-shift in fluorescence (Darzynlciewicz et al., 
1982; Em aus et al., 1986). The m echanism  o f  this fluorescence self-quenching is not well 
understood, and m ay include form ation o f  less or non-fluorescent aggregates (Arbeloa et al., 
1997), energy transition through collision (Huang et al., 2007) or a com bination o f  these 
effects.
These photo-physical properties o f  the rhodam ine dyes are influenced by their chem ical 
structure, as w ell as by the environm ent, such as the nature o f  the m edium  (polarity, 
hydrophobicity), pH  and tem perature (Raha et al., 2009). As photodecom position o f  
fluorescent probes can also decrease the intensity o f  fluorescence over time, and rhodam ine 
dyes have been shown to dem onstrate poor photo-stability w hen exposed to strong light 
radiations (Evans, 1980), rate o f  photodecom position is an im portant factor when 
fluorescence is used to estimate concentration. This chapter details the characterisation o f  the 
physico-chem ical properties o f  R-123 within the in v itro  systems used in this thesis, thus 
allowing accurate interpretation o f  fluorescence readings in subsequent results chapters.
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4 .2  O p t i m a l  w a v e l e n g t h s  f o r  m e a s u r e m e n t  o f  R - 1 2 3  a n d  R - 1 1 0
The wavelength at which both  R-123 and it p rim ary  m etabolite, R-110, absorb the m ost light 
(Amax) was initially determined, as this equates to the m ost efficient excitation wavelength. 
The absorbance o f  samples o f  R-123 and R-110, prepared as 1 pM  solutions in HBSS (1 % 
(v/v) methanol), were scanned using a Perkin E lm er Lam ba 25 UV /Vis spectrophotom eter 
(M ilan, Italy). Absorbance versus w avelength w as plotted  as shown in Figure 4.1 (A). Amax 
was identified as 502 nm and 497 nm  for R-123 and R-110 in these solutions respectively. 
Based on these findings and the recom m endation o f  the R-123 certificate o f  analysis 
(Biotium: R-123 Amax (M eOH) 507 mil), the excitation wavelength for fluorescence 
spectroscopy was set at an intermediate o f  505 nm. N ext, fluorescence em ission spectra over 
a range o f  500-600 nm  w ere obtained using the Varian Cary Eclipse fluorescence 
spectrom eter (California, USA). Fluorescence w as plotted  versus em ission w avelength and 
the Em. Amax was derived for each com pound (Figure 4.1 (B)).
R123 and R110 UV-Vis absorption spectra
B
R123 and R110 fluorescence spectra
Excitation wavelength (nm) Emission wavelength (nm)
Figure 4-1 UV-Vis Absorbance and Fluorescence Spectra of R-123 and R-110.
Solutions of 1 pM R-123 and 1 pM R-110 were prepared in HBSS. UV-Vis absoiption spectra were 
measured using a Perkin Elmer Lambda 25 (Milan, Italy) (A) and the fluorescence emission spectra 
(Aex = 505 mn) was obtained using the Varian Cary Eclipse fluorescence spectrometer (California, 
USA) (B). Absorption Amax for both R-123 and R-110 are approximately 502 nm and 497 nm 
respectively. R-123 emission Amax is -525 nm and R-110 emission Amax is -520 nm. Curves are 
representative of n = 3 repeats.
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For samples o f  the same solvent com position, R-123 emission was determ ined at /.max 525 
nm and R-110 em ission at A.max 520 nm. U nder these conditions, R-123 exhibited higher 
absorption and em ission intensities than R-110 w hen prepared as equim olar solutions. This 
finding has been confirm ed by Jager et al., 1997 (Jager et al., 1997). In subsequent 
experiments, when solvent or detergent conditions varied, optimised fluorescence param eters 
were first determined in the specific environm ent employed.
4 .3  P h o t o - s t a b i l i t y  o f  R - 1 2 3
The photo-stability o f  2 pM  solutions o f  R-123 in HBSS buffer was determ ined in 
quadruplicate by measuring fluorescence intensity (>.ex = 505 nm; le m  = 525 nm) over a one 
hour period (Figure 4-2). Fluorescence did not significantly deviate from linearity (Runs test 
p value =0.15) but there was a slight but significant increase in fluorescence intensity over 
this period (slope = 0.075 ± 0.008, deviation from zero p < 0.0001).
Time (min)
Figure 4-2 Photo-stability ofR-123 in HBSS Buffer
Fluorescence intensities of 2 pM R-123 solutions prepared in HBSS buffer were measured over a one 
hour period (Xex = 505 nm; Xem = 525 nm). Fluorescence intensity was correlated against time and 
results were analysed by linear regression in GraphPad Prism 5 to give a line of best fit. Slope = 0.075 
± 0.008, significant deviation from zero p < 0.0001, non-significant deviation from linearity (runs test 
p = 0.15). The red dotted line refers to the 95 % confidence limits of the linear regression; n = 4.
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4 . 4  L o g D  a n d  P a s s i v e  D i f f u s i o n  o f  R - 1 2 3
R-123 has been reported to cross m em branes easily due to its lipophilic nature and 
accum ulate in areas w ith negative m em brane potentials such as w ithin the matrix o f  
m itochondria (Huang et al., 2007; Jancis et al., 1993). However, baseline diffusion from  
apical to basolateral m em branes in Caco-2 cells was shown to be negligible (Stom ier et al., 
2001), which w ould argue against significant passive diffusion occurring in a cellular context. 
R-123 absorptive transport from apical to basolateral m em branes has also been reported to 
occur prim arily by the paracellular route, w hereas secretory transport from  basolateral to 
apical m em branes w as m ediated by a saturable process (Troutm an and Thakker, 2003). Given 
that R-123 is a m onovalent cation, w hich typically diffuse through lipid bilayers at a slower 
rate than anions o f  the same size (H auser et al., 1972; Papahadj.D  and W atkins, 1967), and 
the conflicting evidence that exists regarding the potential o f  R-123 to passively perm eate 
cells, the affinity o f  R-123 for polar and non-polar phases was determ ined to assess the 
com pound’s ability to passively diffuse. Over the concentration range tested (10-500 nM  R- 
123) betw een 69 -  51 % o f  R-123 partitioned into the octan-l-o l phase, w ith octan -l-o l 
preference decreasing w ith increasing R-123 concentration (Figure 4-3).
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W ater 
Octanol
Concentration of R123 added pre mix (pM)
Figure 4-3 Correlation of [R-123] in HBSS and O ctan-l-o l Fractions with [R-123] Added to Pre­
mix.
Solutions of water and octan-l-ol in a 1:1 (v/v) ratio were vortexed to pre-saturate. The pre-mix 
samples were then spiked with 0 - 0 .5  pM R-123 (0.5% methanol) in triplicate and vortexed a second 
time. The mixture phases were allowed to separate before samples were taken from each fraction and 
the fluorescence measured (Water fraction: Aex 505 nm; Aem 525 nm; Octan-l-ol fraction: Aex 505 
nm; Aem 537 nm). The concentration of R-123 was calculated from standard curves of R-123 in water 
or octan-l-ol and the calculated amount was correlated against the concentration added to the pre-mix. 
Data is expressed as mean (n = 3) ± SD; where no error bars are observed they are contained within 
the limits of the data point.
Next, the partition coefficient o f  R-123 at physiological pH  (Logo) was determ ined as the 
ratio o f  equilibrium  concentrations o f  dissolved R-123 in a tw o-phase system  consisting o f  
oc tan -l-o l and w ater (Figure 4-4). LogD was found to range betw een 0.3 and 0.02  at the p re­
mix concentrations o f  10-500 nM  R-123, w ith LogD decreasing w ith increasing R-123 
concentrations, as predicted from  the distributions show n in figure 4-3. These partitioning 
estimations suggest that diffusion o f  R-123 through cell m em branes w ould be m inim al at the 
concentrations examined. Reasons for the change in logD value over the R-123 concentration 
range are discussed below.
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Concentration of R123 added pre mix (pM)
Figure 4-4 LogD Values over a Range ofR-123 Concentrations
Solutions of water and octan-l-ol in a 1:1 (v/v) ratio were vortexed to pre-saturate. The pre-mix 
samples were then spiked with 0 -  0.5 pM R-123 (0.5 % methanol) in triplicate and vortexed a second 
time. The mixture phases were allowed to separate before samples were taken from each fraction and 
the fluorescence measured (Water fraction: Lex 505 nm; A,em 525 nm; Octan-l-ol fraction: Lex 505 
nm; Xem 537 nm). The concentration ofR-123 was calculated from standard curves ofR-123 in water 
or octan-l-ol. LogD values were calculated at each pre-mix concentration using: Logo = Coctan-i-oi / 
Cwater. Error bars = SD, where no error bars are observed they are contained within the limits of the 
data point.
4 .5  F l u o r e s c e n c e  C h a r a c t e r i s t i c s  a n d  P e r t u r b a t i o n s
For a fluorescent probe to be used as a quantifiable substrate, the factors that perturb 
fluorescence under standard experim ental conditions or during specific procedures m ust be 
determined. In circum stances where a factor cannot be avoided, it is necessary to correct for 
the effect during analysis. Thus, conditions that m ay alter fluorescence have been 
investigated to determine the constraints o f  use and the m agnitude o f  the change that m ay be 
exerted.
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4.5.1 C o n cen tra tio n  e f fe c t s
The intensity o f  fluorescence can deviate from  linearity w ith increasing fluorophore 
concentration, which w ould impact upon the robustness o f  quantitation. Im portantly, such 
deviations usually  becom e obvious at concentrations m uch lower than those that produce 
non-linearity in the dependence o f  absorbance on concentration (i.e. <10"2 M ) (Schulm an, 
1977), m eaning that they m ay be non-trivial under experim ental conditions. In  m ost cases, 
w hen non-linearity occurs, the intensity o f  fluorescence usually decreases w ith  increasing 
fluorophore concentration. At low concentrations (<10"4 M ), this phenom enon occurs due to 
the fact that intensities o f  fluorescence do not truly vary linearly, but exponentially w ith 
fluorophore concentration. For instance, a solution w ith an absorbance o f  0.1 and the 
w avelength o f  excitation w ill have a fluorescence intensity 10.7 % lower than it w ould if  the 
fluorescence intensity were truly linear w ith concentration (Sharma and Schulman, 1999).
A t higher concentrations, solute-solute interactions m ay contribute to the non-linearity  o f  the 
fluorescence intensity versus concentration curve. Two types o f  solute-solute interaction are 
comm on; the aggregation o f  excited solute m olecules w ith ground-state m olecules o f  the 
same type to form  an exited dim er or ‘excim er’, or occasionally the interaction betw een two 
different solute m olecules to form a heteropolym eric excited state complex or 
‘exciplex’(Sharm a and Schulman, 1999). These com plexes w ill often fluoresce at longer 
w avelengths or be non-fluorescent. Energy transfer, w hereby excited donors, pass their 
excitation energy to unexcited donors is m ore probable as concentration increases, and occurs 
by  one o f  tw o ways. First, resonance excitation transfer (RET) is different to other 
fluorescence phenom ena, in that it does not depend on contact betw een m olecules and can act 
at distances o f  7 x 10'7 -  1 x 10‘6 cm  providing the acceptor m olecule is in range o f  the 
donor’s dipole-generated electrical field (Schulm an, 1977). RET can be considered a 
concentration dependent phenom enon, since at higher concentrations o f  donor and acceptor, 
the distance betw een the centres o f  the donor and acceptor dipoles is less and RET becom es 
m ore probable (Schulm an, 1977). Energy transfer results in the donor returning to its 
electronic ground-state and the excited acceptor either returning to its ground-state by 
fluorescence o f  by radiationless pathways. The exchange m echanism  occurs over shorter 
range donor distances, where electron clouds overlap and requires a higher concentration than 
RET (Lakowicz, 2006). This interaction involves the transfer o f  highest energy electrons to
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the acceptor m olecules coupled to the transfer o f  lower energy electrons back to the donor 
m olecule resulting in fluorescence quenching (Lakowicz, 2006).
Second, high concentrations o f  absorbing m olecules, including the fluorophore can also result 
in an inner filter effect. H igh concentrations o r turbid sam ples can m ean that that the intensity 
o f  the excitation light is not constant throughout the solution. As a result, only a sm all 
percentage o f  the excitation light reaches the fluorophores that are visible for the detection 
system. I f  the absorption spectrum  and the fluorescence spectrum  overlap, some or all o f  the 
photons em itted by the fluorophore m ay be absorbed again resulting in the dim inution o f  
fluorescence intensity (Sharm a and Schulman, 1999). Thus, the effect o f  fluorophore 
concentration w as determined to enable correct interpretation o f  the em ission o f  fluorescent 
light.
4 .5 .1 .1  C ritic a l M ice lle  c o n c e n t r a t io n
Am phiphilic compounds are w ater-soluble in the m icro- to m illim olar range, and self- 
assem ble into a colloidal dispersion o f  m olecular aggregates called m icelles above a 
threshold concentration, term ed the critical m icelle concentration (CM C). This definition 
comprises synthetic detergents as well as am phiphilic peptides and lipopeptides, bile salts and 
m any other com pounds (Heerklotz, 2008). Since R-123 is a cationic am phiphilic com pound 
(Bunting et al., 1989), it m ay too assem ble into m icelles above a critical concentration, 
altering its fluorescence spectra and its ability to perm eate cells by passive diffusion or active 
uptake. Dye m aterials such as R-123 have absorption and fluorescence properties which 
differ distinctly in m edia o f  contrasting polarity and organization such as aqueous solutions 
o f  oppositely charged surfactant m onom ers and m icelles (Deum ie and Elbaraka, 1993). 
Surfactant micelles have been show n to solubilise hydrophobic drags inside the core formed 
by the lipophilic part o f  the surfactant (Lavasanifar et al., 2002). Above the CM C, R-123 has 
been shown to incorporate into micelle cores, therefore becom ing m asked from  the external 
m edium  (Liu, 2008). Thus, solutions containing either concentrations o f  rhodam ine-123 or 
surfactants above the CM C could be prone to fluorescence em ission perturbation. The 
critical m icelle concentration o f  R-123 was determ ined in the absence o f  other surfactants 
(Figure 4-5) and surfactant effects w ere investigated independently (Section 4.4.3). The
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critical micelle concentration o fR -123  was calculated to be -1900  ± 70 nM, from an average 
o f  four experiments using the following equation:
CMC = (C2-C1) / (M l-M2)
W here C = y axis intercept, M = slope, 1 or 2 = indicates the number o f  the linear regression 
labeled in figure 4-5.
In figure 4-3, the CMC can be seen at the point at which the two linear regression lines cross.
[R123] (nM)
Figure 4-5 The Critical Micelle Concentration of R-123
CMC was determined by measuring the fluorescence emission (Varian Cary Eclipse; A,ex = 505 nm; 
k m  = 500-600 nm) of increasing concentrations (0-0.5 pM) of R-123 in HBSS (methanol 1%) and 
plotting the A,max (530 nm) at each concentration. Linear regressions were performed using GraphPad 
Prism software, version 5, and the CMC calculated using the following equation: CMC = (C2-C1) / 
(M l-M2), where C = y axis intercept, M = slope, 1/2 = indicates the number of the linear regression. 
Each data point is expressed as a mean (n = 4) ± SD. Where no error bars are observed, they are 
contained within the data point.
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4 .5 .2  S o l v e n t  e f f e c t s  a n d  d i e l e c t r i c  p o i n t  d e t e r m i n a t i o n
Solvent polarity and local environm ent have profound effects on the em ission spectral 
properties and quantum  yield o f  fluorophores. Typically, a fluorophore in an excited state has 
a larger dipole m om ent than a fluorophore in the ground-state. Solvents surround 
fluorophores in their excited state and relax around them, causing m olecule stabilisation and a 
reduction in their energy level (Lakowicz, 2006). This results in fluorescence em ission o f  
longer w avelength or lower energy. Em ission effects increase w ith  solvent polarity, 
especially i f  the fluorophore is itse lf polar (Lakowicz, 2006). Sometimes however, solvent 
polarity is insufficient to explain the spectral shifts observed. In such cases, specific solvent - 
fluorophore interactions such as hydrogen bonding involved in solvation m ay be occurring 
(Sharm a and Schulman, 1999).
To determine the solvent effects on R-123 and R-110 fluorescence, lp M  solutions o f  both 
com pounds w ere prepared in a variety o f  analytical grade laboratory solvents. Each solution 
contained 1% (v/v) m ethanol as the prim ary solvent, and 99% (v/v) test solvent. Using a 505 
nm  excitation wavelength, em ission w avelengths w ere scanned over a 500-600 m n range and 
the fluorescence intensity correlated against w avelength for each com pound (R-123 Figure 4- 
6 , R-110 Figure 4-7). R-123 and R-110 fluorescence intensity and profile are dependent on 
environm ent w ith R-123 having a higher quantum  yield in the solvents butanol, ethanol, 
m ethanol and acetonitrile than it does in the aqueous solvent HBSS used in experim ental 
treatm ents. W ith the exception o f  acetonitrile, these solvents also cause a red-shift com pared 
to HBSS. Solvents that cause a decrease in R-123 quantum  yield and a red-shift include 
isopropanol, butan-2 -ol and octan-l-o l.
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E m is s io n  w a v e le n g th  (n m )
Figure 4-6 Fluorescence Spectra of lpM  R-123 in Different Solvents
A stock solution of 1 mM R-123 was prepared in methanol. 1 pM solutions of R-123 were then 
prepared by performing a 1:1000 dilution into each test solvent. As such, each sample contained 1 % 
(v/v) methanol and 99 % test solvent. Solutions were prepared in triplicate and measured in triplicate 
(A.ex 505 nm; A,em 500-600 nm). Mean fluorescence intensities were correlated against emission 
wavelength. Error bars are not shown so that curves are not obscured.
R-110 fluorescence is sim ilarly affected by its environm ent; however most solvents cause an 
increase in quantum  yield and a red-shift. Ethanol, methanol, butanol, isopropanol and octan-
l-o l all increase fluorescence respective to when HBSS is used as the solvent. Acetonitrile 
and butan-2 -ol however, shift the fluorescence to the left and significantly reduce quantum  
yield at these wavelengths.
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E m is s io n  w a v e le n g th  (n m )
Figure 4-7 Fluorescence Spectra of lpM  R-110 in Different Solvents
A stock solution of approximately ImM R-110 was prepared in methanol. lpM  solutions of R-110 
were then prepared by performing a 1:1000 dilution into each test solvent. As such, each sample 
contained 1% (v/v) methanol and 99% test solvent. Solutions were prepared in triplicate and measured 
in triplicate (Aex 505 nm; Aem 500-600 nm). Mean fluorescence intensities were correlated against 
emission wavelength. Error bars are not shown so that curves are not obscured.
Em ission intensity o f  R-123 and R-110 against solvent dielectric constant (Chapter 2, Table
2-5) was then plotted to obtain an estim ated value o f  E for each fluorophore (Figure 4-8). 
Fluorescence o f  R-123 and R-110 exhibit an approxim ately linear relationship with solvent 
dielectric point up to and slightly beyond E ~30, followed by a plateau. Since both 
compounds solubilise well in m ethanol (Biotium, California, USA) w hich has a E = 33, and 
poorly in aqueous solutions (Gendron et al., 2008), it is reasonable to deduce from the graph 
that the dielectric points o f  both compounds are approxim ately E =30. Exceeding this point in 
both directions reduces the fluorescence intensity o f  each fluorophore.
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Figure 4-8 Correlation of R-123 and R-110 Emission Intensities with Solvent Dielectric 
Constant
Emission intensity of R-123 and R-110 (Lex 505 nm; A.em 520 nm) against solvent dielectric constant 
(Table 2-5) was plotted to obtain an estimated value of E for each fluorophore. Data is presented as 
mean (n = 3 with 3 technical repeats) ±  SD for each data point. Where no error bars are visible they 
are contained within the data point.
The effect o f  increasing the proportion o f  m ethanol present in an otherwise aqueous solution 
on R-123 em ission characteristics was determ ined to find the m aximum  amount o f  m ethanol 
that could be used without altering em ission (Figure 4-9). Solutions o f  R-123 containing less 
than 5 % (v/v) m ethanol in HBSS buffer showed little difference in fluorescence intensity 
com pared to when the m inim um  possible am ount (0.1 %  v/v) o f  m ethanol was present. 
M ethanol concentrations exceeding 5 %  v/v cause both  an increase in em ission intensity and 
a right shift. W ith the intention o f  keeping fluorescence intensity entirely dependent on 
fluorophore concentration and m inim ise solvent effects, all solutions were thus prepared with 
a constant m ethanol concentration below 5 % (v/v).
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EE m is s io n  w a v e le n g th  (n m )
Figure 4-9 Effect of M ethanol Concentration on R-123 Fluorescence
lpM  solutions of R-123 were prepared that contained between 0.1 -  100 % methanol. The co-solvent 
was HBSS. Fluorescence intensities (Aex 505 nm; Aem 500-600 nm) were correlated against emission 
wavelength. Data is expressed as a single data point for each solution.
4 .5 .3  D e t e r g e n t  e f f e c t s
Several peculiarities have been noted for the spectroscopic properties (e.g. change in 
absorption spectra and fluorescence quenching) o f  dyes with detergents that posses an 
opposite charge, particularly i f  approaching the CM C (Sato et al., 1980). M ataga and 
Koizumi, studied the fluorescence quenching o f  the cationic dye Rhodam ine-6G w ith the 
anionic detergent sodium dodecyl sulphate (SDS) (Koizumi and M ataga, 1953) and showed 
that fluorescence quenching was dependent on the concentration o f  SDS around its CMC. 
The quench-effect was attributed to the aggregation o f  dye ions and an orderly array o f  
detergent ions interacting together. How ever, several authors have reported the de- 
aggregation effect o f  the non-ionic detergent Triton X-100 on dyes w hen used above its 
critical m icelle concentration (Kemieywallace et al., 1975; Lessing and Jena, 1976). 
A lteration o f  fluorescence spectra in the presence o f  detergents m ay be due the environm ental 
change (i.e. an increased hydrophobic environm ent) and / or the im m obilisation o f  some dye
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m olecules within the micellar m edia (M aiti et al., 1997). A  com bination o f  de-aggregation 
and im m obilisation effects can improve fluorescence lifetime and quantum  yield (Sato et al., 
1980). The potential o f  an R-123 dye-detergent interaction that might occur within the 
experim ental conditions used herein was determ ined by measuring R-123 fluorescence 
intensity and profile in the presence o f  several com m only used lysis buffers: The lysis buffers 
tested contained either the non-ionic surfactants Triton X-100 or Nonidet p40 or the anionic 
surfactant SDS or a com bination o f  the above.
All o f  the lysis buffers tested caused a reduction in R-123 fluorescence, com pared w ith the 
HBSS control (Figure 4-10). 2 % (v/v) Triton X -100 reduced the fluorescence intensity by 
approxim ately 20 % but caused no shift in the em ission spectrum. Protein extraction buffer 
reduced fluorescence intensity to a sim ilar extent, but caused as red-shift in the em ission 
spectrum. RIP A  buffer reduced R-123 fluorescence intensity by 40 % and caused a red-shift 
similar to that o f  the protein extraction buffer.
E m is s io n  w a v e le n g th  (n m )
Figure 4-10 Effect of Lysis Buffer on R-123 Fluorescence
1 pM R-123 was spiked into three commonly used lysis buffers; Ripa buffer (50 mM TrisHCl pH 7.4, 
150 mM NaCl, 2 mM EDTA, 1 % (v/v) Nonidet p40, 0.1 % (v/v) SDS), Western blot protein 
extraction buffer (0.2 % (v/v) SDS, 2 % (v/v) Nonidet p40 and 1 pM dithiothrietol (DTT)) and 2 % 
(v/v) Triton X-100 100. R-123 fluorescence (A,ex = 505 nm; A,em = 500-600 nm) was then measured 
and profiles were compared to a control (1 pM R-123 in HBSS). Data is expressed as mean values (n 
= 3) for each condition.
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4 .6  I d e n t i f i c a t i o n  o f  R - 1 2 3  a n d  R - 1 1 0  b y  T h i n  L a y e r  
C h r o m a t o g r a p h y
R-123 is reported to be metabolised to R -l 10 by the rem oval o f  a methyl ester group leaving 
R-110 with a free carboxyl group with a negative charge (Jancis et al., 1993; Sweatm an et al., 
1990). Since these dyes are distinct fluorescent m olecules w ith different chem ical structures, 
they are identifiable by their affinities for mobile and stationary phases utilised in thin layer 
chrom atography (TLC). Discrim ination betw een the two species using this m ethod is a useful 
tool to confirm  the occurrence o f  m etabolism  within the in v itro  system. To validate such an 
approach, the separation o f  com m ercial preparations o f  R -l 10 dissolved in m ethanol can be 
achieved using a mobile phase consisting o f  chloroform: methanol (50:50) (Figure 4-11).
R-123 R-110 R123/R-110
Figure 4-11 TLC separation of Commercial Rhodamine Dyes
5 pM solutions of each dye prepared in methanol were spotted onto the origin line individually (4 pi 
each) or in combination (2 pi each). Plates were allowed to dry before introduction to the tank 
containing equilibrated mobile phase composed of 100 ml chloroform: methanol (50:50). Plates were 
developed until the solvent front reached 2 cm from the top of the plate. Spots were visualised under 
UV light using the Gene Genious Bio Imaging System (Syngene, Cambridge, UK).
As dem onstrated in the figure, R-123 rem ains close to the origin, while R-110 m igrates with 
the mobile phase. This separation pattern is observed w hen dyes are loaded separately or in
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combination. It is hence possible to use TLC to clearly discrim inate betw een R-123 and R- 
110, even w hen presented as a mixture.
4 .7  A s s e s s m e n t  o f  R - 1 2 3  T o x i c i t y  u s i n g  L a c t a t e  D e h y d r o g e n a s e  
A c t i v i t y  a s  a  M a r k e r  o f  C e l l  D e a t h
In order to use R-123 as a probe substrate for assessm ent o f  cellular processes such as uptake, 
m etabolism, non-specific binding and efflux, it m ust first be determ ined w hether R-123, or its 
solvent methanol, are them selves toxic to cells w ithin the concentration ranges used in later 
experiments. Lactate dehydrogenase activity was quantified using the LDH assay kit (Roche 
Diagnostics Ltd., Lewes, UK) in response to various proportions o f  m ethanol (up to 10 % 
v/v in HBSS) (Figure 4-12) and various concentrations o f  R-123 (0-200 pM ), prepared in 
HBSS w ith 1 %  m ethanol (Figure 4-13).
As can be seen in figure 4-12, cell viability decreases linearly (slope = -4.1 ±  0.5; r2 = 0.77) 
w ith % (v/v) m ethanol applied however, no significant decrease in cell viability was observed 
until 6 %  (v/v) m ethanol w as exposed to cells (p <  0.05). A t less than 6 % (v/v) m ethanol, the 
small am ount o f  cell death observed is w ithin the error m argins for control cells. Cell death 
increased w ith  m ethanol concentration beyond 6 % (v/v), reducing cell viability to 
approxim ately 60 ±  10 % (p < 0 .001) at 10 % m ethanol (v/v).
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Figure 4-12 Assessment of M ethanol Toxicity Utilising the L D H  Assay
The LDH level was quantified using the LDH assay kit (Roche Diagnostics Ltd., Lewes, UK). Buffer 
from treated cells at 80 % confluence was added to an equal volume of the kit reagents (1:45 bottle 1 : 
bottle 2 ) in a 96 well ELISA plate and left, protected from light, at room temperature for 30 minutes. 
The plate was then read at 490 nm in an ELISA plate reader (BioTEK ELx800). Results were adjusted 
for background and compared to a positive control of cells lysed in 2 % triton X-100 to determine the 
magnitude of cell death in response to various proportions of methanol exposed to the cells for 10 
minutes. Results are expressed as % cell viability, fitted by linear regression and analysed using an 
unpaired t-test to show where cell viability in treatment groups was significantly different to an HBSS 
control (* = p < 0.05, ** = p < 0.01, mean (n = 3) ± SEM; slope = -4.1 ± 0.5; r2 = 0.77; slope p < 
0.001; where no error bars are observed, they are contained within the data point; 5 denotes the % of 
methanol used in in  v i t r o  experiments).
The LD H  assay for R-123 cytotoxicity (Figure 4-13) showed that exposures to 20 pM  R-123 
and above resulted in statistically significant cell death (p < 0 .001) com pared to control cells. 
However, at concentrations o f  20 pM  R-123, w hich is the highest concentration used in in  
v i t r o  assays, -9 0  % cell viability rem ained, w hich is w ithin the error m argins o f  cell death for 
control cells. A  linear regression w as perform ed to test whether cell death w as R-123 
concentration dependent. The slope o f  -0.09 ± 0.008 was statistically significant (p < 0.0001), 
indicating a correlation betw een R-123 concentration and cell viability. Despite the slope 
showing strong statistical significance, the biological significance o f  this relationship is
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minimal. Even at concentrations 10-fold higher than those used ha in v itro  experiments, 
approxim ately 80 % o f  cells rem ain viable.
[R -123] pM
Figure 4-13 Assessment of R-123 Toxicity Utilising the LDH Assay
The LDH level was quantified using the LDH assay kit (Roche Diagnostics Ltd., Lewes, UK). Buffer 
from treated cells at 80 % confluence was added to an equal volume of the kit reagents (1:45 bottle 1 : 
bottle 2) in a 96 well ELISA plate and left, protected from light, at room temperature for 30 minutes. 
The plate was then read at 490 nm in an ELISA plate reader (BioTEK ELx800). Results were adjusted 
for background and compared to a compared to a positive control of cells lysed in 2 % triton X-100 to 
determine the magnitude of cell death in response to various concentrations of R-123 exposed to the 
cells for 10 minutes. Results are expressed as % viability compared to an HBSS (0 pM R123) control, 
fitted by linear regression and analysed using an unpaired t-test to show where cell viability in 
treatment groups was significantly different to the HBSS control (*** p < 0.001; mean (n=3) ±  SEM; 
slope = -0.09 ±  0.0008; r2 = 0.78; slope p < 0.001; where no error bars are observed, they are 
contained within the data point; 8 denotes the maximum concentration of R-123 used in in vitro  
experiments).
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4.8 D iscussion
Rhodam ine dyes such as R-123 are a useful too l for studying cellular processes such as 
intracellular accum ulation and efflux due to their com m ercial availability, high sensitivity, 
specificity, non-invasive detection, safety and low interference w ith underlying metabolic 
processes (Emaus et al., 1986). However, as a fluorophore R-123 is prone to photo-instability 
as w ell as fluorescence enhancem ent and quenching, caused by the nature o f  its surrounding 
environm ent. Thus, the w ork in this chapter set out to determine the robustness o f  R-123 in 
the experim ental environm ent to be used and to optim ise conditions in order to avoid 
undesirable fluorescence effects.
4 .8 .1  O p t im a l  W a v e l e n g t h s  & P h o t o - s t a b i l i t y
Optim al wavelengths for detecting R-123 and R-110 were determined as AEx. 505 nm, AEm. 
525 nm  and AEx. 505 nm, AEm. 520 nm  respectively, w hen solvated in HBSS w ith 1% (v/v) 
methanol. A change in environm ent com position affects fluorescence intensity and profile to 
different degrees depending on the polarity  and hydrophobicity o f  the solvents involved, as 
presented in sections 4.8.4 and 4.8.5. Thus, alteration o f  the environm ent from  the standard 
conditions requires em ploym ent o f  different w avelengths to obtain m axim al fluorescence 
detection. W here this was necessary, alternate w avelengths are stated in figure legends and 
accom panying text.
Fluorescence o f  R-123 appeared stable, and in fact increased slightly (slope: 0.075 ±  0.008, 
r2 =  0.06), probably due to increased hom ogeneity o f  R-123 distribution throughout the 
solution over the one hour period; incom plete initial m ixing could result in heterogeneity in 
local concentrations, which was detectable by fluorescence spectrophotometry. Thus, it is 
reasonable to assume that any loss o f  fluorescence w ithin a one hour period is due to loss o f  
R-123 from  the solution, or interactions w ithin it and not from fluorescence decay. As a 
precaution, solutions containing fluorophores w ere protected from light w hen possible to 
avoid enhancem ent o f  fluorescence decay as suggested by Evans et al., 1980.
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4 .8 .2  L ogD  and  P artition in g
LogD is com m only used as an estim ator o f  passive diffusion; however results should be 
interpreted w ith caution as for lipophilic com pounds w ith logo values greater than 1, there is 
the potential for sequestration w ithin the m em brane itself. Experim ental estim ates o f  this 
retention vary; in Caco-2 cells retention is estim ated at approxim ately 40%  for chemicals 
w ith LogD values in the range o f  3.5 to 5.2 (Wils et al., 1994) whereas Sawada et al., 
observed up to 89% m em brane retention in M D C K  cells for lipophilic chem icals w ith Logo 
values ranging from  1.1 to 15 (Sawada et al., 1999). Low  logD values can also underestim ate 
cellular access if  the com pound is able to form  m icelles at high concentration, w hich are the 
endocytosed and enter cells w ith high efficiency. In the case o fR -1 2 3 , Logo w as estim ated 
to be betw een 0.03 and 0.2 depending on the concentration used. A  Logo o f  0.53 for R-123 
has also been reported in the literature (Lampidis et al., 1989); both  estim ates are suggestive 
o f  low passive diffusion. This finding is consistent with the research o f  Storm er et al., 2001 
and o f  Troutm an and Thaklcer, 2003 who both dem onstrated limited passive diffusion in the 
apical to basolateral direction. However, evidence o f  aggregate form ation above the CM C 
value (Huang et al., 2007), could suggest a role for vesicular m ediated uptake once the CMC 
is exceeded. W hile cell loading can be undertaken w ith R-123 concentrations that exceed the 
CM C, as the m echanism  o f  loading is irrelevant, it is thus im portant to ensure that 
intracellular concentrations do not exceed the CM C, limiting the impact o f  passive efflux as a 
confounding factor.
Partitioning into oc tan -l-o l also appeared to decrease w ith increasing concentration o fR -123 , 
thus decreasing the logD. A  possible explanation for this could be a consequence o f  the 
m ethod used to estimate logo and the behaviour o fR -1 2 3  in aqueous solution: The m ethod 
assum ed that the concentration o f  R-123 in the un-sam pled volume w as equal to that 
sampled; however the un-sam pled volum e is at the interface o f  the two phases. A t low 
concentration, R-123 m ay accum ulate at the interface due to its amphiphilic nature, but at 
higher concentrations R-123 m ay preferentially form  aggregate structures in the aqueous 
phase. This behaviour w ould result in an underestim ation o f  R-123 concentration in the 
aqueous phase at low R-123 pre-m ix concentrations and an over-estim ation at higher ones. 
Since the concentrations o fR -123  in the pre-m ix were below the CM C value o f  1.9 pM , it is 
unlikely that full m icelles had been form ed but it cannot be excluded that some aggregation 
had occurred, thus explaining the observed partitioning effect.
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4 .8 .3  Critical M icelle  C on cen tra tio n
R-123 was found to have a CM C o f  approxim ately 1.9 pM . Since the CM C for most 
detergents ranges from  m icrom olar to m illim olar (Vance and Vance, 2002), R-123 m ay be 
expected to behave in a sim ilar m anor to detergents. It is know n that detergents can insert 
into lipid m em branes and at high concentrations can change the lateral packing density o f  
m em branes (Seelig and Gerebtzoff, 2006) w hich are themselves com posed o f  phospholipids 
assem bled into bilayer structures w hich allow close packing o f  adjacent side chains (Vance 
and Vance, 2002). A low value o f  CM C is generally indicative o f  a high degree o f  
interm olecular hydrophobic interaction. In  the presence o f  membranes, it should lead to a 
high degree o f  partition into the lipid phase (Requero et al., 1995). The low logD value 
obtained from  R-123 partitioning into o c tan -l-o l and w ater phases, suggested that monomeric 
R-123 w ould have limited m em brane solubility. However, since the CM C is low, once 
m icelles are form ed association w ith the m em brane m ay increase. M icelles are not believed 
to passively diffuse across membrane (Amiji, 2007), however vesicular-m ediated uptake o f  
m icelles has been dem onstrated in HepG 2 cells, adipocytes and hum an m icrovascular 
endothelial cells (Porter et al., 2007). Thus, from  these results it is likely that passive 
diffusion o f  R-123 is minimal, but entry into a cell at concentrations exceeding the CMC 
would be a result o f  vesicular-m ediated micelle endocytosis.
4 .8 .4  S o l v e n t  E f f e c t s  a n d  D ie le c t r i c  P o i n t  D e t e r m in a t io n
Polar solvents usually interact with polar fluorophores causing a spectral shift to longer 
em ission w avelengths due to  a stabilisation o f  the ground state and excited electrons by 
rearrangem ent o f  electrons within solvent m olecules. In general, polar solvents such as 
m ethanol, ethanol and octan -l-o l cause red shifts, whereas non-polar solvents such as butanol 
and oc tan -l-o l cause blue shifts. This is largely consistent with the experim ental data for both 
R-123 and R-110, with some exceptions: Acetonitrile caused a blue shift hi R-110 
fluorescence, and oc tan -l-o l caused a red shift. These exceptions m ay be explained by 
specific interactions betw een the solvent and the solute that are not categorised under general 
solvent effects. Specific effects can involve hydrogen bonding, acid-base chemistry, 
preferential solvation, or charge transfer reactions to name a few (Lakowicz, 2006). M ost o f
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the solvents causing a red-shift to longer w avelengths, are protic solvents i.e. those that are 
hydrogen bond donors, as is Acetonitrile, w hich causes solvation via ion-dipole forces 
(Reichardt, 2003). This alternative interaction could explain the shift to shorter wavelengths 
for both  R-123 and R-110 that cannot be explained by  the dielectric point o f  acetonitrile 
(-36 ).
Determ ination o f  the dielectric point o f  R-123 not only allowed assessm ent o f  fluorescence 
characteristics in the presence o f  typical laboratory solvents which m ay be em ployed in 
various analytical procedures, but also indicated the degree o f  m olecule polarity. A  solvent 
w ith a dielectric point o f  approxim ately 30 is considered sem i-hydrophobic (L ow iy  and 
Richardson, 1987). R-123 is often reported  as a lipophilic dye (Huang et al., 2007; Jancis et 
al., 1993), but the dielectric point indicates otherwise. This result could help to explain the 
low logo value obtained for R-123 partitioning into the hydrophobic oc tan -l-o l phase, and the 
reports that R-123 does not passively diffuse across cell m em branes (Storm er et al., 2001; 
Troutm an and Thakker, 2003). The dielectric po in t o f  R-110 was approxim ately the same as 
that o f  R-123, if  not slightly higher. A  higher dielectric point m ay be expected, since R-110 
has a free carboxyl group with a negative charge that w ould increase its polarity  (Jancis et al., 
1993). Thus, any R-110 that arises via m etabolism  o f  R-123 is likely to rem ain in the 
intracellular com partm ent rather than passively diffusing from  the cell.
W hen additions o f  a polar solvent, too small (1-2 % (v/v)) to alter the bulk properties o f  the 
solvent cause large spectral shifts, it is an indication that solvent specific interactions are 
occurring (Lalcowicz, 2006). R-123 fluorescence increased as the proportion o f  m ethanol in 
the solution increased but only once 5 % (v/v) was exceeded. This effect can be explained by 
m eans o f  two different mechanisms: (a) the m ethanol fraction disrupts the organisation o f  the 
aqueous solution and preferentially solvates the non-polar region o f  R-123, disturbing 
m icellar structures (Akhter, 1999). As dem onstrated w ith a variety o f  surfactants, m ethanol 
increases the CM C in a concentration dependent maimer (Akhter, 1999). I f  the CM C is 
increased, higher concentrations o f  m onom ers are free in solution, resulting in greater 
fluorescence intensity, (b) M ethanol m ay also increase fluorescence by  decreasing the 
dielectric constant at the m icellar interface due to replacem ent o f  w ater m olecules w ith 
alcohol m olecules (Baglioni and ICevan, 1987). As the dielectric point o f  R-123 was 
estim ated to be approxim ately 30, m ethanol w ould  act to solvate the dye in an environm ent 
which is considered sem i-hydrophobic (E =15-50) com pared to the polar aqueous solution (E 
> 50), according to the classification o f  polarity  by L ow iy and Richardson, 1987. Given that
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m ethanol concentration can alter fluorescence intensity, w hen quantification is required the 
proportion o f  m ethanol in all samples m ust be kept constant.
4 .8 .5  D e t e r g e n t  e f f e c t s
RIP A  buffer and protein extraction buffer perturbed R-123 fluorescence intensity to the 
greatest degree. B oth o f  these buffers contain the anionic detergent SDS and the non-ionic 
detergent N onidet p40. It is likely that the decreased fluorescence observed w as due to 
interaction o f  cationic R-123 w ith anionic SDS in solution, causing dye-detergent 
aggregation. This phenom enon has also been observed w ith rhodam ine-6G, which is also a 
cationic dye (Koizum i and M ataga, 1953). In addition, it is also possible that m icellisation 
was enhanced by the m ixing o f  the two surfactants in the same w ay that a synergistic 
interaction betw een SDS and Triton X -100 has been observed (Owoyom i et al., 2005).
That RIP A  buffer caused the largest reduction in R-123 fluorescence despite having sim ilar 
concentrations o f  SDS and N onidet p40 as protein  extraction buffer can m ost likely be 
explained by the additional presence o f  the cation chelating agent EDTA. 2%  (v/v) Triton X - 
100 reduced R-123 fluorescence but to a lesser extent than the other detergents. The 
concentration o f  Triton X -100 used (3.3 xlO '2 m ol.L '1, calculated assuming a density  o f  1.07 
g/ml) was above the CM C o f  3 xlO '4 mol1 L '1 (Chattopadhyay and London, 1984), thus de­
aggregation could be expected to occur. The decreased fluorescence observed could, hence, 
have been caused by the hydrophobicity o f  the environm ent. As seen in figure 4-6, R-123 is 
less fluorescent as solvent polarity decreases. As a result o f  these findings and to achieve a 
lower lim it o f  detection, w hen cell lysis w as necessary cells w ere either disrupted 
m echanically or w ith 2 % (v/v) Triton X -100 in conjunction w ith an R-123 standard curve 
also containing 2 % (v/v) Triton X-100. Thus, w here a detergent effect could not be avoided, 
it was corrected for in the subsequent data analysis.
4 .8 .6  T L C  s e p a r a t i o n  o f  r h o d a m i n e  d y e s
It is possible to separate R-123 from  its proposed m etabolite R-110 using TLC. A lthough this 
m ethod camiot identify any non-fluorescent R-123 metabolites, it does confirm  that R-123 is
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lost from  the reaction m atrix and that R -110 is formed, consistent w ith intracellular 
m etabolism. Taken together with the fact that R-110 is less fluorescent than R-123 (Figure 4- 
lb ), R-123 m etabolism  can be followed by m easuring fluorescence decrease over time, and 
confirm ed by m etabolite analysis by TLC.
4 .8 .7  LD H  a s s a y s
The solvent (methanol), in w hich R-123 is dissolved, can be used at a m axim um  o f  4 % (v/v) 
before greater than 10 % cell death occurs over the ten  m inute exposure period used in these 
experiments. Thus, to avoid solvent effects (Figure 4-9) and to limit cellular damage, 
m ethanol concentrations were kept constant at below  4 % (v/v).
R-123 can be used at up to 200 pM  concentrations while m aintaining approxim ately 80% cell 
viability. The concentrations o f  R-123 used in the uptake and efflux assays (Chapter 5, 
sections 5.2 and 5.4) were in the 2 pM  to 20 pM  range, at which a m axim um  o f  10% cell 
death was observed. Thus, even at ten  tim es the required concentration, R-123 causes little 
cellular dam age which makes it a suitable m arker to study cellular processes. A  proportion o f  
the absorbance at 490 nm  could also be attributed to R-123 leakage from  the cells during the 
assay, since R-123 absorbs light at this w avelength (Figure 4-1 (A)). Despite washing the 
cells thoroughly to  avoid this effect, leakage from the cells w ould give a dose-dependent 
increase in absorption at 490 m n that is independent o f  LD H  concentration. How ever, since 
absorption is low even at the highest doses o f  R-123, this effect is o f  no concern.
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4 .9  S u m m a r y
In summary, the physico-chem ical behaviour o f  R-123 indicates that it is a sem i-hydrophobic 
molecule w ith an am phipathic nature that prom otes m icelle form ation at low concentrations. 
That R-123 forms m icelles is not only indicated by the CM C determ ination experiment, but 
by  the fact that increasing m ethanol concentration increases fluorescence intensity by raising 
the concentration o f  free m onomers in solution. Finally, the low logo and dielectric point o f  
approxim ately 30 would suggest limited passive diffusion across cell m em branes. Based on 
these findings alone, cellular entry could be m ediated either by active uptake, endocytosis o f  
m icelles or a com bination o f  both, with the exact m echanism  being concentration dependent. 
M etabolism  o f  R-123 to R-110 should be m easurable, based 011 the different quantum  yields 
o f  both compounds and their distinct chem ical structures which result in altered polarity and 
solvent affinity during TLC. At the concentrations required for cell-based assays, cytotoxicity 
caused by R-123 is m inim al (~ 15 %  cell death at 20 pM  R-123), and should not cause 
spurious results. For quantification o f  R-123 and R-110, solvent and detergent effects must be 
considered, as fluorescence intensity could alter independently o f  fluorophore concentration. 
R-123 is how ever photo-stable for at least one hour; ample time to carry out an assay and 
quantify fluorescence.
In conclusion R-123 is a suitable substrate for studying and quantifying cellular processes 
such as uptake, sequestration, m etabolism  and efflux, providing experim ental conditions are 
tightly controlled to avoid any undesirable fluorescence effects.
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5 .  D e v e l o p m e n t  o f  a n  I n  S i l i c o  M o d e l  f o r  R - 1 2 3  D r u g  
D i s p o s i t i o n
5 .1  I n t r o d u c t i o n
Undesirable absorption, distribution, m etabolism  and excretion (ADM E) properties are the 
cause o f  m any drag developm ent failures and this has led to the need to identify such 
problem s earlier in the developm ent process (Sm ith et al., 2004). In m ost situations, in v itro  
models and experim ental animals are the only option for assessing hum an drag clearance. 
Consequently, the ability to  extrapolate betw een these systems, often bridging species 
boundaries is o f  great importance in drag  developm ent and risk assessment. Rem arkable 
progress has been made in establishing various in v itro  systems and connecting the output 
from  such systems to consequences that should be expected for chem ical entities upon 
adm inistration to hum ans (G ibson and Rostam i-H odjegan, 2007). Part o f  this progress is 
attributable to in s ilic o  m odelling and sim ulation, which has been em braced to give a more 
integrative understanding o f  the system  com ponents. It has been suggested that 15 % o f  drug 
developm ent budgets w ill be spent on sim ulating data using in s ilic o  models in the next 5-10 
years (Rostam i-H odjegan and Tucker, 2007), w ith the expectation that the technology will 
allow savings in both  tim e and m oney and increase the understanding o f  com plex biological 
networks. The FDA has also recognised that simulations that employ quantitative models o f  
drag response may improve study design and dose selection (US FDA, draft advice to 
industry, 2009).
A lthough doubts continue about the usefulness o f  m odel outcomes, vital distinctions need to 
be made betw een useful ‘sim ulation’, w hich is the outcome w hen essential inform ation for 
the m odel is not available, and precise ‘pred iction’ (Rostam i-Hodjegan and Tucker, 2007). It 
is im portant to realise that the outcom e o f  extrapolation is critically dependent on the quality 
o f  the prim ary in v itro  and in v ivo  data, against which the calculations are projected 
(Pellconen and Turpeinen, 2007). B y comparison, simulations, which lack m any precise 
param eters, are useful to answer ‘w hat i f  questions w ithout the need for vast am ounts o f  in 
v itro  work, thus potentially producing an initial screen and refining future experiments. By 
assessing the difference betw een the predicted and observed outcomes, models have also
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identified that m any o f  the biological param eters necessary for extrapolation are missing. The 
importance and source o f  such ‘know n-unknow ns5 can be simulated, and som etim es leads to 
the identification o f  previously unidentified biological interactions. Such an example, where a 
data-based m athem atical m odel added to the understanding o f  an in v itro  system  w as w ith the 
identification o f  the endogenous transporter Abcc4 in a transfected M DCKII cell line, that 
negatively contributed to the total vectorial transport o f  brom osulfophthalein (BSP) by 19 % 
(Bartholome et al., 2007).
5 .1 .1  M e t h o d s  f o r  In  v i t r o - l n  v i v o  E x t r a p o l a t i o n  (IVIVE)
One m ethod that has been w idely used to predict hum an pharm acokinetic param eters from 
pre-clinical species is allometric scaling, w hich relies on relative mass and size o f  each test 
anim al relative to humans. W hereas m any biochem ical processes such as respiration and 
m etabolic rate show reasonable scaling betw een species (W est et al., 2002), enzyme 
activities, tend not to scale allom etrically across species (Espie et al., 2009), lim iting the use 
o f  such approaches. Physiologically based pharm acokinetic (PBPK) models are m athem atical 
descriptions o f  the flow o f  blood throughout the body, w hich have been param eterised for the 
physiology o f  the animal, independent o f  the specific xenobiotic (Brightm an et al., 2006). 
Since num erous factors affect the overall in v iv o  pharm acokinetics, PB PK  software packages 
into w hich xenobiotic ADM E results and drag-specific physicochem ical properties can be 
incorporated are now being utilised to sim ulate the over-all biological effect in v ivo  
(Rostam i-Hodjegan and Tucker, 2007).
The Simcyp® Population-Based ADM E Sim ulator function is an example o f  such a m odel 
that that integrates drag-dependent ADM E properties, physiological and biological 
param eters as they vary betw een species, subjects, genders and ethnicities, w ith age and 
disease state. This IVIVE approach has also im proved predictions o f  biliary clearance b y  
incorporating in v itro  drag  m etabolism  data and accounting for genetic polym orphism s that 
give rise to inter-individual variability (Inoue et al., 2006). However, despite these advances, 
there are still ‘unknow ns’, including how  to incorporate hepatic uptake and secretory 
transporters into predictions o f  drag clearance (Rostam i-Hodjegan and Tucker, 2007). 
Currently, knowledge o f  drag transporter expression levels, variability in different tissues and 
species, and their interplay w ith m etabolising enzym es is inadequate, rendering in s ilic o
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predictions only as good as the in v itro  system s on w hich they rely. As w as dem onstrated in 
chapter 2 , in v itro  systems do not always provide a close representation o f  in v iv o  transporter 
expression levels, w hich could potentially underm ine IV IV E for chem ical entities that are 
prone to active transport.
5 .1 .2  T h e  R -1 2 3  D i s p o s i t i o n  M o d e l
The aim  o f  this research was to examine the u tility  o f  in s ilic o  m odelling o f  drug transport 
processes and to assess the contribution o f  these transport processes to overall cellular 
com pound disposition. In order to achieve this, R-123 was chosen as a test substrate on the 
basis that it participates in a range o f  cellular interactions expected for m any pharm aceuticals, 
including the specific efflux by  ABCB1. In  addition, its innate fluorescence provides an easy 
m eans o f  quantification. That ABCB1 is the focus o f  this m odel is a consequence o f  its 
significant role in absorption, distribution and elim ination o f  a wide variety o f  drags which 
are substrates, and its potential to cause a range o f  drag-drug interactions (A yrton and 
M organ, 2008). ABCB1 is therefore o f  great im portance for safety assessm ent, and the ability 
to sim ulate its effects on drag disposition w ould be highly desirable.
A  schem atic representation o f  the in s il ic o  m odel to be param eterised w ith quantitative RNA 
and protein data derived in chapter 3 and kinetic data derived herein, is shown in figure 5-1. 
This m odel can be used to simulate drag disposition in any cell/tissue type by changing each 
species quantity and reaction kinetic param eters to represent the system  being modelled. 
Since the in v itro  cell system  used to m easure biliary  efflux by ABCB1 is the M DCKII cell, 
this cell type has been represented in figure 5-1. The m odel presented below is a steady state 
model, in w hich the quantities o f  the biological com ponents do not change w ith tim e or in 
response to drag challenge; a m ore com plex dynam ic m odel is presented in the next chapter 
and w ill incorporate changes in drag transporter and drug m etabolising enzym e expression in 
response to nuclear receptor activation, as determ ined in section 5-7 o f  this chapter.
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Reaction I.d Reaction Description
R el Un-identified uptake processes including passive diffusion, in the test cell
system
Re2 Active uptake by OATP1A2 or other identified human drug transporters
Re3 M etabolism  o f  R-123 to R -l 10 by rem oval o f  a methyl ester group
Re4 Non-specific binding (NSB) to intracellular components; On rate
Re5 Non-specific binding (NSB) to intracellular components; O ff rate
Re6 Un-identified efflux processes including passive diffusion, in the test cell
system
Re7 Active efflux by hum an ABCB 1
Figure 5-1 Schematic Representation of the Life-cycle of R-123 within Cells
(A) A graphical representation of the species and reactions directly involved in R-123 cellular 
disposition was generated in CellDesigner 4.0. Lines indicate reactions; transport, metabolism, state 
transitions, or catalysis, whereas rectangles represent proteins; dotted lines denote active species, and 
ovals represent simple molecules such as R-123 and R-110. The function of each reaction, identified 
with a number, has been described in (B). SBML Script for this model is in the Appendix, Section 
9.2.1
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5.2 Cellular Entry of R-123
R-123 has been used extensively as an index o f  ABCB1-m ediated transport in rodents and 
tissue culture models. (Kageyam a et al., 2006; Parasram puria and M ehvar, 2010; Tai et al., 
2010). However, m any o f  these studies are lim ited by an incom plete investigation o f  the R- 
123 uptake kinetics; R-123 m ust be able to accum ulate within cells sufficiently to not limit 
the m aximum  velocity o f  the transport process. As discussed in the previous chapter, R-123 is 
generally reported to passively diffuse across cell membranes (Huang et al., 2007; Jancis et 
al., 1993) due to its lipophilic nature. How ever the Logo and CMC values determ ined in 
chapter 4 were consistent with the findings o f  other researchers and are suggestive that 
passive diffusion is negligible (Stom ier et al., 2001; Troutm an and Thakker, 2003). Evidence 
o f  active uptake m ediated by transporters on the basolateral membrane has also been found, 
and is discussed further in section 5.2.4.
W hether intracellular accum ulation o f  R-123 is a result o f  active uptake by specific 
transporters, endocytosis or a com bination o f  both  as yet, remains unclear. However, for the 
determ ination o f  ABCB1-efflux kinetics, the exact mechanism  is irrelevant, providing 
intracellular concentrations do not limit potential efflux rates. As dem onstrated in Chapter 3, 
im m ortalised cell lines often under-express influx transporters relative to m ortal tissue. The 
M DCKII-ABCB 1 cell line, expressed low levels o f  the influx transporters m easured and 
could potentially limit intracellular uptake o f  R-123 if  passive diffusion is minimal. Thus, 
intracellular accum ulation w ithin the M DCKII-ABCB 1 cell line was first determined to 
assess its suitability for an efflux assay involving the R-123 substrate. Second, the 
m echanism  o f  cellular entry was investigated, reducing the num ber o f  unknow n param eters in 
the simulation.
5 .2 .1 .  I n h ib i t io n  o f  E f f lu x  P r o c e s s e s  t o  M a x im is e  R -1 2 3  A c c u m u l a t i o n
As the rate o f  accum ulation o f  R-123 into cells is dependent upon the rate o f  flux in versus 
flux out, test cells are often loaded w ith R-123 in the presence o f  an inhibitor to block 
ABCB1-m ediated efflux (Bogm an et al., 2001). W e thus examined i f  such an approach 
significantly increased R-123 loading using the m ulti-ABC competitive inhibitor, quinidine 
(Gonzilez-Alvarez et al., 2007). Due to the competitive nature o f  the inhibition, quinidine
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concentrations were m aintained at ten times higher than the R-123 concentrations used in the 
assay, which is approxim ately 10 x the reported I C 5 0  at the highest concentration (Rautio et 
al., 2006). A 4 °C condition was included as a  passive diffusion control in which all active 
transporter functions should be inhibited. Briefly, cells were pre-loaded w ith R-123 for ten 
m inutes at 4 °C or 37 °C in the presence or absence o f  quinidine. Cells were then washed and 
lysed w ith Triton X-100 for the determ ination o f  intracellular fluorescence (Figure 5-2), or 
efflux was initiated and the quantity o f  R-123 extruded from the cell was determined by 
fluorom etry (Figure 5-3). As part o f  this experiment, it was first determined that quinidine 
itself does not fluoresce and does not alter the fluorescence o f  R-123 (data not shown).
minus quinidine 4°C plus quinidine 37°C minus quinidine 37°C
Figure 5-2 Inhibition of ABCB1 during R-123 Pre-loading Does Not Increase Intracellular 
Accumulation of R-123
MDCKII-ABCB1 cells were incubated with 0-10 pmol/pl R-123 at 4 °C, and 37 °C with 01* without 
quinidine at ten times the concentration of R-123. After 10 minutes, cells were lysed with 2 % Triton 
X-100 and the fluorescence intensity of the dilute lysate was determined (Xex 505 nm; k m  525 nm). 
Concentrations of R-123 were determined against a standard curve containing the same amount (v/v) 
of Triton X as the samples. Data was fitted using linear regression analysis (4 °C slope = 3.14 ± 0.25 
pmol/jil; 37 °C -  quinidine slope = 17.61 ± 1.21 pmol/pl; 37 °C + quinidine slope = 17.71 ± 0.71 
pmol/pl. Results are displayed as mean (n = 3) ± S.D. for each condition.
208
Results o f  the pre-loading experim ent are shown in Figure 5-2 and show that at 4 °C, R-123 
intracellular accum ulation is low and is directly linear w ith  concentration (slope = 3.14 ±  
0.25) At 37 °C minus quinidine, accum ulation rates are higher (slope = 17.61 ± 1.21) and 
dem onstrates linearity w ith concentration w ithin the concentration range o fR -1 2 3  examined. 
Inhibition o f  A B C B 1-m ediated efflux by quinidine did not increase intracellular 
accum ulation (slope =  17.71 ±  0.71) com pared to the minus quinidine condition, indicating 
that either ABCB1 inhibition w as ineffective, or that the uptake processes involved are 
equally inhibited by  quinidine.
E x p o s u re  [R123] pm ol/p l
-c- plus quinidine (10 x) minus quinidine
Figure 5-3 Inhibition of ABCB1 during R-123 Pre-loading Does Not Increase R-123 Efflux
MDCKII-ABCB 1 cells were incubated with 0-10 pmol/pl R-123 at 37 °C with or without quinidine at 
ten times the concentration ofR-123. Cells were washed and efflux was initiated by incubating cells 
in drug-free HBSS at 37 °C. After 7.5 minutes of efflux, R-123 fluorescence intensity of the HBSS 
was determined (Lex 505 nm; Xem 525 nm). Concentrations of R-123 were determined against a 
standard curve. Results are displayed as mean (n = 3) ±  S.D for each condition.
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As seen in figure 5-3, inhibition o f  ABCB1 in the R-123 pre-loading stage results in 
decreased R-123 efflux com pared to those cells pre-loaded in the absence o f  quinidine. This 
implies that quinidine inhibition is persistent in the efflux stage o f  the experim ent and w ould 
lead to an increase in the observed K m . These findings also suggest that in Figure 5-2, 
ABCB1 was inhibited during pre-loading and that accum ulation was lim ited due to inhibition 
o f  uptake transporters. Given that quinidine did not increase intracellular accum ulation 
(Figure 5-2), and im peded ABCB1 efflux (Figure 5-3), future uptake and efflux experiments 
were carried out in the absence o f  inhibitor and at 37 °C.
5 .2 .2  R -1 2 3  I n t r a c e l l u l a r  C o n c e n t r a t i o n
In the previous section it was determ ined that to achieve m axim um  R-123 loading w ithout 
im peding efflux, cells should be exposed to R-123 at 37 °C in the absence o f  an efflux 
inhibitor. U nder these conditions, R-123 was shown to accumulate within cells in a 
concentration dependent m anner (Figure 5-2), but w hether the concentration w as sufficient to 
allow ABCB1 efflux to reach Umax had not been determined. For this, several assum ptions 
w ere necessary; the volum e o f  a single M D CK II cell is estim ated to be 2.34 p i (A llen and 
M ills, 1988), the density o f  an average cell is 1000 pg/pl, and 10 % o f  cellular mass is protein 
(Zhang et a l ,  2000). Using the relationship betw een mass, density and volume, it can be 
calculated that the protein mass o f  a single M D C K II cell is 234 pg. Follow ing on from  this, 
the mass o f  total protein in the lysate determ ined by L ow ry assay can thus be used to estimate 
the num ber o f  cells per assay w ell ( -5  x 106 cells per well). This calculation not only rem oves 
the effect o f  cell seeding density on R-123 accum ulation estimates, but also allows the total 
cellular volum e per assay w ell to be calculated. The average total cell volum e responsible for 
R-123 accum ulation was estim ated to be 11.6 pi (2.34 pi * 5 x 106 cells per w ell = 1 1 .6  pi).
In Figure 5-4, the concentrations expressed on the y-axis were calculated as above and 
represent the concentration o fR -123  in the to tal cell volume. As can be seen, accum ulation is 
linear up to exposure concentrations o f  at least 20 pm ol/p l (slope = 3.97 ±  0.16; p < 0.0001). 
These estim ations o f  intracellular R-123 concentration are later used to dem onstrate that 
concentrations w ithin the cell are in excess o f  the concentrations effluxed (Section 5.4.2). It is 
also im portant to note that intracellular concentrations reached per cell exceeded the CMC 
value o f  2 pm ol/pl at all exposure doses. Assum ing that the CM C ofR -123  is the same within
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a cell as it is in an aqueous buffer, these concentrations indicate that form ation o f  micelles 
could occur, providing an A BCB1-independent efflux route.
Figure 5-4. Intracellular Concentrations of R-123 are Linear up to 20 pmol/pl
MDCKII-ABCB 1 cells were incubated with 0-20 pmol/pl R-123 at 37°C in the absence of quinidine. 
After 10 minutes cells were lysed with 2% Triton X-100 and fluorescence intensity of the dilute lysate 
was determined (Aex 505 nm; Aem 525 nm). Concentrations of R-123 were determined against a 
standard curve containing the same amount (v/v) of Triton X-100 as the samples. Results are 
displayed as mean (n = 3) ± S.D. for each condition and fitted by linear regression (slope = 3.97 ± 
0.16; p < 0.0001). Concentrations of intracellular R-123 were adjusted to represent the concentration 
in the total cell volume ( - 11.6 pl) per assay well.
5 .2 .3  T r a n s w e l l  A s s a y  f o r  V e c to r i a l  R -1 2 3  T r a n s p o r t
A  Transw ell assay for the bi-directional m ovem ent o f  R-123 betw een basolateral (B) and 
apical (A) compartm ents was carried out to determine the extent o f  passive diffusion in 
M DCKII cells and that ABCB1-m ediated efflux in the recom binant cell line was only in the 
B-A  direction. M DCKII-ABCB 1 cells growing on Transw ell m em branes were exposed to 
donor solutions containing R-123 w ith or without the ABCB1 inhibitor GF 120918. A second 
set o f  donor solutions w ith and w ithout inhibitor were also prepared containing 3H- 
Am prenavir as a positive control for ABCB1 transport and Lucifer yellow as a marker o f
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m ovem ent via the paracellular route. D onor solutions were placed in either basolateral or 
apical com partm ents depending on the direction o f  movement to be m easured. The 
concentration o f  test compound in each com partm ent following exposure was m easured by 
fluorom etry for both R-123 and Lucifer yellow  and by scintillation counting for 3H- 
Amprenavir. Finally, mass balance calculations were performed to determine whether 
accum ulation or m etabolism  or adsorption to the apparatus had occurred. Table 5-1 
summarises the results o f  the Transwell assay.
Lucifer yellow, a non-transportable substrate control, showed no significant movement, 
confirming that m onolayer integrity w as intact, since there was no leakage betw een cells 
from  the apical to basolateral chamber (data not shown). Thus, it can be confirm ed that any 
com pound m ovem ent observed was by active transport and not m ovem ent via the 
paracellular route. Estim ation o f  the apparent perm eability o f  R-123 by averaging B>A and 
A>B m ovem ent in the presence o f  the GF 120918 inhibitor showed that negligible passive 
diffusion occurred whereas the 3H -Am prenavir control passively diffused at a rate o f  360 ± 
75 nmol/sec, which is consistent w ith the expected diffusion rate for this experiment. The 
ABCB1 efflux ratio for R-123, calculated by dividing the rate o f  m ovem ent in the B>A 
direction by the rate in the A>B direction, was found to be 5.3, which decreased to 1.0 in the 
presence o f  inhibitor. The efflux ratio for 3H-Am prenavir was 34, decreasing to 0.9 in the 
presence o f  inhibitor. This suggests that R-123 has a lower transport rate via ABCB1 than 
does Am prenavir, but inhibition o f  transport is sim ilar for both compounds, confirm ing that 
ABCB1 is the transporter responsible.
Overall mass balance calculations showed that for Amprenavir, greater than 90 % o f  the 
compound could be accounted for at the end o f  the assay in both inhibited and non inhibited 
conditions. Such a 10 % loss is within the limits o f  experim ental error and is not indicative o f  
any other processes attributing to compound loss. For R-123 however, the yield was slightly 
lower (-77 .5  %), suggesting that R-123 had been lost from the system  either by binding to 
the apparatus or by being sequestered or m etabolised within the cells. Since R-110 is not a 
substrate o f  ABCB1 (Hom olya et al., 1993), the assay does not detect ABCB 1-mediated R- 
110 efflux into the apical compartm ent. In addition, as R-110 is also fluorescent, it can be 
assumed that if  m etabolism  occurred, R-110 m ost likely rem ained within the cells, since no 
fluorescence was detected in the basolateral com partm ent as a result o f  passive diffusion. 
Thus, this assay does not discrim inate betw een losses due to m etabolism  or sequestration 
within cells, requiring the loss to be investigated by alternative means.
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5 .2 .4  U p ta k e  A s s a y s  w i th  B a c M a m  T r a n s d u c e d  H E K 2 9 3 -M S R I!  C e l l s
R-123 uptake in sandwich rat hepatocytes has been shown to be a saturable process w ith an 
estimated K m  o f  8.4 pm ol/pL  and a Umax o f  54 pm ol/m in/m g protein, that can be inhibited 
by the typical O atp la4  substrates (digoxin, quinine, J-verapam il, 17p-estradiol-D-17(3- 
glucuronide) (Annaert and Brouwer, 2005). D ecreased expression o f  O ct 1 and Oct 2 protein 
by nitric oxide has also been shown to reduce R-123 cellular accum ulation in isolated rat 
kidneys (Heem skerk et al., 2008). However, attempts to inhibit Oct activity w ith the substrate 
tetraethylam m onium  (TEA), had no effect on R-123 accum ulation in prim ary rat hepatocytes, 
whereas inhibition o f  ABCB1 with cyclosporin A  and verapam il resulted in delayed 
accum ulation despite inhibited efflux (H irsch-Em st et al., 2001). This is indicative o f  an 
uptake m echanism  that is sensitive to ABCB 1-m odulators, and could potentially be O atp l a4- 
mediated, as identified by Annaert and Brouwer, 2005.
Other data in this chapter support the theoiy  that R-123 requires active carriers to cross the 
mem brane; low intracellular accum ulation at 4 °C com pared to 37 °C (Figure 5-2); the failure 
o f  quinidine to increase intracellular accum ulation despite inhibited efflux (Figure 5-3); the 
lack o f  A to B m ovem ent o fR -1 2 3  in the Transw ell assay (Table 5-1). O n the basis o f  the 
above findings, it was decided to assess w hether the m ajor hum an OATP iso forms expressed 
in the liver could actively transport R-123 into cells. HEK293 M SRII cells were singly 
transduced w ith hum an SLCO genes using BacM am  technology and shown to express 
functional OATP proteins by the perform ance o f  uptake assays with radiolabelled m odel 
substrates.
Cells were exposed to concentrations o f  R-123 ranging from 0-2 pM  in the presence or 
absence o f  10 nM  inhibitor specific for the transfected transporter under investigation (Table 
5-2) for 120, 300, 420 and 600 seconds at 37 °C. Following precise incubation times, cells 
were washed with ice-cold buffer to prevent active efflux from the cells and intracellular 
fluorescence was determined using a PO LA Rstar galaxy plate reader (BM G Labtechnologies, 
Germany; Lex  =  485 mn; A,em = 535 nm). Uptake was shown to be linear up to seven m inutes 
at each concentration (data not shown). Linear regression analysis up to seven m inutes was 
therefore perform ed at each concentration to give a rate o f  uptake in relative fluorescence 
units (RFU) per second for both inhibited and lion-inhibited conditions, as shown in figure 5- 
5.
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Inhibitor (10 nM) Transporter Reference
Rifamcyin OATP1B1 (Sharma et a l, 2010)
Montelukast OATP2B1 (Letschert et al., 2006; Mougey et al., 2009)
Ketoconazole OATP1A2 (Cvetkovic et al., 1999)
Rifamycin OATP1B3 (Vavricka et al., 2002)
Table 5-2 Inhibitors used in OATP uptake Assays
10 nM of each compound was used to inhibit the respective transporter indicated during R-123 uptake 
assays
O f the four OATP transporters investigated, only OATP1A2 dem onstrated significant R-123 
uptake w ith a clear difference observed betw een inhibited and non-inhibited conditions. Even 
w hen OATP1A2 was inhibited w ith 10 nM  ketoconazole, R-123 uptake was higher in these 
cells than in other transduced HEK-293 cells, suggesting that OATP1A2 w as not completely 
inhibited by 10 nM ketoconazole in this assay. R-123 uptake by the other OATP transport 
proteins was negligible even though positive control assays utilising radiolabelled m odel 
substrates confirmed the functionality o f  each transporter in these cases (data not shown).
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Figure 5-5 OATP1A2 Actively Uptakes R-123 in BacM am Transduced HEK-293 Cells
HEK-293 MSRII cells were singly transduced with BacMam viruses carrying human OATP1A2, 
OATP1B3, OATP2B1 and OATP IB 1 genes and incubated for 48 hours at 37 °C in a humidified 
incubator to allow expression of the protein. Cells were exposed to concentrations of R-123 ranging 
from 0-2 pM in the presence or absence of 10 nM of an inhibitor specific for the transfected 
transporter under investigation for 120, 300, 420 and 600 seconds at 37 °C. Cells were washed with 
ice-cold buffer and intracellular fluorescence was determined using a POLARstar galaxy plate reader 
(BMG Lab technologies, Germany; Xex = 485 nm; A,em = 535 nm). Data points correspond the rate of 
uptake obtained from linear regressions over three time points with duplicate values at each 
concentration. Functionality of the OATP proteins was confirmed by the performance of a separate 
assay utilising radiolabelled model substrates.
216
5.2.4.1 M ichaeiis-Menten Kinetics o f R-123 uptake by 0ATP1A2
In figure 5-5, OATP1A2 was the only transporter that exhibited significant R-123 uptake. 
Thus, for this transporter, rates o f  uptake in RFU/sec were converted to pm ol/m in/m g protein 
over the R-123 concentration range and fitted to the M ichaeiis-M enten equation below:
Y =V  max* X/(ICm+X)
W here Umax is the m axim um  enzyme velocity  expressed in the same units as the Y -axis and 
K m  is the M ichaeiis-M enten constant, expressed in the same units as the X-axis. Saturable 
kinetics were observed w ith a Km  o f  0.30 ± 0.10 pm ol/pl and Fmax o f  6.80 ±  0.54 
pm ol/m in/m g protein.
E x p o s u re  [R-123] pm ol/pl
F ig u re  5-6 R a te  o f R-123 U p tak e  by  O A TP1A 2 a t  Increasing  S u b s tra te  C o n cen tra tio n s
HEK-293 MSRII cells were transduced with BacMam viruses carrying the human OATP1A2 gene 
and incubated for 48 hours at 37 °C in a humidified incubator to allow OATP1A2 expression. Cells 
were exposed to concentrations ofR-123 ranging from 0-2 pM for 120, 300, 420 and 600 seconds at 
37 °C. Cells were washed with ice-cold buffer and intracellular fluorescence was determined using a 
POLARstar galaxy plate reader (BMG Lab technologies, Germany; A.ex = 485 mn; Xem = 535 nm). 
Intracellular R-123 concentration was calculated using an R-123 standard curve and expressed per mg 
of total protein as determined by Lowry assay. Data points correspond the rate of uptake obtained 
from linear regressions over three time points with duplicate values at each concentration. Data was 
fitted using the Michaeiis-Menten equation; Km 0.30 ±  0.10 pmol/pl, Fmax of 6.80 ±  0.54 
pmol/min/mg protein.
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5 .2 .5  Intracellu lar A ccu m u la tio n  in Prim ary H e p a to c y te s
Uptake rates in prim ary hum an and rat hepatocytes were determined to aid extrapolation 
betw een m odel system s and species (Figure 5-7). The experim ental procedure was the same 
as in section 5.2.4, except that uptake assays w ere perform ed across the R-123 concentration 
range for 120, 300, 420 and 600 seconds, w ithout an inhibited condition. The effect o f  
inhibition w as determ ined separately at one tim e point (300 seconds) at a single 1 pm ol/p l R- 
123 concentration. The three com pounds show n in table 5-2 were used individually to inhibit 
any O A TP-m ediated uptake in the hepatocyte m onolayers. At the R-123 concentrations used, 
uptake into rat hepatocytes was w ithin the linear range, as confirmed by a runs test o f  the data 
(p > 0.05). Exposure concentrations o f  R-123 w ere deliberately m aintained below  the CM C 
value o f  1.9 pm ol/p i to determ ine active uptake rates o f  m onom eric R-123; how ever these 
concentrations were insufficient to saturate uptake processes in prim ary hepatocytes. Thus, in 
figure 5-7, rat and hum an R-123 uptake was fitted using linear regression.
R-123 uptake into prim ary rat hepatocytes occurred at a m uch higher rate (Slope: 0.45 ± 0.02 
pl/m in/m g) than in hum an hepatocytes (Slope = 0.13 ±  0.007 pl/m in/m g), but neither process 
was saturated at the exposure concentrations used. Inhibition o f  the transport process by the 
OATP1A2 inhibitor, ketoconazole also resulted in a 34.4 ±  3 % reduction in intracellular 
accum ulation and M ontelukast inhibited R-123 uptake into hum an hepatocytes by 32.0 ± 3 .1  
%. R ifam ycin was the least effective at reducing R-123 uptake and only caused a 17.6 ±  8.5 
%. This data suggests a role for other transporters in the uptake process or that the inhibitors 
used are not specific for one transporter and also inhibit OATP1A2. In rat hepatocytes, 
uptake was inhibited to a similar extent by rifam ycin and ketoconazole; 30.1 ±  7.5 %  and 
31.9 ±  8.4 % respectively and m ontelukast reduced uptake by 17.8 ±  5.1 %. The effects o f  the 
inhibitors were species-specific, suggesting that different transporters m ay be involved in the 
R-123 uptake process in rats and humans.
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E x p o s u r e  [R -123] pm o l/p l
Human - a-  Rat
B
Com pound % Inhibition o f  H um an U ptake % Inhibition o f  R at Uptake
Rifam ycin 17.6 ± 8 .5 30.1 ± 7 .5
Ketoconazole 34.4 ± 3 .0 31.9 ± 8 .4
M ontelukast 32.0 ±  3.1 17.8 ± 5 .1
F ig u re  5-7 R a te  o f R-123 U p take  by  H u m a n  a n d  R a t P r im a ry  H epatocy tes a t  Increasing  
S u b s tra te  C o n cen tra tio n s  a n d  th e  E ffect o f In h ib itio n
(A) Primary human or rat hepatocytes plated in monolayers were exposed to concentrations ofR-123 
ranging from 0-1.8 pmol/pl for 120, 300, 420 and 600 seconds at 37 °C. Cells were washed with ice- 
cold buffer and intracellular fluorescence was determined using a POLARstar galaxy plate reader 
(BMG Lab technologies, Germany; A,ex = 485 nm; k m  = 535 nm). Intracellular R-123 concentration 
was calculated using an R-123 standard curve and expressed per mg of total protein as determined by 
Lowry assay. Data points correspond the rate of uptake obtained from linear regressions over three 
time points with duplicate values at each concentration. Data was fitted linear regression to give a 
slope of 0.13 ± 0.007 pmol/pl, runs test, p > 0.05 for human hepatocytes and a slope o f 0.45 ± 0.02 
pmol/pl, runs test, p > 0.05 for rat. Uptake ofR-123 into human and rat hepatocytes was inhibited 
using 10 nM Rifamycin, Ketoconazole or Montelukast. Cells were exposed to 1 pmol/pl R-123 in the 
presence or absence of inhibitor for 300 seconds. The difference between intracellular fluorescence in 
the two treatment groups was used to calculate percent inhibition. Results are expressed as mean (n = 
3) ± S.D.
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5.3 Intracellular Sequestration of R-123
Cationic amphiphilic dyes including R-123 have been shown to partition preferentially into 
mitochondria (Bunting et al., 1989). Because of this property, R-123 was the first and 
remains one of the most commonly used dyes to track mitochondrial membrane potential 
changes in both bulk and single mitochondria measurements (Huang et al., 2007). Dyes 
inside the mitochondria, often undergo fluorescence quenching due to dimerisation of dye 
molecules following interaction with membranes bearing potential and this effect can be 
easily tracked (Bunting et al., 1989). It has been suggested that removal of free R-123 from 
the cytoplasm by ABCB1, changes the equilibrium between sequestered compartment and the 
cytoplasm, and therefore, retains a constant supply of substrate for ABCB1 (Jancis et al., 
1993). The mass balance calculations carried out as part of the ABCB1 Transwell assay 
(Section 5.2.3) were also suggestive of intracellular accumulation, biotransformation or non­
specific binding. Determination of the concentration of R-123 within cellular compartments 
is therefore an important requirement for IVIVE.
The amount of R-123 in the soluble (cytosolic) and insoluble (organelle containing) fractions 
was determined by dosing confluent Huh7 or MDCKII with either 10pM R123 or vehicle 
control for 10 minutes at 37°C, shearing the cells and fractionating. Mitochondrial isolation 
buffer (MIB) was used in this procedure to prevent mitochondrial lysis and R-123 release 
(Germain et al., 2002) and optimal conditions for measuring the fluorescence of R-123 in 
MIB were determined: Aex = 505 nm; Aem = 530 nm. The effect of matrix on R-123 
fluorescence was allowed for by preparing standard curves in cellular fractions obtained from 
control cells.
Figure 5-8 shows that R-123 partition into the insoluble fraction i.e. within organelles is 
higher in MDCKII (~50 %) cells than in Huh7 cells (~30 %). This could indicate that 
sequestration varies according to tissue type, since MDCKII cells are derived from the kidney 
and Huh7 cells originate from the liver. The difference could also be due to species variation 
between canine and human, however since R-123 is reported to accumulate quite specifically 
within the mitochondria, the results could indicate a higher metabolic activity in the MDCKII 
cell line, although no reports currently substantiate or refute this theory.
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8(H MDCKII
Huh7
Figure 5-8 Distribution of R-123 between Soluble and Insoluble Cell Fractions in MDCKII and 
Huh7 Cells
MDCKII or Huh7 cells were exposed to either 10 pM R123 or vehicle control for 10 minutes at 37 
°C. After washing, cells were detached from the flask using trypsin-EDTA and suspended in 
mitochondrial isolation buffer (MIB). The cell suspension was centrifuged for 5 minutes at 3000 rpm 
and the resulting pellet re-suspended in MIB and sheered with a 21-gauge needle. Lysate was then 
centrifuged at 9000 x g for 10 minutes to obtain the supernatant (soluble fraction) and the pellet 
(insoluble fraction). The pellet was re-suspended in MIB and the fluorescence intensity of each 
fraction for control and treated cells was determined using the Varian Cary Eclipse fluorescence 
spectrometer (A,ex = 505 nm; ^em = 530 nm). Fluorescence was quantified by comparison to a 
standard curve of R-123 fluorescence prepared by spiking R-123 into the relevant cell fraction 
obtained from control cell lysis. Results are expressed as mean (n = 3) ± S.D; where error bars are not 
observed, they are contained within the limits of the data.
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5.4 Cellular Efflux of R-123
In the literature, estimates of Km for the transport ofR-123 by human ABCB1 vary, although 
data is generally consistent with a Km in the low pmol/pl range. Using ABCB 1-rich plasma 
membrane vesicles from Chinese hamster ovary cells, an apparent Km of 13.5 pmol/pl was 
obtained (Shapiro and Ling, 1997). However, using the difference in accumulation between 
drug sensitive and drug resistant strains of the human leukaemia cell line K562, suggested a 
Km of 7.2 pmol/pl (Wang et al., 2006). Because of these differences, and the need to 
establish baseline kinetics to accurately determine the magnitude of any perturbation (such as 
inhibition or induction), it was important to obtain kinetics for ABCB1 transport using a 
methodology that could be applied to any polarised cell type or cell culture plate format.
5.4.1 Incubation Times for Efflux
The time range over which efflux was linear was determined by exposing MDCKII-ABCB1 
cells to 10 pmol/pl R-123 for ten minutes, washing the cells and determining the fluorescence 
of the buffer after 2.5, 5, 7.5 and 10 minutes of efflux. As shown in figure 5-9, R-123 efflux 
is linear up to at least 10 minutes. Thus, in all subsequent experiments involving R-123 
efflux, the efflux period was limited to a maximum of 7.5 minutes to allow sufficient R-123 
accumulation without risking entering a non-linear phase.
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Figure 5-9 R-123 Efflux from MDCKII-ABCB1 Cells is Linear for up to Ten Minutes
MDCKII-ABCB1 cells were incubated with 10 pmol/pl R-123 at 37 °C for ten minutes. Cells were 
washed and efflux was initiated by incubating cells in R-123-free HBSS at 37 °C. After 0, 2, 5, 7.5 
and 10 minutes of efflux, R-123 fluorescence intensity of the HBSS was determined (Lex 505 nm; 
Xem 525 nm). Results are displayed as mean (n = 3) ± S.D.
5.4.2 Michaeiis-Menten Kinetics of R-123 Efflux by ABCB1
Kinetics ofR-123 efflux was determined in both wild-type and recombinant MDCKII cells to 
control for R-123 transport by endogenous ABCBl. As seen in Figure 5-10 (A), R-123 efflux 
from the recombinant cell line is much greater than in the wild-type cell line and exhibits 
saturable Michaeiis-Menten kinetics (Km 11.12 ± 1.58 pmol/pl; Frnax 25.8 ± 1.73 
pmol/min/mg protein). R-123 loss from the wild-type cell line is linearly related to R-123 
exposure concentration (p < 0.001) and could not be fitted to Michaeiis-Menten non-linear 
regression analysis, which is demonstrated more clearly in Figure 5-10 (B). In figure 5-10 
(C), human ABCB1 specific efflux was calculated by subtracting transport in wild-type 
MDCKII cells from transport in MDCKII-ABCB 1 cells. Rates were plotted against 
intracellular concentrations ofR-123 as determined in section 5.2.2, rather than exposure 
concentrations, and adjusted to reflect free R-123 available for efflux, using the sequestration 
data obtained in section 5.3. Using this approach, the Km of ABCB1 efflux was determined 
to be 17.52 ± 2.76 pmol/pl and the Frnax, 20.38 ± 1.35 pmol/min/mg protein.
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5.4.3 Inhibition of R-123 Efflux by Quinidine
ABCB1 has a broad substrate specificity, which can affect the pharmacokinetics, efficacy, 
safety and target organ specificity of drugs (Rautio et al., 2006). As a result, drug-drag 
interactions occurring due to ABCB1 inhibition or induction are a recognised clinical concern 
(Balayssac et al., 2005; Zhang et al., 2008). Quinidine is a classical inhibitor of ABCB1 and 
the IC5o for inhibition was determined by measuring R-123 efflux in the presence of different 
concentrations of quinidine. Such information allows the inclusion of inhibitors in to the R- 
123 disposition model. Fluorescence intensity of R-123 effluxed from MDCKII-ABCB1 cells 
dosed with 10 pmol/pl R-123 and 0-160 pmol/pl quinidine was determined and correlated 
against log quinidine concentrations (Figure 5-11). An IC50 of 25.87 ± 1.1 pmol/pl was 
determined by fitting data with a dose-response curve using the equation below:
Y=Bottom + (Top-Bottom)/(l+10A((X-LogIC50)
Where, Top and Bottom plateaus are in the same units as the X-axis.
Log  [Quinidine] pmol/pl 
Figure 5-11 Concentration of R-123 Effluxed with Increasing Concentrations of Quinidine
MDCKII-ABCB 1 cells were dosed with 10 pmol/pl R-123 and 0-160 pmol/ pi quinidine for 10 
minutes at 37 °C. R-123 fluorescence intensity after 7.5 minutes of efflux into HBSS buffer was 
determined (kex 505 nm; Xem 525 11m) and R-123 concentration calculated using a standard curve. 
Data was fitted using a log [inhibitor] vs. response curve; IC50 25.87 ±1.1 pmol/pl; n = 3 ± S.D; 
where no error bars are observed, they are contained within the limits of the data point.
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5.5 Metabolism of R-123
R-123 is metabolised by intracellular esterases to R-l 10 (Jancis et al, 1993; Sweatman et al., 
1990). The ester derivatives of some fluorescent dyes, including R-123 are actively 
transported from cells by ABCB1, however upon cleavage, the free dye compounds are no 
longer exported by the protein (Homolya et al., 1993). Instead, the deacetylated metabolites 
are glucuronidated and extruded from the cells by ABCC2 (Jager et al., 1997). A recent 
report has suggested that R-123 may be a useful dual marker for the determination of altered 
functions of both ABCB1 and ABCC2 in perfused rat livers (Parasrampuria and Mehvar, 
2010). However, for determination of R-123 and R-110 disposition, rates of R-123 
disappearance need to be determined, and thus far no estimates of Km or Vmax values have 
been published.
Rates ofR-123 conversion to R-110 were determined in S9 fractions prepared from human 
liver samples and MDCKII cells over a range ofR-123 concentrations below the R-123 CMC 
value of 2 pmol/pl. This precaution was undertaken to ensure that rate plateauing was due to 
the enzyme working at maximum velocity and not due to R-123 aggregation. Control 
experiments confirmed that no decrease in fluorescence was observed in the absence of 
enzyme cofactors or S9 fraction (data not shown). Initial rates of fluorescence loss were 
correlated against R-123 concentration and fitted with a sigmoidal Hill slope on the basis of 
Akailces information criterion which confirmed the selection of the allosteric sigmoidal curve 
fit over a Michaeiis-Menten model with 99 % probability. The allosteric binding equation is 
given below:
Y=V max* X Ah/ (Kprime + XAh)
Where Vmax is the maximum enzyme velocity, expressed in the same units as the Y-axis, 
Kprime is related to the Michaeiis-Menten constant and is expressed in the same units as the 
X-axis, and h is the Hill slope (>1.0 for allosteric enzymes).
R-123 biotransformation in the MDCKII cell line occurred at a higher rate (MDCKII Vmax 
154.6 ± 15.51 pmol/min/mg; Human 136.5 ± 8.6 pmol/min/mg) and with higher enzyme 
affinity for the substrate (MDCKII Kprime 0.048 ± 0.053 pmol/pl; Human 0.32 ± 0.08 
pmol/pl. The low Kprime values for both systems suggest that metabolism is a high affinity 
process. However, as the enzyme(s) responsible have not been identified, their abundance
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within the cell cannot be estimated directly. The Hill slope (h) was approximately 2 for each 
system, which indicates positive cooperativity upon substrate binding to one or more binding 
sites on the enzyme(s).
[R-123] pmoie/gl [R-123] pmole/pi
Figure 5-12 Metabolism of R-123 to R-110 by Human Liver and MDCKII Enzymes
S9 metabolic fractions were extracted from human liver samples and MDCKII cells and used at a 
final concentration of 0.1 mg/ml and 1 mg/ml respectively. The rate of conversion of R-123 to R-l 10 
was determined by measuring the initial fluorescence decrease (Lex = 505 nm; 7em = 530 nm) over 
time over a range of R-123 concentrations. Rate was correlated against R-123 concentration and fitted 
using an allosteric sigmoidal model of enzyme kinetics; Human /Cprime 0.32 ± 0.08 pmol/pl, frinax 
136.5 ± 8.6 pmol/min/mg, h 2.0 ± 0.2; MDCKII /(prime 0.048 ± 0.053 pmol/pl, Frnax 154.6 ± 15.51 
pmol/min/mg, h 2.1 ± 0.7. Results are expressed as mean (n = 3) ± S.D; where error bars are not 
observed, they are contained within the limits of the data point.
TLC separation of the products of biotransformation identified two fluorescence species in 
the reaction mix with the same Rf values as the commercial compounds, thus confirming the 
presence of R-123 and R-110 (Figure 5.13 A & B). No other products were visible, 
suggesting that if other metabolites are formed, they are not fluorescent and would therefore 
not interfere with the interpretation of the metabolism assay.
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Lane RF R-123 RFR-110
1 0.12
2 - 0.67
3 0.12 0.68
4 0.12 0.69
Figure 5-13 TLC Separation of R-123 and R-110 from Commercial and Metabolic Samples
(A) Metabolic reactions were carried out in 100 pl volumes containing 0.1 mg/ml MDCKII S9 
fraction or 1 mg/ml human liver S9 fraction in HBSS with 5 mM MgCL, 5 mM glucose-6-phosphate, 
0.5 mM P-NADP+ and 1 pM R123. These reaction mixtures were diluted 1:1 with methanol before 
spotting 5 pl onto Whatman glass TLC plates coated with a 1000 pl layer of silica. Commercial 
samples of R-123 and R-110 diluted to 2 pM with the same volume of heat deactivated S9 fraction 
used in the metabolic reactions (to allow for matrix dependent migration) and further diluted 1:1 with 
methanol were also loaded as positive controls. The mobile phase consisted of 100 ml methanol: 
chloroform (70:30), which was allowed to equilibrate for one hour before introduction of the plate. 
Plates were developed until the solvent front reached 2 cm from the top of the plate. Spots were 
visualised under UV light. (B) The retention factor (RF) was mathematically described using the ratio: 
Rf = alb, where a is the distance from the origin to the spot centre of the sample and b is the distance 
from the origin to the solvent front. Lanes 1 and 2: commercial R-123 and R-110 respectively; Lane 
3: products of human liver biotransformation and Lane 4: products of MDCKII biotransformation.
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5.6  R -1 2 3  B in d in g  to  H u m a n  S e r u m  A lb u m in
Many drugs and other small molecules bind reversibly to albumin and other serum 
components, which function as carriers and increase the apparent solubility of hydrophobic 
drags (Barbero et al., 2009). Plasma protein binding is known to be a limiting factor in drag 
disposition, since only the unbound drag is distributed in the body and is subjected to liver 
and kidney excretion. Using the method of equilibrium dialysis with a cellulose membrane, 
R-123 was found to be highly bound to plasma proteins, with an unbound fraction of 0.3 in 
control rats (Ando et al., 2001). Plasma proteins are increasingly included in dosing media to 
enable in vitro models to mimic the effects of in vivo binding.
An established method to determine the interaction of small molecules with proteins is 
fluorescence microscopy and is widely used due to its exceptional sensitivity, selectivity and 
convenience (Barbero et al., 2009). In principle, native protein fluorescence or ligand 
fluorescence can be exploited to monitor the complex formation. In this case, in order to 
investigate the binding ofR-123 to albumin, R-123 concentration was held constant and 
increasing concentrations of albumin were added. Fluorescence emission intensity at 525 nm 
was recorded at an excitation wavelength of 505 mn. This excitation wavelength avoids 
excitation of tyrosine and tryptophan residues within the albumin and selectively excites R- 
123 (data not shown). A dilution control experiment was also performed to demonstrate that 
initial fluorescence quenching caused by albumin was greater than the linear dilution effect 
caused by the increased reaction volume. Only once albumin binding is saturated, is the 
increased fluorescence quenching due to dilution alone. Thus, R-123 fluorescence intensity 
was corrected for the dilution effect and absolute values of the difference in RFU (ARFU) 
between total fluorescence quench and dilution only fluorescence quench were correlated 
against albumin concentrations (Figure 5-14). Data was fitted using a one site total saturation 
binding curve defined by the following equation:
Y=Bmax*X/(ICd+X) +NS*X
Where Binax is the maximum specific binding, Kd is the equilibrium binding constant and 
NS is the amount of non-specific binding inferred from the shape of the total binding curve. 
Using these parameters, Kd was 5.25 ± 1.06 pmol/pl, Rmax was 3.02 ± 0.50 ARFU (Total r f u  -  
D iiution r f u ) .  Thus R-123 reached maximal binding to albumin in the test system at albumin
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concentrations of approximately lOpmol/pl. The amount of non-specific binding in this 
system was negligible (-0.0034 ±0.018 ARFU/pmolpl"1).
[Albumin] pmol/jal
Figure 5-14 R-123 -  Albumin Binding Curve
The average fluorescence intensity of 0.1 pmol/pl R-123 was determined over 2-5 minutes (Aex = 505 
nm; Aem = 525 nm) upon sequential 30 pl additions of 0.1 mM human serum albumin. Fluorescence 
intensity was corrected for the dilution effect and absolute values of the difference in RFU (ARFU) 
between total fluorescence quench and dilution only fluorescence quench were correlated against 
albumin concentrations. Data was fitted with a one site total saturation binding curve; £max 3.02 ± 
0.50 ARFU (Total r f u  -  Dilution r f u ) ,  Kd 5.25 ± 1.06 pmol/pl, NS -0.0034 ± 0.018 ARFU/pmolpr1. Data 
points are an average of three separate repeats ± S.D; where no error bars are observed, they are 
contained within the limits of the data point.
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5 .7  A lte ra t io n  o f  T a rg e t  G e n e  E x p r e s s io n  b y  N u c le a r  R e c e p to r  
A c tiv a t io n  in P r im a ry  R a t H e p a to c y te s
It is well known that the nuclear receptor, PXR, which is a central regulator of drug 
metabolism and transporter target genes can induce transport proteins like ABCB1 when 
activated by PXR ligands (Albermann et al. 2005; Harmsen et al. 2009). Altered expression 
and activity of target genes leads to altered drug pharmacokinetics and is often the cause of 
undesirable drag-drug interactions when PXR ligands and enzyme/transporter substrates are 
co-administered (Lin, 2003). In order to study the effect of nuclear receptor agonists on drug 
transporter and drug metabolising enzyme expression, primary rat hepatocytes were exposed 
to one of two compounds: dexamethasone, a GR and PXR agonist (Huss and Kasper, 2000; 
Pascussi et al., 2001); and cyproterone acetate (CPA), a pure PXR agonist (Schuetz et al., 
1998). The dose was set at 50 pM for each compound, as previous studies have shown this 
achieves >90 % receptor occupancy against all receptors. Rat hepatocytes were dosed for 96 
hours during which time samples of the cells were taken at 12, 24, 48, 72 and 96 hours for 
RT-PCR analysis of transcript levels.
5.7.1 Induction of Pregnane X Receptor Expression by Nuclear Receptor 
Agonists
Firstly, the effect of treatment on rat PXR (rPXR) expression was determined to assess 
whether dexamethasone and CPA were differentially regulating rPXR. It can be seen in 
figure 5-15 that dexamethasone treatment significantly (p < 0.001) increased rPXR 
expression levels over that of control PXR expression for up to 72 hours. At 96 hours, no 
induction was observed and Pxr levels were the same as in control cells. CPA caused no 
induction of PXR throughout the tune course and Pxr levels remained comparable levels in 
control cells.
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Figure 5-15 Induction of rPXR in Primary Rat Hepatocytes by Dexamethasone but not 
Cyproterone Acetate over Time in Culture
Primary rat hepatocytes plated in monolayers were exposed to 0.1% DMSO as a vehicle control (•••), 
50 pM dexamethasone (■—■) or 50 pM cyproterone acetate (==»). The level of induction at each time 
point (12, 24, 48, 72 or 96 hours in culture) was determined by quantification of the mRNA target by 
RT-PCR. Data was normalised to Gapdh expression and expressed as a percent of control levels at 
each time point. Results were analysed by repeated measures two-way ANOVA with Bonferroni post- 
hoc test to show where induction of rPXR in response to treatment is significantly different to the 
corresponding DMSO control (*** = p < 0.001; n = 4; error bars = SEM, where no error bars are 
observed they are contained within the limits of the data point).
5.7 .2  In d u c tio n  a n d  R e p re s s io n  o f D rug M etab o lis in g  E n zy m e 
E x p re s s io n  b y  N u c lea r R e c e p to r  A g o n is ts
The expression levels of two rat CYP3A orthologues; Cyp3a9 and Cyp3al/23 were 
determined in response to treatment with the two rPXR ligands. These two orthologues were 
chosen specifically because they were shown to share the highest amino acid similarity with 
human CYP3A4 in chapter 3, and because they have been reported to be regulated differently 
by nuclear receptor activation (Mahnlce et al., 1997). In figure 5-16, it is seen that CPA and
232
dexamethasone both repress Cyp3a9 expression with significant CPA repression occurring 
fust at 24 hours (p < 0.01) and dexamethasone repression occurring at 48 hours (p < 0.01). 
The repressive effect of both of these rPXR ligands diminishes at 72 hours, with Cyp3a9 
expression recovering to control levels at 96 hours with dexamethasone treatment. CPA 
treatment still has a significantly repressive effect at 96 hours; however it is clear that 
recovery is beginning to occur.
In the case of Cyp3al/23 (Figure 5-16), dexamethasone has a strong inducing effect on 
transcript levels, significantly and potently increasing expression up to 72 hours. CPA also 
appears to increase transcript levels compared to control but the increases are not statistically 
significant due to expression variability between repeats. From these results, it is clear that 
the two Cyp iso forms respond very differently to treatment with rPXR ligands. This result 
also acts as a positive control, confirming that the cells responded to the agents as expected.
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In Figure 5-17 transcript levels of the efflux transporter Abcbl and the uptake transporters 
Octl and Oatpla4 respectively were determined in response to dexamethasone and CPA 
treatment so that effect on altered transporter levels could be incorporated into the simulation. 
Abcbl was significantly (p < 0.001) induced by CPA at all time points, with the greatest 
induction occurring at 12 hours. Dexamethasone only induced Abcbl above control levels (p 
< 0.001) at 48 hours and beyond. CPA had the largest inductive effect on Abcbl at all time 
points, suggesting that it is a more potent inducer of this target than dexamethasone.
Both CPA and dexamethasone caused induction of Octl gene expression (p < 0.001), though 
CPA induction occurred more rapidly, becoming significant at 48 hours. CPA had no effect 
of Oatpla4 expression, whereas dexamethasone significantly increased the expression of 
Oatpla4 up to 48 hours (p < 0.001), with Oatpla4 levels decreasing back to control levels at 
96 hours.
5.7.3. Induction of Drug Transporter Expression in Primary Rat
Hepatocytes by Nuclear Receptor Agonists
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5.8 Induction of Target Gene Expression in Primary Human
Hepatocytes by Nuclear Receptor Agonists
Following the rat target gene induction study, human hepatocytes were exposed to either 50 
pM dexamethasone, a GR and PXR agonist (Huss and Kasper, 2000; Pascussi et al., 2001); 
or 50 pM rifampicin, a selective human PXR agonist (Maglich et al., 2003). Human 
hepatocytes were dosed for 48 hours only, as this time period was shown to be sufficient for 
detecting induction in the rat study. Samples were taken for RT-PCR analysis of transcript 
levels and immunoblotting of target protein levels.
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Figure 5-18 Induction of Target Genes in Primary Human Hepatocytes by Rifampicin but not 
Dexamethasone
Primary human hepatocytes plated in sandwich configuration were exposed to 0.1% DMSO as a 
vehicle control (□ ) , 50 pM dexamethasone (H ) or 50 pM rifampicin (Q ). The level of induction at e 
48 hours in culture was determined by quantification of the mRNA target by RT-PCR. Data was 
normalised to GAPDH expression and expressed as a percent of control levels at each time point. 
Results were analysed by one-way ANOVA with Bonferroni post-hoc test to show where induction of 
expression in response to treatment is significantly different to the corresponding DMSO control (* = 
p < 0.05; ** = p < 0.01; *** = p < 0.001; n = 3; error bars = SEM, where no error bars are observed 
they are contained within the limits of the data point).
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Dexamethasone had no effect on the transcript levels of any of the target genes quantified 
(Figure 5-18). Rifampicin however, significantly induced all target genes tested, with the 
exception of hPXR. OCT1, OATP1A2, ABCB1 and CYP3A4 expression levels were 
increased to approximately 150, 160, 200 and 400 % of control human hepatocyte levels 
respectively.
In figure 5-19, ABCB1, OATP1A2 and OCT1 were detected by immunoblotting and 
quantified by band densitometry. Significant inductions were observed for OATP1A2 (p < 
0.01), whose expression levels increased by 3-fold compared to control levels and ABCB1 (p 
< 0.01), whose expression levels doubled in response to rifampicin treatment. Rifampicin 
also resulted in a significant (p < 0.05) increase in OCT1 levels compared to control, 
manifesting in an approximately 4-fold induction. Dexamethasone treatment had no 
significant effect on the expression of any of the transporters, as would be expected from the 
RNA data shown in figure 5-18; however slight increases in ABCB1 and OATP1A2 were 
observable on the immunoblot.
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5.9 Discussion
5.9.1 C ellu lar A c c e s s  o f R-123
Temperature dependency has commonly been used to distinguish passive from active 
transport processes, since the latter will not occur at 4 °C (Grime et al., 2008; Ho et al., 2006; 
Thomas et al., 2004). However, this method has been criticised since low temperatures not 
only prevent active transport but also disrupt membrane integrity and fluidity, resulting in 
lower passive diffusion especially for lipophilic compounds (Poirier et al., 2008). When cells 
were exposed to R-123 at 4 °C, accumulation was much lower compared to 37 °C conditions 
suggesting that cold temperatures either decreased passive diffusion or that uptake is highly 
dependent on active transport processes, or a combination of the two. Given that passive 
diffusion ofR-123 was shown to be negligible in the Transwell assay performed at 37 °C and 
that chemical inhibition of efflux transport resulted in no increase of intracellular R-123 it is 
logical to conclude that R-123 is predominantly transported via active processes, with only a 
minor passive component. OCT and OATP uptake transporters, which have both been 
implicated in R-123 uptake (Annaert and Brouwer, 2005; Heemslcerk et al., 2008) have been 
shown to be inhibited by several basic drags including quinidine and verapamil (Annaert and 
Brouwer, 2005; Ayrton and Morgan, 2001). It is therefore likely that inhibition of one or both 
of these transporters is the reason that intracellular accumulation was not increased despite 
effective inhibition of ABCB1 mediated efflux.
Further evidence of active uptake was obtained when R-123 was shown to be a substrate of 
OATP1A2, by BacMam over-expression, which is in agreement with other research 
implicating the rat orthologue Oatpla4 in basolateral uptake (Annaert and Brouwer, 2005). In 
chapter 3, it was reported that OATP1A2 mRNA was not detected in the MDCKII cell line, 
suggesting that uptake is by other transporters, probably OCT2, as this was detected in these 
cells, or by other mechanisms such as endocytosis, as proposed in chapter 4.
It has been reported that OATP1A2 is not expressed in human primary hepatocytes (Jigorel et 
al., 2005), however it was detected at RNA and protein levels and was shown to be inducible 
herein. Inhibition of transporters in the primary hepatocyte uptake experiment showed that 
ketoconazole, the OATP1A2 inhibitor reduced uptake by 34.4 ± 3%. Montelukast, used
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herein as an inhibitor of OATP2B1 also reduced R-123 uptake to a similar extent, but 
OATP2B1-mediated R-123 uptake was found to be negligible. OATP1A2 however has been 
reported to transport montelukast (Mougey et al, 2009), and so the reduction of R-123 uptake 
observed could be a result of substrate competition for the transporter. In another report, 
montelukast was used as a pan-0 ATP inhibitor, used to investigate among others the role of 
OATP1A2 in saquinavir uptake (Janneh et al., 2008). Rifampicin, though most often used to 
inhibit OATP IB 1 and OATP1B3, has also been shown to reduce OATP 1A2-mediated BSP 
uptake by 49% (Vavriclca et al., 2002), which could explain the 17.6 ± 8.5% reduction of R- 
123 uptake observed in this research. This demonstrates the difficulty of selecting specific 
inhibitors for the study of individual transporters in a homogenous population with over­
lapping substrate profiles. However, the inhibition data together with the BacMam over­
expression data indicates that R-123 into human hepatocytes was mediated mainly by 
OATP1A2.
The uptake rate of R-123 into rat hepatocytes was much higher than in human hepatocytes; 
an observation common for a number of chemically diverse substrates (Paine et al., 2008; 
Sandker et al, 1994). Increased uptake into rat hepatocytes may also be expected due to the 
comparatively higher expression of drug transporter level in rat model systems than in human 
model systems as found in chapter 3. It is possible that due to the expression of Oatp isoforms 
in the rat that are not present in the human, R-123 uptake is higher but occurs with lower 
affinity. The apparent low affinity of uptake processes could also be suggestive of 
counteractive processes such as higher rates of R-123 removal from the cell. That different 
drug transporters are involved in R-123 uptake in rats and humans was indicated by the 
differential inhibition patterns of R-123 uptake mediated by the same inhibitors. These 
findings show that drag uptake into rat hepatocytes may not only lead to an over-estimation 
of human drug access but could also misrepresent potential drag-drug interactions involving 
basolateral uptake transporters.
5.9.2 R-123 L o ss  D ue to  S e q u e s tra tio n , P ro te in  B ind ing  & M etab o lism
Most drugs are lipid soluble organic compounds that bind non-specifically to the lipid-protein 
components of internal membrane structures. Despite this, almost all researchers traditionally 
have used the total, rather than the unbound, drag concentration in kinetic experiments to
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determine Km, which results in overestimation of this parameter and underestimation of in 
vivo drug clearance (McLure et al., 2000). Thus, as has been done in this research, total 
intracellular R-123 concentration needs to be adjusted to represent the free amount ofR-123 
available for efflux in any given cell system at the start of the experiment. The release rate 
from the sequestered fraction can be assumed to be governed by first order kinetics, where 
the reaction rate is directly proportional to substrate concentration (Rubin and Tozer, 1986). 
Simulation of binding kinetics has shown that the ‘O ff rate is rarely low enough (< 1 s '1) to 
limit the extraction of bound compounds and as such should be set at a high enough rate so 
not to limit the concentration of free substrate for efflux (Baker and Parton, 2007). Within the 
cell, R-123 was shown to demonstrate significant partitioning into the insoluble fraction 
where it would be unavailable for efflux. This finding is consistent with the research of 
Masereeuw et al., 1997 who demonstrated that R-123 efflux was delayed by R-123 retention 
within tubular cells. Interestingly, the ratio of free versus sequestered R-123 varied between 
model cell systems, with more R-123 available for efflux in the human liver derived cells. 
Thus, even basic biological parameters can vary between species or systems, which is why it 
is important to characterise all aspects of drug ADME in test systems for accurate simulation 
of drug handling in humans.
The Kd of R-123-Albumin binding was estimated to be 5.25 ± 1.06 pmol/pl, showing that 
binding to plasma proteins could increase the time that R-123 spent in circulation. In a PBPK 
model, the Kd would allow the prediction of R-123 clearance rates based on average 
estimates of blood albumin concentrations (35-50 g/L (Arques et al., 2008)). For the R-123 
drug disposition model, the estimate of Kd is of no immediate utility since protein-free media 
is used to make the total R-123 dose immediately available for uptake. However, to further 
expand such a model to include the systemic circulation component, such information is 
important. Another important means ofR-123 loss from the system is via metabolism and 
investigation ofR-123 metabolism in S9 fractions from human and canine cells showed that 
both systems had a high metabolic capacity for converting R-123 to R-l 10 with low Kprime 
estimations (0.32 ± 0.08 and 0.048 ± 0.053 pmol/pl respectively). However, it has to be 
realised that S9 fractions were harvested from a large number of cells that far outweigh the 
number used in in vitro efflux assays by several orders of magnitude, resulting in high values 
of Frnax obtained in each system (human: 136.5 ± 8.6; canine: 154.6 ± 15.51 pmol/pl), and 
this must be accounted for when simulating single cell events. The extent of R-123
242
metabolism will therefore be estimated in the simulation based on the known uptake and 
efflux rates and the measured concentrations of R-123 in each compartment.
5.9 .3  R-123 Efflux
The final stage of R -l23’s journey through the cell ends in its efflux across the canalicular 
membrane by ABCBl. A Transwell assay established that R-123 efflux occurs only in the 
B>A direction, confirming that ABCB1 is expressed solely on the canalicular membrane of 
recombinant MDCKII cells. This assay also confirmed that R-123 is a substrate of ABCB1 
with an efflux ratio of 5.3; efflux ratios greater than 2 are indicative of ABCB1 substrates that 
could potentially be associated with drug resistance (Balimane et al., 2006; Zhang et al., 
2008). Passive diffusion was shown to be negligible in the Transwell assay at concentrations 
up to 1 pmol/pl R-123. However, the concern is that if concentrations within a cell exceed the 
CMC of 2 pmol/pl, R-123 could cross the membrane by exocytosis. It was shown by 
calculating intracellular concentrations that even at the lowest exposure concentrations of 2 
pmol/pl R-123, the accumulated amount within one cell exceeds the CMC cut-off in an 
aqueous system, which is a cause for concern. However, R-123 loss from wild-type MDCKII 
cells was low, supporting the fact that passive diffusion and exocytosis does not occur 
significantly over the R-123 concentration range utilised in these studies; this suggests that 
the CMC value is higher within a cell compared to HBSS due to the change in environment.
These findings give confidence that in subsequent assays, fluorescence intensity increases in 
buffer arose as a result of specific ABCB1 efflux in the B>A direction only. The Km  for R- 
123 efflux was determined to be 17.52 ± 2.76 pmol/pl, which is close to the estimate of 13.5 
pmol/pl derived by Shapiro and Ling (1997). Wang et al, 2006 derived a lower but close 
estimate of Km (7.2 pmol/pl), relying on a mathematical estimation based on the difference 
in accumulation between drug resistant and drug sensitive cells. The latter estimate did not 
take into account possible metabolic differences between the cell types, which we have 
demonstrated herein, can be substantial.
In this research, the plot of intracellular free R-123 against rate of efflux shows that the 
concentration of R-123 within the MDCKII cells does not limit ABCB1 efflux. Thus, the 
Kmax obtained should be reflective of the maximal rate of ABCB1 efflux in the MDCKII test
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system. Since Vmax is dependent on transporter abundance within a system, adjustment of 
Vmax based on the relative expression levels of ABCB 1 obtained in chapter 3 is necessary to 
adequately replicate the efflux capacity in the system to be simulated. It is also important to 
note that the identification of potential uptake mechanisms discussed above is not relevant in 
terms of deriving efflux parameters in this in vitro assay. However, knowledge of uptake 
processes increases model complexity and is useful if one wishes to simulate the effect of 
drug-drag interactions occurring at the basolateral membrane that may impede drag access 
and therefore alter drag disposition.
The efflux process was also effectively inhibited by quinidine with an IC50 of 26 ± 1 pmol/pl. 
This appears to be a reasonable estimate since quinidine was previously estimated to have an 
IC50 of 14.1 pmol/pl when digoxin was used as a probe substrate (Keogh and Kunta, 2006) 
and an IC50 range of 14-55.5 pmol/pl when various compounds such as Calcein AM, 
vinblastine, colchicine and prazosin were used as probe substrates (Rautio et al., 2006). 
Derivation of this IC50 value allows the effect of ABCB1 efflux inhibition on drag disposition 
to be simulated, and to be confirmed experimentally under the same experimental conditions 
from which the IC50 was obtained.
5 .9.4 R e g u la tio n  o f D rug T ra n s p o r te r  a n d  M etab o lis in g  E nzym e 
E x p re s s io n  by  PXR L ig an d s
Treatment with dexamethasone caused a significant increase in rPXR expression in primary 
rat hepatocytes, which has been previously shown to occur through a feed-forward loop 
through dexamethasone-activated GR (Huss and Kasper, 2000). As a result of dexamethasone 
treatment, significant increases of Abcbl, Octl, Oatpla4 and Cyp3al/23 transcripts and a 
decrease of Cyp3a9 transcript were observed. In humans, dexamethasone had 110 significant 
effect on transcript or protein levels, which confirms the observation that dexamethasone is a 
potent inducer in the rat but a moderate inducer in humans (Lu and Li, 2001; Pascussi et al., 
2004). In the rat, dexamethasone is a well known inducer of Abcbl, acting via the rPXR 
(Narang et al., 2008) and can raise Abcbl levels enough to increase R-123 clearance rates 
(Kageyama et al., 2006). In humans, rifampicin is a more potent inducer than dexamethasone 
(Pascussi et al., 2004), as seen by the induction of ABCB1 transcript and protein expression
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by 2-fold. A two to three fold induction of ABCB1, after exposure to 10 pmol/pl rifampicin 
has also been reported in the literature (Haslam et al, 2008), supporting the magnitude of the 
inductions observed herein.
The ability of rifampicin and dexamethasone to induce human and rat Octl expression 
respectively is more controversial, however clear inductions were observed in this research in 
both species at the RNA level. In one study, induction of OCT2 transcript levels in a dose 
dependent manner was demonstrated in MDCKII cells, but OCT1 could not be examined 
since MDCKII cells are deficient in this isoform, as was confirmed in chapter 3 (Shu et al., 
2001). Based on the similarity of these two Oct transporters, as demonstrated previously, it is 
plausible that they might have similar modes of regulation. However, in other research, rat 
Octl transcript levels were repressed by dexamethasone treatment when doses of 100 pM 
were used, but no changes were seen below this dose (Maeda et al., 2008). Doses of 100 pM 
may be cytotoxic (Cucullo et al., 2004), which could explain the reduction in Octl transcript 
levels observed. Maeda et al., also harvested mRNA only after 24 hours of 0.1-100 pM 
dexamethasone treatment, at which time no induction had been observed in this research. It 
therefore appears that to see induction of OCTl/Octl, exposure to dexamethasone needs to be 
at a non-cytotoxic dose for a prolonged exposure period.
OATP1A2 was significantly induced by rifampicin at both RNA and protein levels, an effect 
that has been previously observed in human breast tissue (Schwabedissen et al., 2008). The 
likely rat orthologue Oatpla4 is also a known rPXR target gene and the fact that it changes so 
robustly in response to drag treatment suggests that the liver is primed to extract circulating 
compounds with high efficiency (Guo et al., 2002; Rausch-Derra et al., 2001). Interestingly, a 
number of Oatp transporters share substrates with Abcbl and are co-expressed in organs of 
importance to drug disposition (Cvetkovic et al., 1999; Kim, 2003). Thus, the co-ordinated 
activity of uptake and efflux transporters may determine the net cellular entry or efflux of 
shared substrates such as R-123.
Xenobiotic-mediated induction of members of the CYP3A family of metabolising enzymes 
occurring via the PXR has also been reported irrespective of species i.e. human, mouse and 
rat (McGinnity et al., 2009; Sakuma et al., 2009; Sugamo et al., 2009). In humans, a 
significant induction of CYP3A4 was achieved by rifampicin exposure, which acted as a 
positive control that cells were responding to treatment in a well established manner 
(Venkatesan, 1992). However, not all Cyp3a members in the rat are regulated in the same
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way by rPXR activation and response may be tissue specific (Hartley et al., 2004; Mahnlce et 
al, 1997). For example, as seen in this research and in research carried out by Hartley et al., 
2004, the Cyp3al/23 isoform is highly induced in response to dexamethasone treatment in the 
liver, but is reported to repressed in the intestine (Hartley et al., 2004). In addition, Cyp3a9 
regulation is suggested to be different to the other Cyp3a iso forms, and is proposed to have a 
distinct physiological role in the liver (Mahnlce et al., 1997). This is supported herein, where 
alternative regulation was observed by the reduction of Cyp3a9 transcript levels in response 
to dexamethasone treatment. The mechanism for repression of some target genes with 
concomitant induction of others remains unclear, however evidence of the occurrence is 
widespread (Shi et al, 2008; Staudinger et al., 2001). It has been suggested that repression of 
some genes occurs via activation of GR, while induction occurs via PXR (Shi et al., 2008).
CPA treatment caused no increase in rPXR transcript level, however this is expected as CPA 
is a known rPXR agonist and not necessarily a transcription inducer (Kretschmer and 
Baldwin, 2005; Schuetz et al., 1998). rPXR was clearly activated by CPA treatment, since 
increased transcription of the rPXR target genes Abcbl and Octl was observed. CPA elicited 
a more rapid and robust induction of Abcbl and Octl than did dexamethasone, suggesting 
that the ligands may be acting via different receptors. However, CPA had no effect on 
Oatpla4 expression, a small non-significant effect on Cyp3al/23 expression and caused 
repression of Cyp3a9 expression. Thus, it appears that induction of target genes is ligand 
specific. As well as being a ligand for rPXR, CPA is also an antagonistic ligand of GR and 
can cause down-regulation of target genes (Cheema and Gibson, 2008; Honer et al., 2003). 
Thus, since both CPA and dexamethasone are both ligands of PXR and GR, it is postulated 
that down-regulation of Cyp3a9 is mediated via rGR and up-regulation of Abcbl, Octl is 
caused by rPXR activation. That dexamethasone treatment induced Oatpla4 and Cyp3al/23 
expression and CPA did not, is likely to reflect the affinity of the ligands for the two nuclear 
receptors and the binding of co-activators and co-repressors to them.
In conclusion, PXR activation and or induction by different ligands results in differential 
regulation of downstream target genes, possibly by co-activation of different receptors. The 
magnitude of induction or repression observed and the time at which it occurs is gene 
specific. These changes could be built into a model to allow simulation of drug clearance at 
different time points, based on the relative levels of influx and efflux transporters.
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5.9.5 Summary
In summary, R-123 has been shown to undergo all aspects of ADME within a cell and is thus 
a relevant substrate on which to base a model of drug disposition. Quantitative data on the 
active uptake by OATP1A2, metabolism by de-esterases, sequestration within mitochondria, 
protein binding and efflux by ABCB1 have been obtained providing both relative expression 
level and kinetic data for each species and reaction to be modelled in silico. The roles of 
passive diffusion and exocytosis in R-123 disposition have been determined negligible, 
simplifying the model and giving confidence that R-123 movement into and out of the cell is 
transporter mediated and in a directional manner. By fully characterising the physicochemical 
characteristics of R-123 as discussed in chapter 4, the in vitro data obtained should be of high 
quality and provide close approximations of true kinetic parameters. Relative expression 
levels of drug transporters obtained in chapter 3, will next allow for extrapolation between 
model systems and in vivo, by altering Vmax values to reflect the system to be simulated. The 
inhibition, induction and repression data obtained herein will also aid extrapolation of the 
effect of altered target expression levels and activity, at the basolateral and apical surfaces. 
Thus, R-123 clearance rates can be estimated based on altered uptake and efflux capacity and 
the relative impact on drug disposition can be used to identify situations in which altered drag 
transporter activity becomes pharmacologically or toxicologically relevant.
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6  T h e  I m p a c t  o f  T r a n s p o r t e r s  o n  P o t e n t i a l  D r u g  D i s p o s i t i o n
6.1 I n tr o d u c t io n
As has been highlighted in previous chapters, transporters have been recognised as key 
determinants o f  drug disposition. A n increasing body o f  evidence dem onstrates that 
m odulation o f  transporter function through inhibition, induction or genetic polym orphism  has 
the potential to profoundly affect the clinical efficacy and safety o f  drugs. However, the 
extent o f  control that drug transporters exert over the total flux o f  a chem ical through its life 
cycle w ithin a cell rem ains a grey area w ith  m ore research being required. It is im portant to 
study regulation and control o f  pathw ay flux for a num ber o f  reasons: It allows us to 
understand how  a pathw ay responds to perturbations o f  protein activities; it aids the search 
for drugs that affect disposition by indentifying appropriate target sites for bringing about the 
required change and it allows the avoidance o f  drags that interact w ith undesirable targets. 
Thus, understanding pathw ay dynamics is an im portant goal o f  the pharm aceutical industry 
and for those involved in identifying disease mechanism s and potential treatm ents.
In any given m ulti-com ponent pathway, the rates for each reaction determ ine the overall 
cellular flux o f  a compound, but some species m ay exert more control over the flux ra te  than 
others. For example, m ost biological netw orks function under steady-state conditions 
w hereby a pathw ay begins w ith  the uptake o f  source material derived at a constant 
concentration from  the external environm ent, and finishes w ith an end product that is 
excreted into the external environm ent at a constant rate. This leads to a dynamic equilibrium  
in w hich the concentration o f  intermediates rem ains constant because th en  rates o f  form ation 
are in exact balance w ith then  rates o f  degradation or removal. However, w ithin this network, 
altered activities o f  some key com ponents w ill either regulate pathw ay flux to m aintain 
hom eostasis in response to external perturbations or exert control over the pathw ay to alter 
the flux as necessary in response to biological demand. Discrete m echanism s for regulation 
and control exist over different time scales: 011 short tim e scales, the activities o f  proteins 
alter in response to changes in substrate concentrations; on intermediate tim e scales, the 
activities o f  ready-form ed proteins are altered by  covalent modification, and on long time 
scales, am ounts o f  enzymes are changed by altered rates o f  enzyme synthesis or degradation 
(Fell, 1997).
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The previous chapters in this thesis have concentrated on the in vitro data required for 
building an in silico model of hepatocyte R-123 disposition. The aim of this chapter is to 
generate an in silico model and use it to firstly examine how well in vitro systems reflect the 
in vivo systems that they attempt to model, by changing ABCB1 expression levels to match in 
vivo expression. Secondly, the overall input of transporters in determining drag disposition 
and life cycle will be examined through two approaches; one, assuming that cellular entry is 
entirely passive; two, assuming that uptake is entirely transporter-mediated. Thirdly, the 
effect of inhibiting and inducing efflux transporters on pathway flux will be determined.
6 .2  S im u la t io n  o f  MDCKII R -1 2 3  D is p o s i t io n
The first step in model validation is to determine whether it is possible to simulate known in 
vitro outcomes based on individually derived kinetic parameters for each component of the 
pathway. Thus, the R-123 disposition model was populated with reaction rates and estimated 
constraints such as cell and extracellular compartment volumes, as determined in Chapter 5. 
Predicted intracellular R-123 concentrations were then simulated based on applied 
extracellular concentrations and efflux rates were subsequently simulated by building in the 
metabolic and binding terms. The details and outcomes of these simulations are discussed in 
the following sections.
6.2.1 S im u la tio n  o f R-123 In tra ce llu la r  C o n c e n tra tio n s  in MDCKII C ells
As discussed in previous chapters, cellular entry ofR-123 is likely to be a result of active 
uptake, endocytosis and passive diffusion however, the transport processes have not been 
fully elucidated in MDCKII cells. Since this cell line does not express OATP1A2; the 
transporter proven capable of active R-123 uptake, and the intracellular accumulation ofR - 
123 in the 0-20 pmol/pl range appeared linear, the slope of external versus internal values 
obtained in vitro were used to simulate R-123 uptake. Thus, uptake ofR-123 at external R- 
123 concentrations of 0-20 pmol/pl was estimated using the linear regression slope of 3.97 ± 
0.16 pmol/pl as derived in Figure 5-4. Figure 6-1 shows the in vitro and in silico derived total
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intracellular concentrations of intracellular R-123 after exposure to different extracellular R- 
123 concentrations using this method. As can be seen, the simulated R-123 concentrations do 
not provide a very good estimate of the in vitro data as the simulated concentrations are 
below the 95 % confidence limits of the in vitro data. Thus, the model underestimates 
intracellular R-123 concentrations, which is a problem that becomes magnified at higher 
concentrations and could lead to in vivo toxicity. Such an underestimation could result in a 
significant error in the predicted uptake of compound, and potentially the under prediction of 
biological effect and/or toxicity.
[R123] pmol/pl
In vitro Simulated
Figure 6-1 Simulated versus In vitro Intracellular Concentrations of R-123 in MDCKII Cells
Total intracellular concentrations of R-123 were determined experimentally by measurement of R-123 
fluorescence intensity in cellular lysate at different exposure concentrations of R-123. Intracellular R- 
123 concentrations were simulated in COPASI v 4.5 using a rate derived from linear regression of in 
vitro data (slope = 3.97 ± 0.16 pmol/pl). Intracellular volume was set as 11.6 pl in this simulation. In 
vitro data points (■ ) are a represented as mean (n = 3) ± SEM, whereas simulated data (—) is based 
on single data points. The 95 % confidence interval for the in vitro data is shown as black perforated 
lines. Both sets of data were fitted using linear regression {In vitro slope = 3.97 ±  0.16 pmol/pl, p < 
0.0001; Simulated slope = 3.402 ± 1.96 xlO'6pmol/pl, p < 0.0001).
To improve the correlation between in vitro and simulated intracellular R-123 concentrations, 
it was necessary to adjust the total intracellular volume from 11.6 pl to 10 pl. Intracellular 
volume was originally estimated based on an average MDCKII cell diameter and 
approximate percentage of protein per cell, both of which are likely to be associated with a
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certain degree of error, whereas other model parameters were experimentally determined. 
Thus, since this value is the likely source of the discrepancy between the two data sets, the 
parameter was adjusted until the data correlated between in vitro and in silico. Figure 6-2 
shows the shows the in silico derived total intracellular concentrations of intracellular R-123 
determined using the 10 pi total cell volume.
In vitro [R-123] pmol/jal
Figure 6-2 Simulated versus In vitro Intracellular Concentrations of R-123 in MDCKII Cells
(A) Total intracellular concentrations of R-123 were determined experimentally by measurement of 
R-123 fluorescence intensity in cellular lysate at different exposure concentrations of R-123. 
Intracellular R-123 concentrations were simulated in COPASI v 4.5 using a rate derived from linear 
regression of in vitro data (slope = 3.97 ± 0.16). Intracellular volume was adjusted to 10 pi in this 
simulation. In vitro data points (■ ) are a represented as mean (n = 3) ± SEM, whereas simulated data 
(—) is based on single data points. The 95 % confidence interval for the in vitro data is shown as 
black perforated lines. Both sets of data were fitted using linear regression (In vitro slope = 3.97 ± 
0.16 pmol/pl, p < 0.0001; Simulated slope = 3.85 ± 0.0002 pmol/pl, p < 0.0001). (B) In vitro data was 
correlated against simulated data and analysed by linear regression (r2 = 0.99) and Pearson rank 
correlation (r = 0.99 p < 0.0001).
As is shown above, by adjusting the intracellular volume in the model, the simulation can 
achieve similar intracellular concentrations of R-123 to those seen in vitro over the dose 
range used experimentally. The linear regression line of the simulated intracellular R-123 
concentrations falls within the 95 % confidence intervals the in vitro data and the correlation 
between in vitro and simulated data gives a highly significant correlation coefficient of 0.99
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(p < 0.0001). This is a good example of how an in silico model can help to improve the 
quality of the in vitro data obtained.
6.2.2 S im u la tio n  o f R-123 Efflux fro m  MDCKII C ells
In Chapter 5, human ABCB1 transport kinetics were determined (Km = 17.52 pmol/pl, Fmax 
= 20.38 pmol/min/mg), based on the free intracellular R-123 concentration available for 
efflux. In MDCKII cells, the free R-123 concentration was approximately 50% of the total 
concentration, so total intracellular concentrations derived in figure 6-2 were adjusted 
accordingly to represent free and bound fractions. ‘On’ and ‘Off rates for non-specific 
intracellular binding were set at 100 pl/min each, thus representing a rapid equilibrium 
between the fractions. Metabolism ofR-123 to R-l 10 was also included in this simulation to 
account for loss ofR-123 substrate for efflux via bio transformation. Figure 6-3 shows the in 
vitro and in silico derived R-123 efflux concentrations at a range of exposure R-123 
concentrations.
As can be seen in Figure 6-3 (A), and confirmed in (B) the simulated R-123 efflux values 
closely match those measured in vitro, with a linear regression r2 value of 0.99, and Pearson 
correlation of r = 0.99, p < 0.0001. To obtain in silico data that simulated the in vitro 
situation, the ABCB1 and de-esterase concentrations were set at 1.4 pmol/pl and 0.01 
pmol/pl respectively. Using Avogadro’s number and the number of moles per cell, the 
amount of ABCB1 and de-esterase molecules per MDCKII cell was calculated to be 
approximately 2.1 x 106 and 1.4 x 104 molecules per cell respectively.
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Exposure [R123] pmol/pl In vitro pmoles effluxed
In vitro Simulated
Figure 6-3 Simulated versus In vitro Efflux of R-123 by ABCB1
(A) ABCB1-mediated efflux of R-123 was determined experimentally by measurement of R-123 
fluorescence intensity extruded into HBSS at 0-20 pmol/pl exposure concentrations of R-123 after 7.5 
minutes. R-123 efflux was simulated over 7.5 minutes in COPASI v 4.5 using ABCB1 efflux kinetics 
(Km = 17.52 pmol/pl, Fmax = 20.38 pmol/min/mg) at different intracellular R-123 concentrations 
adjusted for percent binding. MDCKII R-123 metabolism was also included in the simulation (Kprime 
= 0.048 pmol/pl, Fmax = 154.6 pmol/min/mg). In vitro data points (■  ) are a represented as mean (n 
= 3) ± SEM, whereas simulated data (—) is based on single data points. Both sets of data were fitted 
using non-linear regression {In vitro Km = 10.17 ± 1.11 pmol/pl, Fmax = 221.7 ±  10.45 pmol/7.5 
min/unit ABCB1; Simulated Km = 13.47 ± 3.50 pmol/pl, Fmax = 239.4 ± 0.39 pmol/7.5 min/unit 
ABCB1). (B) In vitro data was correlated against simulated data and analysed by linear regression (r2 
= 0.99) and Pearson rank correlation (r = 0.99 p < 0.0001).
6 .3  S im u la t io n  o f  P r im a ry  H e p a to c y te  R -1 2 3  D is p o s i t io n
6.3.1 R-123 U p tak e  in to  H um an  H e p a to c y te s
In Chapter 5, the concentration of R-123 entering primary human hepatocytes was measured 
over an R-123 exposure concentration range of 0-1.8 pmol/pl, and a Km of 0.30 ± 0.10 
pmol/pl and Fmax of 6.80 ± 0.54 pmol/min/mg protein of OATPlA2-mediated uptake were 
determined by BacMam assay. Given that the volume of an average human hepatocyte is 11
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pi (Meeks et al., 1991) and that cells were plated at a density of 0.4 x 106 cells per well, the 
total intracellular volume of cells is approximately 4.4 pi. Using these parameters, 
intracellular concentrations ofR-123 after a 10 minute exposure period were calculated from 
in vitro data and compared to simulated values (Figure 6-4).
Exposure [R123] pmol/pl In v itro  [R-123] pm ol/pl
■ In vitro - - • Simulated
Figure 6-4 Simulation ofR-123 Intracellular Concentrations in Primary Human Hepatocytes
(A) R-123 uptake into primary human hepatocytes was simulated in silico at 0-1.8 pmol/pl exposure 
concentrations. R-123 uptake was simulated over 10 minutes in COPASI v 4.5 using OATP1A2- 
mediated uptake kinetics (Km = 0.30 ± 0.10 pmol/pl, Vmax = 6.8 ± 0.54 pmol/min/mg). During this 
simulation, efflux and metabolism were assumed to be insignificant and set to zero. In vitro data (n =
2) and in silico data (n = 1) were fitted using linear regression (In vitro slope = 0.042 ± 0.004, runs 
test < 0.05; Simulated slope = 0.036 ± 0.006, runs test < 0.05). The 95 % confidence interval for the in 
vitro data is shown as black perforated lines. (B) In vitro data was correlated against simulated data 
and analysed by linear regression (r2 = 0.94) and Pearson rank correlation (r = 0.97 p < 0.0001).
As can be seen in Figure 6-4, intracellular concentrations ofR-123 can be closely modelled 
over the concentration range used in vitro. No alteration to the intracellular volume was 
required to achieve this outcome, suggesting that estimates of primary cell culture volume 
was more accurate for that of the MDCKII cell line. The best-fit line of the simulated data 
falls within the 95 % confidence interval of the in vitro data and the slope of the simulated 
data (0.036 ± 0.006 pmol/pl) falls within the standard deviation of the value derived 
experimentally (0.042 ± 0.004 pmol/pl). The goodness of fit of the data was confirmed by 
correlation analysis of in vitro and simulated intracellular concentrations (Figure 6-3 B); this
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analysis yielded a linear regression r2 value of 0.94 and a Pearson rank correlation of 0.97 ( p 
< 0.0001). Although the data points give the impression of curvature, a runs test of the data 
suggests that the data does not deviated significantly from linear, over this concentration 
range (p < 0.05). Indeed, the uptake of R-123 may saturate at exposure concentrations close 
to these, but since the CMC of R-123 is approximately 2 pmol/pl, this critical concentration 
was not exceeded experimentally. Fitting a Michaelis-Menten regression to this data produces 
ambiguous estimates of Km  and Fmax, and thus a linear regression was used in preference. 
To achieve this fit of the data, OATP1A2 levels were set at 0.006 pmol/pl, which is 
equivalent to 3.97 x 106OATP1A2 molecules per cell.
6 .3 .2  R-123 Efflux from  H um an H e p a to c y te s
In the previous section, it was demonstrated that at exposure concentrations of R-123 up to 
1.8 pmol/pl, intracellular R-123 concentrations could be closely simulated. Next, using the 
pre-derived rate of human R-123 metabolism and ratio of free versus non-specifically bound 
R-123 (70:30), the amount of R-123 effluxed from the cells by ABCB1 was simulated. 
Human ABCB1 concentrations within the cell were approximated using the fold differences 
between immunoblots of ABCB1 in MDCKII cells and human hepatocytes, obtained in 
Chapter 3 and was as such set at 0.21 pmol/pl. ABCB 1-mediated efflux over 7.5 minutes was 
then simulated in COPASI v 4.5 as shown in Figure 6-5.
In figure 6-5, it can be seen that at R-123 exposure concentrations ranging from 0-1.8 
pmol/pl R-123 flux through the cell displays saturable kinetics with an estimated Km of 0.25 
± 0.006 pmol/pl and Finax of 0.1 ± 0.0006 pmol/7.5 min/unit ABCBl.
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Exposure [R123] pmol/pl
Figure 6-5 Simulated R-123 Efflux from Primary Human Hepatocytes
ABCB1-mediated efflux of R-123 was simulated in silico at 0-1.8 pmol/pl exposure concentrations of 
R-123. R-123 efflux was simulated over 7.5 minutes in COPASI v 4.5 using ABCB1 efflux kinetics 
(Km = 17.52 pmol/pl, Fmax = 20.38 pmol/min/mg). Total intracellular R-123 concentrations were 
partitioned between free and bound fractions at a ratio of 70:30. Human R-123 metabolism was also 
included in the simulation (Kprime = 0.32 pmol/pl, Fmax = 136.5 pmol/min/mg). Data points (n=l) 
were fitted by non-linear regression (Km = 0.25 ± 0.006 pmol/pl; Fmax — 0.1 ± 0.0006 pmol/7.5 
min/unit ABCB1).
6.3.3 R-123 U p take  in to  R at H e p a to c y te s
In accordance with the uptake studies in human hepatocytes, primary rat hepatocytes in 
sandwich culture were also exposed to an R-123 concentration range up to 1.8 pmol/pl. Rat 
hepatocytes are reported to have a hepatocyte volume of approximately half of the human 
volume (Meeks et al., 1991), and as such total cellular volume was calculated assuming a 
volume of 5.5 pl. However, given that primary rat hepatocytes were plated at twice the 
density of human hepatocytes (0.8 x 106 cells/well), the total cellular volume of the transport 
assays is approximately equivalent in both assays. In Chapter 5, (Figure 5-7), intracellular 
accumulation into rat hepatocytes was directly proportional to exposure concentrations 
between 0-1.8 pmol/pl and a slope of 0.45 ± 0.02 pl/min/mg was obtained for R-123 uptake 
over the linear time period. This rate was used in the in silico model to predict R-123
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intracellular concentrations of R-123 after exposures of R-123 concentrations used 
experimentally.
Expsure [R-123] pmol/pl In vitro [R-123] pmol/pl
In vitro —  Simulated
Figure 6-6 Simulation ofR-123 Intracellular Concentrations in Primary Rat Hepatocytes
(A) R-123 uptake into primary human hepatocytes was simulated in silico at 0-1.8 pmol/pl exposure 
concentrations. R-123 uptake was simulated over 7 minutes in COPASI v 4.5 using a rate of 0.45 
pl/min/mg. During this simulation, efflux and metabolism were assumed to be insignificant and set to 
zero. In vitro data (n = 2) and in silico data (n = 1) were fitted using linear regression (In vitro slope = 
0.17 ± 0.0065 pmol/pl, p < 0.0001; Simulated slope = 0.17 ± 1.55 x 10"6 pmol/pl, p < 0.0001). The 95 
% confidence interval for the in vitro data is shown as black perforated lines. (B) In vitro data was 
correlated against simulated data and analysed by linear regression (r2 = 0.99) and Pearson rank 
correlation (r = 0.99 p < 0.0001).
Figure 6-6 demonstrates that R-123 uptake into rat hepatocytes can be accurately simulated, 
giving close approximations of the uptake rate (A) and a highly significant correlation 
between data sets (B). The slope of in vitro R-123 uptake was 0.17 ± 0.0065 pmol/pl and the 
slope of simulated R-123 uptake was 0.07 ± 1.55 x 10‘6 pmol/pl, giving a correlation coefficient of r = 
0.99, using a Pearson’s correlation test.
6.3.4. R-123 Efflux from  R at H e p a to c y te s
Intracellular concentrations of R-123 in primary rat hepatocytes, as determined in the 
previous section, were next incorporated into the model of a complete simulation ofR-123
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efflux. Metabolism and intracellular sequestration of R-123 were not determined in a rat cell 
system, so for the purpose of simulating ABCB 1-mediated efflux based on different ABCB1 
and R-123 intracellular accumulation levels, human values for these parameters were used, 
with the assumption that they would be similar to these parameters in rat primary 
hepatocytes. ABCB1 concentration was set to 0.252 pmol/pl based on the fold difference 
between the rat and MDCKII-ABCB 1 band densitometry obtained from the immunoblot in 
Chapter 3, Figure 3-22. ABCB 1-mediated efflux over 7.5 minutes was then simulated in 
COPASI v 4.5 as shown in Figure 6-7.
Exposure [R123] pmol/pl
Figure 6-7 Simulated R-123 Efflux from Primary Rat Hepatocytes
ABCB 1-mediated efflux of R-123 was simulated in silico at 0-1.8 pmol/pl exposure concentrations of 
R-123. R-123 efflux was simulated over 7.5 minutes in COPASI v 4.5 using ABCB1 efflux kinetics 
(Km = 17.52 pmol/pl, Fmax = 20.38 pmol/min/mg) at experimentally derived intracellular R-123 
concentrations adjusted for percent binding in human hepatocytes. Human R-123 metabolism was 
also included in the simulation (/(prime = 0.32 pmol/pl, Fmax = 136.5 pmol/min/mg). Data points 
(n=l) were fitted by non-linear regression (/Cm = 4.31 ± 0.132 pmol/pl; Fmax = 1.02 ± 0.023 
pmoles/7.5 minutes.
After 7.5 minutes of efflux, human hepatocytes demonstrated almost saturated R-123 efflux 
following R-123 exposures up to 1.8 pmol/pl, whereas rat hepatocyte efflux remained in the 
lower part of the saturation curve (Figure 6-7). The MDCKII system had the capacity to 
efflux a maximum of -240 pmol R-123 in 7.5 minutes and human hepatocytes only effluxed 
-0.1 pmol in the same period. Rat hepatocytes effluxed approximately three-fold more R-123
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than did human hepatocytes in the same time period. The Km of efflux in rat hepatocytes was 
determined to be 4.31 ± 0.132 pmol/pl compared to approximately 0.25 pmol/pl in humans. 
The Fmax of efflux in rat hepatocytes was 1.02 ± 0.023 pmoles/7.5 minutes, whereas the 
Fmax in human hepatocytes was approximately 0.1 pmoles/7.5 minutes. Therefore the human 
transporter has a higher affinity but a lower maximum rate. These values do not necessarily 
represent the maximum efflux capacities of the primary cell systems, since intracellular 
concentrations of R-123 were lower than those achieved in the MDCKII cell line. Rather, 
these values predict the maximum efflux possible, given the intracellular concentrations of R- 
123 available in each cell type at the exposure R-123 concentrations used. R-123 
concentrations exposed to MDCKII cells were 10-fold higher than those used in the primary 
hepatocyte study and so a direct comparison of efflux between the immortalised cell line and 
primary cells cannot be made under these circumstances?
6.3.5 C o m p a riso n  o f R-123 D isp o s itio n  in P rim ary  H e p a to c y te s  a n d  th e  
MDCKII-ABCB1 M ode! S y s te m
To make a comparison between efflux capacity in primary hepatocytes and the recombinant 
MDCKII-ABCB 1 cell system it was assumed that intracellular concentrations of R-123 prior 
to efflux simulation were equivalent. For this purpose, the total intracellular concentrations of 
R-123 after 0-20 pmol/pl exposures determined in MDCKII cells were .used, but adjustment 
for intracellular binding was still applied based on cell specific parameters. Efflux was 
simulated in COPASI v 4.5, for 7.5 minutes using the relative ABCB1 concentrations in each 
cell type determined by immunoblot. Curves were fitted to Michaelis-Menten kinetics for 
determination of system Km and Fmax values (Figure 6-8).
When intracellular R-123 concentrations are standardised in rat and human primary 
hepatocytes, both systems exhibit very similar efflux capacity with Km and Fmax values in 
the same order of magnitude. Thus, differences in R-123 disposition between systems are 
most likely to manifest as a result of different uptake and metabolism kinetics, at basal 
ABCB1 levels. This is feasible, since ABCB1 protein expression levels are similar in both 
human and rat hepatocytes, as shown in Chapter 3, Figure 3-22. The Km for R-123 flux in 
primary hepatocytes from both species were lower than that of the MDCKII-ABCB 1 cell
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system, indicating a higher affinity for R-123 or fewer opposing processes. Given that the 
ABCB1 used in the over-expression system is the same protein found in human hepatocytes, 
the latter scenario is more favourable and possible explanations for this can be suggested. 
For example, the higher percentage of R-123 bound in MDCKII cells would increase the 
apparent Km since less R-123 is available for efflux.
Exposure [R-123] pmol/pl
MDCKII-ABCB1 -a- Human Rat
Figure 6-8 Comparison of Simulated R-123 Efflux from Primary Hepatocytes and MDCKII 
ABCB1 Cells
ABCB 1-mediated efflux of R-123 was simulated in silico based on theoretical intracellular 
concentrations ofR-123 after 0-20 pmol/pl R-123 exposures. R-123 efflux was simulated over 7.5 
minutes in COPASI v 4.5 using ABCB1 efflux kinetics (Km = 17.52 pmol/pl, Fmax = 20.38 
pmol/min/mg) at experimentally derived intracellular R-123 concentrations adjusted for percent 
binding in human hepatocytes and MDCKII cells. Human R-123 metabolism was also included in the 
simulation of human and rat efflux (Kprime = 0.32 pmol/pl, Fmax = 136.5 pmol/min/mg) and canine 
metabolism was included in the simulation of MDCKII-ABCB 1 efflux (Kprime = 0.048 pmol/pl, 
Fmax = 154.6 pmol/min/mg). All three curves were fitted by non-linear Michaeiis-Menten kinetics; 
MDCKII-ABCB1 Km = 13.47 ± 0.39 pmol/pl, Fmax = 239.4 ± 3.5 pmol/7.5 min; Rat hepatocyte Km 
= 8.039 ± 0.30 pmol/pl, Fmax = 41.45 ± 0.64 pmol/7.5 min; Human Hepatocyte Km = 7.78 ± 0.28 
pmol/pl, Fmax = 34.27 ± 0.49 pmol/7.5 min.
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As expected, the ABCB1 over-expressing cell system had a much higher Fmax of -240 
pmol/7.5 min, which is reflective of the higher concentration of ABCB1 molecules within 
these cells. The Fmax in rat hepatocytes (-41 pmol/7.5 min) is slightly higher than in human 
hepatocytes (-34 pmol/7.5 min), demonstrating the small difference in ABCBl/Abcbl 
expression between these systems that was observed in Chapter 3.
6 .4  S im u la t in g  R -123  D is p o s i t io n  o v e r  T im e  in C u ltu re
So far, the simulations have assumed a steady-state, in which the concentrations of 
transporters remain constant over tune in an in vitro system. In the case of MDCKII-ABCB 1 
cells, it was shown in Chapter 3, Figure 3-20 that ABCB1 expression is indeed stable and 
does not vary with time, making the steady-state simulation a useful one under such 
circumstances. However, also in Chapter 3, it was observed with primary rat hepatocytes and 
rat liver slices in culture that transporter expression changes over time, making it necessary to 
simulate a dynamic situation. Whereas it is not possible to model a truly dynamic system, the 
use of time slices allows the production of multiple steady-states, which together form a 
reproduction of the dynamic system. This is important to ensure that extrapolations are 
accurately based upon the current state of the in vitro model, and not an arbitrary snap-shot.
In Chapter 3, Figures 3-9 -  3-11, expression of Abcbl increased with culture period in rat 
liver slices, reaching a several-fold increase compared to control rat liver. The 
pharmacological relevance of these changes can now be examined using the in silico model, 
by simulating the intracellular and extracellular concentrations of R-123 observed after 7.5 
minutes of efflux. Within the model, Abcbl concentrations were changed to reflect relative 
Abcbl expression levels compared to control rat liver as determined by immunoblotting and 
band densitometry. Control levels of Abcbl were set to an arbitrary value of 1 pmol/pl and 
intracellular concentrations at 10 pmol/pl R-123 exposure concentrations were simulated. 
Simulations were based on Abcbl protein expression levels from rat 2 in the study as this rat 
demonstrated changes of the highest magnitude and therefore exemplifies a worst case 
scenario. Figure 6-9 shows the calculated concentrations of Abcbl used in the simulation and 
the simulation outcomes.
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It is clearly demonstrated that as Abcbl levels increase relative to control rat liver expression 
levels, the amount ofR-123 effluxed from the cells increases and the amount of free R-123 
remaining within the cells decreases. The largest change in R-123 disposition compared to 
control rat liver levels occurs immediately after slice preparation, at time points 0-6 hours, 
where the AUC decreases from 213 pmol min/pl to 115 pmol min/pl. After 6 hours, R-123 
efflux remains higher than would be seen in control rat liver, but is relatively constant with 
time in culture. The peak in Abcbl protein expression levels occurred at 48 hours, and is 
mirrored by the increase in R-123 effluxed and the decrease in the AUC to 94 pmol min/pl. 
However, the 3-fold increase in protein at 48 hours results in a 2.5 fold increase in efflux 
capacity, suggesting that overall efflux is not solely determined by Abcbl protein 
concentration.
6.4.1 S u m m ary  of S im u la tio n s  b a s e d  on  In v itro  S y s te m s
In the work presented above, the purpose of the simulations was primarily to demonstrate that 
the in silico model ofR-123 hepatocyte disposition was capable of accurately replicating the 
concentrations of R-123 measured in various in vitro systems. As such, these simulations 
acted as a fust stage in model validation and gave confidence that the individual parameters 
derived in vitro were of sufficient accuracy to allow simulation ofR-123 flux. Simulation of 
R-123 flux in primary rat and human hepatocytes revealed that efflux capacity was similar in 
both systems given uniform intracellular R-123 concentrations but that uptake rates in rat 
hepatocytes was much high when exposed to the same R-123 dose range as human 
hepatocytes. Changes to ABCB1 expression in rat liver slices over time in culture were also 
used to simulate the effect on R-123 efflux and intracellular accumulation. Simulations like 
these provide scaling factors to extrapolate both between in vitro systems and within them 
based on dynamic changes that occur as a result of experimental conditions. The next section 
of work aims to use the in silico model in a different way, probing the R-123 network to find 
the key elements involved in determination of drag disposition. This purpose of this more in 
depth analysis is to increase understanding of each network component and to quantify the 
effects that result from their perturbation.
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6 .5  T h e  E ffe c t  o f  R e la t iv e T r a n s p o r t  R a te s  o n  R -1 2 3  D is p o s i t io n
So far we have demonstrated that changing ABCB1 levels alters R-123 pharmacokinetics, but 
we have yet to determine if uptake or efflux processes have the most impact on R-123 
disposition. Previously, simulation was performed in two stages; a loading stage used to 
determine intracellular concentrations when external R-123 was in excess, and an efflux stage 
used to determine R-123 efflux when the initial external R-123 concentration was zero. 
Although this approach was necessary to mimic the experimental design and therefore the in 
vitro results, a more biologically relevant model would simultaneously simulate uptake and 
efflux processes upon application of a substrate. Thus, now that we have established using 
kinetic parameters derived in vitro, that both uptake and efflux can be closely simulated to 
match experimental results, these processes are combined to determine the effect of alteration 
of first uptake rates and then efflux rates on R-123 disposition.
6.5.1 Active Uptake
Since OATPlA2-mediated kinetics of R-123 transport was determined in vitro, these 
parameters have been used in the simulation to alter uptake rates whilst keeping ABCB1- 
mediated efflux constant. Uptake rates were altered by changing the concentration of 
OATP1A2, which essentially alters the Fmax of the process. OATP1A2 levels were 
previously set to 0.006 pmol/pl in the model of R-123 uptake into primary human 
hepatocytes and this value is set as the baseline level in the following model. OATP1A2 
expression was changed by 2, 5 and 10-fold (0.012, 0.03 and 0.06 pmol/pl respectively) from 
this baseline to assess the effect of uptake rates on R-123 disposition (Figure 6-10, Table 6-
3). In this model parameters of human R-123 sequestration and metabolism were included.
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OATP1A2 (pmol/pl) 0.006 0.012 0.03 0.06 0.3
Fold Change 0 2 5 10 50
Intracellular R-123 AUC (pmol min/pl) 3.71 6.39 12.48 17.33 21.36
Table 6-3 AUC values for Intracellular R-123 at different concentrations of OATP1A2
The AUC values for total intracellular concentrations of R-123 were calculated in GraphPad Prism 
from the plots generated in figure 6-10. The table presents the concentration of OATP1A2 and the 
fold-change in concentration from the baseline levels observed in primary human hepatocytes.
In Figure 6-10, it can be seen that as OATP1A2 concentrations are raised, R-123 uptake from 
the buffer increases (blue line), which is mirrored by the increased intracellular free (green) 
and bound (red) R-123. As OATP1A2 is increased, the amount effluxed into the canaliculi by 
ABCB1 (black) also increases in response, while metabolism ofR-123 to R-110 (purple) 
decreases. This demonstrates that R-123 is preferentially transported out of the cell rather 
than metabolised, once higher intracellular concentrations are reached. This indicates that 
there is excess capacity within the efflux system, even at relatively high uptake levels, while 
there is a limitation to the metabolic capacity.
Table 6-3 shows that as OATP1A2 levels increase, the intracellular R-123 AUC also 
increases. However, the magnitude of the increase in AUC starts to decrease as 
concentrations of OATP1A2 exceed 0.06 pmol/pl, suggesting that efflux and metabolism 
both act to limit intracellular concentrations ofR-123 once the system becomes saturated. For 
example, when OATP1A2 was increased 50-fold compared to baseline levels, the AUC 
(21.36 pmol min/pl) was only 1.2-fold higher than the AUC observed when OATP1A2 was 
increased by 10-fold.
6.5.2 P a s s iv e  D iffusion
For molecules without a specific earner protein, entry into the cell is limited to simple 
passive diffusion and is thus governed by mass action kinetics. Slower rates of uptake can 
impact on drug bioavailability, especially for substrates that are removed from the cell by
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metabolism or efflux. To determine the effect of removing active uptake as a means of 
crossing the membrane, concentrations of OATP1A2 were set to zero in the model and 
passive diffusion rates of R-123 into MDCKII cells determined under 4 °C conditions 
(Chapter 5, Section 5.2.1) were included. Although the measurement of passive diffusion at 4 
°C often underestimates rates of compound accumulation (Poirier et al., 2008), it is the best 
measure available under conditions where active uptake is inhibited. The rate (kl = 0.03 ± 
0.0003 pmol/pl) was derived from the slope of the linear regression in figure 5-2 and 
converted to pmol/pl of MDCKII cell volume for use in the in silico model (Figure 6-11).
Exposure [R-123] pmol/pl
- In vitro — Simulated
o
E
Q.
COCM
T 30)J2
3
E
<75
0.40.0 0.1 0.2 0.3
In vitro Intracellular pmol/pl
Figure 6-11 Simulated versus In vitro Intracellular Concentrations ofR-123 in MDCKII Cells 
at 4 °C as an Measure of Passive Diffusion
(A) Total intracellular concentrations ofR-123 were determined experimentally by measurement of 
R-123 fluorescence intensity in cellular lysate at different exposure concentrations of R-123 at 4 °C. 
Intracellular R-123 concentrations were simulated in COPASI v 4.5 using a rate derived from linear 
regression of in vitro data (slope = 0.03 ± 0.0003 pmol/pl). In vitro data points (*) are a represented as 
mean (n = 3) ± SEM, whereas simulated data (—) is based on single data points. The 95 % 
confidence interval for the in vitro data is shown as black perforated lines. Both sets of data were 
fitted using linear regression (In vitro slope = 0.03 ± 0.0003 pmol/pl, p < 0.001; Simulated slope = 
0.03 ± 0.0001 pmol/pl, p < 0.0001). (B) In vitro data was correlated against simulated data and 
analysed by linear regression (r2 = 0.96) and Pearson rank correlation (r = 0.98 p < 0.0001).
Figure 6-11 (A) shows that the simulated and in vitro intracellular concentrations ofR-123 
correlated well giving uptake rates of 0.03 ± 0.003 pmol/pl and 0.03 ± 0.0001 pmol/pl 
respectively. In B, correlation analysis confirmed that the data are well matched, with a
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correlation coefficient of r = 0.98. Given that the model can predict uptake rates of R-123 due 
to passive diffusion, the effect of different passive diffusion rates on R-123 disposition were 
next simulated and compared to active uptake conditions. In the previous chapter it was 
concluded that R-123 had a low rate of passive diffusion, therefore a rate of 0.03 pmol/min 
must also be low compared to compounds that readily passively diffuse. Thus, the rate of R- 
123 passive diffusion in MDCKII cells was adjusted for human hepatocyte cellular volumes 
to a baseline of 0.1 pmol/pl and was increased by 2, 5 and 10-fold to simulate the disposition 
of compounds with higher passive diffusion constants (Figure 6-12). For this simulation, 
metabolism, binding and efflux rates were set using human hepatocyte parameters.
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Rate (pmol/pl) 0.1 0.2 0.5 1
Fold Change 0 2 5 10
Intracellular R-123 AUC (pmol min/pl) 5.48 8.03 11.28 17.75
Table 6-4 AUC values for Intracellular R-123 at Different Rates of Passive Diffusion
The AUC values for total intracellular concentrations of R-123 were calculated in GraphPad Prism 
from the plots generated in figure 6-13. The table presents the rate of passive diffusion and the fold- 
change in rate from the baseline levels determined in primary human hepatocytes.
In Figure 6-12, it is illustrated that as the rates of passive diffusion increase, R-123 uptake 
from the buffer increases (blue line), which is mirrored by the increased intracellular free 
(green) and bound (red) R-123. As passive diffusion is increased, the amount effluxed into 
the canaliculi by ABCB1 (black) also increases in response to higher R-123 intracellular 
concentrations and metabolism of R-123 to R-110 (purple) decreases. This demonstrates that 
R-123 is preferentially transported out of the cell rather than metabolised, once higher 
intracellular concentrations are reached.
Table 6-4 shows that as passive diffusion increases, the intracellular R-123 AUC also 
increases. In contrast to increasing active uptake rates, when passive diffusion rates were 
increased up to 10-fold, the magnitude of AUC increase did not plateau, suggesting that 
intracellular concentrations had not reached the threshold where metabolism and efflux 
processes counteract uptake. The AUC values also indicate that increasing passive diffusion 
rates increases intracellular concentrations by a smaller magnitude than the same fold 
increase in OATP1A2 uptake does. For example, increasing OATP1A2 by 5-fold increases 
the AUC by 236 % compared to baseline AUC, whereas a 5-fold increase in the passive 
diffusion rate increases the AUC by 105 %.
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6.5.3 Active Efflux
ABCB1 expression is up-regulated in tumour cells transformed from tissues that express 
ABCB1 normally (e.g., colon cancer) and in tumour cells transformed from tissues that do 
not normally express ABCB1 (e.g., breast cancer) after exposure to chemotherapeutic agents 
(Hochhauser and Harris, 1991). Because ABCB1 transports several chemotherapeutic agents, 
these tumours may become resistant to the agent(s) administered due to an effective decrease 
in intracellular concentration caused by increased efflux. In addition, such tumours may 
concurrently develop resistance to other chemotherapeutic agents that are ABCB1 substrates. 
Changes in the expression or activity of ABCB1 could alter drug absorption from the 
gastrointestinal tract, drug and metabolite excretion in the liver and/or kidney, and 
distribution of parent ding and active metabolites to sites of action. To determine the effect of 
increased expression of ABCB1 011 R-123 drug disposition, levels of ABCB 1 were increased 
by 5, 10 and 50-fold from a baseline human hepatocyte level of 0.21 pmol/pl. Simulations 
were ran over 10 minutes incorporating both human binding and metabolism parameters 
(Figure 6-13, Table 6-5).
In the figure below it is clearly demonstrated that at constant R-123 exposure levels and 
uptake rates, increasing ABCB1 expression results in a higher rate ofR-123 efflux from the 
cell (black) and a lower rate ofR-123 metabolism to R-110 (purple). Concentrations of both 
free (green) and bound (red) intracellular R-123 decrease in response to ABCB1 over­
expression. In table 6-5 it can be seen that when ABCB1 levels are 50-fold higher than 
baseline primary hepatocyte levels, total intracellular concentrations are reduced to 0.40 pmol 
min/pl, with ABCB 1-mediated efflux being the predominant process. At 10.5 pmol/pl 
concentrations of ABCB1, efflux rates from the cell match uptake rates (linear regression 
slope = -0.39 ± 0.0002 and 0.39 ± 0.0007, respectively). Thus, for efflux rates to match 
uptake rates, a significant up-regulation is required, yet smaller increases in expression, such 
as 5-fold, can reduce intracellular AUC values by 34 % and could significantly alter 
pharmacological and toxicological outcomes.
It is now possible to compare the effects of altering uptake and efflux rates on R-123 
disposition to determine their relative contribution to hepatic clearance. Whereas 5-fold 
increases in OATP1A2 expression and passive diffusion rates resulted in 236 % and 105 % 
increases in intracellular R-123 AUC respectively, a 5-fold increase in ABCB1 expression 
resulted in a 34 % decrease.
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ABCB1 (pmol/pl) 0.21 1.05 2.1 10.05
Fold Change 0 5 10 50
Intracellular R-123 AUC (pmol min/pi) 3.71 2.44 1.64 0.40
Table 6-5 AUC values for Intracellular R-123 at different concentrations of ABCB1
The AUC values for total intracellular concentrations of R-123 were calculated in GraphPad Prism 
from the plots generated in figure 6-15. The table presents the concentration of ABCB1 and the fold- 
change in concentration from the baseline levels observed in primary human hepatocytes.
6 .6  S im u la t in g  th e  E ffe c t  o f  A B C B 1 In h ib it io n  o n  R -1 2 3  D is p o s i t io n
An alternate method by which compound flux through a pathway could be altered is the 
inhibition of one or more of the steps within that pathway. Inhibition of ABCB 1-mediated 
transport in vitro through the use of competitive inhibitors such as quinidine reduces the 
efflux of compound across the bile canaliculi as was demonstrated in Chapter 5. Chemical 
inhibition of ABCB1 is one strategy under development to combat the development of multi­
drug resistance (Veinglcar and Dandelcar, 2010), making it a relevant scenario to simulate in 
silico. It is possible to include expressions for enzyme inhibition within the kinetic equations 
of the generated model as is shown in Figure 6-14 and this was done to examine how 
inhibition of Abcbl-mediated transport might affect compound disposition. The IC50 of 
quinidine derived in vitro in the previous chapter, plus IC50 values obtained from the 
literature were used in these simulations.
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V = V maxx [S ]
Km x • l u / f
IC\  iy-'so y
+ [S]
Figure 6-14 Schematic Representation of the ABCBl-Mediated Efflux of R-123 Modulated by 
an Inhibitor, Constructed in CellDesigner v 4.0
ABCB1 reaction kinetics (rel) based on the Michaeiis-Menten equation were modified by the 
inclusion of an inhibitory term. Equation from (Berg et al., 2002).
6.6.1 Q u in id in e
First, the rate of R-123 efflux resulting from a starting intracellular concentration of 10 
pmol/pl R-123 was simulated in the presence of 0.1 -  1000 pmol/pl quinidine over 7.5 
minutes using MDCKII parameters (Figure 6-15). This was repeated using an excess ofR - 
123 (100 pmol/pl Figure 6-15) to ensure >80% occupancy of ABCB1 by R-123. In both 
simulations, the IC50 of quinidine was set to the pre-determined value of 25.87 pmol/pl. With 
both concentrations ofR-123 a dose-dependent inhibition was observed, with 10 pmol/pl R- 
123 producing an IC50 of 41.3 ± 0.001 pmol/pl, whereas 100 pmol/pl R-123 resulting in an 
increased IC50 of 129 ± 0.004 pmol/pl.
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10 pmol/pl R-123 
100 pmol/pl R-123
Log [Quinidine] pmol/pl
Figure 6-15 Inhibition of R-123 Efflux by Increasing Concentrations of Quinidine where the 
Concentration of R-123 was kept constant
Quinidine concentrations were modelled between starting concentrations of 0.1 pmol/pl and 1000 
pmol/pl with a constant concentration of 10 pmol/pl (black) or 100 pmol/pl (grey) R-123. One 
thousand data points were generated over a period of 7.5 minutes using ABCB1 efflux kinetic 
parameters (Km = 17.52 pmol/pl Vmax = 20.38 pmol/min/mg) and an input IC50 of 25.87 pmol/pl for 
ABCB1 inhibition. Quantitative data from COPASI v 4.5 was converted to rate of production over the 
linear portion of the simulation and fitted to a non-linear regression (log [inhibitor] versus rate) using 
GraphPad Prism. The IC50 values were calculated as 41.3 ± 0.001 pmol/pl with 10 pmol/pl R-123 and 
129 ± 0.004 pmol/pl with 100 pmol/pl R-123.
As can be seen from the data generated, an IC50 is dependent on the concentration of the 
competing substrate; it is therefore of only limited value for a simulation. A better measure is 
the inhibition rate constant of the inhibitor (Kj) which includes an expression for dose ratio 
(dr) and hence is independent of where on the dose-response curve experiments are 
undertaken. The equations used to determine Kj are given below:
[Inhibitor]
Km with antagonist 
Km without antagonist
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Simulations were undertaken using increasing concentrations ofR-123 from 0.1 pmol/pl to 
15000 pmol/pl, with multiple concentrations of inhibitor at each dose (0, 50, 100, 200 or 400 
pmol/pl). The log of the concentration was plotted against rate to plot a Schild graph, which 
shows the shift to the right in the rate of R-123 efflux as the concentration of inhibitor 
increases (Figure 6-16 A); such a plot is indicative of a competitive inhibitor, which is 
consistent with the known action of quinidine on ABCB1 (Fromm et al., 1999). Whereas a 
Schild plot shows competitive inhibition, it is no longer used to calculate a rate constant, as 
this would first require linearisation of the data, which could introduce error. Therefore to 
calculate the IQ the concentration of basolateral R-123 was plotted against rate of efflux ofR- 
123 for each concentration of inhibitor and fitted using a non-linear regression competitive 
inhibition function in GraphPad Prism (Figure 6-16 B). This analysis resulted in a calculated 
Kj for ABCB1 inhibition as 29.05 ± 0.42 pmol/pl.
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A0 pmol/pl Quinidine 
50 pmol/pl Quinidine 
100 pmol/pl Quinidine 
200 pmol/pl Quinidine 
400 pmol/pl Quinidine
0 pmol/pl Quinidine
—  5 pmol/pl Quinidine 
50 pmol/pl Quinidine 
100 pmol/pl Quinidine 
200 pmol/pl Quinidine
—  400 pmol/pl Quinidine
0
[R123] pmol/pl
Figure 6-16 The Simulated Rate of R-123 Efflux with Increasing Concentrations of R-123 
and Increasing Concentrations of the ABCB1 Inhibitor, Quinidine.
R-123 efflux rates were simulated in an MDCKII-based model between starting concentrations of 0.1 
pmol/pl and 15000 pmol/pl over a period of 7.5 minutes using ABCBlefflux parameters (Km = 17.52 
pmol/pl Vmax = 20.38 pmol/min/mg) and an input IC50 of 25.87 pmol/pl for ABCB1 inhibition. The 
concentration of quinidine was kept constant at 0, 50, 100, 200 and 400 pmol/pl and each simulation 
generated 2000 data points. Quantitative data from COPASI v 4.5 was converted to rate of production 
over the linear portion of the simulation and fitted to either Schild kinetics (A) or non-linear 
regression (competitive inhibition) (B) using GraphPad Prism. The latter analysis resulted in a K ; of 
29.05 ± 0.42 pmol/pl for quinidine inhibition of ABCB1-mediated efflux.
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A time course simulation was next performed to observe how increasing the concentration of 
inhibitor affects R-123 disposition over 7.5 minutes (Figure 6-17). The Ki value calculated 
above for quinidine inhibition of ABCB 1-mediated efflux was used in place of the IC50 in the 
kinetic input of the model. As seen in figure 6-13, the rate of accumulation ofR-123 in the 
bile canaliculi (black) is reduced as ABCB1 is inhibited, leading to an increase in 
intracellular R-123 concentrations (red and green; green is obscured by the red line). The 
AUCs for intracellular concentration are shown in Table 6-3, and demonstrate clearly that R- 
123 accumulates as ABCB1 is inhibited. As the amount ofR-123 within the cell increases, so 
does the rate of conversion of R-123 to R-110 (purple). Thus, as efflux is inhibited, 
metabolism somewhat compensates and reduces the concentration ofR-123 within the cell, 
but does not work at a high enough rate to prevent R-123 accumulation compared to the non­
inhibited condition (A).
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Tim e (min) Tim e (min)
100 pmol/pl quinidine 200 pmol/pl quinidine
i ■
2 4 6
Tim e (min)
2 4 6
Tim e (min)
— R-123_buffer — R-123_lntracelular free — R-123Jntracelular bound — R-110JntraceHular — R-123_Canalicular
Table 6-6 Quinidine (pmol/pl) 0 50 100 200
Intracellular R-123 AUC (pmol min/pl) 7.45 13.70 17.08 20.75
Figure 6-17 The Simulated Disposition of R-123 in the In Silico Model with Increasing 
Concentrations of the ABCB1 inhibitor, Quinidine
A kinetic simulation of the model was run for 7.5 minutes with 10 pmol/pl R-123 and 0 pmol/pl, 50 
pmol/pl, 100 pmol/pl or 200 pmol/pl quinidine. The graphs show a decrease in extracellular R-123 
(blue) as R-123 enters the cells, followed by an increase in intracellular R-123 (red; the green line is 
obscured by the red), which is rapidly depleted as R-123 is metabolised to R-110 (purple) and 
effluxed from the cell by ABCB1 into the bile canaliculi (black). The kinetics of each step are altered 
by increasing the concentrations of quinidine. Table 6-6 Concentration of Quinidine and Intracellular 
R-123 AUC: AUC values for total intracellular concentrations of R-123 calculated in GraphPad Prism 
v.5.
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6.6.2 Cyclosporin
The immunosuppressant drug, cyclosporin, used clinically to prevent organ rejection post­
transplant has been recognised as a potent inhibitor of ABCB1, and has thus been 
investigated as a potential means to reverse the multi-drag resistance phenotype (Demeule et 
al., 1999b; Wang et al., 1995). Cyclosporin-mediated ABCB1 inhibition at the BBB has been 
shown to significantly increase accumulation ofR-123 into rat brain (Wang et al., 1995). The 
IC50 of cylcosporin has been previously reported as 1.6 pmol/pl (Rautio et al., 2006) and this 
value was included in the R-123 disposition model to determine the effect on R-123 
accumulation when a more potent inhibitor of ABCB 1-efflux than quinidine was present.
A time course simulation of the model was performed to observe how increasing the 
concentration of cyclosporin affects R-123 disposition over 7.5 minutes (Figure 6-18). The 
IC50 value derived by Rautio et al., 2006 was used as the inhibition constant. Concentrations 
of 1, 10 or 100 pmol/pl were used in the simulation. As seen in figure 6-18, the rate of 
accumulation of R-123 in the bile canaliculi (black) is reduced as ABCB1 is inhibited, 
leading to an increase in intracellular R-123 concentrations (red and green; green is obscured 
by the red line). The AUCs for intracellular concentration are shown in Table 6-7, and 
demonstrate clearly that R-123 accumulates as ABCB1 is inhibited. As the amount ofR-123 
within the cell increases, so does the rate of conversion ofR-123 to R-110 (purple). Whereas 
200 pmol/pl quinidine was required to increase the intracellular R-123 AUC to 20 pmol/pl 
(Table 6-6), only 10 pmol/pl was required to produce the same effect (Table 6-7). Almost 
total ABCB1 inhibition was achieved at 100 pmol/pl concentrations of cyclosporin, 
indicating the relative potency of the compound compared to quinidine.
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1 pmol/pl cyclosporin
1 r
2 4 6
Time (min)
10 pmol/pl cyclosporin
2 4 6
Tim e (min)
Time (min)
Table 6-7
Cyclosporin
(pmol/pl)
1 10 100
Intracellular R-123 10.27 20.25 26.6
AUC (pmol min/pl)_____________________
— R-123 buffer — R-123 Intracelular free — R-123 Intracelular bound — R-110 Intracelular — R-123 Canalicular
Figure 6-18 The Simulated Disposition of R-123 in the In Silico Model with Increasing 
Concentrations of the ABCB1 inhibitor, Cyclosporin
A kinetic simulation of the model was run for 7.5 minutes with 10 pmol/pl R-123 and 1 pmol/pl, 10 
pmol/pl or 100 pmol/pl cyclosporin with an IC5o of 1.6 pmol/pl. The graphs show a decrease in 
extracellular R-123 (blue) as R-123 enters the cells, followed by an increase in intracellular R-123 
(red; the green line is obscured by the red), which is rapidly depleted as R-123 is metabolised to R- 
110 (purple) and efflux ed from the cell by ABCB1 into the bile canaliculi (black). The kinetics of 
each step are altered by increasing the concentrations of cylcosporin. Table 6-7 Concentration of 
Cyclosporin and Intracellular R-123 AUC: AUC values for total intracellular concentrations of R-123 
calculated in GraphPad Prism v.5.
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6 .7  S i m u l a t i n g  t h e  E f f e c t  o f  T r a n s p o r t e r s  o n  R - 1 2 3  D i s p o s i t i o n
As discussed in chapter 5, the R-123 disposition m odel previously presented is a steady-state 
model, in w hich the concentrations o f  proteins do not change in response to drag challenge. 
However, as is w idely recognised and presented herein, activation o f  nuclear receptors such 
as the PX R  results in downstream  up-regulation o f  target proteins, and as such is a dynamic 
rather than steady-state system. As w ith  the sim ulation o f  transporter expression changes over 
tim e in cultured rat liver slices, it is necessary to sim ulate time sections in order to mimic a 
true steady-state. The m odel presented below (Table 6-8; Figure 6-19) incorporates nuclear 
receptor activation by the hum an PX R  ligand, rifampicin. Follow ing PX R  activation, 
increased transcription o f  the ABCB1 gene (ABCB1_G ) and OATP1A2 gene (OATP_G) and 
subsequent translation o f  the RN A  can be sim ulated to achieve the protein levels observed in 
vitro  following rifam picin exposure. Subsequently, the effect o f  increased expression o f  
uptake and efflux transporters can be sim ulated in silico  to predict the outcom e o f  such a DDI 
that could occur in the clinic. The m odel in Figure 6-19 has been sim plified by rem oving 
passive diffusion, since in the previous chapter passive diffusion w as determ ined to be 
negligible com pared to the active transport processes.
Reaction I.d. Reaction Description
Rel Translation of ABCB1 RNA to ABCB1 protein
Re3 Transcription of ABCB1 gene to ABCB1 RNA, modulated by PXR
Re4 ABCB1 RNA degradation
Re5 ABCB1 protein degradation
Re8 Reversible rifampicin and PXR heterodimer association
Rel 2 Active uptake of R-123 by OATP1A2
Rel 4 Active efflux of R-123 by human ABCB1 (± inhibition)
Rel 6 Metabolism of R-123 to R-l 10 by removal of a methyl ester group
Rel 7 Non-specific binding (NSB) to intracellular components; O n rate
Rel 8 Non-specific binding (NSB) to intracellular components; O ff rate
Re20 Transcription of OATP1A2 gene to OATP1A2 RNA, modulated by PXR
Re21 Translation of OATP1A2 RNA to OATP1A2 protein
Re24 OATP1A2 RNA degradation
Re25 OATP1A2 protein degradation
Table 6-8 Reaction I.ds and Descriptions in the Induction Model of R-123 Disposition
The reactions (lines) in Figure 6-19 represented by Re_# are described in the table above.
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6.7.1 Simulation of Rifampicin Binding to PXR
To m odel induction o f  target genes by PXR, the affinity o f  ligand binding to the receptor 
m ust first be closely simulated. The IQ  o f  rifam picin binding to PX R  is reported to be 5.6 
pm ol/pl (Luke et al., 2010), w hich is related to the ratio o f  the association (K on) and 
dissociation (K 0ff) constants; thus as accurate K on and IQff rates are currently not known, 
these were set as arbitrary num bers in order to achieve the desired IQ. For this sim ulation the 
concentration o f  PX R  was estim ated at 0.6 pm ol/pl based on the ratios o f  RN A  to protein 
observed for other species in the model. Figure 6-20 shows the concentrations o f  free and 
liganded PX R  present as the concentration o f  rifam picin increases from  0-50 pm ol/pl. As 
rifam picin concentrations increase, the concentration o f  free PX R  decreases and the 
concentration o f  rifam picin-PX R com plex increases proportionally. The IQ o f  the binding 
curve w as calculated to be 6.02 ± 0.05 pm ol/pl, w hich is consistent w ith the published value. 
A t 50 pm ol/pl rifam picin, 90% receptor occupancy is achieved, w hich was the target o f  the 
selected in vitro dose.
[R ifam picin] pm ol/pl
• Free PXR ■—  Rif_PXR Complex
Figure 6-20 Simulation of Rifampicin Binding to the PXR
Concentrations of free and liganded PXR were simulated in CellDesigner v. 4.0 over a concentration 
range of 0-50 pmol/pl rifampicin, while keeping PXR constant at 0.6 pmol/pl. IQn and IQff rates for 
rifampicin binding and release were set to achieve a IQ of 5.6 pmol/pl. A binding curve was fitted to 
the simulated data points of Rif-PXR complex in Graphpad Prism v. 5, which yielded a ICd of 6.02 ± 
0.05 pmol/pl.
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6.7.2 Simulation of Rifampicin Induction of ABCB1 and OATP1A2
Basal RN A  quantities for ABCB1, OATP1A2 and PX R  in prim ary hum an hepatocytes 
m easured in Chapter 3 were approxim ately 50,000, 300 and 30,000 copies per 50 ng RN A 
respectively. As was discussed in Chapter 3, R N A  quantity does not always directly correlate 
w ith protein quantity. For example, for OA TP1A 2, RN A  expression levels bore little 
resem blance to protein expression levels w ithin cell types and were indicatory o f  post- 
transcriptional regulation. For this reason, rather than estimating protein levels based on RN A  
levels, OATP1A2 and ABCB1 concentrations w ere set to 0.006 pm ol/pl and 0.21 pm ol/pl 
respectively in prim ary hum an hepatocytes, based on modelling o f  know n uptake and efflux 
processes (Sections 6.3.1 and 6.3.2). Since the rates o f  degradation o f  both RN A  and protein 
species are unknown, rates were set at arbitrary values to reach a steady-state betw een 
synthesis and degradation, such that the desired species concentrations above w ere achieved.
For this simulation, using the research o f  D egenhardt et al., (2009), the duration o f  one 
transcriptional cycle was calculated to take 60 m in (Degenhardt et al., 2009), which is 
approxim ately 0.3 m olecules/m in/gene. This num ber fits w ell w ith the estim ate o f  Zenklusen 
et al., 2008 who established that the transcription rate is within a range o f  0.04-6 
m olecules/m in/gene (Zenklusen et al., 2008). For translation o f  m RN A  to protein, the rate 
was set as 10 proteins/m in/RNA m olecule (Personal comm unication: Dirk De Vos, Specialist 
in Translation M odelling: N etherlands Institute o f  Systems Biology).
In  the previous chapter it was dem onstrated that exposure to 50 pM  rifam picin resulted in a 
doubling o f  ABCB 1 RN A  and protein levels observed after 48 hours o f  treatm ent. OATP1A2 
R N A  w as increased by 1.6 fold and protein was increased by 3 -fold, again indicating 
differential post-transcriptional regulation. Thus, in the sim ulation shown in Figure 6-21 
below, protein levels are shown to increase over tim e as liganded PX R  induces target gene 
transcription and translation. ABCB1 approxim ately doubles from  basal levels o f  0.21 
pm ol/pl to induced levels o f  0.41 pm ol/p l in approxim ately 150 m inutes and are thereafter 
m aintained at a steady-state. OATP1A2 levels triple from a baseline o f  0.006 pm ol/pl to 
0.018 pm ol/pl, taking approxim ately 4 m inutes to reach a new steady-state. The induction is 
OATP1A2 is rapid, suggesting that up-regulation o f  uptake transport is an important 
m echanism  in cellular protection against drug challenge.
2 8 5
ABCB1 0ATP1A2
Time (min) Time (min)
Figure 6-21 Simulation of Rifam picin-Induction of ABCB1 and OATP1A2 Protein Expression
The inductive effect of 50 pmol/pl rifampicin treatment on human primary hepatocytes was simulated 
in CellDesigner v. 4.0 over 48 hours. Basal PXR, ABCB1 and OATP1A2 levels were set to 0.6, 0.21 
and 0.006 pmol/pl and Kon and Koff rates for rifampicin binding and release were set to achieve a K d 
of 5.6 pmol/pl. Activation constants (kact) of 0.87 and 1.9 were set for ABCB1 and OATP1A2 
respectively to achieve a doubling and tripling of protein expression. RNA and protein degradation 
rates were set using arbitrary values to achieve a steady-state. ABCB1 protein expression levels 
reached a steady state of 0.41 pmol/pl after 400 minutes and OATP1A2 reached a steady state of 
0.018 pmol/pl after 4 minutes.
Next, R-123 disposition was sim ulated in both basal- and induced-protein expression states to 
observe the effect o f  increasing both uptake and efflux transporter expression simultaneously. 
For this simulation, carried out in COPASI v 4.5 uptake, efflux, binding and m etabolism  
kinetics as previously defined in prim ary hum an hepatocytes were used. Figure 6-22 shows 
the concentration o f  R-123 species in different compartm ents in both  conditions w hen 
exposed to 10 pm ol/pl R-123 over 10 m inutes. In the un-induced state, the AUC for 
intracellular R-123 is 1.82 pm ol.m in/pl, w hereas after exposure to rifampicin, the AUC is 
increased to 3.39 pm ol.m in/pl. This suggests that although ABCB 1-m ediated efflux was also 
induced by rifam picin treatm ent, increasing the R-123 canalicular AUC by 4-fold, the 3-fold 
increase in O A TPlA 2-m ediated  uptake causes R-123 to accumulate w ithin cells.
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0 pmol/pl Rifam picin 50 pmol/pl Rifam picin
Time (min) Time (min)
—  R-123_lntraceBular free —  R-123Jntracellular bound —  R-110Jntracellular —  R-123_Canalicular
Total Intracellular R-123 Canalicular R-123
(AUC (pmol.min/pl)) (AUC (pmol.min/pl))
0 pmol/pl Rif 1.82 1.46
50 pmol/pl Rif 3.39 5.88
Figure 6-22 Simulated R-123 Disposition in Prim ary Human Hepatocytes in Response to 
Rifampicin Treatm ent
At 0 pmol/pl concentrations of rifampicin, R-123 disposition was simulated in COPASI v. 4.5 using 
0.21 and 0.006 pmol/pl concentrations of ABCB1 and OATP1A2 respectively. At 50 pmol/pl 
concentrations of rifampicin, R-123 disposition was simulated using 0.41 and 0.018 pmol/pl 
concentrations of ABCB1 and OATP1A2 as determined in vitro. Both simulations utilised 10 pmol/pl 
R-123 in the buffer for a 10 minute period. Human parameters for metabolism, uptake, efflux and 
binding kinetics were included in the simulations. The graphs show an increase in intracellular free 
(green) and bound (red) R-123 as it enters the cells via OATP1A2. R-123 is rapidly depleted as it is 
metabolised to R-110 (purple) and effluxed from the cell by ABCB1 into the bile canaliculi (black). 
The kinetics of each step are altered by increasing concentrations of OATP1A2 and ABCB1 
following rifampicin treatment. The table shows the AUC values for total intracellular and canalicular 
concentrations of R-123 calculated in GraphPad Prism.
As dem onstrated above, 50 pm ol/pl rifam picin treatm ent caused an up-regulation o f  both 
OATP1A2 and ABCB1, which resulted in an increase in R-123 intracellular AUC by 
approxim ately two-fold. Next, sim ulations were perform ed to achieve a dose-response curve 
o f  rifampicin exposure and protein expression. Figure 6-23 (A) shows that as rifampicin dose
2 8 7
increases from  0-50 pm ol/pl, concentrations o f  ABCB1 and OATP1A2 also increase. 
Transporter expression increases by the greatest m agnitude at concentrations o f  rifampicin 
below  10 pm ol/pl; beyond this concentration, expression levels rem ain high but increase only 
slightly. Sim ulated concentrations o f  ABCB1 and OATP1A2 were then used to predict the 
AUC o f  intracellular R-123 after exposure to 10 pm ol/pl R-123 for 10 m inutes (Figure 6-23 
B). It can be clearly seen that as the concentration o f  rifam picin increases, more R-123 
accum ulates within the cell, increasing the AUC. The greatest change in AUC occurs below 
10 pm ol/pl rifampicin, w hich reflects the change in transporter expression that occurs at these 
doses.
[Rifampicin] pmol/pl [Rifampicin] pmol/pl
— - A B C B 1  —  O A T P 1 A 2
Figure 6-23 A: Simulation of Rifampicin-Induced Over-Expression of ABCB1 and OATP1A2 
and B: Resulting R-123 Disposition
In (A) concentrations of ABCB1 and OATP1A2 were simulated in COPASI v. 4.5 at increasing 
concentrations of rifampicin (0-50 pmol/pl). At 0 pmol/pl rifampicin, basal concentrations of ABCB1 
and OATP1A2 were 0.21 and 0.006 pmol/pl respectively. In (B), total intracellular R-123 
concentrations were simulated for a 10 minute period at concentrations of ABCB1 and OATP1A2 
derived in (A). R-123 exposure concentration was set to 10 pmoFpl R-123 and human parameters for 
metabolism, uptake, efflux and binding kinetics were included in the simulations. Intracellular AUC 
was calculated in GrapliPad Prism and correlated against rifampicin dose.
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6 .8  S e n s i t i v i t y  A n a l y s i s
Sensitivity analysis (SA) or metabolic control analysis is the study o f  how  the variation in 
output o f  a m athematical m odel can be apportioned, qualitatively or quantitatively, to 
different sources (nodes) o f  variation in the input param eters (Fell, 1997). The fundam ental 
difference to this approach and the traditional rate-lim iting step concept is that each 
param eter can be assigned a quantitative control coefficient that allows predictions to be 
made about how  the metabolic flux w ill change in response to a change in a species quantity 
or activity. So-called ‘robust’ nodes refer to those proteins where alteration o f  their 
expression levels has little impact on either the to tal flux through the pathw ay or the kinetic 
profile o f  individual chem ical species. B y com parison, a ‘fragile’ node refers to a protein 
w ithin a netw ork for which even small alterations in expression levels can have significant 
impact on the pathway, altering both the total flux through the pathw ay and the kinetic profile 
o f  individual chemical species.
This phenom enon has been investigated in the generated rifampicin induction in silico  m odel 
o f  R-123 disposition through sequential alteration o f  each node in the network. A lteration o f  
pathw ay flux was determ ined by m easuring the change in intracellular R-123 as an end point. 
Figure 6-24 dem onstrates that o f  the nodes exam ined, OATP1A2 has the greatest influence 
over pathw ay flux; alteration o f  the Fmax and K m  o f  transport changed intracellular R-123 
concentrations the most, followed by changes to the translation rates and protein  and RNA 
degradation rates o f  OATP1A2. The extent o f  intracellular R-123 binding also impacts on 
pathw ay flux m ore than changing other nodes such as m etabolism  or efflux.
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Figure 6-24 Sensitivity Analysis Showing the Robust and Fragile Nodes of the R-123 Model
Sensitivity analysis of each of the nodes (species/reactions) represented in figure 6-20 was 
sequentially changed using COPASI v 4.5 software. The magnitude of alteration to R-123 
intracellular concentrations is represented by the size of the bars for each of the nodes. Negative 
values indicate a reduction in R-123 intracellular concentration caused by negative variation of a node 
parameter. Positive values represent the increase in R-123 intracellular concentration caused by 
positive variation of a node parameter. Altering OATP1A2 expression and activity levels had the most 
impact on pathway flux. NSB = Non-specific binding; deg = degradation, r if  =  rifampicin.
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6.9 The CDF D isposition Model of CDF Efflux
In previous research presented by Dr Kat Howe (Howe et al., 2009), a simple model o f  
carboxydichlorofluroscein (CDF) efflux by Abcc2 was presented to show the importance o f  
drug transporters in determ ining drug disposition. In this model, presented in Figure 6-25, 
carboxydichlorofluroscein diacetate (CDFDA) passively diffuses into cells where it is 
hydrolysed to fluorescent CDF; a substrate for efflux by canalicular Abcc2 and basolateral 
Abcc3. Although an active uptake transporter for CDFDA was included in the model, active 
uptake was discounted on the basis o f  the lipophilicity o f  the compound and the fact that no 
uptake occurred at tem peratures o f  4 °C. Likewise, the potential for album in binding was 
included but was discounted as the dosing m edium  contained no extracellular protein. Table 
6-9 details the reaction param eters used in the simulation.
Figure 6-25 Schematic Representation of the Disposition of CDF within Cells
Cell Designer (v3.5.1) was used to construct an in silico model of the reaction/transport processes 
involved in CDF disposition. Reaction kinetics are displayed in Table 6-9. Figure courtesy of Dr Kat 
Howe (University of Surrey, UK). SBML script for this model is in the Appendix, Section 9.2.3
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R eaction  D escrip tion K inetics
R e_ l: Intracellular Hydrolysis o f  CD FDA All CD FD A  converted to CDF within 10 
seconds1
Presum e this is 20 h a lf  lives, therefore t l /2  = 
0.5 seconds.
For a first order reaction, t l /2  = ln2/k 
k  = 0.693/0.5 = 1.39 s e c 1
Re 2: Passive D iffusion o f  CD FDA into the 
Cell
U ptake clearance o f  CD FD A  into rat 
hepatocytes =  4.9 +/- 0.3 pl/m in/mg protein 
and w as not inhibited by low tem perature (10 
pM  dose)1.
In reference 1, 100 pM  and 500 pM  CD FDA 
gave rate o f  687 pl/m in/m g protein and 3374 
pl/m in/m g protein respectively.
A ssum e to be a reversible fust order process, 
so rate = lc[s] 
k  ~  6.8 m in 1
Re_3: Efflux o f  CDF by Abcc2 Using an Abcc2 over expression system  in 
HEIC cells2:
K m  =  18.9 +/- 2 pm ol/p l
F m ax  =  95.5 +/- 14.8 pm ol/m in/m g p ro te in
Re_13: Conversion o f  CDFDA to CDF 
Outside o f  the Cell
M easured as zero over 60 minutes in HBSS 
(section 6 .3.2 .2).
In PBS t l /2  =  7.6 +/- 0.1 hours1.
For a first order reaction, t l /2  =  ln2/lc 
k  =  0.693/456 =  0.00152 m in '1
R e_ l 1: Active U ptake o f  CDF U ptake clearance o f  CDF into rat hepatocytes
= 1.9 +/- 0.1 pl/m in/mg protein
and w as inhibited by low tem perature (10 pM
dose)1.
K m  o f 22 +/-10 pm ol/p l
F m ax  =  97 +/- 9 pm ol/m in/m g p ro te in 1.
Re 12: Passive D iffusion o f  CDF into the 
Cell
D iscounted
Re_14: Efflux o f  CDF by Abcc3 R ate o f  efflux is approxim ately a quarter o f  
efflux via A bcc21, so:
F m ax  s  24 pm ol/m in/m g p ro te in .
Assum e Km  is the same as for Abcc3, so:
K m  «  20 pm ol/p l
Table 6-9 The Kinetics of Utilised Reaction/Transport Steps in the in silico Model of CDF 
Disposition
Each reaction or transport process is identified by a number in the model and refers to a specific step. 
The kinetics of each reaction were collated from literature sources: 1 (Zamelc-Gliszczynski et al., 
2003); 2 (Pratt et al., 2006). The kinetic values used in the model are shown in bold type. Table is 
courtesy of Dr Kat Howe (University of Surrey, UK).
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The above CDF m odel has been used herein to dem onstrate that changing Abcc2 expression 
levels to mimic those seen in vitro over the experim entation period can alter drug disposition 
ju st as A bcbl can. Although Abcc2 is a low affinity transporter o f  R-123 (Twentym an et al., 
1994), its conjugated m etabolite, R-110 is readily excreted by Abcc2 (Jager et al., 1997). 
Thus, as suggested by  Parasram puria & M ehvar, 2010, R-123 could be used as a m arker o f  
altered function o f  A bcb l and Abcc2 (Parasram puria and M ehvar, 2010). Currently, kinetics 
o f  A BCC2-m ediated efflux o f  R-110 have not been generated making inclusion o f  Abcc2 
kinetics into the R-123 disposition m odel impossible at this time. Instead, in Figure 6-26, 
CDF has been used as a m odel substrate to show how  intracellular dye AUC in rat liver slices 
varies depending on culture period and hence A bcc2 expression.
It can be seen that as Abcc2 levels decrease over the culture period, the amount o f  CDF 
effluxed into the bile canaliculi also reduces. In parallel, intracellular concentrations o f  CDF 
increase as Abcc2 decreases. A t the end o f  the 72 hour rat liver slice culture period, the 
predicted AUC o f  CDF has increased by  1.7-fold com pared to the predicted AUC in control 
rat liver. These results are opposite to the sim ulation o f  A bcbl levels in rat liver slice culture 
(Figure 6-9), which showed A bcbl increasing w ith  tim e in culture and decreasing the AUC 
o f  R-123. Thus, if  A bcbl and Abcc2 were working in the same pathway, i.e. effluxing parent 
com pound and m etabolite respectively, then one m ight predict reduced form ation and efflux 
o f  the m etabolite within the cell.
293
co
O
3OSZ
3Osz 3oin
d  CD
3Osz
CM
3OSZ
f tCM
3OSZ
00ft f t
f tCM cof t d
oo
OO COf t d
COf t f tCM d
CMCM vq
d
VO
VO VO
d
in f tVO
d d
f t
o f t
d
3H
a *—Ho
o
3 .—s r*P
£ oa
© a
.9 CM
H ©OSZ
<
VO
©
IH
I f
0CL
£O+3
_ra
3
E
w
|ri/ |o u id  [d d 0 3  JB |n ||0OBJju[
co
O
3oJ3
©r lo 
o  d
I— i—3 i—3 1—3 1—33 O O o oo SZ SZ sz szsz CM ■©• 00 CMCD
1 [
CM
1
ft
1
ft
i
0CL
£O3m
3
E
<35
f tCM in
f t CM
f t
OO inf t CM
T—1
f t f tCM CM
OCM O
CM
CO
VO ° v1—1
in ftov
d (—1
o
o oo
T—I
3
3
oo
f t
o V-H
O
3 .
. 2
£ B
© 3a
H
u
p
<d
CO
JD
aH
|rl/|ouid [j q o ] PQxnijja
©Li3
S
U
© • pH
<ua
L©>©
CO©
aC/5
L©
ft
IS
&
fl
a©
sco©ftm•pH
Q
ft
QULh©
a0
1aa
CO
COCMlv©
©
a60r”1ft
o
a
.2
3
■§©oao©
1
§
S>
'5b
©
<i3
£
<i3>
©a
o
«4=J
TJ©
ft
Q
O
o
§o©
a
CM©©rP
<
00
a
ft
a• —H
ao
’cO
CO©L
*ft
co
60
§©3o
2
3ft
o
3
VO
r2
"©ft
a 1
in
ft
>
ft
&
<5
©rjQ
0 
d  
© 60
1 ©
ft
ft©
©
£
ao
©ft
f t
§ft
■8
©
I
CM©©
©>
ft
s
”3.f tQ
©
s
«§
co©
3©>
c/o U
f t  P
ft
ft©
ft
<3ft
©
©
£
s0
3
1**—<C/5
ft 60 • rH
a0
3
1
©>o
r—ift
Q0
M3
3©
-g.9
1
ft©
•©
H
ft©
oft
0
1o
60a
ftaoft
CO
EOO
a
‘Sft
3©ft
©ftH
<9
aft
f t
a0
1  ©
1©
<
Oft
Q
0
ft
1ft
ft©
OlTOHo
ft©
a
3©
COa
.2
s©
1©L
3
J2
3©©
ftOv
CM
6.10 Transport A ssa y s in Sandwich-cultured Primary Human
H epatocytes
Since prim ary hepatocytes are considered the ‘gold standard’ in vitro test for predicting 
hum an response, it was considered desirable to compare the sim ulation outcom es to those 
from  this biological system. The sandwich culture m ethod was chosen since it results in 
hepatocytes that repolarise, have functional uptake processes, tight junctions betw een cells, 
and express efflux transporters such as ABCB1 and ABCC2 on the canalicular m em brane 
that excrete compounds into functional biliary canalicular networks (Hoffm aster et al., 2004; 
Liu et al., 1999). The intention was to m easure R-123 efflux under control conditions and in 
conditions in which transporters had been pharm acologically inhibited or induced.
Prim ary hum an plated hepatocytes overlaid w ith Geltrex™  were purchased from  Invitrogen 
(Paisley, UK) and cultured for four days using conditions outlined in section 2.2.3.3 o f  the 
methods chapter. Following this, cells were exposed to a 0-20 pm ol/pl concentration range o f  
R-123 in HBSS buffer. Figure 6-27 shows that after washing and incubating in R-123-free 
buffer at 37 °C, intracellular fluorescence increases w ith R-123 dose but has not been 
effluxed into canalicular networks. An image o f  CDF effluxed into the canalicular netw orks 
o f  rat prim ary hepatocytes obtained from  Qualyst Incorporation is included in the figure as a 
positive control to show the desired result. It is clear that in hum an hepatocytes functional 
canaliculi have not formed; a problem  that has been faced by other users in different 
laboratories. The reason for the lack o f  canaliculi form ation is as yet unknown, but the 
images below show that the cells are not closely packed, w hich is a necessity for the 
form ation o f  tight junctions. This assay w ould need further optim isation before it could be 
used as a useful in vitro system, however due to tim e constraints, this process was not viable.
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Figure 6-27 R-123 is Retained within Human Primary Hepatocytes in Sandwich Culture
Primary human hepatocytes cultured in sandwich configuration were dosed with 0-20 pmol/pl R-123 
(0.1 % Methanol) and incubated at 37 °C for 10 minutes. Fluorescent images were taken after a 30 
minute efflux period using an Axiovert 135TV microscope (Ziess, Hertfordshire, UK); differential 
interference contrast (DIC) position 3-4, filter wheel in position 1 (Zeiss filter set 09; Aex 450-490nm. 
Em. Colour = green), with a Lambda 10-2 filter wheel changer (Sutter, California, USA). Images 
were captured using the Starlight Xpress CCD camera (Starlight Xpress, Berks, UK) with a 0.1 
second exposure, and manipulated in Nebulosity 2 software (Stark Labs, Pordenone, Italy). 
Fluorescence was retained within cells and no bile canaliculi were visible. An image of CDF excreted 
into rat hepatocyte bile canaliculi using B-CLEAR® technology (Qualist Inc) is included as a positive 
control of what is expected when functional canaliculi are present.
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6.11 D iscussion
M easurem ent o f  drag transporter transcript or protein levels allows the generation o f  vast 
amounts o f  data that give an initial indication as to the uptake and efflux processes that m ay 
be involved in com pound flux in any given biological system. W e have show n herein that 
protein levels are superior to RNA levels in term s o f  in vitro system  correlations and 
prediction o f  functional transporter levels, but activity assays are better than  both. Purely 
quantitative m easurem ents o f  protein give no indication o f  the affinities o f  transporters 
towards their substrate, m aking it essential to carry out kinetic substrate assays. These assays, 
though crucial to determine rates o f  substrate uptake or efflux by a specific transporter, often 
study the transport process in isolation, in situations where substrate is in excess. Such 
conditions m ay be far from  the reality o f  a com plex biological system, where substrate 
concentrations are usually lower and other processes such as m etabolism  and protein binding 
m ay act to lower concentrations even further. Thus, this section o f  w ork investigated the flux 
o f  R-123 through a m ulti-component pathw ay w ith the use o f  an in silico  m odel to predict the 
contribution o f  each process to overall disposition.
6.11.1 The MDCKII-ABCB1 Over-Expression Model
In the previous chapter, the M DCKII-ABCB 1 over-expressing cell line was used to derive 
intracellular concentrations o f  R-123, and ABCB 1-m ediated efflux kinetics at given exposure 
doses. Since the in vitro  experiment was conducted as a two stage process w hereby cells were 
first loaded w ith R-123 followed by the initiation o f  efflux, the in silico sim ulation was also 
carried out in two stages. In the loading phase, R-123 efflux and m etabolism  was considered 
negligible, since substrate was in excess and any losses o f  R-123 would be readily replaced. 
Using a rate o f  R-123 uptake previously determ ined and estimates o f  total cell volume, the 
sim ulation under-predicted intracellular concentrations o f  R-123. Given that the rate o f  
uptake was an experim entally derived value, w hereas the total intracellular volume was an 
estimate based on averages o f  cell num ber and cell diam eter, it was concluded that the 
discrepancy betw een the in vitro and in silico  concentrations were due to an overestim ation o f  
volume. Alteration o f  the total cell volum e by approxim ately 15 % yielded a m uch better 
correlation betw een the two data sets. Such an adjustm ent made on the basis o f  a sim ulation
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outcome is an example o f  where in silico  analysis can improve the quality and accuracy o f  in 
vitro data.
In the efflux phase, re-uptalce o f  effluxed R-123 was considered negligible since 
concentrations o f  R-123 in the buffer were extrem ely low com pared to loading conditions. 
H owever, m etabolism  o f  R-123 was included in the sim ulation given that it was determined 
in the previous chapter that R-123 is m etabolised to R-110 by intracellular de-esterases. The 
concentration o f  de-esterases present in any o f  the in vitro  cell systems used is unknown, so 
their exact contribution to R-123 bio trans form ation could not be accurately simulated. 
Instead, enzyme concentrations were set at the m axim um  concentrations achievable (0.01 
pm ol/pl) w ithout alteration o f  the know n R-123 efflux kinetics. Pre-determ ined distribution 
o f  R-123 betw een soluble and insoluble cell fractions was also included in the simulation. 
The K m  for ABCB1-m ediated efflux (17.52 pm ol/pl) w as close to the published value o f  
13.5 pm ol/pl obtained using inside-out m em brane vesicles (Shapiro and Ling, 1997) and was 
thus considered reliable data on which to base efflux rates. Using these param eters, it was 
possible to closely sim ulate R-123 efflux, giving confidence that the in silico  m odel could 
reflect likely efflux from  other biological systems. Obviously, the M DCK II cell system  over­
expresses ABCB1 and w ould therefore have a higher Fmax o f  R-123 efflux than w ould be 
expected from  wild-type cells. To sim ulate R-123 efflux in the M DCK II cell line, ABCB1 
concentrations w ere required to be at 1.4 pm ol/pl, w hich is equivalent to 2.1 x 106 m olecules 
o f  ABCB1 per cell. In  other cell lines, concentrations o f  ABCB1 are lower and thus the Fmax 
o f  the efflux process would also be reduced.
6.11.2 Uptake and Efflux of R-123 from Primary Hepatocytes
R-123 uptake rates into hum an and rat prim ary hepatocytes were determ ined in the previous 
chapter and used herein to simulate intracellular concentrations o f  R-123 at exposure doses o f  
0-2 pm ol/pl compound. In  hum ans, OATP1A2 was identified as the transport protein 
responsible for uptake, and in OATP1 A 2-inhibited conditions uptake into HEIC-293 cells was 
negligible. Thus, to simulate uptake into hum an hepatocytes, the contribution o f  passive 
diffusion to R-123 uptake w ere ignored and kinetics o f  OATP 1A2-m ediated R-123 transport 
were used in the simulation. For uptake into rat hepatocytes, OATP1A2 kinetics could not be 
used due to differences betw een OATP orthologues in humans and rats. Instead it is more
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likely that O atp la4  is the m ajor determ inant o f  uptake in rat hepatocytes (Annaert and 
Brouwer, 2005), but kinetic data for rat O atp la4-m ediated  uptake was not determ ined in this 
research. As an alternative, R-123 uptake rates w ere based on the linear relationship betw een 
external and internal concentrations o f  R-123, thus fitting the sim ulation to the observed in 
vitro endpoints. Using these tw o m ethods to  sim ulate uptake resulted in close approxim ations 
betw een in vitro and in silico  outcomes.
R-123 efflux from  prim ary hepatocytes w as sim ulated based on differences in ABCB1 
protein expression levels betw een the M DCKII-ABCB 1 over-expressing system  and prim ary 
hepatocytes. Band densitom etry o f  W estern blots show ed that hum an and rat hepatocytes 
expressed 85 % and 80 % lower levels o f  ABCB1 protein respectively, w hich equates to 0.21 
and 0.252 pm ol/pl ABCB1 respectively to  be used in the simulations. These values also 
indicate that the M DCKII cell system  over-expressed ABCB1 by approxim ately 7-fold, 
which is a realistic figure for a transfected cell line.
Kinetics o f  rat A bcbl-m ediated  efflux o f  R-123 w as unfortunately not determined as a clone 
o f  the transporter was unavailable. Thus, for the purpose o f  this work, rat A bcbl-m ediated  R~ 
123 kinetics w ere assum ed to be the same as those o f  hum an ABCB1: W hile such an 
assum ption is not without merit, an im portant avenue o f  future w ork would be to derive 
species-specific kinetic param eters. H um an param eters o f  R-123 intracellular non-specific 
binding were also used on the assum ption that the same cell type w ould display sim ilar 
features despite the species difference. A lthough rates o f  R-123 m etabolism  are likely to be 
different betw een hum ans and rats, as it was betw een hum ans and dogs, the enzyme 
responsible has not been isolated or quantified; therefore even i f  kinetics w ere determined, 
concentration w ould still be arbitrarily set. Thus, for the simulations in rat hepatocytes, the 
use o f  hum an m etabolism  kinetics was deem ed sufficient.
Setting ABCB1 at 0.21 pm ol/pl in hum an hepatocytes resulted in a saturation o f  the efflux 
process at R-123 exposure concentrations betw een 0-2 pm ol/pl. How ever, hi rat hepatocytes, 
where the concentration o f  A bcb l was only 0.042 pm ol/pl higher, the R-123 efflux process 
rem ained in the lower part o f  the saturation curve. W ithout prior knowledge that R-123 
uptake into hum an hepatocytes is m uch lower than that observed in rat hepatocytes, one 
m ight w rongly assum e that rat hepatocytes have a A bcbl expression level, whereas in fact 
their efflux capacity is sim ilar to hum ans and it is their uptake ability that is enhanced. This 
becom es clearer w hen intracellular R-123 concentrations are assum ed to be the same as those
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m easured in M DCKII cells, allowing a direct comparison o f  the efflux rates o f  R-123 based 
on ABCB1 concentrations alone. In  M DCKII cells, the Fmax is m uch higher, as is expected 
from  an over-expressing system  and the Fmax values obtained in both  hum an and rat 
hepatocytes are lower; 34.27 pm ol/m in/m g and 41.45 pm ol/min/m g respectively, reflecting 
the lower but very similar ABCB1 expression levels in the prim ary cells. K m  for ABCB1 
efflux in M DCKII cells was reduced from  13.47 pm ol/pl in to ~8 pm ol/pl in both prim ary 
cell systems. This reduced Km  reflects the relative availability o f  R-123 in hum an and rat 
hepatocytes as a result o f  reduced non-specific binding to intracellular components.
These results suggest that rat hepatocytes are a good m odel o f  hum an drug efflux providing a 
compound achieves sim ilar intracellular concentrations in both species: For example, a 
com pound that crosses the m em brane by simple passive diffusion should enter hum an and rat 
hepatocytes at approxim ately the same rate. I f  however, a compound relies on uptake by a 
specific m em brane transporter, rat hepatocytes m ay under- or over-predict drag efflux if  
uptake transporters in the two species are expressed at different levels or display different 
substrate affinities.
6.11.3 The Effect of Culture Time on R-123 Disposition
As was dem onstrated in Chapter 3, expression levels o f  drug transporters vary over time in 
culture, either increasing or decreasing in response to culture conditions. A bcbl expression 
levels changed m arkedly in rat liver slices cultured for up to 78 hours, w ith a peak protein 
expression at 48 hours post-slicing (Section 3 .4 .2 .I. Figure 3-12). The fact that in vitro 
systems are dynamic; constantly changing in response to their environm ent highlights the 
need for simulations that can predict drug disposition in the event o f  such changes. The 
sim ulation revealed that at peak A bcbl protein levels, the AUC o f  R-123 intracellular 
concentrations was reduced by 2.5 fold, w hich w ould impact on the pharm acology o f  m any 
drags. Indeed, such an over-expression o f  A bcbl in rat hepatocytes at 48 hours was 
dem onstrated by Fardel et al., 1992 and was shown to decrease sensitivity to  doxorubicin by 
reducing cellular AUC (Fardel et al., 1992). This simulation however assum ed that R-123 
uptake into the cells rem ained the same over the culture period; an assum ption we know  not 
to be true. In the case o f  O atp la4  protein in rat liver slices, expression was higher than 
control rat liver levels for up to 30 minutes post-slicing and then fell to below  control levels
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for the rem ainder o f  the culture period. A  decreased uptake capacity at 48 hours coupled to an 
increased efflux capacity could lead to  significant decreases in intracellular drug 
concentrations, possibly resulting in a failure to achieve therapeutic intracellular 
concentrations. In the case o f  liver slices, w hich are used as a 3D in vivo surrogate, this m ight 
lead to under-prediction o f  the effects in vivo , and is therefore an im portant scalar that should 
be em ployed in any extrapolation. In  addition, it is know n that protein levels changes 
significantly in tum our form ation (Fletcher et al., 2010; M arin et al., 2010), w ith an increase 
in efflux transporters being im plicated in the developm ent o f  M D R phenotype: The current 
w ork suggests that it m ay be pertinent to study the role o f  uptake transporters in determ ining 
drug disposition in such cases as well.
6.11.4 The Relative Importance of Active Uptake, Passive Diffusion and 
Active Efflux
As has been previously discussed, transporter kinetics w ill only be im portant in determining 
drug disposition if  a drug is a substrate for said transporters and has lim ited ability to 
passively diffuse. D uring the drug design process, researchers can choose whether to 
specifically target an uptake process or to avoid it by  m aking compounds w ith incompatible 
structures or properties. This section set out to determine whether it is better, from a 
pharm acological perspective, to design drugs w ith  properties that are traditionally assum ed to 
predispose them  to passive diffusion, or to design drugs to be substrates for specific 
transporters. A nother aim  was to m easure the extent to which increasing efflux from  the cell 
alters the flux through the pathway. This allows us to assess whether it w ould be preferential 
to avoid drag candidates that are potential substrates o f  ABCB1 or whether efflux by ABCB1 
is o f  little concern.
Using OATP1A2 as a representative for any active transporter-m ediated process showed that 
as concentrations o f  the transporter w ere increased, the kinetics o f  all dow nstream  processes 
were altered. Intracellular concentrations o f  R-123 increased, as did rates o f  m etabolism  o f  R- 
123 to R-110. Interestingly, although de-esterase levels were kept at a m inim um  in order not 
to impede efflux, concentrations o f  R-110 produced within cells w as higher than the 
concentration o f  R-123 effluxed from  them. The in silico  m odel therefore indicates that 
m etabolism  plays a bigger role in R-123 disposition than w ould be suggested by the in vitro
301
data and is useful for understanding the disposition o fR -1 2 3 , or indeed any drug, as a whole. 
As R-123 concentrations w ithin the cells rose, the contribution o f  active efflux also increased, 
suggesting that at low concentrations, m etabolism  is the principle route o f  substrate reduction 
but at higher concentrations, efflux takes over, reducing the amount o fR -1 2 3  available for 
metabolism. This is a consequence o f  the K m  for m etabolism  by de-esterase being lower than 
the Km  for efflux by ABCB 1, which is an affinity relationship com m only observed betw een 
DM Es and drag transporters (Boulton et al., 2002; Chang et al., 1997; H ijazi and Boulieu, 
2002; W atkins, 1997). Indeed, it m akes sense biologically that metabolic enzymes have a 
higher affinity for substrates than efflux transporters; otherwise crucial m olecules w ould be 
extraded before m etabolism  could occur (W atkins, 1997).
Increasing rates o f  passive diffusion can be used to mimic the uptake o f  drags w ith increasing 
degrees o f  lipophilicity, or the passive diffusion o f  drags into cells w ith more fluid, 
hydrophilic membranes. The net result o f  such sim ulations was a sim ilar effect on R-123 
disposition to changing the Fmax o f  active uptake, although the impact w as proportionally 
decreased. For example, a 5-fold increase in OATP1A2 Fmax, increased the intracellular 
AUC by 236 % compared to baseline AUC, w hereas a 5-fold increase in the passive diffusion 
rate increased the AUC by 105 %. Thus, it w ould seem that targeting a drug to a specific 
uptake transporter m ay achieve higher intracellular accum ulation rates than relying on 
passive diffusion alone. This o f  course depends on whether the transporter o f  the specific 
substrate is expressed at high enough levels in the target tissues; a param eter that is usually 
readily obtainable. A  caveat o f  this sim ulation was that the effect o f  exceeding the CM C o f  
R-123 was ignored and cellular entry and exit was presum ed to follow the same kinetics. 
Once CM C is bypassed, active uptake and efflux w ould be impeded by the form ation o f  R- 
123 m icelles, and endocytosis w ould contribute to R-123 m ovem ent across membranes. This 
effect is o f  m ore importance in vitro , since experim ental exposure concentrations com pound 
are norm ally far in excess o f  those achieved in vivo  (Fell, 1997). Simulation o f  this effect is 
currently beyond the scope o f  this research, since the kinetics o f  m icelle transport has not 
been m easured, but it would be an interesting factor to include in future work, to allow better 
extrapolation betw een in vitro and in v ivo .
R-123 efflux from  the cell was predicted using 5, 10 and 50-fold increases in ABCB1 
expression com pared to the levels observed in hum an hepatocytes to estimate the effects o f  
innate inter-individual variability or variability acquired through M D R phenotype. It is clear 
that individuals expressing high levels o f  ABCB1 experience lower intracellular
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concentrations o f  drug and that a lower proportion o f  this drug undergoes metabolism. There 
are two im portant conclusions from  this: First, for compounds that require bio-activation or 
enzymatic detoxification, increased efflux w ould cause these processes to be reduced, 
resulting in excretion o f  parent com pound and altered pharm acological activity. Second, 
w hen biologically active compounds are adm inistered, rapid excretion into the bile w ould 
reduce their bioavailability and lower the proportion o f  drug distributed to its site o f  action.
W hen A B C B 1 levels were increased by 50-fold, efflux rates m atched uptake rates, meaning 
that R-123 was effluxed im m ediately from  the cell. I f  this were to occur in vivo, a compound 
would have no therapeutic effect and could explain the m ultidrug resistance observed in 
cancer chemotherapy. Little quantitative data exists on the increases in ABCB1 protein 
expression that arise in some tum our tissues, so the biological significance o f  a 50-fold 
increase in ABCB1 is not known. How ever, it is com m on for system ic exposure to anti­
cancer drugs to vary up to 40-fold (Felici et al., 2002), w ith genetic polym orphism s in 
ABCB1 thought to account for approxim ately 2-fold o f  this (Hoffm eyer et al., 2000). The 
data in Table 6.5 show that fold-increase in ABCB1 expression is not directly proportional to 
decrease in intracellular AUC, suggesting that fold increases in ABCB1 o f  up to 50-fold or 
higher m ay be necessary to decrease systemic exposure by 40-fold.
N ot only can ABCB1 levels be induced at the site o f  the cancer, but increases in liver and 
intestinal levels m ay also be seen, w hich act to excrete the com pound before it even reaches 
its target tissue. It is therefore likely that drug resistance is acquired in response to treatm ent 
w ith anticancer agents by increases in ABCB1 expression at both tum our sites and in 
clearance organs. G iven that m ost anticancer drugs are characterised by a narrow  therapeutic 
w indow, a small change in dose can lead to poor anti-tum our effects or an unacceptable 
degree o f  toxicity (Felici et al., 2002). Even a 5-fold increase in ABCB1 expression resulted 
in a 34 % decrease o f  the intracellular AUC from  control levels, w hich w ould significantly 
alter the effects o f  such an agent.
In summary, alteration o f  active uptake, passive diffusion and efflux rates all effect R-123 
disposition but to different degrees. A ltering active uptake had the largest effect on 
intracellular AUC, increasing it by 236%  w hen OATP1A2 Fmax w as increased by 5-fold. 
Increasing passive diffusion rates by 5-fold increased intracellular AUC by 105% and the 
process w ith the least influence on disposition was surprisingly, A B C B L Thus, although 
altered ABCB1 levels can im pact on drug efficacy and safety, the roles o f  active uptake and
i
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passive diffusion m ust not be ignored, and could be used to help assuage the effects o f  
increased ABCB1 expression.
It is w orth m entioning here, that although intracellular AUC was used as an indicator o f  drug 
concentrations and therefore likely efficacy or toxicology, AUC is not always the m ost usefi.il 
measure. For example, for m any antibiotic drugs it is the percentage o f  a dosage interval in 
w hich the serum  level exceeds the m inim al inhibitory concentration (M IC), given as T>M IC 
(time over M IC), that is more effective at predicting pharm acodynam ics (M outon and Punt, 
2001). In the case o f  chem otherapeutic agent paclitaxel, avoidance o f  drug-induced 
neutropenia is best achieved by m onitoring the duration o f  peak serum  concentrations (Cmax) 
(Jiko et al., 2007). Thus, understanding o f  the pharm acokinetics and pharm acodynam ics o f  a 
drag can aid the decision o f  w hich PK  param eter to use in an in silico model, w hich w ill in 
turn  help to better predict the outcom es o f  different dosing strategies.
6.11.5 The Effect of Inhibiting ABCB1
Chem ical inhibition o f  drag transporters is a com m on cause o f  adverse effects w hen drugs 
transported by  the same protein are taken concom itantly (Zhang et al., 2008). The effect o f  
inhibiting R-123 efflux w ith the ABCB1 com petitive inhibitor, quinidine w as investigated 
using the in silico  model. N ot only could the effect on each pathw ay com ponent be 
determined, but the m odel could be used to  rapidly determ ine a Kj, w hich is a more useful 
m easure o f  inhibition as it is independent o f  substrate concentration. The Ki derived from  this 
sim ulation w as found to be 29.05 ±  0.42 pm ol/pl, which is within the range o f  ICi values 
reported hi the literature: A  Kj o f  1.5 pm ol/p l for ABCB1 inhibition using [3H]-taxol as the 
probe substrate (Gao et a l ,  2001) and a K, o f  303 pm ol/pl using [3H]-V erapam il as the probe 
substrate (Doppenschm itt et al., 1998) were determ ined in the Caco-2 cell line. Such a 
derivation in vitro w ould have required m ultiple experiments, which are avoided by the use 
o f  an in silico  model. As expected, inhibition o f  ABCB1 resulted in a higher intracellular 
accum ulation o f  R-123, but again surprisingly the biggest impact was on the amount o f  R- 
110 that was formed. W hen efflux is reduced sufficiently for R-123 to accumulate, 
m etabolism  plays a m uch greater role in R-123 elim ination than w ould norm ally be seen.
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Quinidine is not a particularly potent inhibitor o f  ABCB1, especially com pared to the 
im m unosuppressant cyclosporin, w hich has an IC 50 o f  1.6 pm ol/pl (Rautio et al., 2006). Thus, 
the IC50 o f  cyclosporin was used in the in silico  m odel to compare the effects o f  inhibitors o f  
different potency. W hereas 200 pm ol/pl quinidine was required to increase the intracellular 
R-123 AUC to  20 pm ol/pl only 10 pm ol/pl cyclosporin was required to produce the same 
effect; thus a 16-fold increase in inhibitor potency m anifests as a 20-fold decrease in the dose 
needed to reach the same m agnitude o f  inhibition. ABCB 1 substrate and inhibition assays are 
routinely earned  out in the early stages o f  drug developm ent and IC 50 values obtained from 
these assays could be easily used in an in silico  m odel to predict lilcely alterations in drug 
disposition. This is advantageous as an in silico  m odel provides a m ore quantitative 
prospective on the outcom es o f  inhibition than w ould a single IC 50 value.
6.11.6 The Effect of Transporter Induction
Currently, 110 in silico  m odels incorporate induction o f  transport proteins into m odels o f  drag 
disposition, despite it being w idely accepted that drugs com m only induce the expression o f  
transporters involved in ADM E (A lberm ann et al., 2005). Progress has been made in 
identifying ligands that bind to nuclear receptors, using quantitative structure-activity 
relationship (QSAR) m odelling (Ekins et al., 2009), but downstream  consequences o f  this 
binding has yet to be simulated. This is partially  due to the inadequacies o f  m any in vitro 
systems expressing no or poor levels o f  key receptors and the cost o f  using prim ary 
hepatocytes for induction studies (H uynh et al., 2009; Plant, 2004). Several groups have 
induced or transfected CYP3A4 into Caco-2 cells to investigate the relationship betw een 
ABCB1 and CYP3A4 in co-ordinating drag m etabolism  and excretion (C han et al., 2004a; 
Cummins et al., 2001; Fan et al., 2009), but this approach is not used as part o f  a routine 
screen for transport-inducing agents.
Herein, a m ore com plex m odel o fR -1 2 3  disposition that included the effects o f  transporter 
induction via PX R  w as constructed in order to m odel the effects o f  DD Is acting at the 
transcriptional level. Inclusion o f  gene transcription and translation rates allowed RN A  and 
protein levels in prim ary hum an hepatocytes to increase to levels observed in vitro after 
treatm ent w ith 50 pm ol/p l rifam picin. A n interesting finding was the tim e taken for each 
transporter to reach its new  steady-state; ABCB1 protein took 150 m inutes to double in
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concentration, whereas OATP1A2 tripled in ju st 4 minutes. The rapidity and magnitude o f  
the OATP1A2 response indicates the importance o f  uptake transporters as a first line o f  
defence against xenobiotic exposure, followed by induction o f  key efflux transporters. In 
Chapter 5, Section 5.7.3 the probable rat orthologue o f  OATP1A2, O atp la4  was also induced 
by exposure to dexamethasone to levels m uch higher than those observed for other 
transporters and DM Es. This suggests that although PX R  ligands are species specific 
(Blumberg et a l ,  1998; Jones et al., 2000; Lehm ann et al., 1998), the response that they elicit 
is not; m aking the liver in both species prim ed to extract circulating com pounds w ith high 
efficiency.
Changing both uptake and efflux expression levels sim ultaneously showed that 50 pm ol/pl 
rifampicin treatm ent would likely cause a doubling o f  R-123 intracellular AUC, as despite 
rifam picin being know n as an inducer o f  ABCB1 expression (Ott et al., 2009), it w ill also 
induce O A TPlA 2-m ediated uptake (Schwabedissen et al., 2008). Thus, as this latter process 
is affected m ore than the efflux, the net effect is an increase in intracellular concentration and 
a more rapid clearance o f  the drug from  extracellular fluids. I f  R-123 w ere a pharm aceutical 
compound w ith a narrow therapeutic w indow , an approxim ately 2 -fold increase in 
intracellular concentrations could lead to adverse effects. Alternatively, deliberately dosing 
w ith a com pound that induces uptake transporters could be useful to achieve therapeutic 
concentrations if  com pound access to a cell type expressing a particular uptake transporter is 
low. The ability to predict quantitatively the effect o f  either deliberate or accidental drag-drug 
interactions allows distinction o f  those interactions that m ay be o f  consequence and those that 
would not. Greater understanding o f  a biological netw ork improves targeted intervention and 
ability to achieve desired pharm acological outcomes.
Given that the sim ulation closely m imics the IQ  o f  rifam picin binding to PXR, it was possible 
to simulate the inductive effect o f  lower doses o f  rifampicin. The sim ulation predicted that a 
10 pm ol/pl dose o f  rifam picin w ould have been sufficient to cause a sim ilar increase in 
intracellular AUC. The standard clinical dose o f  rifam picin used to treat tuberculosis is 600 
m g per day (W HO; M odel Lists o f  Essential M edicines, 2009), which is usually sufficient to 
achieve a therapeutic plasm a concentration range o f  9-29 pm ol/pl in non-HIV infected 
patients (M ehta et al., 2001; Sahai et al., 1997; U nsalan et al., 2005). Thus, clinical doses o f  
rifam picin are potentially high enough to produce the inductive effects observed in vitro, 
w hich could help to explain the subtherapeutic drag  levels in some tuberculosis patients. The 
m ost com m only reported consequence o f  rifam picin-induction is increased clearance o f
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rifam picin itse lf or o f  a co-adm inistered drag from  system ic circulation: D igoxin (Greiner et 
al., 1999), fexofenidine (Ham m an et al., 2001), ritonavir (Niemi et al., 2003) and sim vastatin 
(Kyrklund et al., 2000) am ongst m any others have all suffered reduced efficacy due to 
rifam picin-m ediated induction o f  ADM E proteins. In  particular, CYPs and ABCB1 have 
been identified as the culprits m ediating increased drag clearance (Chen and Raym ond, 
2006b), however few reports have studied the im plications o f  increased hepatic uptake on 
clearance rates. The results o f  this induction study and subsequent sim ulation suggest that it 
w ould be w ise to do so.
6.11.7 Sensitivity Analysis
In section 6.11.4 the importance o f  R-123 active uptake com pared to passive diffusion or 
active efflux in determ ining R-123 disposition w as discussed. However, such an analysis m ay 
be flawed by  the selectivity o f  param eters that w ere analysed. It is thus im portant to 
undertake a formal sensitivity analysis o f  all o f  the nodes in the in silico  model, w hich is a 
more unbiased approach. Such an analysis confirm ed the findings o f  the selective analysis, 
w ith uptake being the m ost sensitive node for determ ining intracellular R123 concentrations. 
Thus, OATP1A2 has been identified as the fragile node in the network; the node that has the 
m ost control over the flux o f  the overall pathway. In the pharm aceutical and m edical fields, 
this inform ation is extremely im portant as it allows drugs to be targeted specifically to the 
controlling node for m odulation o f  the pathw ay to the desired effect. For example, if  higher 
intracellular concentrations o f  a drag are required  in the hepatocyte, the current w ork 
dem onstrates that, in this case at least, targeting OA TP1A 2 to increase uptake would be m uch 
m ore efficacious than inhibiting efflux by A B C B l. Conversely, high uptake by  OATP1A2 
would increase drag clearance rates and decrease system ic concentrations; this m ay be 
undesirable i f  a tissue other than those that express OAT1A2 is the target for treatm ent. In 
addition, a m ajor obstacle in treatm ent o f  CNS disorders is the ability to cross the blood-brain 
barrier effectively (Urquhart and Kim, 2009). Current strategies have focussed on the 
inhibition o f  ABCB 1-m ediated efflux, but as OATP1A2 is also expressed in the brain, an 
alternative strategy to achieve better BBB penetration w ould be the increased utilisation o f  
OATP1 A2-m ediated uptake.
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O f course, reaction kinetics are dependent on substrate and the fragile node w ill depend on 
the pathw ay being analysed. How ever, since m any o f  the param eters required for sensitivity 
analysis are readily obtained in routine tests carried out early on in the developm ent process, 
it would be possible to use them  in in silico  m odels such as this. It is postulated herein and in 
other research that active uptake o f  drugs plays a m uch larger role in determ ining drag 
disposition than originally thought (D obson et a l ,  2009). It is therefore speculated that active 
uptake could be the fragile node in m any other netw orks and that the R-123 m odel is not 
sim ply an exceptional case. Thus, using an in silico  m odel w ould allow prelim inary data to be 
interpreted m uch m ore thoroughly and w ould lead to better predictions o f  drag action in vivo.
6.11.8 The CDF Disposition Model of ABCC2 Efflux
The CD F-ABCC2 m odel was included herein to dem onstrate that in silico  models can be 
constructed for any transporter, providing the kinetics o f  the reactions involving a probe 
substrate are known, and that m odels can be integrated to provide a m ore in-depth analysis i f  
required. The m odel was used to dem onstrate that alteration o f  ABCC2 expression over 
culture period in rat liver slices decreased the am ount o f  CDF effluxed from  the cell and 
increased the intracellular CDF AUC. I f  this w ere a sim ulation o fR -1 2 3 , the m etabolite R- 
110 w ould build up in the cell. The ABCC2 m odel can also be incorporated into the ABCB1 
m odel so that R -110 efflux can be simulated. For this to occur, kinetics o f  A B CC 2-m ediated 
efflux m ust first be determined, along w ith any passive processes that m ay be taking place. 
Using the findings o f  the CDF sim ulation, it can be postulated that in a m odel sim ulating 
O A T PlA 2-m ediated  R-123 uptake and ABCB1- and ABCC2-m ediated efflux o fR -1 2 3  and 
R-110 respectively, that at 48 hours o f  culture, intracellular concentrations o fR -123  w ould be 
decreased and any R-110 produced w ould accum ulate w ithin the cell com pared to control rat 
liver.
This kind o f  sim ulation, involving parent drag  and m etabolite are particularly im portant in 
situations w here the m etabolite has pharm acological and/or toxicological activity. I f  both 
efflux transporters were over-expressed, the reduction o f  therapeutic concentrations w ould be 
two-fold. How ever, in the induction investigation using rifampicin, OA TP1A 2 and ABCB1 
were induced, w hich resulted in an increased R-123 AUC. ABCC2 is also a know n target for 
rifam picin induction by PX R  (ICyrklund et al., 2004), and if  this were included in the
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sim ulation, an increased rate o f  R-110 efflux from  the cell m ight be observed following 
rifam picin exposure. I f  any negative feedback w ere involved in this pathway, rem oval o f  the 
m etabolite w ould stim ulate m etabolism  and decrease the AUC. By adding layers o f  
com plexity to the model, it is possible to understand the individual interactions taking place 
in a com plex biological network. It allows us to see the concentrations o f  all intermediates, 
w hich m ay be just as im portant in determ ining overall drag effect, rather than sim ply 
m easuring input and output param eters that tell us nothing about drug mechanism.
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6.11.9 Summary
In the previous chapters, expression levels o f  transporters were determined in various in vitro 
systems and the kinetics o f  R-123 life-cycle through the cell was determined. The purpose o f  
this chapter was to use this data to sim ulate R-123 disposition in these system s and to allow 
extrapolation betw een them. It has been show n that R-123 disposition can be closely 
sim ulated to m atch in vitro results. Expression or activity changes to the system  have also 
been sim ulated to show how  R-123 disposition changes in response to transporter inhibition 
and induction. Such sim ulations provide useful inform ation about the best time to perform  
assays using in vitro  system s that are prone to changes in transporter expression and the types 
o f  transporter interactions that m anifest in significant changes to disposition.
A n interesting finding was the contribution that active uptake made to the whole system, 
despite the fact that R-123 is m arketed as a hydrophobic dye that passively diffuses into cells 
and is effluxed by A B C B l. Sensitivity analysis revealed that cellular access is param ount to 
achieving high intracellular concentrations o f  R-123 and the rate o f  efflux is relatively 
unim portant. The contribution o f  m etabolism  to R-123 rem oval is also surprisingly high since 
very few literature sources acknowledge cellular m etabolism  at all. Thus, in silico  m odels can 
be used to help understand the interm ediate processes that determine drug bioavailability. In  
vitro systems are an essential first stage to identify individual reactions and to  obtain kinetics, 
however in silico  models are more useful to understand how  the individual processes fit 
together to form  a coherent network. It is im perative that expression and activity o f  key 
AD M E proteins are know n to aid interpretation o f  in vitro  results, but it is also essential to 
use in silico  models to bridge the gap betw een in vitro  and in vivo  response so that m ore 
accurate predictions o f  drag disposition can be made.
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7 Discussion
According to industry estimates, bringing out a new drug typically takes up to 15 years and 
costs $1 billion or m ore (Shekhar, 2008). M oreover, failure rates rem ain high: Only 1 or 2 
com pounds out o f  10,000 tested make it to the m arket (Shekhar, 2008). A  large proportion o f  
the expense in drug developm ent can be attributed to late-stage failures in pre-clinical anim al 
m odels, or even worse still, in clinical trials (Schachter and Ramoni, 2007). It has been 
estim ated that just a 5% reduction in phase III failures could reduce costs by 5.5 -  7.1 % 
(Schachter and Ram oni, 2007), underlining the importance o f  not only an increased success 
rate, but earlier identification o f  those com pounds exhibiting undesirable pharm acokinetic 
and pharm acodym am ic properties. Considering the complexity, risk, and cost involved in the  
drug discovery and developm ent process, it is crucial that companies adopt strategies and 
technologies that w ill facilitate rapid identification and developm ent o f  new drugs that have 
desirable properties w ith respect to hum an safety and efficacy and rejection o f  those that do 
not. A balance betw een identifying good drug candidates and rejecting poor ones needs to be 
reached in order to achieve a desirable ratio o f  false negatives to false positives. Too many 
false positives w ould substantially increase the cost o f  late-stage failures, yet too many false 
negatives, w ould slow the developm ent o f  useful drugs to be used against life threatening 
diseases for the sake o f  a precautionary approach.
For AD M E/PK departments, a tactical shift in the w ay in which lead compounds are selected 
has been occurring for some tim e, m otivated by  concerns that poor pharm acokinetics are a 
m ajor cause o f  com pound failure in drug developm ent program mes (Prentis et al., 1988). 
However, attributing m ultiple failures to one general cause such as toxicity or poor 
pharm acokinetics is m isleading, since they are often caused by more specific but interrelated 
factors such as prolonged system ic exposure and low  efficacy (Eddershaw et al., 2000). It is 
therefore pertinent to identify the precise causes that lead to drug failure in order the optimise 
drugs in the lead developm ent stage.
The preclinical phase o f  drug developm ent includes a num ber o f  in vitro and anim al studies 
to screen compounds for potential efficacy and safety in humans. However, predictions made 
in this preclinical phase often do not extrapolate accurately to humans, potentially leading to 
the abandonm ent o f  useful com pounds after m uch tim e and resources have already been 
invested in them. The use o f  in silico  m odelling is increasingly being used in conjunction
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with preclinical data early to aid extrapolation o f  data to humans, define dose-concentrations 
needed to reach pharm acological effects, assess the potential for DD Is and m uch more 
(Breimer, 2008). An explosion in the capabilities and availability o f  com puter-based tools 
and m odelling techniques have led to an increase in the num ber o f  in silico  models utilised 
today; how ever none o f  these models represent a com plete system. M any w ill incorporate the 
kinetics o f  the so-called rate-lim iting step from  the m echanism  o f  action, and other covariates 
such as species differences in protein binding, receptor occupancy and competitive 
endogenous ligands, thus allowing a reasonably accurate extrapolation (Rajman, 2008). 
However, m any o f  these systems have two disadvantages: First, they tend to adopt a 
reductionist approach, where several biological param eters are described by a single 
m athem atical term  (Chandra, 2009). Such an approach m ay allow accurate extrapolation, but 
tends to be m ore limited with regard to understanding the input o f  individual com ponents into 
the total netw ork dynamics. Second, alm ost all o f  the current system s do not include 
transporter terms, either abundance o r kinetic, m eaning that they cannot be used to examine 
the role o f  these proteins in drug disposition (Rostam i-H odjegan and Tucker, 2007).
D rag  transporters are critical in determ ining the fate o f  xenobiotics as they im pact upon their 
absorption, distribution, m etabolism  and excretion (A yrton and M organ, 2008). In addition to 
influencing system ic disposition by acting at the m ain sites o f  oral absorption and urinary and 
biliary excretion, drag transporters m ay control the am ount o f  a drug that is accessible to a 
particular organ or cell type. W hile traditional drug design aims to produce lipophilic 
com pounds that cross m em branes by passive diffusion following the ‘rale o f  5 ’ defined by 
Lip inski (Lipinski et al., 1997), it now  appears that m any o f  the properties sought after are 
also the properties necessary for active transport by  m em brane-inserted proteins (Dobson and 
Kell, 2008; D obson et a l ,  2009). Predicting hum an drag bioavailability from  animal data 
rem ains a challenge due to the expression o f  drug transporters and m etabolic enzymes in the 
gut wall (H eikkinen et al., 2010). As w e have dem onstrated, direct orthologues o f  hum an 
transporters in rats and dogs do not always exist and the correlation o f  drug transport betw een 
anim als and hum ans has not been extensively studied (Cao et al., 2006).
In addition to the gastrointestinal tract, the liver is particularly im portant in  determ ining drag 
disposition as it is a m ajor site o f  drag m etabolism  and excretion (G ibson and Skett, 2001). 
Reflecting its role, disposition in the liver can be difficult to predict due to the multiple 
transport processes that occur in the hepatocyte. Therefore, the current w ork focussed on
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m easuring the level and activity o f  drug transporters in a num ber o f  liver-based in vitro 
systems and com paring them  to those seen in hum an hepatocytes. These values were then 
used in an in silico  m odel to simulate in drug disposition and to test the hypothesis that drug 
transporters are a lcey determ inant o f  drug disposition, and that differences in expression 
levels/activity in biological test systems result in misleading estimates o f  hum an clearance. 
The overall goal o f  this research was to  increase the understanding o f  the importance o f  drug 
transporters and to increase the accuracy o f  extrapolation from in vitro to in vivo.
7.1 Transporter Expression and Activity in vitro and in silico
This research found that overall transporter expression levels in in vitro systems correlated 
poorly to those observed in hum an liver, a finding that is consistent w ith published literature 
(H ilgendorf et al., 2007; H ow e et al., 2009). Relationships improved w hen the systems 
examined were more ‘liver-like’ in their overall structure; for example, the retention o f  a 
three-dim ensional liver architecture and/or the presence o f  polarised cell membranes. In the 
hum an liver-derived im m ortalised Huh7 cell line, where cell polarity is lost (Sainz et al.,
2009), influx transporters were relatively under-expressed, while efflux transporters were 
over-expressed com pared to hum an liver. I f  this cell line were used to approxim ate hum an 
drug clearance, m isleading estimates w ould be obtained, indicating lower com pound access 
than w ould be observed in vivo.
To complicate m atters further, loss o f  polarity  in the cell line means that though over­
expressed, efflux transporters norm ally located on the canalicular m em brane are poorly 
trafficked and rem ain internally rendering them  non-functional. Thus, efflux from these cell 
lines w ould also be potentially underestim ated. The reason for localisation o f  transporters to 
the basolateral m em brane but not to the canalicular m em brane was proposed herein to reflect 
the different trafficking m echanism s that have been identified for basolateral- and 
canalicular-located transport proteins (Huet et al., 2003; Ikonen and Simons, 1998; Nies et 
al., 2002). It has also been shown that basolateral transporters or their trafficking system  are 
m ore resistant to loss o f  polarity than their canalicular counterparts, since hepatocytes in 
suspension retain com pound uptake capacity but efflux capacity is lost due to internalisation 
o f  canalicular transporters (Bow et al., 2008).
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In agreement w ith other research (H ilgendorf et al., 2007), hum an and rat prim ary 
hepatocytes displayed m uch im proved correlations to hum an liver than did the imm ortalised 
cell line. However, the isolation and culturing procedures still caused an under-expression o f  
uptake transporters and an over-expression o f  efflux transporters, although not to the same 
degree as seen w ith im m ortalised cells such as Huh7. The ability o f  prim ary hepatocytes to 
re-polarise after isolation is dependent on the m ethods used; fresh hepatocytes re-polarise 
better than cryopreserved, and the species from  w hich the hepatocytes were isolated; rat 
hepatocytes re-polarise better than hum an (H ew itt et al., 2007). Thus, transporter expression 
levels in cryopreserved hum an hepatocytes are m ore likely to misrepresent hum an liver levels 
than cyropreserved rat hepatocytes m isrepresent rat liver levels. Im provem ents in culturing 
techniques and understanding o f  these effects is however beginning to narrow the gap 
betw een in vitro  and in vivo (Hewitt et al., 2007).
The over-expression o f  efflux transporters in prim ary hepatocytes w ith culture tim e is a 
phenom enon observed by other researchers (Fardel et al., 1992; H ow e et al., 2009) and was 
also observed in rat liver slices, in this research. Rat liver slices have been suggested to be a 
useful system  for m easuring drug transport (Olinga et al., 2001), however the changes in 
relative expression o f  uptake and efflux transporters were shown to increase w ith tim e in 
culture and could potentially com plicate extrapolation from  in vitro to in vivo . Differences in 
transporter expression betw een all in vitro system s w ere more apparent at the RNA than 
protein levels, emphasising the im portance o f  protein  characterisation, rather than relying on 
R N A  data as a predictor o f  protein concentrations (Brockm ann et al., 2007). The best 
correlation in transporter expression w as observed betw een rat liver and hum an liver, 
although this relationship was view ed w ith  caution, since rat transporters are often 
functionally different to their hum an counterparts. W ith this in mind, hum an hepatocytes 
w ere recognised as the ‘gold standard’ for estimating hum an drug clearance in vitro.
The in silico  m odel o f  R-123 cellular disposition was used to simulate intracellular and 
effluxed concentrations o f  R-123 m easured in vitro in the M DCKII-ABCB 1 cell line and 
intracellular concentrations in prim ary hum an and rat hepatocytes. The m odel proved capable 
o f  accurately sim ulating R-123 disposition based on in vitro derived transport and 
m etabolism  kinetics, together w ith estim ations o f  cellular volume and binding constants. It 
was know n from  in vitro m easurem ent that the intracellular concentrations o f  R-123 reached 
in rat hepatocytes was m uch higher than those observed in hum an hepatocytes; a situation 
that has been observed for a num ber o f  chem ically diverse compounds (Paine et al., 2008;
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Sandker et al., 1994). I f  this relationship w ent unrecognised, high uptake into rat hepatocytes 
could lead to a significant overestim ation o f  hum an cellular access o fR -1 2 3  and m any other 
compounds.
Since hum an and rat hepatocytes express sim ilar levels o f  ABCB1, the in silico  model 
showed that at actual intracellular concentrations o fR -1 2 3 , hum an hepatocyte efflux rates 
were capped, whereas rat hepatocyte efflux rates were almost linear. However, when 
intracellular R-123 concentrations were uniform , the in silico m odel showed that rat 
hepatocytes could be a useful system  in w hich to closely predict hum an efflux. Thus, for 
com pounds requiring active uptake, rat hepatocytes m ay overestim ate both uptake and efflux 
rates, but for compounds that enter by  passive diffusion or via a transporter with sim ilar 
hum an kinetics, rat hepatocytes would dem onstrate similar efflux capacity. It is therefore 
im portant to understand the nature o f  the drug in order to choose the correct test system in 
which to predict hum an disposition.
Alterations to transporter expression levels over tim e in culture for rat liver slices were also 
used in a sim ulation to demonstrate how  drug disposition is dependent on the experim ental 
design. Unlike studies o f  com pound uptake, which can be m easured in m inutes or hours, drug 
induction and safety studies need to be perform ed over days before changes becom e apparent. 
A  standard study design for rat liver slices w ould be exposure to compound 0.5 hours p o s t­
slicing, w ith  assessm ent o f  biological response after 48 hours; in such a situation, results m ay 
be confounded by the peak in A bcbl expression that occurs at 48 hours post slicing. D rag 
would be effluxed from  the cells w ith  increasing rapidity over tim e in culture, conferring a 
high level o f  drag resistance. The in silico  m odel predicted that a 3-fold increase in ABCB1 
expression w ould decrease intracellular AUC by 2.5-fold, which if  unrecognised could lead 
to a gross m isinterpretation o f  in vivo drug disposition. However, i f  such responses are 
known, they can be accounted for, allowing extrapolation back to a m ore realistic in vivo  
condition. This process could be applied to any in vitro  system  in w hich the expression o f  
drag transporters has been quantified over time.
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7.1.1 Coordinate Induction of ADME Genes
Cells exposed to exogenous compounds, including pharm aceutical drugs, m aintain a defence 
against potential toxicity by regulating a netw ork o f  proteins involved in all aspects o f  
ADM E (Staudinger and Lichti, 2008). For example, m any phase I and II DM Es and efflux 
transporters are under coordinated transcriptional control by nuclear receptors such as PX R  to 
increase drag m etabolism  and efflux respectively w hen intracellular drag concentrations are 
high (Blumberg et al., 1998; Kohle and Bock, 2009). W hereas m any studies have 
investigated the induction o f  D M Es such as CY P3A4 and efflux transporters belonging to the 
ABC super fam ily (Blum berg et al., 1998; G oodw in et al., 1999; Lehm ann et al., 1998), 
fewer studies have looked at the induction o f  uptake transporters (M ild et al., 2006). Even 
less research has been conducted to show how  the balance betw een uptake and efflux 
contributes to altered drag disposition in an induced state. Thus, this research has added to 
the sum  o f  scientific know ledge by exam ining the effect(s) o f  treating rat and hum an 
hepatocytes with the prototypical species-specific PX R  inducers dexam ethasone (Pascussi et 
al., 2001) and CPA (Schuetz et al., 1998) and dexam ethasone (Huss and Kasper, 2000) and 
rifam picin (M aglich et a l ,  2003) respectively.
In rat hepatocytes, A bcbl and C yp3al/23 w ere readily  induced by dexam ethasone and CPA 
treatm ent, in agreem ent with published literature (H artley et al., 2004; N arang et al., 2008). 
This investigation also revealed isoform  specific regulation o f  Cyp3a fam ily m em bers, since 
Cyp3a9, a m em ber w ith a distinct cellular function (M ahnke et a l ,  1997) was down-regulated 
by both treatm ents. The O ctl and O a tp la4  transporters were also induced as a result o f  Pxr 
activation, w ith O atp la4  demonstrating an induction response o f  the highest magnitude; this 
is significant since both  O a tp la4  and O ctl have been im plicated in R-123 uptake in rat liver 
(Annaert and Brouwer, 2005) and kidney (H eem skerk et a l ,  2008). I f  R-123 uptake studies 
were to be carried out in prim ary cells expressing an induced phenotype, intracellular R-123 
concentrations would be hugely overestim ated. For example, a situation o f  lesser m agnitude 
could be experienced inadvertently by the inclusion o f  dexam ethasone in cell culture m edium  
(Kwiatkowslci et a l ,  1994; Tuschl and M ueller, 2006), used comm only to m aintain cell 
integrity and polarity (Silva et a l ,  1998).
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The expression o f  hum an ABCB1, 0C T 1  and OATP1A2, the likely hum an orthologue o f  rat 
O atp la4 , were next exam ined at the R N A  and protein levels and shown to exhibit sim ilar 
patterns o f  induction. All three transporters were induced by rifam picin treatm ent, in 
accordance w ith published literature, (Haslam  et a l ,  2008; Schwabedissen et al., 2008) w ith 
OATP1A2 displaying the largest induction com pared to control levels. These findings are 
interesting in m any respects: First, results indicate that rat hepatocytes are a good m odel o f  
hum an inductive response providing species specific agonists are used; second, results draw 
attention to the importance o f  induction o f  uptake transporters as a potential determ inant o f  
drag disposition.
Fold inductions o f  ABCB1 and OATP1A2 com pared to control hum an hepatocyte levels 
were used in the induction m odel o f  R-123 disposition to show the effect o f  these changes on 
intracellular concentrations o f  R-123. Simulations predicted that despite increases in ABCB1 
expression and efflux capacity, the increase in OATP1A2 was sufficient to increase 
intracellular concentrations o f  R-123 com pared to basal transporter levels. Increased 
intracellular concentrations also increased the proportion o f  R-123 that was m etabolised to R- 
110. This has im portant implications for any adm inistered drugs adm inistered chronically that 
are also PX R  agonists: induction o f  uptake and efflux could result in m ore rapid systemic 
clearance, reducing drug efficacy, and higher hepatic concentrations, w hich could increase 
the risk o f  liver toxicity. From  a biological perspective, it makes sense that systems would 
have evolved to increase the uptake o f  endogenous hormones or exogenous compounds so 
that they could be presented to DM Es and efflux transporters for m etabolism  and removal. 
From  a pharm acological perspective, uptake processes could be targeted to improve 
therapeutic outcomes: For example, in breast tum our tissue, OATP1A2 is selectively over­
expressed; m aking the tissue more sensitive to  stimulus by oestrogen (Schwabedissen et al., 
2008). Chem ical blockade o f  OA TP1A 2 could be used to reduce oestrogen stimulus, or 
alternatively, chem otherapeutic agents could utilise the over-expression on OATP1A2 to 
achieve high breast tum our concentrations.
7.1.1.1 Drug Resistance
As discussed above, w hen cells respond in a protective m anner to defend them selves against 
xenobiotics, lower systemic concentrations can result in reduced drug efficacy. This is m ost
317
often seen in drug resistance during chem otherapy for cancer, but can be seen in any 
condition where chronic adm inistration is required, such as epilepsy, A lzheim ers and AIDS 
(Lee et al., 2010). The general opinion on the biological response to chronic chem ical 
exposures is that there is an increase in efflux transporter expression that results in the 
observed decrease in systemic concentrations and loss o f  efficacy. To date, m uch tim e and 
m oney has been spent on chem ically inhibiting ABCB1 in an effort to decrease drag 
clearance, and although successful in test anim als (Schinlcel et al., 1997), this approach has 
had limit success in humans due to low potency and toxicity o f  the inhibitors (Shukla et al., 
2008).
Given the findings o f  the induction study carried out in this research, it is postulated that 
uptake transporters play a bigger role in drag  resistance than was first thought. Increased 
uptake into excretory organs such as the liver and kidneys will enhance system ic clearance 
and reduce the proportion o f  drag reaching then  target sites. In addition, uptake into 
m etabolically active hepatocytes w ill increase com pound m etabolism  and in m ost cases 
render it inactive. These effects, in com bination w ith ABCB1 acting as a bander to influx at 
m em branes in the BBB and intestine, w ould m ount a formidable defence against xenobiotics. 
This research focussed on the transporter OATP1A2, w hich is expressed at relatively low 
levels in the liver com pared to the liver-specific OATP IB  1 and OATP1B3 fam ily members. 
Thus, uptake transporters could potentially im pact on drag disposition to an even greater 
extent than dem onstrated herein.
Ideally, part o f  the drag design process w ould be to identify possible nuclear receptor ligands, 
through Q SAR m odelling (Eldns et al., 2009), to m inim ise the num ber o f  m arketed drags that 
cause m ultiple gene up-regulation and D D I’s w hen adm inistered concurrently w ith other 
drags. However, avoidance o f  one feature, e.g. PX R activation, may result in another feature 
that is ju st as unw anted and possibly less understood. One w ay to avoid N R  activation is to 
increase the potency o f  compounds so that the dose o f  drag needed in m an is reduced. 
Evidence that substrates o f  drug transporters can bo th  increase and decrease the efficacy o f  a 
co-adm inistered drug in a tim e-dependent m anner via N R  activation underlines the need for 
m ore detailed characterisation new biologically targeted anticancer drags (Azzariti et al., 
2010). For example, short exposures (<  24 hour) o f  tyrosine kinase inhibitors (TKIs) compete 
w ith topoisom erase inhibitors for transport by  ABCG 2 and prolong their therapeutic action, 
w hereas longer exposures to TKIs reduce topoisom erase action by up-regulating ABCG 2 via 
PX R  (Azzariti et al., 2010). In particular, analysing periods o f  both  short and prolonged drag
318
exposure needs to reflect potentially distinct situations in the clinic in order to optim ise future 
developm ent in com bination w ith established chem otherapeutic approaches.
7.2 The R-123 model as a Useful Tool in Drug Development
M odels investigating transport processes to date have predicted rates o f  passive diffusion 
across cell m onolayers (Tran et al., 2004) and rates o f  transport by  ABCB1 in the presence 
and absence o f  inhibitors (Acharya et al., 2008). Though these models produce reasonable 
predictions o f  transport o f  a chem ically diverse set o f  compounds, the in vitro test systems 
used to test the in silico  predictions are relatively simple com pared to in vivo systems. Thus, 
where it m ay be possible to ignore the effect o f  active uptake or drug m etabolism  in an 
M DCKII-ABCB 1 cell line used to predict passive diffusion and active efflux respectively, it 
w ould not be possible to do so in prim ary hepatocytes; thus the predictive pow er o f  the model 
is diminished. W hen extrapolating betw een sim ple in vitro systems and com plex in vivo ones, 
the importance o f  identifying and quantifying all processes in a netw ork becom e apparent. In 
the in silico  m odel presented herein, all species and processes involved in the life-cycle o f  R- 
123 have been assigned quantitative and kinetic values, giving this m odel a distinct advantage 
over the existing ones.
In this research, the in silico m odel o f  R-123 disposition w as used as a useful tool to assess 
the contribution o f  different m echanism s o f  m em brane bypass to the extent o f  intracellular 
accum ulation o f  a test compound. RN A  and protein quantification can provide some idea as 
to the likely transport processes occurring in a cell type, but such analysis is lim ited hi two 
ways: First, as shown above, RN A  levels do not always represent protein levels, nor the latter 
indicate activity. Second, if  the levels o f  transcripts/proteins are studied in isolation then it is 
harder to envisage the interplay betw een uptake, efflux and passive diffusion and to thus 
predict the net effect on drag disposition. Exam ples within this research o f  w here the in silico 
m odel served to increase in vitro understanding include the elevation o f  the importance o f  
O A T PlA 2-m ediated  uptake in determ ining drag  disposition to position originally reserved 
for ABCB1, and the revelation that R-123 m etabolism  is m uch more im portant than fu st 
indicated by  prelim inary in vitro results. Thus, given the correct in vitro input data, an in 
silico  m odel offers a more com prehensive understanding o f  the individual processes that
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define the overall outcome. It therefore becom es easier to manipulate a system  if  the targets 
that exert the m ost control over it have been identified.
Simulations were also used to obtain an inhibitory constant (lq) for quinidine inhibition o f  
A B C B l. Kj values are superior to IC 50 as they are independent o f  substrate concentration and 
therefore provide are more robust estimate o f  the inhibitory effect o f  a substrate on a system. 
However, Kj is seldom  determ ined experim entally as the derivation requires m ultiple 
experiments using different substrate and inhibitor concentrations; but derivation in silico  is a 
m uch m ore rapid process as it requires only m ultiple simulations. The sim ulated ICj was then 
used to dem onstrate the effect o f  ABCB1 inhibition on R-123 disposition, a sim ulation that 
could be very  useful clinically if  substrates for the same transporter were to be adm inistered 
clinically, or if  the potential impact o f  chem ical inhibitors as part o f  a therapeutic cocktail 
was to be investigated.
It is clear that the success o f  a model, and thus its ability to accurately predict hum an drag 
disposition, depends on the quality and availability o f  the input in vitro/in vivo  data (Pellconen 
and Turpeinen, 2007). As dem onstrated by the am ount o f  physicochem ical and biological 
data collected for R-123, obtaining high quality data for every substrate under test would be a 
time consuming task and w ould not be essential in every case. For instance, if  substrates are 
chemically sim ilar to a pre-m odelled species, only small adjustments w ould be needed to 
achieve a fitting in silico  model. A lternatively, a m odel such as the one presented here could 
be used to predict the likely disposition o f  a new  drag  candidate by m easuring perturbation 
caused to R-123 disposition. For example, if  a new  chem ical species reduced intracellular 
concentrations o f  R-123, it can be speculated that the com pound w ould be transported by 
OATP1A2, and the extent o f  the perturbation could be used to estimate uptake kinetics in a 
sim ulation utilising m ultiple substrate concentrations. Similarly, if  R-123 efflux was 
perturbed, an IC 50 or k j for the inhibition o f  ABCB1 -m ediated efflux could easily be 
sim ulated and be used to determine w hether interaction w ith ABCB1 w ould be clinically 
significant.
Once an in silico m odel has been created, it is easy to populate it w ith  m ore data and 
inform ation as it arises, or to combine it w ith other m odels to create m ore encompassing 
models. Such an approach can be seen w ith  the potential integration o f  the m odel for 
A BCC2-m ediated efflux o f  CDF, to encom pass R-110 efflux. To utilise m odelling and 
sim ulation to its optim um  potential, m odels should be developed early on and be continually
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updated and validated at each stage. In  this way, m odels w ill provide valuable support to 
make decisions w ith an increased confidence in the analysed data.
7.3 Future Work
There are m any exciting developm ents in the field o f  AD M E and toxicology testing, m any o f  
them  em bracing in silico  m odelling as the future o f  drug development. It has been suggested 
that in silico  approaches could represent up to 15 % o f  research and developm ent expenditure 
in the next 5 -1 0  years and be involved in all stages from  drug design to clinical testing 
(Rostam i-Hodjegan and Tucker, 2007). For this to be successful, efforts need to be m ade to 
base sim ulations on the best data available and to update and improve m odels regularly.
In this research, transporters were quantified at the RN A  and protein levels, revealing that 
transcript level is not always representative o f  protein levels. W here possible, 
im m unoblotting was perform ed so that relative levels o f  transporters betw een in vitro systems 
could be estimated. Although, this w as the best m ethod available w ithin our laboratory, it is a 
far from  an ideal m ethod o f  quantification since antibodies are unreliable, blots are difficult 
to compare and quantity o f  total protein does not indicate the amount that is active w ithin a 
cell. M ethods o f  protein quantification based on m ass spectrom etry are now  being developed 
as sensitive and specific tools to quantify low abundance target proteins (Le B ihan et al.,
2010). Sensitivity is so great that different glycosylation states o f  proteins can be 
discrim inated, alluding to functionality and m em brane location (Sigm a-A ldrich, Poole, UK). 
However, since the role o f  glycosylation is not yet completely understood, our biological 
understanding firstly has to be im proved before this m ethod could fulfil its frill potential. 
Ideally, im m unofluorescence could be used to determ ine to location o f  each transporter type 
(D aood et al., 2008) and the functional activity o f  each transporter could be determ ined in 
each in vitro  system  o f  interest, using specific m odel substrates. How ever, due to substrate 
overlap betw een m any transporters o f  the sam e or different sub-fam ilies (A yrton and 
M organ, 2008) this latter task m ay prove difficult.
It is also essential to obtain species-specific param eters if  extrapolation betw een species is to 
be successful. For example, in this research, kinetics o f  rat A bcbl-m ediated  R-123 efflux was 
assum ed to be the same as in hum ans, due to the lack o f  a rat A bcbl clone. How ever, it is
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clear from  estim ation o f  R-123 binding in M D CK II and hum an hepatocytes that even the 
extent o f  non-specific binding can be different betw een cell type and species, and these 
differences can have significant impacts on the biological outcome. Extension o f  this m odel 
w ould include R-110 efflux by ABCC2, so that the R-123 could be used as a m arker o f  
altered function o f  both a parent drug transporter and one m ainly involved in conjugate 
efflux. This w ould be o f  particular use for m onitoring the ability o f  com pounds to act as 
inducing agents and could help in the straggle to avoid the m anifestation o f  drag resistance.
As m entioned above, a key to the success o f  any m odel is stringent validation to test a 
m odel’s robustness and to make im provem ents where necessary. Unfortunately, the m odel 
presented herein could not be tested  against a prim ary hum an hepatocyte system  due to 
drawbacks in the cell culturing m ethodology. Once these problem s have been overcome, it 
w ill be possible to  test the m odel and to see if  it accurately predicts R-123 disposition under 
norm al and chem ically perturbed conditions. A ny failures on the part o f  the m odel can then 
be addressed and as a result, gains in the understanding o f  the processes occurring in prim ary 
hepatocytes will be made.
In general term s, future m odellers need to m ake headw ay by incorporating transport kinetics 
into existing models and digress from  the assum ption that passive diffusion is the m ost 
comm on m eans o f  cellular entry. Transport could also be extended encom pass entry into 
intracellular com partm ents such as the nucleus, m itochondria and endoplasm ic reticulum. 
Overall, m odels need to include m ore detailed individual m echanism s, working from  the 
bottom  up, as it is these individual com ponents that summate to a coherent and adaptive 
system. Only by understanding the individual com ponents can w e hope to m anipulate the 
system  as a whole.
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7.4 Summary
In summary, this w ork has shown that drug transporter expression is altered in cell culture 
systems and that this expression m ay change w ith tim e in culture in cells w ith a short 
lifespan. A ny differences in transporter expression in vitro compared to in vivo results in 
changes to the disposition o f  a compound, as exem plified by the m odel substrate, R-123. 
Understanding how  transporter expression varies naturally in vitro and in response to 
chem ical challenge allows us to make better predictions o f  drug disposition in m an and to 
m ake better dose selections in clinical trials. This study showed that in the case o f  R-123 and 
potentially m any other compounds, uptake into the cell was the controlling factor 
determining intracellular concentrations. Even upon induction o f  the ABCB1 efflux 
transporter via PXR, OATP1A2 rem ained the dictator o f  intracellular accumulation. In 
conclusion, in silico  modelling has been shown to be a useful tool to explore the complicated 
interactions betw een drug transporters, drug m etabolising enzymes and nuclear receptors. 
Future w ork will advance m odels such as this so that they can produce accurate ADM E 
predictions o f  drug disposition in different species, organs or hum an disease states with the 
aim  o f  increasing efficacy and safety in phenotypically diverse populations.
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9 Appendices
9.1 Drug Transporter Aliasis
Below are tables containing the official gene and/or protein names of the drag transporters in 
humans and rats that are regularly referred to in this work.
O fficial G ene Sym bol O fficial Protein Sym bol 
(w here different to gene)
O ther Aliases
ABCB1 P-glycoprotein (P-gp) 
MDR1
ABCB4 MDR2
MDR3
ABCB11 BSEP
SPGP
ABCC1 MRP1
ABCC2 MRP2
ABCC3 MRP3
ABCC4 MRP4
ABCG2 BCRP
SLCO IB 1 OATP IB 1 Cmoat
LST-1
OATP2
OATP-C
SLC21A6
SLC01B3 OATP1B3 LST-3
OATP-8
SLC21A8
SLC02B1 OATP2B1 OATP-B
SLC21A9
SLC01A2 OATP1A2 OATP-A
SLC21A3
SLC10A1 NTCP
SLC10A2 ABST IBST
SLC22A1-3 OCT 1-3
SLC22A6-9 OAT 1-3
Table 9-1 The Official Names and Aliases of the Human Transporter Genes/Proteins 
Commonly Referred to in this work
Compiled from the following Resources: (Dean et al., 2001; Hagenbuch and Meier, 2004; He et al., 
2009; ICoepsell and Endou, 2004)
372
Official Gene Symbol Official Protein Symbol 
(where different to gene)
Other Aliases
Abcbla Mdrla
Abcblb P-glycoprotein (P-gp)
Mdrbl
Abcbl
Abcb4 Mdr2
Abcbl1 Bsep
Spgp
Abccl Mrpl
Abcc2 Mrp2
Abcc3 Mrp3
Abcc4 Mrp4
Abcg2 Bcip
Slcolal Oatplal Oatpl
Slc22al
Slc23al
Slcola4 Oatpla4 Oatp2
Slc21a5
Slcola5 Oatpla5 Oatp3
Slc21a7
Slcola6 Oatpla6 Oatp5
Slc21al3
Slcolb2 Oatplb2 Oatp4
Slc21al0
Rlst-1
Slc22al-3 Oct 1-3
Table 9-2 The Official Names and Aliases of the Rat Transporter Genes/Proteins 
Commonly Referred to in this work
Compiled from the following Resources: Entrez Gene Database: 
http://www.ncbi.nlm.nih.gov/sites/entrez ; (He et al., 2009; ICoepsell and Endou, 2004)
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9.2 In Silico Model SBML Files
9.2.1 R-123 Steady-State Model
<?xml version="1.0" encoding="UTF-8"?>
<sbml xmlns="http://www.sbml.org/sbml/level2" level="2" version="1"> 
Cmodel id="untitled">
<1istOfCompartments>
<compartment id="default" size="l"/>
Ccompartment id="cl" name="Cells" size="l" outside="default"/> 
<compartment id=Mc2" name="Basolateral" size="l" outside="default"/> 
<compartment id="c3" name="canalicular" size="l" outside="default"/> 
</listOfCompartments>
< 1 i s t O f S p e c i e s >
<species id="sl" name="R-12311 compartment=uc3" initialAmount^"0"/> 
<species id="s2" name="R~123n compartment="cl" initialAmount=nO"/> 
<species id="s3" name="R-110" compartment="cl" initialAmount="0"/> 
<species id="s4" name="Influx_MDCKII" compartment="cl" 
initialAmount=!,On/>
<species id="s5" name=f,0ATPlA2" compartment="cl" initialAmount="On/> 
<species id="s6" name="De-esterase" compartment="cl" 
initialAmount="0"/>
<species id="s7n name="NSB" compartment="cl" initialAmount="0"/> 
<species id=,ls9" name="Efflux_MDCKII" compartment="cl" 
initialAmount="0"/>
<species id="slO" name=nABCBl" compartment="cl" initialAmount="0"/> 
<species id="sllM name=" R-12311 compartment=nc2" initialAmount="0"/> 
</listOfSpecies>
<1istOfReactions>
Creaction id="rel" reversible="false">
<listOfReactants>
< s p e c i e s R e f e r e n c e  s p e c i e s = " s l l " / >
< / l i s t O f R e a c t a n t s >
<1istOfProducts>
<speciesReference species="s2"/>
</listOfProducts>
< l i s t O f M o d i f i e r s >
<modifierSpeciesReference species="s4"/>
</listOfModifiers>
</reaction>
< r e a c t i o n  i d = " r e 2 "  r e v e r s i b l e = " f a l s e n >
<listOfReactants>
< s p e c i e s R e f e r e n c e  s p e c i e s = n s l l M/ >
</listOfReactants>
<listOfProducts>
<speciesReference species="s2"/>
</listOfProducts>
<listOfModifiers>
<modifierSpeciesReference species="s5"/>
</listOfModifiers>
</reaction>
<reaction id="re3" reversible="falsen>
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< 1 i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = u s 2 " / >  
< / l i s t O f R e a c t a n t s >
< 1 i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = u s 3 " / >
< / l i s t O f P r o d u c t s >
< l i s t O f M o d i f i e r s >
< m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s 6" / >  
< / l i s t O f M o d i f i e r s >
< / r e a c t i o n >
< r e a c t i o n  i d = n r e 4 "  r e v e r s i b l e = " f a l s e " >  
< l i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 2 , I / >
< / l i s t O f R e a c t a n t s >
< 1 i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 7 " / >
< / l i s t O f P r o d u c t s >
< / r e a c t i o n >
< r e a c t i o n  i d = " r e 5 "  r e v e r s i b l e = " f a l s e " >
< 1 i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 7 " / >  
< / l i s t O f R e a c t a n t s >
< 1 i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 2 ” / >
< / l i s t O f P r o d u c t s >
< / r e a c t i o n >
< r e a c t i o n  i d ~ " r e 6n r e v e r s i b l e = " f a l s e ” >  
< l i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = n s 2 " / >  
< / l i s t O f R e a c t a n t s >
< l i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = Ms l " / >
< / l i s t O f P r o d u c t s >
< l i s t O f M o d i f i e r s >
< m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s  9 " / >  
< / l i s t O f M o d i f i e r s >
< / r e a c t i o n >
< r e a c t i o n  i d = " r e 7 n r e v e r s i b l e = " f a l s e n >
< 1 i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 2 " / >
< / l i s t O f R e a c t a n t s >
< l i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = u s l " / >
< / l i s t O f P r o d u c t s >
< l i s t O f M o d i f i e r s >
C m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = , l s l O u / >  
< / l i s t O f M o d i f i e r s >
< / r e a c t i o n >
< / l i s t O f R e a c t i o n s >
< / m o d e l >
< / s b m l >
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9.2.2 R-123 Dynamic Model
< ? x m l  v e r s i o n = " l . 0 "  e n c o d i n g = " U T F - 8" ? >
< s b m l  x m l n s = " h t t p : / / w w w . s b m l . o r g / s b m l / l e v e l 2"  l e v e l = " 2 "  v e r s i o n = " l " >  
< m o d e l  i d = " I n d u c t i o n _ m o d e l " >
< 1 i s t O f C o m p a r t m e n t s >
C c o m p a r t m e n t  i d = " d e f a u l t "  s i z e = " l " / >
< c o m p a r t m e n t  i d = " c l "  n a m e = " C e l l "  s i z e = " l "  o u t s i d e = " d e f a u l t " / >  
C c o m p a r t m e n t  i d = " c 2 "  n a m e = " B a s o l a t e r a l "  s i z e = " l "  o u t s i d e = " d e f a u l t " / >  
C c o m p a r t m e n t  i d = " c 3 "  n a m e = " C a n a l i c u l a r "  s i z e = " l "  o u t s i d e = " d e f a u l t " / >  
C / l i s t O f C o m p a r t m e n t s >
ClistOfSpecies>
C s p e c i e s  i d = " s l "  n a m e = " A B C B l "  c o m p a r t m e n t = " c l "  
i n i t i a l C o n c e n t r a t i o n = " 0 . 2 1 "  c h a r g e = " 0 " / >
c s p e c i e s  i d = " s 3 3 "  n a m e = " A B C B l "  c o m p a r t m e n t = " c l "  i n i t i a l A m o u n t = " 6"  
c h a r g e = " 0" / >
C s p e c i e s  i d = " s 4 "  n a m e = " A B C B l _ G "  c o m p a r t m e n t = " c l "  
i n i t i a l C o n c e n t r a t i o n = " 1 "  h a s O n l y S u b s t a n c e U n i t s = " t r u e "  
b o u n d a r y C o n d i t i o n = " t r u e "  c h a r g e = M0 "  c o n s t a n t = " t r u e " / >
C s p e c i e s  i d = " s 2 "  n a m e = " A B C B l _ S "  c o m p a r t m e n t = " c l "  
i n i t i a l C o n c e n t r a t i o n = " l "  h a s O n l y S u b s t a n c e U n i t s = " t r u e "  
b o u n d a r y C o n d i t i o n = " t r u e "  c h a r g e = " 0 n c o n s t a n t = " t r u e " / >  
c s p e c i e s  i d = " s l 9 "  n a m e = " D e - e s t e r a s e "  c o m p a r t m e n t = " c l "  
i n i t i a l C o n c e n t r a t i o n = " 0 . 0 1 "  c h a r g e = " 0 " / >
C s p e c i e s  i d = " s 2 4 "  n a m e = " I n h i b i t o r "  c o m p a r t m e n t = " c l "  
i n i t i a l C o n c e n t r a t i o n = " 0 "  c h a r g e = " 0 " / >
C s p e c i e s  i d = " s 2 0 "  n a m e = = " N S B "  c o m p a r t m e n t = " c l " 
i n i t i a l C o n c e n t r a t i o n = " 0 "  c h a r g e = " 0 " / >
C s p e c i e s  i d = " s l 4 "  n a m e = " O A T P l A 2 "  c o m p a r t m e n t = " c l "  
i n i t i a l C o n c e n t r a t i o n = " 0 . 0 0 6 "  c h a r g e = " 0 " / >
C s p e c i e s  i d = " s 3 4 "  n a m e = " O A T P l A 2 "  c o m p a r t m e n t = " c l "  
i n i t i a l A m o u n t = " 0 . 0 3 "  c h a r g e = " 0 " / >
c s p e c i e s  i d = " s 2 6 "  n a m e = " O A T P l A 2 _ j 3 "  c o m p a r t m e n t = " c l "  
i n i t i a l A m o u n t = " l "  h a s O n l y S u b s t a n c e U n i t s = " t r - u e "  
b o u n d a r y C o n d i t i o n = " t r u e "  c h a r g e = " 0 "  c o n s t a n t = " t r u e " / >  
c s p e c i e s  i d = " s 2 8 "  n a m e = " O A T P l A 2 _ S "  c o m p a r t m e n t = " c l "  
i n i t i a l A m o u n t = " l "  h a s O n l y S u b s t a n c e U n i t s = " t r u e "  
b o u n d a r y C o n d i t i o n = " t r u e "  c h a r g e = " 0 "  c o n s t a n t = " t r u e " / >
C s p e c i e s  i d = " s 7 "  n a m e = " P X R "  c o m p a r t m e n t = " c l " 
i n i t i a l C o n c e n t r a t i o n = " 0 . 6"  c h a r g e = " 0 " / >  
c s p e c i e s  i d = " s 9 "  n a m e = " P X R _ A c t i v e "  c o m p a r t m e n t = " c l "  
i n i t i a l C o n c e n t r a t i o n = " 0 "  c h a r g e = " 0 " / >
C s p e c i e s  i d = " s l 8"  n a m e = " R - 110"  c o m p a r t m e n t = " c l "  
i n i t i a l C o n c e n t r a t i o n = " 0 "  c h a r g e = " 0 " / >
C s p e c i e s  i d = " s l 2 "  n a m e = " R - 1 2 3 "  c o m p a r t m e n t - " c 2 "  
i n i t i a l C o n c e n t r a t i o n = " 1 0 "  c h a r g e = " 0 " / >
C s p e c i e s  i d = " s l 3 "  n a m e = " R - 1 2 3 "  c o m p a r t m e n t = " c l "  
i n i t i a l C o n c e n t r a t i o n = " 0 "  c h a r g e = " 0 " / >
C s p e c i e s  i d = " s l 6"  n a m e = " R - 1 2 3 "  c o m p a r t m e n t = " c 3 "  
i n i t i a l C o n c e n t r a t i o n = " 0 "  c h a r g e = " 0 " / >
C s p e c i e s  i d = " s 8"  n a m e = " R i f "  c o m p a r t m e n t = = " c l "  
i n i t i a l C o n c e n t r a t i o n = " 5 "  c h a r g e = " 0 " / >
C s p e c i e s  i d = " s 6"  n a m e = " A B C B l _ p r o t _ d e g "  c o m p a r t m e n t = " c l "  
i n i t i a l C o n c e n t r a t i o n = " 0 "  c h a r g e = " 0 " / >
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< s p e c i e s  i d = " s 5 "  n a m e = " A B C B l _ R N A _ d e g "  c o m p a r t m e n t = " c l "  
i n i t i a l C o n c e n t r a t i o n = " 0 "  c h a r g e = " 0 " / >
< s p e c i e s  i d = " s 3 1 "  n a m e = " O A T P l A 2 _ R N A _ d e g "  c o m p a r t m e n t = " c l "  
i n i t i a i A m o u n t = " 0 " / >
< s p e c i e s  i d = " s 3 2 "  n a m e = " O A T P l A 2 _ p r o t _ d e g "  c o m p a r t r a e n t = , f c l ' , 
i n i t i a i A m o u n t = " 0 " / >
< / l i s t O f S p e c i e s >
< 1 i s t O f R e a c t i o n s >
< r e a c t i o n  i d = " r e l "  r e v e r s i b l e = " f a l s e "  f a s t = " f a l s e " >  
< l i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 2 " / >
< / l i s t O f R e a c t a n t s >
< 1 i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = H s l " / >
< / l i s t O f P r o d u c t s >
< l i s t O f M o d i f i e r s >
C m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s 3 3 u / >
< / l i s t O f M o d i f i e r s >
< k i n e t i c L a w >
< m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< t i m e s / >
< c i >  k l  < / c i >
< c i >  s 2 < / c i >
< c i >  s 3 3  < / c i >
< / a p p l y >
< / m a t h >
< 1 i s t O f P a r a m e t e r s >
< p a r a m e t e r  i d = , , k l "  n a m e = " T r a n s l a t i o n  r a t e "  v a l u e = " 1 0 " / >  
< / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
< r e a c t i o n  i d = " r e 3 "  r e v e r s i b l e ^ " f a l s e "  f a s t = " f a l s e " >
< 1 i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 4 " / >
< / l i s t O f R e a c t a n t s >
< 1 i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 3 3 " / >
< / l i s t O f P r o d u c t s >
< l i s t O f M o d i f i e r s >
< m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s 9 " / >  
< / l i s t O f M o d i f ± e r s >
< k i n e t i c L a w >
< m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< p l u s / >
< a p p l y >
< t i m e s / >
< c i >  s 4  < / c i >
< c i >  k l  < / c i >
< c i >  k a c t  < / c i >
< c i >  s 9  < / c i >
< / a p p l y >
< c i >  k 2 < / c i >
< / a p p l y >
< / m a t h >
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< 1 i s t O f P a r a m e t e r s >
< p a r a m e t e r  i d = " k l "  n a m e = " A B C B l _ P X R _ _ t r a n s c "  v a l u e = " 0 . 2 " / >  
< p a r a m e t e r  i d = " k a c t M n a m e = " K a c t  f o r  P X R _ A B C B 1 "  v a l u e = " 0 . 8 7 " / >  
< p a r a m e t e r  i d = ” k 2 "  n a m e := n A B C B l  l e a k y  t r a n s c  "  v a l u e = " 0 . 1 " / >  
< / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
< r e a c t i o n  i d = " r e 4 "  r e v e r s i b l e = " f a l s e "  f a s t = " f a l s e " >  
< l i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 3 3 " / >
< / l i s t O f R e a c t a n t s >
< 1 i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 5 " / >
< / l i s t O f P r o d u c t s >
< k i n e t i c L a w >
< m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< t i m e s / >
< c i >  k l  < / c i >
< c i >  s 3 3  < / c i >
< / a p p l y >
< / m a t h >
< l i s t O f P a r a m e t e r s >
< p a r a m e t e r  i d = n k l n n a m e = " A B C B l _  R N A  d e g u v a l u e = M0 . 0 1 6 " / >  
< / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
< r e a c t i o n  i d = " r e 5 "  r e v e r s i b l e = " f a l s e "  f a s t = " f a l s e " >
< l i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = n s l M/ >
< / l i s t O f R e a c t a n t s >
< 1i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 6n / >
< / l i s t O f P r o d u c t s >
< k i n e t i c L a w >
< m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< t i m e s / >
< c i >  k l  < / c i >
< c i >  s i  < / c i >
< / a p p l y >
< / m a t h >
< l i s t O f P a r a m e t e r s >
< p a r a m e t e r  i d = " k l "  n a m e = " A B C B l _ p r o t  d e g "  v a l u e = " 3 0 0 , f / >  
< / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
< r e a c t i o n  i d = ,Tr e 8n f a s t = " f a l s e n >
< l i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 7 u / >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 8" / >
< / l i s t O f R e a c t a n t s >
< 1 i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 9 , , / >
< / l i s t O f P r o d u c t s >
< k i n e t i c L a w >
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< m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< m i n u s / >
< a p p l y >
< t i m e s / >
< c i >  k l  < / c i >
< c i >  s 8 < / c i >
< c i >  s 7  < / c i >
< / a p p l y >
< a p p l y >
< t i m e s / >
< c i >  k 2 < / c i >
< c i >  s 9  < / c i >
< / a p p l y >
< / a p p l y >
< / m a t h >
c l i s t O f P a r a m e t e r s >
< p a r a m e t e r  i d = " k l "  n a m e = " k o n _ R i f _ _ P X R "  v a l u e = " 2 " / >  
c p a r a m e t e r  i d = " k 2 "  n a m e = " K o f f _ R i f _ P X R "  v a l u e = " l l . 2 " / >  
< / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
< r e a c t i o n  i d = " r e l 2 "  r e v e r s i b l e = " f a l s e "  f a s t = " f a l s e " >
< 11s t O f R e a c t a n t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s l 2 " / >
< / l i s t O f R e a c t a n t s >
< 1 i s t O f P r o d u c t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s ! 3 " / >
< / l i s t O f P r o d u c t s >
C l i s t O f M o d i f i e r s >
< m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s ! 4 " / >  
< / l i s t O f M o d i f i e r s >
< k i n e t i c L a w >
< m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< d i v i d e / >
< a p p l y >
< t i m e s / >
< c i >  v l  < / c i >
< c i >  s l 2 < / c i >
< c i >  s l 4  < / c i >
< / a p p l y >
< a p p l y >
< t i m e s / >
< c i >  k l  < / c i >
< c i >  s l 2 < / c i >
< / a p p l y >
< / a p p l y >
< / m a t h >
< l i s t O f P a r a m e t e r s >
< p a r a m e t e r  i d = " k l "  n a m e = " K m  f o r  0 A T P 1 A 2 "  v a l u e = " 0 . 3 " / >  
< p a r a m e t e r  i d = " v l "  n a m e = " V m a x  f o r  0 A T P 1 A 2 " v a l u e = " 6 . 8" / >  
< / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
< r e a c t i o n  i d = " r e ! 4 "  r e v e r s i b l e = " f a l s e "  f a s t = " f a l s e " >
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< 1 i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s l 3 " / >
< / l i s t O f R e a c t a n t s >  
c l i s t O f P r o d u c t s >
<speciesReference species="sl6"/>
< / l i s t O f P r o d u c t s >  
c l i s t O f M o d i f i e r s >
< m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s l " / >
< m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s 2 4 " / >
< / l i s t O f M o d i f i e r s >
<kineticLaw>
< m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< d i v i d e / >
< a p p l y >
< t i m e s / >
< c i >  v i  < / c i >
< c i >  s l 3  < / c i >
< c i >  s i  < / c i >
< / a p p l y >
< a p p l y >
< p l u s / >
< a p p l y >
< t i m e s / >
< c i >  k l  < / c i >
< a p p l y >
< p l u s / >
< c n  t y p e = " i n t e g e r " >  1 < / c n >
< a p p l y >
< d i v i d e / >
< c i >  s 2 4  < / c i >
< c i >  I C 5 0  < / c i >
< /a p p ly >
< / a p p l y >
< / a p p ly >
< c i >  s l 3  < / c i >
< / a p p l y >
< / a p p l y >
< / m a t h >
< 1 i s t O f P a r a m e t e r s >
< p a r a m e t e r  i d = " k l "  n a m e = " K m  o f  A B C B 1  e f f l u x "  v a l u e = " 1 7 . 5 2 " / >  
< p a r a m e t e r  i d = " v l "  n a m e = " V m a x  o f  A B C B 1  e f f l u x "  v a l u e = " 2 0 . 3 8 " / >  
< p a r a m e t e r  i d = " I C 5 0 "  n a m e = " Q u i n i d i n e  "  v a l u e = " 2 5 . 8 7 " / >
< / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
< r e a c t i o n  i d = " r e l 6"  r e v e r s i b l e = " f a l s e "  f a s t = " f a l s e " >
< 1 i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s l 3 " / >
< / l i s t O f R e a c t a n t s >
< l i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s l 8" / >
< / l i s t O f P r o d u c t s >
C l i s t O f M o d i f i e r s >
C m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s l 9 " / >
< / l i s t O f M o d i f i e r s >
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< k i n e t i c L a w >
< m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< d i v i d e / >
< a p p l y >
< t i m e s / >
< c i >  v l  < / c i >
< a p p l y >
< p o w e r / >
< c i >  s l 3  < / c i >
< c n  t y p e = " i n t e g e r " >  2 < / c n >
< / a p p l y >
< c i >  s l 9  < / c i >
< / a p p l y >
< a p p l y >
< p l u s / >
< c i >  k l  < / c i >
< a p p l y >
< p o w e r / >
< c i >  s l 3  < / c i >
< c n  t y p e = " i n t e g e r " >  2 < / c n >
< / a p p l y >
< / a p p l y >
</apply>
< / m a t h >
< l i s t O f P a r a m e t e r s >
< p a r a m e t e r  i d = " k l "  n a m e = " K m  f o r  d e e s t e r a s e "  v a l u e = " 0 . 3 2 " / >  
< p a r a m e t e r  i d = " v l "  n a m e = " V m a x  f o r  d e e s t e r a s e "  v a l u e = " 1 3 6 . 5 " / >  
< / l i s t O f P a r a m e t e r s >
</kineticLaw>
< / r e a c t i o n >
< r e a c t i o n  i d = " r e l 8"  f a s t = " f a l s e " >
< 1 i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 20" / >
< / l i s t O f R e a c t a n t s >
C l i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s l 3 " / >
< / l i s t O f P r o d u c t s >
< k i n e t i c L a w >
< m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< m i n u s / >
< a p p l y >
< t i m e s / >
< c i >  s 20 < / c i >
< c i >  k l  < / c i >
< / a p p l y >
< a p p l y >
< t i m e s / >
< c i >  s l 3  < / c i >
< c i >  k 2 < / c i >
< / a p p l y >
< / a p p l y >
< / m a t h >
< 1 i s t O f P a r a m e t e r s >
< p a r a m e t e r  i d = " k l "  n a m e = " k o f f  f r o m  N S B "  v a l u e = " 1 0 0 " / >
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< p a r a m e t e r  i d = ,' k 2 "  n a m e = " K o n  f o r  N S B "  v a l u e = " 3 0 " / >
< / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
C r e a c t i o n  i d = " r e 20"  r e v e r s i b l e = " f a l s e "  f a s t = " f a l s e " >
< 1 i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 2 6 " / >
< / l i s t O f R e a c t a n t s >
< 1 i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 3 4 " / >
< / l i s t O f P r o d u c t s >
< 1 i s t O f M o d i f i e r s >
C m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s 9 " / >
< / l i s t O f M o d i f i e r s >
< k i n e t i c L a w >
< m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< p l u s / >
< a p p l y >
< t i m e s / >
< c i >  s 2 6  < / c i >
< c i >  k l  < / c i >
< c i >  k a c t  < / c i >
< c i >  s 9  < / c i >
< / a p p l y >
< c i >  k 2 < / c i >
< / a p p l y >
< / m a t h >
< 1 i s t O f P a r a m e t e r s >
< p a r a m e t e r  i d = " k a c t "  n a m e = " k a c t  f o r  P X R _ 0 A T P 1 A 2 "  v a l u e = " l . 9 " / >  
< p a r a m e t e r  i d = " k l "  n a m e = " 0 A T P l A 2 _ P X R _ t r a n s c "  v a l u e = " 0 . 2 " / >  
< p a r a m e t e r  i d = " k 2 "  n a m e = " O A T P l A 2 _ _ l e a k y  t r a n s c "  v a l u e = " 0 . ! " / >
< / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
< r e a c t i o n  i d = " r e 21"  r e v e r s i b l e = " f a l s e "  f a s t = " f a l s e " >
< 1 i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 2 8 " / >
< / l i s t O f R e a c t a n t s >
< 1 i s t O f P r o d u c t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s l 4 " / >
< / l i s t O f P r o d u c t s >
< l i s t O f M o d i f i e r s >
C m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s 3 4 " / >
< / l i s t O f M o d i f i e r s >
< k i n e t i c L a w >
C m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< t i m e s / >
< c i >  s 3 4  < / c i >
< c i >  k l  < / c i >
< / a p p l y >
< / m a t h >
< 1 i s t O f P a r a m e t e r s >
C p a r a m e t e r  i d = " k l "  n a m e = " k l "  v a l u e = " 10" / >
< / l i s t O f P a r a m e t e r s >
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< / k i n e t i c L a w >
< / r e a c t i o n >
c r e a c t i o n  i d = " r e 2 4 "  r e v e r s i b l e = " f a l s e "  f a s t = " f a l s e " >  
c l i s t O f R e a c t a n t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 3 4 " / >
< / l i s t O f R e a c t a n t s >
< l i s t O f P r o d u c t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 3 1 " / >
< / l i s t O f P r o d u c t s >
< k i n e t i c L a w >
< m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< t i m e s / >
< c i >  s 3 4  < / c i >
< c i >  k l  < / c i >
< / a p p l y >
< / m a t h >
c l i s t O f P a r a m e t e r s >
Cparameter id="kl" name="0ATPlA2_RNA deg" value="3.4"/> 
c/iistOfParameters>
< / k i n e t i c L a w >
< / r e a c t i o n >
C r e a c t i o n  i d = " r e 2 5 "  r e v e r s i b l e ^ " f a l s e "  f a s t = " f a l s e " >
c l i s t O f R e a c t a n t s >
c s p e c i e s R e f e r e n c e  s p e c i e s = " s l 4 " / >
< / l i s t O f R e a c t a n t s >
C l i s t O f P r o d u c t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 3 2 " / >
c / l i s t O f P r o d u c t s >
c k i n e t i c L a w >
C m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
C a p p l y >
< t i m e s / >
C c i >  s l 4  c / c i >
C c i >  k l  < / c i >
< / a p p l y >  
c / m a t h >
c l i s t O f P a r a m e t e r s >
C p a r a m e t e r  i d = " k l "  n a m e = " 0 A T P l A 2 _ p r o t  d e g "  v a l u e = " 4 8 . 5 " / >  
c / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
< / l i s t O f R e a c t i o n s >
< / m o d e l >
< / s b m l >
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9.2.3 CDF Efflux by ABCC2 Model
< ? x m l  v e r s i o n = " l . 0 "  e n c o d i n g = " U T F ~ 8" ? >
<sbml xmlns="http://www.sbml.org/sbml/level2" level="2" version="l"> 
<model id="CDF_Transport">
< l i s t O f C o m p a r t m e n t s >
< c o m p a r t m e n t  i d = " d e f a u l t "  s i z e = " l " / >
< c o m p a r t m e n t  i d = " c 3 "  n a m e = " h e p a t o c y t e "  s i z e = " l "  o u t s i d e = " d e f a u l t " / >  
< c o m p a r t m e n t  i d = " c 5 "  n a m e = " b i l e  c a n a l i c u l i "  s i z e = " l "  
o u t s i d e = " d e f a u l t " / >
< c o m p a r t m e n t  i d = " c 4 "  n a m e = " H B S S "  s i z e = " l "  o u t s i d e = " d e f a u l t " / >
< / l i s t O f C o m p a r t m e n t s >
c l i s t O f S p e c i e s >
< s p e c i e s  i d = " s l 2 "  n a m e = " C D F "  c o m p a r t m e n t = " c 5 "  i n i t i a l A m o u n t = " 0 " / >  
< s p e c i e s  i d = " s l 3 "  n a m e = " C D F D A "  c o m p a r t m e n t = " c 4 "  i n i t i a l A m o u n t = " 1 0 "  
c h a r g e = " 0" / >
< s p e c i e s  i d = " s l 4 "  n a m e = " C D F D A "  c o m p a r t m e n t = " c 3 "  i n i t i a l A m o u n t = " 0 " / >  
< s p e c i e s  i d = " s 5 "  n a m e = " C D F "  c o m p a r t m e n t = " c 3 "  i n i t i a l A m o u n t = " 0 " / >  
< s p e c i e s  i d = " s 2 0 "  n a m e = " a c t i v e _ b r _ _ t r a n s p o r t e r "  c o m p a r t m e n t = " c 3 "  
i n i t i a l A m o u n t = " 0 " / >
< s p e c i e s  i d = " s 21" n a m e = " s e r u m  b o u n d "  c o m p a r t m e n t = " c 4 " 
i n i t i a l A m o u n t = " 0 " / >
< s p e c i e s  i d = " s 2 6 "  n a m e = " C D F "  c o m p a r t m e n t = " c 4 "  i n i t i a l A m o u n t = " 0 " / >  
< s p e c i e s  i d = " s 2 7 "  n a m e = " O A T P s "  c o m p a r t m e n t = " c 3 "  i n i t i a l A m o u n t = " 0 " / >  
< s p e c i e s  i d = " s 3 3 "  n a m e = " s e r u m  b o u n d "  c o m p a r t m e n t = " c 4 " 
i n i t i a l A m o u n t = " 0 " / >
< s p e c i e s  i d = " s l 5 "  n a m e = " I n h i b i t o r "  c o m p a r t m e n t = " c 3 "  
i n i t i a l A m o u n t = " 5 "  c h a r g e = " 0 " / >
< s p e c i e s  i d = " s 3 6 "  n a m e = " A B C C 2 "  c o m p a r t m e n t = " c 3 "  i n i t i a l A m o u n t = " 0 " / >  
< s p e c i e s  i d = " s 3 7 "  n a m e = " A B C C 3 "  c o m p a r t m e n t = " c 3 "  i n i t i a l A m o u n t = " 0 " / >  
< / l i s t O f S p e c i e s >
< 1 i s t O f R e a c t i o n s >
< r e a c t i o n  i d = " r e l "  n a m e = " h y d r o l y s i s "  r e v e r s i b l e ^ " f a l s e "  
f a s t = " f a l s e " >
< l i s t O f R e a c t a n t s >
< s p e c i e s R e f e r e n c e  s p e c i e s = " s l 4 " / >
< / l i s t O f R e a c t a n t s >
<listOfProducts>
< s p e c i e s R e f e r e n c e  s p e c i e s = " s 5 " / >
< / l i s t O f P r o d u c t s >
<kineticLaw>
< m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
< t i m e s / >
< c i >  k l  < / c i >
< c i >  s l 4  < / c i >
< / a p p l y >
< / m a t h >
< l i s t O f P a r a m e t e r s >
< p a r a m e t e r  i d = " k l "  n a m e = " r a t e  c o n s t a n t  f o r  h y d r o l y s i s  i n  c e l l  l y s a t e  
( e s t i m a t e ) "  v a l u e = : " 8 . 3 4 5 " / >
< / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
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C r e a c t i o n  i d = " r e 2 " n a m e = " p a s s i v e  d i f f u s i o n "  f a s t = " f a l s e " >
C l i s t O f R e a c t a n t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 1 3 " / >
< / l i s t O f R e a c t a n t s >  
c l i s t O f P r o d u c t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s l 4 " / >
< / l i s t O f P r o d u c t s >  
c k i n e t i c L a w >
C m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
C m i n u s / >
C a p p l y >  
c t i m e s / >  
c c i >  k 2 < / c i >
< c i >  s l 3  < / c i >
< / a p p l y >
< a p p l y >
c t i m e s / >
< c i >  k 2 < / c i >
C c i >  s l 4  < / c i >
< / a p p l y >
< / a p p l y >
c / m a t h >
C l i s t O f P a r a m e t e r s >
C p a r a m e t e r  i d = " k 2 "  n a m e = " r a t e  c o n s t a n t  f o r  C D F D A  p a s s i v e  d i f f u s i o n  
( e s t i m a t e ) "  v a l u e = " 2 5 " / >
< / l i s t O f P a r a m e t e r s >  
c / k i n e t i c L a w >
< / r e a c t i o n >
C r e a c t i o n  i d = " r e 3 "  n a m e = " a c t i v e  t r a n s p o r t "  r e v e r s i b l e ^ " f a l s e "
f a s t = " f a l s e " >
c l i s t O f R e a c t a n t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 5 " / >
< / l i s t O f R e a c t a n t s >  
c l i s t O f P r o d u c t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s l 2 " / >
< / l i s t O f P r o d u c t s >
C l i s t O f M o d i f i e r s >
C m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s l 5 " / >
C m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s 3 6 " / >
< / l i s t O f M o d i f i e r s >
C k i n e t i c L a w >
C m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
< a p p l y >
c p l u s / >
C a p p l y >
< d i v i d e / >
< a p p l y >
< t i m e s / >
< c i >  V m a x 3  C / c i >
C c i >  s 3 6  C / c i >
C c i >  s 5  < / c i >
< / a p p l y >
< a p p l y >
C t i m e s / >  
c c i >  K m 3  c / c i >
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< a p p l y >
< p l u s / >
< c n  t y p e = " i n t e g e r " >  1 < / c n >
< a p p l y >
< d i v i d e / >
< c i >  s l 5  < / c i >
< c i >  1 3  < / c i >
</apply>
< / a p p l y >
< / a p p l y >
< / a p p l y >
< c i >  s 5  < / c i >
< / a p p l y >
< / m a t h >
< 1 i s t O f P a r a m e t e r s >
C p a r a m e t e r  i d = " K m 3 "  n a m e = " K m  f o r  M R P 2 - C D F  ( e x p e r i m e n t a l ) "  
v a l u e = " 1 8 . 9 " / >
c p a r a m e t e r  i d = " V m a x 3 "  n a m e = " V m a x  f o r  M R P 2 - C D F  ( e x p e r i m e n t a l ) " 
v a l u e = " 9 5 . 5 " / >
C p a r a m e t e r  i d = " I 3 "  n a m e = " I C 5 0  f o r  i n h i b i t o r  ( M K 5 7 1 ) "  v a l u e = " 4 " / >  
< / l i s t O f P a r a m e t e r s >
</kineticLaw>
< / r e a c t i o n >
C r e a c t i o n  i d = " r e 4 "  n a m e = " a c t i v e  t r a n s p o r t "  r e v e r s i b l e ^ " f a l s e "  
f a s t = " f a l s e " >
< 1 i s t O f R e a c t a n t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s l 3 " / >
< / l i s t O f R e a c t a n t s >
< 1 i s t O f P r o d u c t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s l 4 " / >
< / l i s t O f P r o d u c t s >
< 1 i s t O f M o d i f i e r s >
c m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s 2 0 " / >
c / l i s t O f M o d i f i e r s >
c k i n e t i c L a w >
C m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
Capply> 
cdivide/> 
capply> 
ctimes/> 
cci> vl c/ci>
C c i >  s ! 3  c / c i >  
c / a p p l y >
Capply>
CpluS/>
Cci> kl c/ci>
C c i >  s l 3  C / c i >  
c/apply> 
c/apply> 
c/math>
c l i s t O f P a r a m e t e r s >
C p a r a m e t e r  i d = " v l "  n a m e = " v l "  v a l u e = " 0 " / >  
c p a r a m e t e r  i d = " k l "  n a m e = " k l "  v a l u e = " 0" / >  
c / l i s t O f P a r a m e t e r s >
C / k i n e t i c L a w >
c / r e a c t i o n >
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C r e a c t i o n  i d = " r e 8"  n a m e = " s e q u e s t r a t i o n "  f a s t = " f a l s e " >
ClistOfReactants>
C s p e c i e s R e f  e r e n c e  s p e c i e s = " s l 3 " / >
</listOfReactants>
C l i s t O f P r o d u c t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 2 1 " / >
< / l i s t O f P r o d u c t s >
CkineticLaw>
c m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
C c n  t y p e = " i n t e g e r " >  0 c / c n >  
c / m a t h >
</kineticLaw>
c / r e a c t i o n >
C r e a c t i o n  i d = " r e l O "  n a m e = " h y d r o l y s i s "  r e v e r s i b l e = " f a l s e "  
f a s t = " f a l s e " >  
c l i s t O f R e a c t a n t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s l 3 " / >
< / l i s t O f R e a c t a n t s >  
c l i s t O f P r o d u c t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 2 6 " / >
< / l i s t O f P r o d u c t s >
< k i n e t i c L a w >
C m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
Capply>
c t i m e s / >
Cci> klO </ci>
< c i >  s ! 3  < / c i >
</apply>
< / m a t h >
c l i s t O f P a r a m e t e r s >
C p a r a m e t e r  i d = " k l O "  n a m e = " r a t e  c o n s t a n t  f o r  h y d r o l y s i s  i n  H B S S  
( d e r i v e d ) "  v a l u e = " 0 . 0 0 1 5 2 " / >
C / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
c r e a c t i o n  i d = " r e l l "  n a m e = " a c t i v e  t r a n s p o r t "  r e v e r s i b l e = " f a l s e "  
f a s t = " f a l s e " >
< 1 i s t O f R e a c t a n t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 2 6 " / >  
c / l i s t O f R e a c t a n t s >  
c l i s t O f P r o d u c t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 5 " / >
< / l i s t O f P r o d u c t s >
C l i s t O f M o d i f i e r s >
C m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s 2 7 " / >  
c / l i s t O f M o d i f i e r s >
< k i n e t i c L a w >
C m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
Capply>
c p l u s / >
<apply>
< d i v i d e / >
Capply>
< t i m e s / >
<ci> Vmaxll </ci>
< c i >  s 2 6  c / c i >
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< / a p p l y >
<ci> Kmll </ci>
</apply>
< c i >  s 2 6  < / c i >
< / a p p l y >
< / m a t h >
< 1 i s t O f P a r a m e t e r s >
C p a r a m e t e r  i d = " V m a x l l "  n a m e = " V m a x  f o r  O A T P - C D F  ( e x p e r i m e n t a l ) " 
v a l u e = " 9 7 " / >
C p a r a m e t e r  i d = " K m l l "  n a m e = " K m  f o r  O A T P - C D F  ( e x p e r i m e n t a l ) "
value="22"/>
c / l i s t O f P a r a m e t e r s >
C/kineticLaw>
c / r e a c t i o n >
c r e a c t i o n  i d = " r e l 2 "  n a m e = " p a s s i v e  d i f f u s i o n "  f a s t = " f a l s e " >  
c l i s t O f R e a c t a n t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 2 6 " / >
c / l i s t O f R e a c t a n t s >
c l i s t O f P r o d u c t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 5 " / >
C/listOfProducts> 
ckineticLaw>
c m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
C c n  t y p e = " i n t e g e r " >  0 c / c n >
c / m a t h >
c / k i n e t i c L a w >
c / r e a c t i o n >
C r e a c t i o n  i d = " r e l 3 "  n a m e = " s e q u e s t r a t i o n "  f a s t = " f a l s e " >
C 1 i s t O f R e a c t a n t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 2 6 " / >  
c / l i s t O f R e a c t a n t s >  
c l i s t O f P r o d u c t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 3 3 " / >
< / l i s t O f P r o d u c t s >  
c k i n e t i c L a w >
C m a t h  x m l n s - " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
c c n  t y p e = " i n t e g e r " >  0 c / c n >
c/math>
c / k i n e t i c L a w >
c / r e a c t i o n >
c r e a c t i o n  i d = " r e l 4 "  n a m e = " a c t i v e  t r a n s p o r t "  r e v e r s i b l e = " f a l s e "
f a s t = " f a l s e " >
c l i s t O f R e a c t a n t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 5 " / >
< / l i s t O f R e a c t a n t s >  
c l i s t O f P r o d u c t s >
C s p e c i e s R e f e r e n c e  s p e c i e s = " s 2 6 " / >
< / l i s t O f P r o d u c t s >  
c l i s t O f M o d i f i e r s >
C m o d i f i e r S p e c i e s R e f e r e n c e  s p e c i e s = " s 3 7 " / >
c / l i s t O f M o d i f i e r s >
c k i n e t i c L a w >
C m a t h  x m l n s = " h t t p : / / w w w . w 3 . o r g / 1 9 9 8 / M a t h / M a t h M L " >
Capply>
Cplus/> 
capply>
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< d i v i d e / >
< a p p l y >
< t i m e s / >
< c i >  V m a x l 4  < / c i >
< c i >  s 5  < / c i >
< / a p p l y >
< c i >  K m l 4  < / c i >
< / a p p l y >
< c i >  s 5  < / c i >
< / a p p l y >
< / m a t h >
c l i s t O f P a r a m e t e r s >
< p a r a m e t e r  i d = " K m l 4 "  n a m e = " K m  f o r  M R P 3 - C D F  ( e s t i m a t e ) "  v a l u e = " 2 0 " / >  
< p a r a m e t e r  i d = " V m a x l 4 "  n a m e = " V m a x  f o r  M R P 3 - C D F \  ( e s t i m a t e ) "  
v a l u e = " 2 4 " / >
< / l i s t O f P a r a m e t e r s >
< / k i n e t i c L a w >
< / r e a c t i o n >
< / l i s t O f R e a c t i o n s >
< / m o d e l >
< / s b m l >
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